

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 July 2003 (17.07.2003)

PCT

(10) International Publication Number
WO 03/057672 A2

(51) International Patent Classification⁷: **C07D 215/00**

(21) International Application Number: **PCT/US02/41617**

(22) International Filing Date:
23 December 2002 (23.12.2002)

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/344,722 28 December 2001 (28.12.2001) **US**

(71) Applicant: **ACADIA PHARMACEUTICALS, INC.**
[US/US]; 3911 Sorrento Valley Boulevard, San Diego, CA
92121-1402 (US).

(72) Inventors: **SKJAERBAEK, Niels**; Fagerparken 33,
DK-2950 Vedback (DK). **KOCH, Kristian, Norup**; Bor-
thigsgade 11, DK-2100 Copenhagen (DK). **FRIBERG,**
Bo, Lennart, Mikael; Nikolaigatan 24, S-214 21 Malmoe
(SE). **TOLF, Bo-Ragnar**; Ringstedgade 2, DK-2100
Copenhagen (DK).

(74) Agent: **HUNT, Dale, C.**; Knobbe, Martens, Olson & Bear,
LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT (util-
ity model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (util-
ity model), DE, DK (utility model), DK, DM, DZ, EC, EE
(utility model), EE, ES, FI (utility model), FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR,
TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS**

(57) Abstract: The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.

WO 03/057672 A2

TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS**FIELD OF THE INVENTION**

[0001] The present invention relates to compounds that affect cholinergic receptors, especially muscarinic receptors. The present invention provides compounds that are agonists of cholinergic receptors including muscarinic receptors, especially the M_1 and M_4 subtype of muscarinic receptors. The invention also provides methods of using the provided compounds for modulating conditions associated with cholinergic receptors, especially for treating or alleviating disease conditions associated with muscarinic receptors, such as the M_1 and/or M_4 receptor subtypes.

BACKGROUND

[0002] Muscarinic cholinergic receptors mediate the actions of the neurotransmitter acetylcholine in the central and peripheral nervous systems. Muscarinic receptors play a critical role in the central nervous system mediating higher cognitive functions, as well as in the peripheral parasympathetic nervous system where they mediate cardiac, respiratory, digestive, and endocrine and exocrine responses. Five distinct muscarinic receptor subtypes have been identified, M_1 - M_5 . The muscarinic M_1 receptor subtype is predominantly expressed in the cerebral cortex and is believed to be involved in the control of higher cognitive functions; the M_2 receptor is the predominant subtype found in heart and is involved in the control of heart rate; the M_3 receptor is widely expressed in many peripheral tissues and is believed to be involved in gastrointestinal and urinary tract stimulation as well as sweating and salivation; the M_4 receptor is present in brain and may be involved in locomotion; the M_5 receptor is present in the brain where its role is at present poorly defined. M_1 and M_4 have been particularly associated with the dopaminergic system.

[0003] Conditions associated with cognitive impairment, such as Alzheimer's disease, are accompanied by a reduction of acetylcholine content in the brain. This is believed to be the result of degeneration of cholinergic neurons of the basal forebrain, which widely innervate multiple areas of the brain, including the association cortices and hippocampus, that are critically involved in higher processes.

[0004] Efforts to increase acetylcholine levels have focused on increasing levels of choline, the precursor for acetylcholine synthesis, and on blocking acetylcholinesterase (AChE), the enzyme that metabolizes acetylcholine. Attempts to augment central cholinergic function through the administration of choline or phosphatidylcholine have not been successful. AChE inhibitors have shown therapeutic efficacy, but have been found to have frequent cholinergic side effects due to peripheral acetylcholine stimulation, including abdominal cramps, nausea, vomiting, and diarrhoea. These gastrointestinal side effects have been observed in about a third of the

patients treated. In addition, some AChE inhibitors, such as tacrine, have also been found to cause significant hepatotoxicity with elevated liver transaminases observed in about 30% of patients. The adverse effects of AChE inhibitors have severely limited their clinical utility.

[0005] The dopamine hypothesis of schizophrenia suggests that increased dopamine neurotransmission underlies the positive symptoms of the disease and is supported by the evidence that dopamine receptor blockade is effective in ameliorating such psychotic symptoms. Further, drugs that enhance dopamine neurotransmission in the brain cause psychotic-like episodes in man and exacerbate psychotic symptoms in schizophrenic patients. In animal studies, drugs that increase dopamine neurotransmission cause behavioural effects such as increased locomotion, climbing and deficits in prepulse inhibition. Known antipsychotics and dopamine receptor antagonists can block these behavioural effects. Unfortunately, dopamine receptor antagonists also cause severe extrapyramidal side effects in patients as predicted by induction of catalepsy in animal models. These extrapyramidal side effects include tremor, bradykinesia, akathesias, and tardive dyskinesias.

[0006] Due in part to these observations, the discovery of agents with M₁ receptor agonist activity has been sought after for the treatment of dementia. However, existing agents lack specificity in their actions at the various muscarinic receptor subtypes. Known M₁ muscarinic agonists such as arecoline have also been found to be weak agonists of M₂ as well as M₃ receptor subtypes and are ineffective in the treatment of cognitive impairment, due in large part to their dose-limiting M₂ and M₃ receptor mediated side effects.

[0007] Xanomeline (Shannon et al., *J. Pharmacol. Exp. Ther.* 1994, 269, 271; Shannon et al., *Schizophrenia Res.* 2000, 42, 249) is an M₁/M₄ preferring muscarinic receptor agonist with little or no affinity for dopamine receptors despite inhibiting A10 but not A9 dopamine cells. The thiadiazole derivative PTAC has been reported (Shannon et al., *European Journal of Pharmacology*, 1998, 356, 109) to have partial agonist effect at muscarinic M₂ and M₄ receptors and antagonist effect at muscarinic M₁, M₃, and M₅ receptors as well as exhibiting functional dopamine antagonism.

[0008] Recently, muscarinic agonists including xanomeline have been shown to be active in animal models with similar profiles to known antipsychotic drugs, but without causing catalepsy (Bymaster et al., *Eur. J. Pharmacol.* 1998, 356, 109, Bymaster et al., *Life Sci.* 1999, 64, 527, Shannon et al., *J. Pharmacol. Exp. Ther.* 1999, 290, 901, Shannon et al., *Schizophrenia Res.* 2000, 42, 249). Further, xanomeline was shown to reduce psychotic behavioural symptoms such as delusions, suspiciousness, vocal outbursts, and hallucinations in Alzheimer's disease patients (Bodick et al., *Arch. Neurol.* 1997, 54, 465), however treatment induced side effects that severely limit the clinical utility of this compound.

[0009] Analogues of 1,2,5-thiadiazole have been reported (Sauerberg et al., *J. Med. Chem.* 1998, 41, 4378) to have high affinity and selectivity for central muscarinic receptors as well as exhibiting functional dopamine antagonism despite lack of affinity for dopamine receptors.

[0010] The present investigators have, in part, focussed their efforts on the development of molecules that simultaneously reduced the positive symptoms and improved the negative symptoms and the cognitive impairments associated with schizophrenia as a novel treatment of mental disorders. It is the intent of the present investigators to demonstrate that muscarinic M₁ and/or M₄ agonists with combined D₂ antagonist activity may possess superior antipsychotic efficacy without the side effects associated with high dose D₂ antagonism alone. The D₂ antagonist properties of some of the compounds of the present invention may contribute to a reduction in the positive symptoms of this disease.

[0011] Based on distribution of M₁ and M₄ receptors in the cerebral cortex and hippocampus (the areas involved in higher order cognitive functions), the M₁ and/or M₄ agonist properties of these compounds may reduce the cognitive dulling and perhaps ameliorate other negative symptoms associated with schizophrenia. (Friedman, *Biol. Psychiatry*, 1999, 45, 1; Rowley, *J. Med. Chem.* 2001, 44, 477; Felder, *J. Med. Chem.* 2000, 43, 4333). This unique combination of central nervous system activities in one molecule is unprecedented and may lead to the development of an entirely new class of antipsychotic drugs, ones with the superior clinical properties without the limiting side-effect profile.


[0012] US 3,324,137 and US 3,365,457 describe N-[indolyl-lower-alkanoyl]-1,5-iminocycloalkanes and iminocycloalkanes not encompassed by the invention.

[0013] EP 0 584 487 describes 4,5-dihydro-4-oxo-pyrroles with linked to piperazine rings not encompassed by the invention.

[0014] Mokrosz et al (*Pharmazie*, 52, 1997, 6, p423) describes N[3-(4-aryl)-1-piperazinyl]propyl derivatives of indolin-2(1H)-one, quinolin-2-(1H)-one and isoquinolin-1-(2H)-one, which are not encompassed by the invention.

SUMMARY OF THE INVENTION

[0015] The invention provides novel compounds of formula I, as well as salts and isomers thereof



I

wherein R^1 is a monoradical selected from the group consisting of optionally substituted C_{1-6} -alkyl, optionally substituted C_{2-6} -alkylidene, optionally substituted C_{2-6} -alkenyl, optionally substituted C_{2-6} -alkynyl, optionally substituted $O-C_{1-6}$ -alkyl, optionally substituted $O-C_{2-6}$ -alkenyl, optionally substituted $O-C_{2-6}$ -alkynyl; optionally substituted $S-C_{1-6}$ -alkyl, optionally substituted $S-C_{2-6}$ -alkenyl, optionally substituted $S-C_{2-6}$ -alkynyl;

m is 0, 1 or 2;

C_3-C_4 is CH_2-CH or $CH=C$ or C_4 is CH and C_3 is absent;

R^2 and R^3 are independently selected from the group consisting of hydrogen, optionally substituted C_{1-6} alkyl, optionally substituted $O-C_{1-6}$ alkyl, halogen, hydroxy or selected such that R^2 and R^3 together form a ring system;

each R^4 and R^5 is independently selected from the group consisting of hydrogen, halogen, hydroxy, optionally substituted C_{1-6} -alkyl, optionally substituted $O-C_{1-6}$ alkyl, optionally substituted aryl- C_{1-6} alkyl, and optionally substituted arylheteroalkyl;

L^1 and L^2 are biradicals independently selected from the group consisting of $-C(R^6)=C(R^7)$, $-C(R^6)=N-$, $-N=C(R^6)-$, $-S-$, $-NH-$ and $-O-$; wherein only one of L^1 and L^2 may be selected from the group consisting of $-S-$, $-NH-$ and $-O-$;

Y is selected from the group consisting of O , S , and H_2 ;

X is a biradical selected from the group consisting of $-C(R^6)(R^7)-C(R^6)(R^7)-$, $-C(R^6)=C(R^7)-$, $-O-C(R^6)(R^7)-$, $C(R^6)(R^7)-O-$, $-S-C(R^6)(R^7)-$, $-C(R^6)(R^7)-S-$, $-N(R^N)-C(R^6)(R^7)-$, $-C(R^6)(R^7)-N(R^N)-$, $-C(R^6)(R^7)-C(R^6)(R^7)-C(R^6)(R^7)-$, $-O-C(R^6)(R^7)-C(R^6)(R^7)-$, $-S-C(R^6)(R^7)-C(R^6)(R^7)-$, $N(R^N)-C(R^6)(R^7)-C(R^6)(R^7)-$, $-C(R^6)(R^7)-C(R^6)(R^7)-O-$, $-C(R^6)(R^7)-C(R^6)(R^7)-S-$, $-C(R^6)(R^7)-C(R^6)(R^7)-N(R^N)-$, $-C(R^6)(R^7)-C(R^6)=C(R^7)-$, and $-C(R^6)=C(R^7)-C(R^6)(R^7)-$, wherein R^6 and R^7 are independently selected from the group consisting of hydrogen, halogen, hydroxy, nitro, cyano, $NR^N R^N$, $N(R^N)-C(O)N(R^N)$, optionally substituted C_{1-6} -alkyl, C_{2-6} -alkenyl, C_{2-6} -alkynyl, , optionally substituted $O-C_{1-6}$ -alkyl, optionally substituted O -aryl, optionally substituted $O-C_{2-6}$ -alkenyl, optionally substituted $O-C_{2-6}$ -alkynyl

wherein R^N is selected from the group consisting of hydrogen, and optionally substituted C_{1-6} -alkyl.

[0016] The invention further provides compositions comprising

- i) one or more compounds of formula I, and;
- ii) at least one pharmaceutically acceptable excipient or carrier.

[0017] The invention also provides methods of treating a disease in a mammal, such as a human, wherein modulation of the activity of a cholinergic receptor is associated with a physiologically beneficial response in said disease of said mammal. In one embodiment, a method includes administering an effective amount of a compound of formula I.

[0018] Thus, the invention provides methods of treating or preventing or alleviating one or more symptoms associated with a disorder in a mammal, such as a human, said disorder associated with a muscarinic receptor, for example, the M_1 muscarinic receptor subtype. In one embodiment, a method includes the administration of an effective amount of the compound of formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, or a pharmaceutical composition comprising either entity. Particular disorders treatable by a method of the invention include, for example, Alzheimer's disease, Parkinson's disease, schizophrenia, Huntington's chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Down Syndrome, Pick disease, dementia, clinical depression, age-related cognitive decline, cognitive impairment, forgetfulness, confusion, memory loss, attentional deficits, deficits in visual perception, depression, pain, sleep disorders, psychosis, sudden infant death syndrome, increased intraocular pressure and glaucoma.

[0019] The invention additionally provides a method of treating a mental disorder wherein the physiologically beneficial response is due to modulation in terms of M_1 agonism; M_1 and M_4 agonism; both M_1 agonism and D_2 antagonism; or M_1 and M_4 agonism and D_2 antagonism.

[0020] The invention additionally provides the use of a compound of formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, or a pharmaceutical composition comprising either entity, for the preparation of a medicament for the treatment of diseases or disorders associated with a cholinergic receptor or ligand thereof.

[0021] The invention therefore provides methods for the preparation of a medicament for the treatment of diseases or disorders selected from the group consisting of Alzheimer's disease, Parkinson's disease, schizophrenia, Huntington's chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Down Syndrome, Pick disease, dementia, clinical depression, age-related cognitive decline, cognitive impairment, forgetfulness, confusion, memory loss, attentional deficits, deficits in visual perception, depression, pain, sleep disorders, psychosis, sudden infant death syndrome, increased intraocular pressure and glaucoma.

[0022] The invention further provides methods of increasing an activity of a cholinergic receptor. In one embodiment, a method includes contacting the cholinergic receptor or a system containing the cholinergic receptor with an effective amount of at least one compound of formula I to increase an activity of the cholinergic receptor.

[0023] The invention provides kits including one or more compounds of the invention, and instructions for practicing a method of the invention. In one embodiment, instructions are for treating or preventing or alleviating one or more symptoms associated with a disorder in a mammal, such as a human, said disorder associated with a muscarinic receptor, for example, the M_1 muscarinic receptor subtype. In another embodiment, instructions are for increasing cholinergic receptor activity or activating cholinergic receptors.

DESCRIPTION OF THE INVENTION

[0024] For the purpose of the current disclosure, the following definitions shall in their entireties be used to define technical terms.

[0025] The term "agonist" is defined as a compound that increases the activity of a receptor when it contacts the receptor.

[0026] The term "antagonist" is defined as a compound that competes with an agonist or inverse agonist for binding to a receptor, thereby inhibiting or blocking the action of an agonist or inverse agonist on the receptor. However, an antagonist (also known as a "neutral" antagonist) has no effect on constitutive receptor activity.

[0027] The term "inverse agonist" is defined as a compound that decreases the basal activity of a receptor (i.e., signaling mediated by the receptor). Such compounds are also known as negative antagonists. An inverse agonist is a ligand for a receptor that causes the receptor to adopt an inactive state relative to a basal state occurring in the absence of any ligand. Thus, while an antagonist can inhibit the activity of an agonist, an inverse agonist is a ligand that can alter the conformation of the receptor in the absence of an agonist. The concept of an inverse agonist has been explored by Bond et al. in *Nature* 374:272 (1995). More specifically, Bond et al. have proposed that unliganded β_2 -adrenoceptor exists in an equilibrium between an inactive conformation and a spontaneously active conformation. Agonists are proposed to stabilize the receptor in an active conformation. Conversely, inverse agonists are believed to stabilize an inactive receptor conformation. Thus, while an antagonist manifests its activity by virtue of inhibiting an agonist, an inverse agonist can additionally manifest its activity in the absence of an agonist by inhibiting the spontaneous conversion of an unliganded receptor to an active conformation.

[0028] The " M_1 -receptor" is defined as a receptor having an activity corresponding to the activity of the $m1$ muscarinic receptor subtype characterized through molecular cloning and pharmacology.

[0029] The term "subject" refers to an animal, for example a mammal, such as a human, who is the object of treatment, observation or experiment.

[0030] The term "selective" is defined as a property of a compound whereby an amount of the compound sufficient to effect a desired response from a particular receptor type, subtype, class or subclass causes a substantially smaller or no effect upon the activity of other receptor types.

[0031] The EC_{50} for an agonist is intended to denote the concentration of a compound needed to achieve 50% of a maximal response seen in an in vitro assay such as R-SAT. For inverse

agonists, EC50 is intended to denote the concentration of a compound needed to achieve 50% inhibition of an R-SAT response from basal, no compound, levels.

[0032] As used herein, the term "coadministration" of pharmacologically active compounds refers to the delivery of two or more separate chemical entities, whether in vitro or in vivo. Coadministration refers to the simultaneous delivery of separate agents; to the simultaneous delivery of a mixture of agents; as well as to the delivery of one agent followed by delivery of a second agent or additional agents. In all cases, agents that are coadministered are intended to work in conjunction with each other.

[0033] In the present context, the term "C₁₋₆-alkyl" means a linear or branched saturated hydrocarbon chain wherein the longest chain has from one to six carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, and hexyl.

[0034] In the present context, the term "C₂₋₈-alkenyl" means a linear or branched hydrocarbon group having from two to eight carbon atoms and containing one or more double bonds. Illustrative examples of C₂₋₈-alkenyl groups include allyl, homo-allyl, vinyl, crotyl, butenyl, pentenyl, hexenyl, heptenyl and octenyl. Illustrative examples of C₂₋₈-alkenyl groups with more than one double bond include butadienyl, pentadienyl, hexadienyl, heptadienyl, heptatrienyl and octatrienyl groups as well as branched forms of these. The position of the unsaturation (the double bond) may be at any position along the carbon chain.

[0035] In the present context the term "C₂₋₈-alkynyl" means a linear or branched hydrocarbon group containing from two to eight carbon atoms and containing one or more triple bonds. Illustrative examples of C₂₋₈-alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl and octynyl groups as well as branched forms of these. The position of unsaturation (the triple bond) may be at any position along the carbon chain. More than one bond may be unsaturated such that the "C₂₋₈-alkynyl" is a di-yne or enedi-yne as is known to the person skilled in the art.

[0036] In the present context, the term "C₃₋₈-cycloalkyl" includes three-, four-, five-, six-, seven-, and eight-membered rings comprising carbon atoms only, whereas the term "heterocyclyl" means three-, four-, five-, six-, seven-, and eight-membered rings wherein carbon atoms together with from 1 to 3 heteroatoms constitute said ring. The heteroatoms of such heterocyclyl groups are independently selected from oxygen, sulphur, and nitrogen.

[0037] The term "Heterocyclyl" groups may further contain one or more carbonyl or thiocarbonyl functionalities, so as to make the definition include oxo-systems and thio-systems such as lactams, lactones, cyclic imides, cyclic thioimides, cyclic carbamates, and the like.

[0038] C₃₋₈-cycloalkyl and heterocyclyl rings may optionally contain one or more unsaturated bonds situated in such a way, however, that an aromatic π -electron system does not arise.

[0039] Heterocyclyl rings may optionally also be fused to aryl rings, such that the definition includes bicyclic structures. Examples of such fused heterocyclyl groups share one bond with an optionally substituted benzene ring. Examples of benzo-fused heterocyclyl groups include, but are not limited to, benzimidazolidinone, tetrahydroquinoline, and methylenedioxybenzene ring structures.

[0040] Illustrative examples of "C₃₋₈-cycloalkyl" are the carbocycles cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclopentadiene, cyclohexane, cyclohexene, 1,3-cyclohexadiene, 1,4-cyclohexadiene, cycloheptane, cycloheptene, 1,2-cycloheptadiene, 1,3-cycloheptadiene, 1,4-cycloheptadiene and 1,3,5 cycloheptatriene.

[0041] Illustrative examples of "heterocyclyls" are the heterocycles tetrahydrothiopyran, 4H-pyran, tetrahydropyran, piperidine, 1,3-dioxin, 1,3-dioxane, 1,4-dioxin, 1,4-dioxane, piperazine, 1,3-oxathiane, 1,4-oxathiin, 1,4-oxathiane, tetrahydro-1,4-thiazine, 2H-1,2-oxazine, maleimide, succinimide, barbituric acid, thiobarbituric acid, dioxopiperazine, hydantoin, dihydrouracil, morpholine, trioxane, hexahydro-1,3,5-triazine, tetrahydrothiophene, tetrahydrofuran, pyrroline, pyrrolidine, pyrrolidone, pyrrolidione, pyrazoline, pyrazolidine, imidazoline, imidazolidine, 1,3-dioxole, 1,3-dioxolane, 1,3-dithiole, 1,3-dithiolane, isoxazoline, isoxazolidine, oxazoline, oxazolidine, thiazoline, thiazolidine, 1,3-oxathiolane. Binding to the heterocycle may be at the position of a heteroatom or via a carbon atom of the heterocycle, or, for benzo-fused derivatives, via a carbon of the benzenoid ring.

[0042] In the present context the term "aryl" means a carbocyclic aromatic ring or ring system. Moreover, the term "aryl" includes fused ring systems wherein at least two aryl rings, or at least one aryl and at least one C₃₋₈-cycloalkyl share at least one chemical bond. Illustrative examples of "aryl" rings include optionally substituted phenyl, naphthalenyl, phenanthrenyl, anthracenyl, tetralinyl, fluorenyl, indenyl, and indanyl. An example of an aryl group is phenyl. The term "aryl" relates to aromatic, typically benzenoid groups connected via one of the ring-forming carbon atoms, and optionally carrying one or more substituents selected from halo, hydroxy, amino, cyano, nitro, alkylamido, acyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ aminoalkyl, C₁₋₆ alkylamino, alkylsulfenyl, alkylsulfinyl, alkylsulfonyl, sulfamoyl, or trifluoromethyl. As stated, aryl groups may be phenyl, and, most suitably, substituted phenyl groups, carrying one or two, same or different, of the substituents listed above. One pattern of substitution is *para* and/or *meta*. Representative examples of aryl groups include, but are not limited to, phenyl, 3-halophenyl, 4-halophenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 3-aminophenyl, 4-aminophenyl, 3-methylphenyl, 4-methylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-cyanophenyl, 4-cyanophenyl,

dimethylphenyl, naphthyl, hydroxynaphthyl, hydroxymethylphenyl, trifluoromethylphenyl, alkoxyphenyl.

[0043] In the present context the term "aryl(C₁₋₆-alkyl)" means a carbocyclic aromatic ring as defined above connected via a C₁₋₆-alkyl group.

[0044] The term arylheteroalkyl should be interpreted as an aryl group, as defined above, connected, as a substituent, via a C₁₋₆-alkyl tether which, additionally, contains, in the chain, at least one atom selected from the group consisting of oxygen, sulfur, and nitrogen.

[0045] In the present context, the term "heteroaryl" means a heterocyclic aromatic group where one or more carbon atoms in an aromatic ring have been replaced with one or more heteroatoms selected from the group comprising nitrogen, sulphur, phosphorous and oxygen.

[0046] Furthermore, the term "heteroaryl" comprises fused ring systems wherein at least one aryl ring and at least one heteroaryl ring, at least two heteroaryl rings, at least one heteroaryl ring and at least one heterocyclyl ring, or at least one heteroaryl ring and at least one C₃₋₈-cycloalkyl ring share at least one chemical bond.

[0047] The term "heteroaryl" is understood to relate to aromatic, C₂₋₆ cyclic groups further containing one O or S atom or up to four N atoms, or a combination of one O or S atom with up to two N atoms, and their substituted as well as benzo- and pyrido-fused derivatives, typically connected via one of the ring-forming carbon atoms. Heteroaryl groups may carry one or more substituents, selected from halo, hydroxy, amino, cyano, nitro, alkylamido, acyl, C₁₋₆-alkoxy, C₁₋₆-alkyl, C₁₋₆-hydroxyalkyl, C₁₋₆-aminoalkyl, C₁₋₆-alkylamino, alkylsulfenyl, alkylsulfinyl, alkylsulfonyl, sulfamoyl, or trifluoromethyl. Particular heteroaryl groups are five- and six-membered aromatic heterocyclic systems carrying 0, 1, or 2 substituents, which may be the same as or different from one another, selected from the list above. Representative examples of heteroaryl groups include, but are not limited to, unsubstituted and mono- or di-substituted derivatives of furan, benzofuran, thiophene, benzothiophene, pyrrole, pyridine, indole, oxazole, benzoxazole, isoxazole, benzisoxazole, thiazole, benzothiazole, isothiazole, imidazole, benzimidazole, pyrazole, indazole, and tetrazole, as well as furazan, 1,2,3-oxadiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, triazole, benzotriazole, quionoline, isoquinoline, pyridazine, pyrimidine, purine, pyrazine, pteridine, pyrrole, phenoxazole, oxazole, isoxazole, oxadiazole, benzopyrazole, indazole, quinolizine, cinnoline, phthalazine, quinazoline, and quinoxaline. The most typical substituents are halo, hydroxy, cyano, O-C₁₋₆-alkyl, C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, amino-C₁₋₆-alkyl.

[0048] When used herein, the term "O-C₁₋₆-alkyl" means C₁₋₆-alkyloxy, or alkoxy, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, neopentyloxy and hexyloxy

[0049] The term "halogen" includes fluorine, chlorine, bromine and iodine.

[0050] When used herein, the term "optionally substituted" means that the group in question may be substituted one or several times, such as 1 to 5 times, 1 to 3 times, or 1 to 2 times, with one or more groups selected from C₁₋₆-alkyl, C₁₋₆-alkoxy, oxo (which may be represented in the tautomeric enol form), carboxyl, amino, hydroxy (which when present in an enol system may be represented in the tautomeric keto form), nitro, alkylsulfonyl, alkylsulfenyl, alkylsulfinyl, C₁₋₆-alkoxycarbonyl, C₁₋₆-alkylcarbonyl, formyl, mono- and di(C₁₋₆-alkyl)amino; carbamoyl, mono- and di(C₁₋₆-alkyl)aminocarbonyl, amino-C₁₋₆-alkyl-aminocarbonyl, mono- and di(C₁₋₆-alkyl)amino-C₁₋₆-alkyl-aminocarbonyl, C₁₋₆-alkylcarbonylamino, cyano, guanidino, carbamido, C₁₋₆-alkanoyloxy, C₁₋₆-alkylsulphonyloxy, dihalogen-C₁₋₆-alkyl, trihalogen-C₁₋₆-alkyl, and halo. In general, the above substituents may be susceptible to further optional substitution

[0051] The term "salt" means pharmaceutically acceptable acid addition salts obtainable by treating the base form of a functional group, such as an amine, with appropriate acids such as inorganic acids, for example hydrohalic acids; typically hydrochloric, hydrobromic, hydrofluoric, or hydroiodic acid; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example acetic, propionic, hydroacetic, 2-hydroxypropanoic acid, 2-oxopropanoic acid, ethandioic, propanedioic, butanedioic, (Z)-2-butenedioic, (E)-butenedioic, 2-hydroxybutanedioic, 2,3-dihydroxybutanedioic, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic acid, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic, and other acids known to the skilled practitioner.

[0052] The method of the invention relates to the modulation of a cholinergic receptor. Typically, said cholinergic receptor is a muscarinic receptor; one example of a cholinergic receptor is a muscarinic receptor of M₁-receptor subtype. As can be seen from the Examples, in suitable embodiments, the cholinergic receptor may be either or both the muscarinic M₁-receptor and the muscarinic M₄-receptor subtypes. The physiologically beneficial response in the method of the invention is typically associated with the specific activation of the M₁-receptor subtype over the M₂- or M₃-receptor subtype, or the specific activation of the M₁- and M₄- receptor subtypes over the M₂- or M₃-receptor subtype. Moreover, a physiologically beneficial response in a method of the invention is typically associated with the agonistic activity of the compound of formula I or IA. Thus, in one embodiment, the compound of formula I or IA is a muscarinic agonist, such as an M₁ agonist or an M₁ and M₄ agonist.

[0053] A further aspect of the invention relates to a method of increasing the activity of a cholinergic receptor. In one embodiment, a method includes contacting a cholinergic receptor or a system containing a cholinergic receptor with an effective amount of at least one compound of formula I or IA, as defined *supra*.

[0054] A related aspect of the invention is directed to a method of treating or preventing or alleviating one or more symptoms associated with a disorder in a mammal, such as a

human. In one embodiment, a method includes the administration of an effective amount of a compound of formula I or IA, said disorder associated with a muscarinic receptor, for example, M₁ muscarinic receptor subtype.

[0055] The disorders associated with the M₁ muscarinic receptor subtype are typically mental disorders. Suitable mental disorders which can be treated by the method of the invention may be selected from the group comprising of cognitive impairment, forgetfulness, confusion, memory loss, attentional deficits, deficits in visual perception, depression, pain, sleep disorders, psychosis, and increased intraocular pressure.

[0056] Disorders associated with the M₁ muscarinic receptor subtype need not be a mental disorder. For instance, increased intraocular pressure is associated with the M₁ muscarinic receptor subtype. Disorders to which the method of the invention are directed therefore include non-mental disorders.

[0057] Disorders to which the method of the invention are directed may be further selected from the group comprising neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, schizophrenia, Huntington's chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Down Syndrome, Pick disease, dementia, clinical depression, age-related cognitive decline, attention-deficit disorder, sudden infant death syndrome, and glaucoma.


[0058] As stated, the compounds of the invention have high selectivity and affinity for the muscarinic M₁ receptor subtypes. As can be seen from the Examples, the compounds also have high affinity for one or both of the M₁ and M₄ receptor subtypes, selectively over other receptors such as the M₂, M₃ and M₅ receptor subtypes. The compounds of the invention typically act, at least in part, as an M₁ agonist or as M₁ and M₄ agonist.

[0059] The compounds of the invention also have an affinity for the dopamine D₂ receptor. As discussed supra in connection with the dopamine hypothesis in relation to schizophrenia, compounds which act as both muscarinic agonists and dopamine antagonists may be keys to adequately treat many mental disorders. Thus, the invention is also directed to methods of treating mental disorders, using compounds of the invention, said compounds acting as a D₂ antagonist or D₂ inverse agonist as well as a muscarinic agonist, particularly an M₁ agonist or as M₁ and M₄ agonist. Thus, the method of the invention may be such that the disease in a mental disorder and the physiologically beneficial response to due to modulation in terms of M₁ agonism; M₁ and M₄ agonism; both M₁ agonism and D₂ antagonism; or M₁ and M₄ agonism and D₂ antagonism.

[0060] In one aspect of the invention, the compounds of the invention are anti-psychotic agents, said anti-psychotic activity due to the compounds of the invention acting as M₁ agonist; or as M₁ and M₄ agonists; or acting as an both M₁ agonists and D₂ antagonist; or as M₁ and M₄ agonists and D₂ antagonists.

[0061] Another aspect of the invention relates to the use of a compound of formula IA, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising either entity, for the preparation of a medicament for the treatment of diseases or disorders associated with a cholinergic receptor or ligand thereof. The medicament may be for the treatment of diseases associated with the receptors as discussed *supra* and for disorders as discussed *supra*. A related aspect of the invention is directed to a pharmaceutical composition comprising an effective amount of a compound of formula I, as defined *supra*, or pharmaceutically acceptable salts thereof, a stereoisomer thereof, or a pharmaceutical composition comprising either entity, together with pharmaceutically acceptable carriers or excipients.

[0062] The invention provides novel compounds of formula I, as well as salts and isomers thereof



wherein R¹ is a monoradical selected from the group consisting of optionally substituted C₁₋₆-alkyl, optionally substituted C₂₋₆-alkylidene, optionally substituted C₂₋₆-alkenyl, optionally substituted C₂₋₆-alkynyl, optionally substituted O-C₁₋₆-alkyl, optionally substituted O-C₂₋₆-alkenyl, optionally substituted O-C₂₋₆-alkynyl; optionally substituted S-C₁₋₆-alkyl, optionally substituted S-C₂₋₆-alkenyl, optionally substituted S-C₂₋₆-alkynyl;

m is 0, 1 or 2;

C₃-C₄ is CH₂-CH or CH=C or C₄ is CH and C₃ is absent;

R² and R³ are independently selected from the group consisting of hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted O-C₁₋₆ alkyl, halogen, hydroxy or selected such that R² and R³ together form a ring system;

each R⁴ and R⁵ is independently selected from the group consisting of hydrogen, halogen, hydroxy, optionally substituted C₁₋₆-alkyl, OC₁₋₆alkyl, aryl-C₁₋₆alkyl, and arylheteroalkyl;

L¹ and L² are biradicals independently selected from the group consisting of -C(R⁶)=C(R⁷), -C(R⁶)=N-, -N=C(R⁶)-, -S-, -NH- and -O-; wherein only one of L¹ and L² may be selected from the group consisting of -S-, -NH- and -O-;

Y is selected from the group consisting of O, S, and H₂;

X is a biradical selected from the group consisting of -C(R⁶)(R⁷)-C(R⁶)(R⁷)-, -C(R⁶)=C(R⁷)-, -O-C(R⁶)(R⁷)-, C(R⁶)(R⁷)-O-, -S-C(R⁶)(R⁷)-, -C(R⁶)(R⁷)-S-, -N(R^N)-C(R⁶)(R⁷)-, -C(R⁶)(R⁷)-N(R^N)-, -C(R⁶)(R⁷)-C(R⁶)(R⁷)-C(R⁶)(R⁷)-, -O-C(R⁶)(R⁷)-C(R⁶)(R⁷)-, -S-C(R⁶)(R⁷)-C(R⁶)(R⁷)-, N(R^N)-

$C(R^6)(R^7)-C(R^6)(R^7)-$, $-C(R^6)(R^7)-C(R^6)(R^7)-O$, $-C(R^6)(R^7)-C(R^6)(R^7)-S$, $-C(R^6)(R^7)-C(R^6)(R^7)-N(R^N)-$, $-C(R^6)(R^7)-C(R^6)=C(R^7)-$, and $-C(R^6)=C(R^7)-C(R^6)(R^7)$, wherein R^6 and R^7 are independently selected from the group consisting of hydrogen, halogen, hydroxy, nitro, cyano, $NR^N R^N$, $N(R^N)-C(O)N(R^N)$, optionally substituted C_{1-6} -alkyl, C_{2-6} -alkenyl, C_{2-6} -alkynyl, optionally substituted $O-C_{1-6}$ -alkyl, optionally substituted O -aryl, optionally substituted $O-C_{2-6}$ -alkenyl, optionally substituted $O-C_{2-6}$ -alkynyl

wherein R^N is selected from the group consisting of hydrogen, and optionally substituted C_{1-6} -alkyl.

[0063] The present investigators have found that the compounds of the invention have a high affinity and specificity for the M_1 muscarinic receptor. The compounds of the invention may be of use in an array of conditions associated with the modulation of the M_1 muscarinic receptor subtype.

[0064] Typically, the compounds of formula I are such that R^1 is selected from the group consisting of optionally substituted C_{1-6} -alkyl, optionally substituted C_{1-6} -alkylidene, optionally substituted C_{2-6} -alkenyl, optionally substituted C_{2-6} -alkynyl, optionally substituted $O-C_{1-6}$ -alkyl, and optionally substituted $O-C_{2-6}$ -alkenyl. R^1 can be selected from the group consisting of optionally substituted C_{1-6} -alkyl, optionally substituted C_{1-6} -alkylidene, optionally substituted C_{2-6} -alkenyl, optionally substituted $O-C_{1-6}$ -alkyl. R^1 can typically be selected from the group consisting of optionally substituted C_{1-6} -alkyl, optionally substituted C_{1-6} -alkylidene, and optionally substituted $O-C_{1-6}$ -alkyl. Most typically, R^1 is selected from the group consisting of optionally substituted C_4 -alkyl, optionally substituted C_5 -alkyl, optionally substituted C_4 -alkylidene, and optionally substituted $O-C_{1-6}$ -alkyl. In a preferred embodiment, R^1 may be unsubstituted C_4 -alkyl, unsubstituted C_5 -alkyl, or unsubstituted $O-C_3$ -alkyl, e.g. n-butyl, n-pentyl, or n-propyloxy.


[0065] In a particular embodiment of the invention, the compounds of formula I are such that R^1 is an optionally substituted C_{1-6} -alkyl, selected from the group consisting of unsubstituted C_{1-6} -alkyl, and C_{1-6} -alkoxyalkyl. The C_{1-6} -alkoxyalkyl may be C_{1-3} -alkoxy C_{1-3} alkyl. Typically, the C_{1-6} -alkoxyalkyl is selected from methoxypropyl, ethoxyethyl, propyloxymethyl, and methoxyethyl.

[0066] In one embodiment of the invention, the compounds of formula I are piperidines, bicyclic piperidines, 3-4-unsaturated piperidines or bicyclic 3-4-unsaturated piperidines. Within this embodiment, the C_3-C_4 bond may be a single bond to form either a piperidine ring or a bicyclic piperidine. Alternatively, piperidine may be 3-4 unsaturated. That is to say that C_3-C_4 may be a double bond ($C_3=C_4$) so as to form either a 3-4-unsaturated piperidine or bicyclic 3-4-unsaturated piperidine.


[0067] In another embodiment of the invention, m is 0 and C_3 is absent while C_4 is CH , so as to result in an azetidine ring. Bicyclic analogues of azetidine are also included.

[0068] In an alternative embodiment, m is 0 so as to result in a pyrrolidine ring or a 3-pyrroline, when C3-C4 is a single bond or a double bond, respectively. Bicyclic analogues of pyrrolidine ring or a 3-pyrroline are further included. In a further suitable embodiment, m is 2 so as to form a 7-membered ring. In a particular embodiment, m is 1.

[0069] In one embodiment, R² and R³ together form a bicyclic ring system such that




is selected from the group consisting of




wherein R⁸ is present 0, 1, or 2 times and is independently selected from the group consisting of optionally substituted C₁₋₆ alkyl, optionally substituted O-C₁₋₆ alkyl, halogen, hydroxy.

[0070] Within such an embodiment, R² and R³ may preferably be selected such that R² and R³ together form a ring system such that



is selected from the group comprising




[0071] In a more preferred embodiment, the substituents R² and R³ are selected so that the bicyclic ring is 3-substituted 8-azabicyclo[3.2.1]octane.

[0072] However, in a particular embodiment, R² and R³ are independently selected from the group consisting of hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted O-C₁₋₆ alkyl, halogen and hydroxy.


[0073] Thus, in a combination of embodiments of compounds of formula I, C₃-C₄ is a single bond, R² and R³ are independently selected from the group consisting of hydrogen,

optionally substituted C_{1-6} alkyl, optionally substituted $O-C_{1-6}$ alkyl, halogen and hydroxy, and m is 1. Suitably, R^2 and R^3 are hydrogen.

[0074] In a further combination, m can be 0, C_3 can be absent, and C_4 can be CH such that




is




[0075] In a further combination of embodiments, C_3-C_4 and m are so as to form a piperidine ring, for example, wherein R^2 and R^3 are hydrogen. In additional embodiments, C_3-C_4 and m are so as to form a piperidine ring, R^2 and R^3 are hydrogen, and R^1 an unsubstituted C_4 -alkyl, an unsubstituted C_5 -alkyl, or an $O-C_3$ -alkyl, such as butyl, pentyl, or propyloxy.

[0076] Thus, in one embodiment



is a 4-butyl piperidine.


[0077] In another embodiment



is 4-butyl piperidine.

[0078] In one embodiment of the invention, C_3-C_4 and m are such as to form an azetidine ring,


[0079] R^2 and R^3 are hydrogen, and R^1 is selected from unsubstituted C_4 -alkyl, unsubstituted C_5 -alkyl, and $O-C_3$ -alkyl. Thus, in one embodiment



is a 4-butylazetidine.

[0080] In one aspect of the invention a 3-carbon tether is linking the two nitrogen atoms of the two ring systems of the compounds of formula I. The present investigators have found that this optionally substituted propylene spacer unit provides for compounds with highly efficacious binding capacity to the cholinergic receptors. More specifically, the compounds of the invention show agonistic properties at cholinergic receptors, especially muscarinic receptors.

[0081] In one embodiment, the tether



is unsubstituted, meaning that all of R^4 and R^5 are hydrogen.

[0082] In another embodiment one of the substituents R^4 is selected from the group consisting of C_{1-6} -alkyl, $\text{O}-\text{C}_{1-6}$ -alkyl, and halogen, while the other two of the substituents R^4 are hydrogen.

[0083] In a combination of embodiments one of the substituents R^4 is selected from the group consisting of C_{1-6} -alkyl, $\text{O}-\text{C}_{1-6}$ -alkyl, and halogen, while the other two of the substituents R^4 are hydrogen, and all of R^5 are hydrogen.

[0084] In a preferred embodiment one of the substituents R^4 is selected from the group consisting of methyl, methoxy, ethyl, and fluoro while the remaining R^4 and R^5 are all hydrogen.

[0085] Typically, when one of the substituents R^4 is C_{1-6} -alkyl, $\text{O}-\text{C}_{1-6}$ -alkyl, or halogen, the tether is a 2-substituted-1,3-propylene group.

[0086] In a further suitable embodiment, the tether is a 2,2-disubstituted-1,3-propylene group, in which one of R^4 and one of R^5 are typically C_{1-6} -alkyl or fluoro.

[0087] Certain embodiments of the invention, wherein the propylene tether carries one or more substituents possess a stereogenic atom in the propylene tether. As set forth in the Examples, such chiral compounds may be preferred either in racemic or enantiomerically enriched form. Pure enantiomers and racemates are both included in the invention.

[0088] X may be a 1-, 2-, or 3-atom linear unit such that, together with the atoms in the ring comprising X, a 5-, 6- or 7-membered ring is formed. As stated, X, within the ring, is a biradical selected from the group consisting of $-\text{C}(\text{R}^6)(\text{R}^7)-\text{C}(\text{R}^6)(\text{R}^7)-$, $-\text{C}(\text{R}^6)=\text{C}(\text{R}^7)-$, $-\text{O}-\text{C}(\text{R}^6)(\text{R}^7)-$, $\text{C}(\text{R}^6)(\text{R}^7)-\text{O}-$, $-\text{S}-\text{C}(\text{R}^6)(\text{R}^7)-$, $-\text{C}(\text{R}^6)(\text{R}^7)-\text{S}-$, $-\text{N}(\text{R}^N)-\text{C}(\text{R}^6)(\text{R}^7)-$, $-\text{C}(\text{R}^6)(\text{R}^7)-\text{N}(\text{R}^N)-$, $-\text{C}(\text{R}^6)(\text{R}^7)-\text{C}(\text{R}^6)(\text{R}^7)-\text{C}(\text{R}^6)(\text{R}^7)-$, $-\text{O}-\text{C}(\text{R}^6)(\text{R}^7)-\text{C}(\text{R}^6)(\text{R}^7)-$, $-\text{S}-\text{C}(\text{R}^6)(\text{R}^7)-\text{C}(\text{R}^6)(\text{R}^7)-$, $-\text{N}(\text{R}^N)-\text{C}(\text{R}^6)(\text{R}^7)-\text{C}(\text{R}^6)(\text{R}^7)-$, $-\text{C}(\text{R}^6)(\text{R}^8)-\text{C}(\text{R}^6)(\text{R}^7)-\text{O}-$, $-\text{C}(\text{R}^6)(\text{R}^7)-\text{C}(\text{R}^6)(\text{R}^7)-\text{S}-$, $-\text{C}(\text{R}^6)(\text{R}^7)-\text{C}(\text{R}^6)(\text{R}^7)-\text{N}(\text{R}^N)-$, $-\text{C}(\text{R}^6)(\text{R}^7)-\text{CH}=\text{CH}-$ and $-\text{CH}=\text{CH}-\text{C}(\text{R}^6)(\text{R}^7)-$.

[0089] In a preferred embodiment X is selected from the group consisting of $-\text{C}(\text{R}^6)(\text{R}^7)-\text{C}(\text{R}^6)(\text{R}^7)-$, $-\text{C}(\text{R}^6)=\text{C}(\text{R}^7)-$, $-\text{O}-\text{C}(\text{R}^6)(\text{R}^7)-$, $\text{C}(\text{R}^6)(\text{R}^8)-\text{O}-$, $-\text{S}-\text{C}(\text{R}^6)(\text{R}^7)-$, $-\text{C}(\text{R}^6)(\text{R}^7)-\text{S}-$, $-\text{N}(\text{R}^N)-\text{C}(\text{R}^6)(\text{R}^7)-$, $-\text{C}(\text{R}^6)(\text{R}^7)-\text{N}(\text{R}^N)-$.

[0090] In a more preferred embodiment X is selected from the group consisting of -C(R⁶)(R⁷)-C(R⁶)(R⁷)-, -O-C(R⁶)(R⁷)-, C(R⁶)(R⁸)-O-, and -C(R⁶)=C(R⁷)-.

[0091] R⁶ and R⁷ are optional substituents of the ring system. An array of substituents is anticipated by the present investigators and are known to the person skilled in the art. The substituents R⁶ and R⁷ may independently be selected from the group consisting of hydrogen, halogen, hydroxy, nitro, cyano, NR^NR^N, N(R^N)-C(O) N(R^N), optionally substituted C₁₋₆-alkyl, C₂₋₆-alkenyl, C₂₋₆-alkynyl, optionally substituted O-C₁₋₆-alkyl, optionally substituted O-aryl, optionally substituted O-C₂₋₆-alkenyl, optionally substituted O-C₂₋₆-alkynyl.

[0092] Suitably, when the substituents R⁶ and R⁷ occur within the definition of X, they are typically selected from hydrogen, halogen, hydroxy and C₁₋₆-alkyl. More typically, R⁶ and R⁷, when constituting part of the definition of X, are both hydrogen.

[0093] In one embodiment, Y is selected from the group consisting of O, S and H₂.

[0094] In a preferred embodiment, Y is O.

[0095] As stated, L¹ and L² are biradicals independently selected from the group consisting of -C(R⁷)=C(R⁸), -C(R⁷)=N-, -N=C(R⁷)-, -S-, -NH- and -O-; wherein only one of L¹ and L² may be selected from the group consisting of -S- and -O-. Typically, L¹ and L² are such that



is an aromatic or heteroaromatic ring. In one embodiment, L¹ and L² are independently selected from the group consisting of -C(R⁶)=C(R⁷)-, -C(R⁶)=N-, -N=C(R⁷)-, and -S-; wherein only one of L¹ and L² is -S-. In another embodiment, at least one of L¹ and L² is C(R⁶)=C(R⁷). In yet another embodiment, L¹ and L² are so as to form a 6-membered ring. In still another embodiment, both of L¹ and L² are -C(R⁶)=C(R⁷)-.

[0096] Suitably, when the substituents R⁶ and R⁷ occur within the definition of




they are typically selected from hydrogen, halogen, hydroxy, C₁₋₆-alkyl and O-C₁₋₆-alkyl.

[0097] Preferably, when the substituents R⁶ and R⁷ occur within the definition of



they are selected from hydrogen, fluoro, chloro, methyl, and methoxy.

[0098] Thus, in a combination of embodiments, the compounds of the invention are of formula Ia



Ia

wherein R^1 is selected from the group consisting of optionally substituted C_{1-6} -alkyl, optionally substituted C_{1-6} -alkylidene, optionally substituted C_{2-6} -alkenyl, optionally substituted C_{2-6} -alkynyl, optionally substituted O - C_{1-6} -alkyl, optionally substituted O - C_{2-6} -alkenyl; and R^2 , R^3 , R^4 , X , Y , R^6 , and R^7 are as defined *supra*.

[0099] In another combination of embodiments, the compounds of the invention are of formula Ia, wherein X is selected from the group consisting of $-C(R^6)(R^7)-C(R^6)(R^7)-$, $-C(R^6)=C(R^7)-$, $-O-C(R^6)(R^7)-$, $C(R^6)(R^8)-O-$, $-S-C(R^6)(R^7)-$, $-C(R^6)(R^7)-S-$, $-N(R^N)-C(R^6)(R^7)-$, $-C(R^6)(R^7)-N(R^N)-$,

wherein R^6 and R^7 are suitably hydrogen.

[0100] In a further combination of embodiments, the compounds of the invention are of formula Ia, wherein Y is O .

[0101] In yet another combination of embodiments, the compounds of the invention are of formula Ia, wherein R^4 is selected from hydrogen, C_{1-6} -alkyl, O - C_{1-6} -alkyl, and halogen.

[0102] In a further combination of embodiments, the compounds of the invention are of formula Ia, wherein R^6 and R^7 are selected from hydrogen, halogen, hydroxy, C_{1-6} -alkyl and O - C_{1-6} -alkyl.

[0103] In another combination of embodiments, the compounds of the invention are of formula Ia, wherein the optionally substituted C_{1-6} -alkyl is selected from the list comprising unsubstituted C_{1-6} -alkyl, and C_{1-6} -alkoxyalkyl, and wherein Y is selected from the group consisting of O and H_2 , and wherein X is selected from the group consisting of $-C(R^6)(R^7)-C(R^6)(R^7)-$, $-C(R^6)=C(R^7)-$, $-O-C(R^6)(R^7)-$, $-C(R^6)(R^7)-O-$, $-S-C(R^6)(R^7)-$, $-C(R^6)(R^7)-S-$, and wherein L^1 and L^2 are independently selected from the group consisting of $-C(R^6)=C(R^7)-$, $-C(R^6)=N-$, and $-N=C(R^7)-$, and wherein R^4 selected from the group consisting of hydrogen, halogen, hydroxy, optionally substituted C_{1-6} -alkyl, and optionally substituted O - C_{1-6} alkyl.

[0104] In a further combination of embodiments, the compounds of the invention are optionally substituted 1-[3-(4-alkylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolines, optionally substituted 1-[3-(4-alkylpiperidin-1-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-ones, optionally substituted 1-[3-(4-alkylpiperidin-1-yl)propyl]-1*H*-quinolin-2-ones, optionally substituted 4-[3-(4-alkylpiperidin-1-yl)propyl]-4*H*-benzo[1,4]oxazin-3-ones, optionally substituted 4-[3-(4-alkylpiperidin-1-yl)propyl]-4*H*-benzo[1,4]thiazin-3-ones; optionally substituted 1-[3-(3-alkyl-8-

azabicyclo[3.2.1]oct-8-yl)propyl]-1,2,3,4-tetrahydroquinolines; optionally substituted 1-[3-(3-alkyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-ones, optionally substituted 1-[3-(3-alkyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-1*H*-quinolin-2-ones, optionally substituted 4-[3-(3-alkyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-4*H*-benzo[1,4]oxazin-3-ones; optionally substituted 4-[3-(3-alkyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-4*H*-benzo[1,4]thiazin-3-ones; optionally substituted 1-[3-(3-alkylazetidin-1-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-ones, optionally substituted 1-[3-(3-alkylazetidin-1-yl)propyl]-1*H*-quinolin-2-ones, optionally substituted 1-[3-(3-alkylazetidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolines; optionally substituted 4-[3-(3-alkylazetidin-1-yl)propyl]-4*H*-benzo[1,4]oxazin-3-ones; optionally substituted 4-[3-(3-alkylazetidin-1-yl)propyl]-4*H*-benzo[1,4]thiazin-3-ones.

[0105] Suitable embodiments of the compounds of the invention may be selected from the group consisting of 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-1,2,3,4-tetrahydro-quinoline; 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-2-methyl-1,2,3,4-tetrahydro-quinoline; 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-6-methyl-1,2,3,4-tetrahydro-quinoline; 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-8-methyl-1,2,3,4-tetrahydro-quinoline; 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-7-fluoro-2-methyl-1,2,3,4-tetrahydro-quinoline; 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-7-trifluoromethyl-1,2,3,4-tetrahydro-quinoline; 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-6-methoxy-3,4-dihydro-1*H*-quinolin-2-one; 4-[3-(4-Butyl-piperidin-1-yl)-propyl]-4*H*-benzo[1,4]thiazin-3-one; 4-[3-(4-Butyl-piperidin-1-yl)-propyl]-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butyl-piperidin-1-yl)-propyl]-6-methyl-4*H*-benzo[1,4]oxazin-3-one; 6-Acetyl-4-[3-(4-butyl-piperidin-1-yl)-propyl]-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butyl-piperidin-1-yl)-propyl]-6-methyl-3,4-dihydro-2*H*-benzo[1,4]oxazine; and 4-[3-(4-Butyl-piperidin-1-yl)-propyl]-6-ethyl-3,4-dihydro-2*H*-benzo[1,4]oxazine; (R)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-4*H*-benzo[1,4]thiazin-3-one; (R)-4-[2-Methyl-3-(4-propoxypiperidin-1-yl)propyl]-4*H*-benzo[1,4]thiazin-3-one; (R)-4-[3-(4-Butylidene-piperidin-1-yl)-2-methyl-propyl]-4*H*-benzo[1,4]thiazin-3-one; (R)-4-[3-(3-Butyl-8-aza-bicyclo[3.2.1]oct-8-yl)-2-methyl-propyl]-4*H*-benzo[1,4]thiazin-3-one; (R)-4-[2-Methyl-3-(3-pentyl-8-aza-bicyclo[3.2.1]oct-8-yl)propyl]-4*H*-benzo[1,4]thiazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-6,8-dichloro-7-methyl-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butyl-piperidin-1-yl)propyl]-6,8-dimethyl-4*H*-benzo[1,4]oxazin-3-one (81MF2237F); 6-*tert*-Butyl-4-[3-(4-butyl-piperidin-1-yl)propyl]-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-5-methyl-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-7-methyl-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-6-chloro-7-nitro-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-7-chloro-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-6-fluoro-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-7,8-difluoro-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-4*H*-pyrido[4,3-*b*][1,4]thiazin-3-one; 4-[3-(4-Propoxypiperidin-1-

yl)propyl]-4*H*-benzo[1,4]thiazin-3-one; 4-[3-(4-Propoxypiperidin-1-yl)propyl]-4*H*-
 benzo[1,4]oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-7-fluoro-4*H*-benzo[1,4]oxazin-3-one;
 4-[3-(4-Butylidenepiperidin-1-yl)propyl]-4*H*-benzo[1,4]thiazin-3-one; 4-[3-(4-Butylidenepiperidin-
 1-yl)propyl]-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(3-Butylidene-8-aza-bicyclo[3.2.1]oct-8-yl)-propyl]-
 4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-6-methoxy-4*H*-benzo[1,4]oxazin-
 3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-6,8-dichloro-7-ethyl-4*H*-benzo[1,4]oxazin-3-one; 4-[3-
 (4-Butylpiperidin-1-yl)propyl]-8-fluoro-4*H*-benzo[1,4]oxazin-3-one; 6-Bromo-4-[3-(4-
 butylpiperidin-1-yl)propyl]-8-fluoro-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butylpiperidin-1-
 yl)propyl]-8-isopropyl-4*H*-benzo[1,4]oxazin-3-one; (*R,S*)-4-[3-(4-Butylpiperidin-1-yl)-2-hydroxy-
 propyl]-6-methyl-4*H*-benzo[1,4]oxazin-3-one; (*R,S*)-4-[3-(4-Butylpiperidin-1-yl)-2-
 hydroxypropyl]-4*H*-benzo[1,4]oxazin-3-one; (-)-4-[3-(4-Butylpiperidin-1-yl)-2-hydroxypropyl]-4*H*-
 benzo[1,4]oxazin-3-one; (*R,S*)-4-[3-(4-Butylpiperidin)-2-methoxypropyl]-4*H*-benzo[1,4]oxazin-3-
 one; (*R,S*)-4-[2-Hydroxy-3-(3-pentylbicyclo[3.2.1]oct-8-yl)-propyl]-4*H*-benzo[1,4]oxazin-3-one; 4-
 [2-(4-Butylpiperidin-1-ylmethyl)allyl]-4*H*-benzo[1,4]oxazin-3-one; (*R,S*)-4-[3-(4-Butylpiperidin-1-
 yl)-2-fluoropropyl]-4*H*-benzo[1,4]oxazin-3-one; (*S*)-4-[3-(4-Butyl-piperidin-1-yl)-2-methyl-
 propyl]-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-4*H*-
 benzo[1,4]oxazin-3-one; (*R*)-4-[2-Methyl-3-(4-propoxypiperidin-1-yl)-propyl]-4*H*-
 benzo[1,4]oxazin-3-one; (*R*)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-4*H*-
 benzo[1,4]oxazin-3-one; (*R*)-4-[3-(3-Butyl-8-aza-bicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4*H*-
 benzo[1,4]oxazin-3-one; (*R*)-4-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-4*H*-
 benzo[1,4]oxazin-3-one; (*R*)-6-Fluoro-4-[2-methyl-3-(4-propoxy-piperidin-1-yl)-propyl]-4*H*-
 benzo[1,4]oxazin-3-one; (*R*)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methyl-propyl]-6-fluoro-4*H*-
 benzo[1,4]oxazin-3-one; (*R*)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6-fluoro-4*H*-
 benzo[1,4]oxazin-3-one; (*R*)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-fluoro-
 4*H*-benzo[1,4]oxazin-3-one; (*R*)-6-Fluoro-4-[2-methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)-
 propyl]-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(4-Butylpiperidin-1-yl)2-methylpropyl]-7-Fluoro-4*H*-
 benzo[1,4]oxazin-3-one; (*R*)-7-Fluoro-4-[2-methyl-3-(4-propoxypiperidin-1-yl)propyl]-4*H*-
 benzo[1,4]oxazin-3-one; (*R*)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-7-fluoro-4*H*-
 benzo[1,4]oxazin-3-one; (*R*)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-7-fluoro-
 4*H*-benzo[1,4]oxazin-3-one; (*R*)-7-Fluoro-4-[2-methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)-
 propyl]-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(4-Butylpiperidin-1-yl)-2-methyl-propyl]-6-methoxy-
 4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-6-methoxy-4*H*-
 benzo[1,4]oxazin-3-one; (*R*)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-
 methoxy-4*H*-benzo[1,4]oxazin-3-one; (*R*)-6-Methoxy-4-[2-methyl-3-(3-pentyl-8-aza-
 bicyclo[3.2.1]oct-8-yl)propyl]-4*H*-benzo[1,4]oxazin-3-one; (*R*)-6-Methoxy-4-[2-methyl-3-(4-
 propoxypiperidin-1-yl)propyl]-4*H*-benzo[1,4]oxazin-3-one; (*R*)-6-Methyl-4-[2-methyl-3-(4-

propoxypiperidin-1-yl)-propyl]-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-6-methyl-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6-methyl-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-methyl-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(3-Pentyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-methyl-4*H*-benzo[1,4]oxazin-3-one; 1-[3-(4-Propoxypiperidin-1-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-6-fluoro-3,4-dihydro-1*H*-quinolin-2-one; 6-Fluoro-1-[3-(4-propoxypiperidin-1-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-one; (*R,S*)-1-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6-fluoro-3,4-dihydro-1*H*-quinolin-2-one; (*R,S*)-6-Fluoro-1-[3-(4-propoxypiperidin-1-yl)-2-methylpropyl]-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-6-chloro-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-6-methyl-3,4-dihydro-1*H*-quinolin-2-one; 6-Methyl-1-[3-(4-propoxypiperidin-1-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-7-fluoro-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-5-methyl-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-7-methyl-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-7-fluoro-6-methyl-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-6,7-difluoro-3,4-dihydro-1*H*-quinolin-2-one; 6,7-Difluoro-1-[3-(4-propoxypiperidin-1-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-one; (*R,S*)-1-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6,7-difluoro-3,4-dihydro-1*H*-quinolin-2-one; (*R,S*)-6,7-Difluoro-1-[3-(4-propoxypiperidin-1-yl)-2-methylpropyl]-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-6-fluoro-7-methyl-3,4-dihydro-1*H*-quinolin-2-one; 6-Fluoro-7-methyl-1-[3-(4-propoxypiperidin-1-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-one; (*R,S*)-1-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6-fluoro-7-methyl-3,4-dihydro-1*H*-quinolin-2-one; (*R,S*)-6-Fluoro-7-methyl-1-[2-methyl-3-(4-propoxypiperidin-1-yl)-propyl]-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-6-fluoro-5-methyl-3,4-dihydro-1*H*-quinolin-2-one; 6-Fluoro-5-methyl-1-[3-(4-propoxypiperidin-1-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-one; (*R*)-1-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-3,4-dihydro-1*H*-quinolin-2-one; (*R*)-1-[2-Methyl-3-(4-propoxypiperidin-1-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-one; (*R*)-1-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-3,4-dihydro-1*H*-quinolin-2-one; (*R*)-1-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-3,4-dihydro-1*H*-quinolin-2-one; (*R*)-1-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-1*H*-quinolin-2-one; 1-[3-(4-Propoxypiperidin-1-yl)propyl]-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-6-fluoro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-6-methyl-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-7-fluoro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-6-methoxy-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-6-chloro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-5-methyl-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-7-methyl-1*H*-quinolin-2-one; (*R*)-1-[3-(4-Butylpiperidin-1-yl)-2-

methylpropyl]-1*H*-quinolin-2-one; (R)-1-[2-Methyl-3-(4-propoxypiperidin-1-yl)-propyl]-1*H*-quinolin-2-one; 1-[3-(4-Allyloxypiperidin-1-yl)propyl]-1*H*-quinolin-2-one; (R,S)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6-methyl-4*H*-benzo[1.4]oxazin-3-one; (R,S)-4-[2-Methyl-3-(4-propoxypiperidin-1-yl)propyl]-6-methyl-4*H*-benzo[1.4]oxazin-3-one; (R,S)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-6-methyl-4*H*-benzo[1.4]oxazin-3-one; (R,S)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-methyl-4*H*-benzo[1.4]oxazin-3-one; (R,S)-4-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-6-methyl-4*H*-benzo[1.4]oxazin-3-one; (R,S)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6-fluoro-4*H*-benzo[1.4]oxazin-3-one; (R,S)-6-Fluoro-4-[2-methyl-3-(4-propoxypiperidin-1-yl)propyl]-4*H*-benzo[1.4]oxazin-3-one; (R,S)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-6-fluoro-4*H*-benzo[1.4]oxazin-3-one; (R,S)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-fluoro-4*H*-benzo[1.4]oxazin-3-one; (R,S)-6-Fluoro-4-[2-methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-4*H*-benzo[1.4]oxazin-3-one; (R,S)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-7-fluoro-4*H*-benzo[1.4]oxazin-3-one; (R,S)-7-Fluoro-4-[2-methyl-3-(4-propoxypiperidin-1-yl)propyl]-4*H*-benzo[1.4]oxazin-3-one; (R,S)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-7-fluoro-4*H*-benzo[1.4]oxazin-3-one; (R,S)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-7-fluoro-4*H*-benzo[1.4]oxazin-3-one; (R,S)-7-Fluoro-4-[2-methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-4*H*-benzo[1.4]oxazin-3-one; (R,S)-3-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-3*H*-benzothiazol-2-one; (R,S)-4-[2-Methyl-3-(4-propoxypiperidin-1-yl)propyl]-3*H*-benzothiazol-2-one; (R,S)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-3*H*-benzothiazol-2-one; (R,S)-3-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-3*H*-benzothiazol-2-one; (R,S)-3-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-3*H*-benzothiazol-2-one; (R,S)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-4*H*-benzo[1.4]oxazin-3-one; (R,S)-4-[2-Methyl-3-(4-propoxypiperidin-1-yl)propyl]-4*H*-benzo[1.4]oxazin-3-one; (R,S)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-4*H*-benzo[1.4]oxazin-3-one; (R,S)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4*H*-benzo[1.4]oxazin-3-one; (R,S)-4-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-4*H*-benzo[1.4]oxazin-3-one; (R,S)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-4*H*-benzo[1.4]thiazin-3-one; (R,S)-1-[2-Methyl-3-(4-propoxypiperidin-1-yl)propyl]-4*H*-benzo[1.4]thiazin-3-one; (R,S)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-4*H*-benzo[1.4]thiazin-3-one; (R,S)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4*H*-benzo[1.4]thiazin-3-one; (R,S)-4-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-4*H*-benzo[1.4]thiazin-3-one; (R,S)-1-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-3,4-dihydro-1*H*-quinolin-2-one; (R,S)-1-[2-Methyl-3-(4-propoxypiperidin-1-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-one; (R,S)-1-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-3,4-dihydro-1*H*-quinolin-2-one; (R,S)-1-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-3,4-dihydro-1*H*-quinolin-2-one; (R,S)-1-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-one; (R,S)-4-[3-(4-Butylpiperidin-1-

yl)-2-methylpropyl]-6-methoxy-4*H*-benzo[1,4]oxazin-3-one; (R,S)-4-[2-Methyl-3-(4-propoxypiperidin-1-yl)-6-methoxy]-4*H*-benzo[1,4]oxazin-3-one; (R,S)-4-[3-(4-Butyridenepiperidin-1-yl)-2-methylpropyl]-6-methoxy-4*H*-benzo[1,4]oxazin-3-one; (R,S)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-methoxy-4*H*-benzo[1,4]oxazin-3-one; (R,S)-1-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-6-methoxy-4*H*-benzo[1,4]oxazin-3-one; (R,S)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6,7-difluoro-4*H*-benzo[1,4]oxazin-3-one; (R,S)-6,7-Difluoro-4-[2-methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-4*H*-benzo[1,4]oxazin-3-one; (R,S)-4-[3-(3-Butoxy-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-fluoro-4*H*-benzo[1,4]oxazin-3-one; (R,S)-6-Fluoro-4-{3-[3-(2-methoxyethyl)-8-azabicyclo[3.2.1]oct-8-yl]-2-methylpropyl}-4*H*-benzo[1,4]oxazin-3-one; (R,S)-4-[3-(3-Butylazetidin-1-yl)-2-methylpropyl]-6-fluoro-4*H*-benzo[1,4]oxazin-3-one; (R,S)-6-Fluoro-4-[2-methyl-3-(3-propoxyazetidin-1-yl)propyl]-4*H*-benzo[1,4]oxazin-3-one; (R,S)-4-[3-(3-Butylazetidin-1-yl)-2-methoxypropyl]-6-fluoro-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butyl-3-fluoropiperidin-1-yl)-2-methylpropyl]-6-fluoro-4*H*-benzo[1,4]oxazin-3-one.

[0106] The compounds of the invention have the ability to increase cholinergic receptor activity or activate cholinergic receptors. Cholinergic receptor activity includes signaling activity or any other activity that is directly or indirectly related to cholinergic signalling or activation. The cholinergic receptors include muscarinic receptors, especially the m1 or m4 subtype of muscarinic receptors. The muscarinic receptor can be, for example, in the central nervous system, peripheral nervous system, gastrointestinal system, heart, endocrine glands, or lungs. The muscarinic receptor can be a wild-type, truncated, mutated, or modified cholinergic receptor.

[0107] Kits comprising the compounds of the present invention, and instructions for practicing a method of the invention, for example, increasing cholinergic receptor activity or activating cholinergic receptors, are also provided.

[0108] The system containing the cholinergic receptor may, for example, be a subject such as a mammal, non-human primate or a human. The system may also be an in vivo or in vitro experimental model, such as a cell culture model system that expresses a cholinergic receptor, a cell-free extract thereof that contains a cholinergic receptor, or a purified receptor. Non-limiting examples of such systems are tissue culture cells expressing the receptor, or extracts or lysates thereof.

[0109] Cells that may be used in a method of the invention include any cell capable of mediating signal transduction via cholinergic receptors, such as the m1 muscarinic receptor, either via endogenous expression of receptor (certain types of neuronal cells lines, for example, natively express the m1 receptor), or such as following introduction of an exogenous gene into the cell, for example, by transfection of cells with plasmids containing the receptor gene. Such cells are

typically mammalian cells (or other eukaryotic cells, such as insect cells or *Xenopus* oocytes), because cells of lower life forms generally lack the appropriate signal transduction pathways for the present purpose. Specific non-limiting examples of suitable cells include: the mouse fibroblast cell line NIH 3T3 (ATCC CRL 1658), which responds to transfected m1 receptors by increased growth; RAT 1 cells (Pace *et al.*, *Proc. Natl. Acad. Sci. USA* 88:7031-35 (1991)); and pituitary cells (Vallar *et al.*, *Nature* 330:556-58 (1987)). Other useful mammalian cells include but are not limited to HEK 293 cells, CHO cells and COS cells.

[0110] The compounds of the present invention also have the ability to reduce intraocular pressure and therefore can be used in the treatment of such diseases associated with intraocular pressure, e.g., glaucoma. Glaucoma is a disease in which an abnormality is observed in the circulation-control mechanism of the aqueous humor filling up the anterior chamber, *i.e.*, the space formed between the cornea and the lens. This leads to an increase in the volume of the aqueous humor and an increase in intraocular pressure, consequently leading to visual field defects and even to loss of eyesight due to the compulsion and contraction of the papillae of the optic nerve.

[0111] Accordingly, the invention also provides methods of treating a disease in a mammal, such as a human, wherein modulation of the activity of a cholinergic receptor is associated with a physiologically beneficial response in said disease of said mammal. In one embodiment, a method includes administering an effective amount of a compound of formula I, as defined supra, to achieve a physiologically beneficial response. Typically, the cholinergic receptor is a muscarinic receptor, more typically the cholinergic receptor is a muscarinic M₁-receptor subtype. Alternatively, the cholinergic receptor is the muscarinic M₄-receptor subtype.

[0112] The invention further provides methods of treating or preventing or alleviating the symptoms associated with a disorder in a mammal, such as a human. In one embodiment, a method includes the administration of an effective amount of the compound of formula I, said disorder associated with a muscarinic receptor, such as the M₁ muscarinic receptor subtype, to treat or prevent or alleviate one or more symptoms associated with the disorder.

[0113] The physiologically beneficial response is typically associated with the selective modulation of the muscarinic M₁-receptor subtype in relation to the muscarinic M₂- or M₃-receptor subtypes. In one embodiment, the compound in the method of the invention is a muscarinic agonist.

[0114] The disease or disorder treated by the compounds of the invention is typically a mental disorder and the physiologically beneficial response is due to modulation in terms of M₁ agonism; M₁ and M₄ agonism; both M₁ agonism and D₂ antagonism; or M₁ and M₄ agonism and D₂ antagonism.

[0115] A further and related aspect of the invention relates to methods of increasing an activity of a cholinergic receptor. In one embodiment, a method includes contacting the cholinergic receptor or a system containing the cholinergic receptor with an effective amount of at least one compound as defined supra to increase an activity of a cholinergic receptor.

[0116] As can be ascertained from the above discussion, the compounds of the invention are intended, at least in part, for use as pharmaceutical medicaments. Thus, the invention provides compositions comprising i) one or more compounds of formula I, as defined supra; and ii) at least one pharmaceutically acceptable excipient or carrier. As the invention relates to the use of a compound of formula I, as defined supra, the invention also provides a compound of formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, or a pharmaceutical composition comprising either entity, for the preparation of a medicament for the treatment of diseases or disorders associated with a cholinergic receptor or ligand thereof.

[0117] The invention thus relates, in part, to a method of treating or preventing or alleviating one or more symptoms associated with a disorder in a mammal, such as a human. In one embodiment, a method includes the administration of an effective amount of the compound of formula I, said disorder associated with a muscarinic receptor, such as the M₁ muscarinic receptor subtype, to prevent or alleviate one or more symptoms. Disorders include those selected from the group consisting of cognitive impairment, forgetfulness, confusion, memory loss, attentional deficits, deficits in visual perception, depression, pain, sleep disorders, psychosis, and increased intraocular pressure. Disorders also include those selected from the group consisting of neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, schizophrenia, Huntington's chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Downs Syndrome, Pick disease, dementia, clinical depression, age-related cognitive decline, attention-deficit disorder, sudden infant death syndrome, and glaucoma. Consequently, the invention further relates to a use of a compound of formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, or a pharmaceutical composition comprising either entity, for the preparation of a medicament for the treatment of diseases or disorders including those selected from the group consisting of Alzheimer's disease, Parkinson's disease, schizophrenia, Huntington's chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Down Syndrome, Pick disease, dementia, clinical depression, age-related cognitive decline, cognitive impairment, forgetfulness, confusion, memory loss, attentional deficits, deficits in visual perception, depression, pain, sleep disorders, psychosis, sudden infant death syndrome, increased intraocular pressure and glaucoma.

[0118] Compounds according to the invention may be used alone at appropriate dosages defined by routine testing in order to obtain optimal pharmacological effect on a muscarinic receptor, in particular the muscarinic M₁ or M₄ receptor subtype, while minimizing any potential toxic or otherwise unwanted effects. In addition, co-administration or sequential

administration of other agents that improve the effect of the compound may, in some cases, be desirable.

[0119] The pharmacological properties and selectivity of the compounds of the invention for specific muscarinic receptor subtypes may be demonstrated by a number of different assay methods using, for example, recombinant receptor subtypes, the human receptors as available, *e.g.*, conventional second messenger or binding assays. A particularly convenient functional assay system is the receptor selection and amplification assay (R-SAT assay) in U.S. Patent No. 5,707,798, which describes a method of screening for bioactive compounds by utilizing the ability of cells transfected with receptor DNA, *e.g.*, coding for the different muscarinic subtypes, to amplify in the presence of a ligand of the receptor. Cell amplification is detected as increased levels of a marker also expressed by the cells.

[0120] The invention is disclosed in further detail in the following examples.

EXAMPLES

Example 1

Synthetic Chemistry

General analytical LC-MS procedures

Procedure 1:

[0121] Spectra were obtained using a HP1100 LC/MSD-instrument. A set-up with a binary pump, auto sampler, column oven, diode array detector, and electro spray ionisation interface was used. A reversed phase column (C18 Luna 3 μ , 75 x 4.6 mm ID) with a guard column cartridge system was used. The mobile phase was MeCN/8 mM aqueous ammonium acetate. A 15-minute gradient program was used, starting at 70% MeCN over 12 minutes to 95% MeCN, over 1 minute to 70% MeCN, hold for 2 minutes. The flow rate was 0.6 ml/min.

Procedure 2:

[0122] Spectra were obtained using a Waters LC/ZMD-instrument. A set-up with a 600 gradient pump, 2700 sample manager, 996 diode array detector, and electro spray ionisation interface was used. A reversed phase column (C18 X-Terra 5 μ , 50 x 4.6 mm ID) with a guard column cartridge system was used. The mobile phase was MeCN/10 mM aqueous ammonium acetate. A 14-minute gradient program was used; starting at 30% MeCN, over 10 minutes to 95% MeCN, hold for 2 minutes, over 0.5 minutes to 30% MeCN, hold for 4.5 minutes. The flow rate was 1 ml/min.

General preparative LC-MS procedures

Procedure 1:

[0123] Preparative purification was performed on a Waters auto purification system (600 pumps, 2700 sample manager, 996 PDA detector, ZMD mass spectrometer).

[0124] The columns used were YMC C18 F'sphere ODS H80. Buffer A was 0.15% TFA in water, buffer B was 0.15% TFA in MeCN/water 95/5. The columns were operated at 17 ml/min. Following an initial hold of 2.5 min at 30% buffer B, compounds were separated using a gradient of 30-100% buffer B in 8.5 min. A dual column set-up with two pumps was used to equilibrate one column, while running on the other.

Procedure 2:

[0125] Preparative purification was performed on Waters Delta 4000 preparative system, Water 2487 dual absorbance detector, and Waters Fraction collector II. The column used was a Luna 15 μ m C18, 250x21.2 mm. The following mobile phases were used: H₂O/MeCN ammonium acetate buffer (25 nM) or H₂O/MeCN TFA buffer (25 nM).

[0126] Heating with microwave irradiation was performed with a Smith Creator single-mode cavity (Personal Chemistry AB, Uppsala, Sweden) producing continuous irradiation at 2.45 GHz. The microwave-assisted reactions were performed in capped Smith process vials with a magnetic stirring bar. To secure sufficient irradiation absorption the liquid sample volume was \geq 0.5 mL.

[0127] Cation exchange CC was performed with Varian BOND ELUT (mega BE-SCX, 1 g, 6 ml) columns. After applying the compound to the column, it was first washed with MeOH (2 column volumes) and thereafter the desired compound was eluted applying 2 column volumes of an NH₄OH (25% NH₃ in H₂O)/MeOH mixture (1:9).

(R,S)-1-(4-Butylpiperidin-1-yl)-3-chloropropan-2-ol (101IS93-1)

[0128] A 4 mL vial was charged with 4-butylpiperidine (0.29 g, 2.0 mmol) and epichlorohydrin (0.190 g, 2.1 mmol) and was shaken at rt for 4 h. The resulting thick oil was purified by flash chromatography (SiO₂; CH₂Cl₂/acetone/MeOH 85/10/5) to yield the title compound as an oil (0.31 g, 64%). ¹H NMR (CDCl₃) δ 3.95 - 3.85 (m, 1H), 3.60 - 3.48 (m, 1H), 2.97 - 2.88 (m, 1H), 2.82 - 2.72 (m, 1H), 2.46 - 2.35 (m, 1H), 2.30 - 2.20 (m, 1H), 1.98 - 1.88 (m, 1H), 1.70 - 1.58 (m, 2H), 1.35 - 1.08 (m, 9H), 0.88 (t, J = 6.8 Hz, 3H); ¹³C NMR (CDCl₃) δ 66.7, 61.5, 55.9, 53.1, 47.4, 36.4, 35.8, 32.9, 32.6, 29.2, 23.1, 14.3.

(R,S)-4-Butyl-1-(3-chloro-2-fluoropropyl)piperidine (101IS93-2)

[0129] DAST (1.9 mmol, 230 μ l) was added drop wise to a solution of 1-(4-butylpiperidin-1-yl)-3-chloropropan-2-ol (101IS93) (0.31 g, 1.28 mmol) in CH₂Cl₂ (5 mL). After 2h the reaction was quenched by the addition water (5 mL) and the organic phase was extracted with CH₂Cl₂ (2 x 15 mL) and the combined organic phase was dried (Na₂SO₄), filtered, concentrated under reduced pressure and the residue was purified by flash chromatography (SiO₂;

heptane/EtOAc 60:40) to yield the title compound as an oil (0.025 g, 9 %); ^1H NMR (CDCl_3) δ 4.79 (dm, $J = 48$ Hz, 1H), 3.78 - 3.60 (m, 2H), 2.92 - 2.83 (m, 2H), 2.72 - 2.56 (m, 2H), 2.15 - 2.00 (m, 2H), 1.69 - 1.58 (m, 2H), 1.35 - 1.16 (m, 9H), 0.88 (t, $J = 6.8$ Hz); ^{13}C NMR (CDCl_3) δ 91.1 (d, $J = 111$ Hz), 59.9 (d, $J = 22$ Hz), 55.2, 54.9, 44.9 (d, $J = 25$ Hz), 36.4, 35.6, 32.7, 32.6, 29.2, 23.1, 14.3.

General procedure 1 (GP1)

[0130] To a flask or vial was charged 2-aminophenol (1.0 equiv) dissolved in DMF (0.1 g/mL) and 2-Chloroacetyl chloride (1.1 equiv) was added. The reaction was stirred in rt for 12-20 hours and K_2CO_3 (2.1 equiv) was added. The reaction was stirred in rt for another 12-20 hours then evaporated to dryness, redissolved in water (10 mL) and extracted using EtOAc (3x 20 mL). The combined organic phases concentrated to a crude that was used directly or purified by CC (Heptane:EtOAc).

4H-Pyrido[4,3-b][1,4]thiazin-3-one (81MF939a)

[0131] 3-Amino-4-thiopyridine (0.10 g, 0.79 mmol) and 2-Chloroacetyl chloride (0.098 g, 0.87 mmol) and K_2CO_3 (0.23 g, 1.66 mmol) were mixed according to GP1 to give the title compound as a crude (81MF939a) (0.087 g)

8-Fluoro-4H-benzo[1,4]oxazin-3-one (95MF45)

[0132] 2-Amino-6-fluorophenol (95MF2085) (0.256 g, 2.0 mmol), 2-chloroacetyl chloride (0.25 g, 2.2 mmol) and K_2CO_3 (0.583 g, 4.2 mmol) were mixed according to GP1 to give the title compound as a crude (95MF45) (0.29 g)

7-Fluoro-4H-benzo[1,4]oxazin-3-one (111MF12)

[0133] 2-Amino-5-fluorophenol (111MF10) (10.3 g, 81 mmol), 2-chloroacetyl chloride (10.1 g, 89 mmol) and K_2CO_3 (23.5 g, 170 mmol) were mixed according to GP1. CC (SiO_2 ; Heptane/EtOAc 4:1-4) to give the title compound (111MF12) (12.6 g, 93%); ^1H NMR (DMSO) δ 10.68 (s, 1 H), 6.83-6.91 (m, 2 H), 6.75-6.80 (m, 1 H), 4.57 (s, 2 H); ^{13}C NMR (DMSO) δ 164.2, 157.8 (d, $J = 238.6$ Hz), 144.0 (d, $J = 12.4$ Hz), 123.9 (d, $J = 2.7$ Hz), 116.3 (d, $J = 9.6$ Hz), 108.6 (d, $J = 22.7$ Hz), 104.0 (d, $J = 26.5$ Hz), 66.7.

7,8-Difluoro-4H-benzo[1,4]oxazin-3-one (81MF2082A)

[0134] 6-Amino-2,3-difluorophenol (81KK30a) (0.113 g, 0.78 mmol), 2-chloroacetyl chloride (0.10g, 0.89 mmol) and K_2CO_3 (0.226 g, 1.6 mmol) were mixed according to GP1 to give the title compound as a crude (81MF2082A) (0.12 g)

6-Bromo-8-fluoro-4H-benzo[1,4]oxazin-3-one (95MF44)

[0135] 2-Amino-4-bromo-6-fluorophenol (95MF2084) (0.078 g, 0.38 mmol), 2-chloroacetyl chloride (0.048 g, 0.42 mmol) and K_2CO_3 (0.11 g, 0.79 mmol) were mixed according to GP1 to give the title compound as a crude (95MF44) (0.091 g)

8-Isopropyl-4H-benzo[1,4]oxazin-3-one (95MF83)

[0136] Crude 2-Amino-6-isopropylphenol (95MF80(2240)) (0.16 g, 1.1 mmol), 2-chloroacetyl chloride (0.14 g, 1.2 mmol) and K_2CO_3 (0.32 g, 2.3 mmol) were mixed according to GP1 to give the title compound as a crude (95MF83) (0.115 g).

6,8-Dichloro-7-methyl-4H-benzo[1,4]oxazin-3-one (81MF2225)

[0137] 6-Amino-2,4-dichloro-3-methylphenol (1.9 g, 10 mmol), 2-chloroacetyl chloride (1.2 g, 11 mmol) and K_2CO_3 (3.0 g, 22 mmol) were mixed according to GP1 to give the title compound as a crude (80MF2225) (2.33 g).

6,8-Dichloro-7-ethyl-4H-benzo[1,4]oxazin-3-one (95MF46)

[0138] 6-Amino-2,4-dichloro-3-ethylphenol (95MF2226) (0.293 g, 1.5 mmol), 2-chloroacetyl chloride (0.19 g, 1.7 mmol) and K_2CO_3 (0.44 g, 3.2 mmol) were mixed according to GP1 to give the title compound as a crude (95MF46) (0.34 g).

7-fluoro-6-methyl-3,4-dihydro-1H-quinolin-2-one (97KK40)

[0139] 3-Fluoro-4-methylaniline (1.247 g, 9.96 mmol), 3-chloropropionyl chloride (1.269 g, 9.99 mmol), and K_2CO_3 (1.450 g, 10.5 mmol) in MeCN (10 mL) were stirred at 40 °C for 3 h. The reaction mixture was quenched with 4M HCl and the product extracted into CH_2Cl_2 . The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated. The residue (1.168 g) was heated to 145 °C and small portions of $AlCl_3$ (3.538 g, 26.5 mmol) were added over a period of 30 min. The reaction mixture was then cooled and 4M HCl added under stirring followed by extraction of the product into CH_2Cl_2 . The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated. The residue was purified by flash CC (SiO_2 ; CH_2Cl_2 /MeOH 40:1) to give the title compound (97KK40) (0.201 g, total yield 11%). 1H NMR ($CDCl_3$) δ 8.15 (br s, 1H), 6.94 (d, J = 7.8 Hz, 1H), 6.47 (d, J = 10.0 Hz, 1H), 2.91 – 2.87 (m, 2H), 2.62 – 2.60 (m, 2H), 2.19 (d, J = 1.8 Hz, CH_3).

6-Fluoro-1H-quinolin-2-one (97KK38)

[0140] DDQ (0.38 g, 1.7 mmol) was added to a solution of 6-fluoro-3,4-dihydro-1H-quinolin-2-one (0.18 g, 1.1 mmol) in dioxane (25 mL) and the resulting solution was refluxed for 16 h. The mixture was concentrated, and sat aqueous Na₂CO₃ (25 mL) was added followed by extraction into an organic mixture (MeOH:CH₂Cl₂; 1:10, 3 x 50 mL). The combined organic phase was dried (Na₂SO₄), filtered, concentrated under reduced pressure and purified by flash CC (SiO₂; CH₂Cl₂/MeOH 20:1) to give the title compound (0.056 g, 31%). ¹H NMR (DMSO-D₆) δ 11.8 (brs, 1H), 7.85 (d, *J* = 9.4 Hz), 7.50 (dd, *J* = 2.8, 9.2 Hz), 7.43 - 7.37 (m, 1H), 7.37 - 7.25 (m, 1H), 6.54 (d, *J* = 9.4 Hz).

7-Fluoro-1H-quinolin-2-one. (97KK34).

[0141] DDQ (0.42 g, 1.9 mmol) was added to a solution of 7-fluoro-3,4-dihydro-1H-quinolin-2-one (0.20 g 1.2 mmol) in dioxane (25 mL) and the resulting mixture was refluxed under an Argon atmosphere for 16 h. The mixture was concentrated under reduced pressure and sat aqueous Na₂CO₃ solution (25 mL) was added, and this was extracted with an organic mixture (MeOH/CH₂Cl₂ 1:10, 3 x 50 mL). The combined organic phase was dried (Na₂SO₄), filtered, concentrated under reduced pressure and purified by combi flash LC (SiO₂; CH₂Cl₂/MeOH 10:1) to give the title compound (0.037 g, 18%). ¹H NMR (DMSO-D₆) δ 11.8 (s, 1H), 7.88 (d, *J* = 9.6 Hz, 1H), 7.74 - 7.65 (m, 1H), 7.05 - 6.95 (m, 2H), 6.43, (d, *J* = 9.6 Hz); ¹³C NMR (CDMSO-D₆) δ 163.0 (d, *J* = 247 Hz), 161.9, 140.4 (d, *J* = 13 Hz), 130.4 (d, *J* = 11 Hz), 120.9, 116.1, 109.8 (d, *J* = 23), 101.0 (d, *J* = 25 Hz).

6-Fluoro-7-methyl-3,4-dihydro-1H-quinolin-2-one (10LH75-1) and 6-Fluoro-5-methyl-3,4-dihydro-1H-quinolin-2-one (107LH75-2)

[0142] 3-Chloro-*N*-(4-fluoro-3-methyl-phenyl)-propionamide (3.8 g, 30 mmol), 3-chloropropionyl chloride (2.9 mL, 30 mmol) and K₂CO₃ (5.0 g, 36 mmol) were added to CH₃CN (50 mL) and the mixture was stirred for 44 h at rt. Thereafter, the reaction was diluted with EtOAc (50 mL) and washed with water (20 mL), HCl (20 mL, 4N) and brine (20 mL). The organic phase was dried with Na₂SO₄, filtered and concentrated under reduced pressure. The residue (5.9 g) was heated to 135 °C and small portions of AlCl₃ (11 g, 82 mmol) were added during 30 min, the reaction was then cooled to 50 °C and HCl (4N 20, mL) was added and the resulting mixture was stirred for 15 min. The mixture was extracted with EtOAc (50 mL) and the organic phase was washed with water (20 mL). The resulting organic phase was dried (Na₂SO₄), filtered concentrated under reduced pressure and purified by prep HPLC to yield 6-fluoro-7-methyl-3,4-dihydro-1H-quinolin-2-one (0.76 g, 14%) and 6-fluoro-5-methyl-3,4-dihydro-1H-quinolin-2-one (0.190 g, 4%). 6-Fluoro-7-methyl-3,4-dihydro-1H-quinolin-2-one (107LH75-1). ¹H NMR (CDCl₃) δ 8.86 (brs,

8.86, 1H), 6.81 (d, $J = 9.2$ Hz, 1H), 6.62 (d, $J = 6.8$ Hz, 1H), 2.91 (brt, $J = 7.6$ Hz, 3H), 2.94 - 2.87 (m, 2H), 2.20 (d, $J = 2.0$ Hz). 6-Fluoro-5-methyl-3,4-dihydro-1*H*-quinolin-2-one (107LH75-2). ^1H NMR (CDCl_3) δ 8.78 (brs, 1H), 6.85 (t, $J = 8.8$ Hz, 1H), 6.62 (dd, $J = 4.5, 8.8$ Hz, 1H), 2.92 (brt, $J = 7.6$ Hz, 2H), 2.64 - 2.58 (m, 2H), 2.20 (d, $J = 2.4$ Hz, 3H).

(*R*)-4-(3-Hydroxy-2-methylpropyl)-4*H*-benzo[1,4]oxazin-3-one (108LM40-37)

[0143] A 25 mL flask was charged with 4*H*-benzo[1,4]oxazin-3-one (0.100 g, 0.670 mmol), (*S*)-3-bromo-2-methylpropanol (0.103 g, 0.670 mmol) and cesium carbonate (0.208 g, 0.670 mmol) in MeCN (10 mL) and stirred at 40°C for 2 days. The reaction mixture was quenched with water (5 mL), and the product extracted into EtOAc (2 x 10 mL). The combined organic layers were dried (Na_2SO_4) and evaporated to give the crude title compound (108LM40-37) (0.219 g).

GENERAL PROCEDURE 2 (GP2)

[0144] A dry 50 mL flask was charged with the appropriate heterocycle (1.1 equiv), (*R*)-(3-bromo-2-methyl-propoxy)-*tert*-butyldimethylsilane (95MF94) (1 equiv) and cesium carbonate (2.5 equiv) in DMF (20 mL) and stirred at 55°C for 20 h. The reaction mixture was quenched with water (10 mL), and the product extracted into EtOEt (3 x 20 mL). The combined organic layers were washed with brine, dried (Na_2SO_4), evaporated and purified by flash CC (SiO_2 ; EtOAc/heptane 1:10).

(*S*)-4-[3-(*tert*-Butyldimethylsilyloxy)-2-methylpropyl]-4*H*-benzo[1,4]oxazin-3-one (108LM24-21)

[0145] 4*H*-Benzo[1,4]oxazin-3-one (2.47 g, 16.5 mmol), (*R*)-(3-bromo-2-methyl-propoxy)-*tert*-butyldimethylsilane (95MF94) (4.01 g, 15.0 mmol) and Cs_2CO_3 (12.2 g, 37.6 mmol) in DMF (20 mL) were reacted according to GP2 to give the title compound (108LM24-21) (3.92 g, 78%). ^1H NMR (CDCl_3) δ 7.15 - 7.11 (m, 1H), 6.99 - 6.91 (m, 3H), 4.60 - 4.50 (m, 2H), 3.98 (dd, $J = 8.3$ Hz, $J = 12.4$ Hz, 1H), 3.81 (dd, $J = 5.5$ Hz, $J = 12.4$ Hz, 1H), 3.51 (dd, $J = 4.1$ Hz, $J = 9.7$ Hz, 1H), 3.40 (dd, $J = 6.9$ Hz, $J = 9.7$ Hz, 1H), 2.12 - 2.02 (m, 1H), 0.90 - 0.82 (m, 12H), 0.02 (s, 6H).

(*S*)-4-[3-(*tert*-Butyldimethylsilyloxy)-2-methylpropyl]-4*H*-benzo[1,4]thiazin-3-one (108LM25-22)

[0146] 4*H*-Benzo[1,4]thiazin-3-one (2.75 g, 16.7 mmol), (*R*)-(3-bromo-2-methylpropoxy)-*tert*-butyldimethylsilane (95MF94) (4.04 g, 15.1 mmol) and cesium carbonate (12.3 g, 37.9 mmol) in DMF (20 mL) were reacted according to GP2 to give the title compound (108LM25-22) (3.74 g, 70%). ^1H NMR (CDCl_3) δ 7.35 (d, $J = 7.6$ Hz, 1H), 7.28-7.18 (m, 2H), 6.99

(t, $J = 7.6$ Hz, 1H), 4.13 (dd, $J = 8.9$ Hz, $J = 13.3$ Hz, 1H), 3.95 (dd, $J = 5.9$ Hz, $J = 13.3$ Hz, 1H), 3.52-3.40 (m, 2H), 3.37 (s, CH₂), 1.96-2.07 (m, 1H), 0.92-0.83 (m, 12 H), 0.02 (s, 6H).

GENERAL PROCEDURE 3 (GP3)

[0147] A 50 mL flask was charged with the appropriate heterocycle (1 equiv) and tetrabutylammonium fluoride (TBAF) (1.3 equiv) in THF (30 mL) and stirred at rt for 20 h. The reaction mixture was concentrated to syrup and dissolved in EtOAc (30 mL). The mixture was washed with brine (2 x 20 mL). The combined organic layers were dried (Na₂SO₄), evaporated and purified by flash CC (SiO₂; EtOAc/heptane 7:3).

(S)-4-(3-Hydroxy-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (108LM26-23)

[0148] The compound (S)-4-[3-(*tert*-Butyldimethylsilyloxy)-2-methylpropyl]-4H-benzo[1,4]oxazin-3-one (108LM24-21) (3.92 g, 11.7 mmol) and TBAF (4.78 g, 15.2 mmol) in THF (30 mL) were reacted according to GP3 to give the title compound (108LM26-23) (2.52 g, 98%). ¹H NMR (CDCl₃) δ 7.05 - 6.95 (m, 4H), 4.63 (s, CH₂), 4.23 (dd, $J = 10.3$ Hz, $J = 13.9$ Hz, 1H), 3.56 (dd, $J = 4.8$ Hz, $J = 13.9$ Hz, 1H), 3.52 - 3.49 (m, 1H), 3.46 - 3.38 (m, 1H), 2.92 - 2.85 (m, 1H), 2.09 - 1.97 (m, 1H), 1.06 (d, $J = 7.3$ Hz, CH₃).

(S)-4-[3-(*tert*-Butyldimethylsilyloxy)-2-methylpropyl]-4H-benzo[1,4]thiazin-3-one

[0149] The compound (108LM25-22) (3.69 g, 10.5 mmol) and TBAF (4.30 g, 13.6 mmol) in THF (30 mL) were reacted according to GP3. Purified by flash CC (SiO₂; EtOAc/heptane 7:3) to give the title compound (108LM34-31) (2.36 g, 95%). ¹H NMR (CDCl₃) δ 7.38 (d, $J = 7.9$ Hz, 1H), 7.28 - 7.18 (m, 2H), 7.03 (t, $J = 7.0$ Hz, 1H), 4.32 (dd, $J = 9.0$ Hz, $J = 15.2$ Hz, 1H), 3.70 (dd, $J = 5.5$ Hz, $J = 15.2$ Hz, 1H), 3.52 (dd, $J = 3.4$ Hz, $J = 11.7$ Hz, 1H), 3.34 - 3.42 (m, 3H), 2.82 (bs, OH), 1.92 - 1.83 (m, 1H), 0.98 (d, $J = 6.9$ Hz, CH₃).

GENERAL PROCEDURE 4 (GP4)

[0150] A 50 mL flask was charged with the appropriate heterocycle (1 equiv), triphenylphosphine (2 equiv) and imidazole (2.5 equiv) in CHCl₃ (30 mL). When all of the material was dissolved iodine (3 equiv) was added while stirring. Stirring was continued at rt for 20 h. The reaction mixture was washed with sat. aqueous sodium thiosulfate (30 mL), dried (Na₂SO₄), evaporated and purified by flash CC (SiO₂; EtOAc/heptane 3:1).

(S)-4-(3-Iodo-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (108LM27-24)

[0151] The compound (S)-4-(3-Hydroxy-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (108LM26-23) (2.52 g, 11.4 mmol), triphenylphosphine (6.12 g, 23.3 mmol), imidazole (1.98 g,

29.1 mmol) and iodine (8.88 g, 35.0 mmol) in CHCl_3 (30 mL) were reacted according to GP4 to give the title compound (108LM27-24) (3.02 g, 80%). ^1H NMR (CDCl_3) δ 7.07 – 7.00 (m, 4H), 4.65 – 4.55 (m, 2H), 3.94 (dd, $J = 1.7$ Hz, $J = 6.7$ Hz, CH_2), 3.23 – 3.14 (m, 2H), 2.18 – 2.07 (m, 1H), 1.05 (d, $J = 6.1$ Hz, CH_3).

(R)-4-(3-Iodo-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (108LM46-43)

[0152] Crude (R)-4-(3-hydroxy-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (108LM40-37) (1.040 g), triphenylphosphine (0.99 g, 3.77 mmol), imidazole (0.32 g, 4.71 mmol) and iodine (1.43 g, 5.65 mmol) in CHCl_3 (30 mL) were reacted according to GP4 to give the crude title compound (108LM46-43) (0.312 g).

(S)-4-(3-Iodo-2-methylpropyl)-4H-benzo[1,4]thiazin-3-one (108LM37-34)

[0153] The compound (S)-4-(3-Hydroxy-2-methylpropyl)-4H-benzo[1,4]thiazin-3-one (108LM34-31) (2.33 g, 9.82 mmol), triphenylphosphine (5.15 g, 19.7 mmol), imidazole (1.67 g, 24.6 mmol) and iodine (7.48 g, 29.5 mmol) in CHCl_3 (30 mL) were reacted according to GP4 to give the title compound (108LM37-34) (2.57 g, 75%). ^1H NMR (CDCl_3) δ 7.37 (d, $J = 7.8$ Hz, 1H), 7.24 (t, $J = 7.8$ Hz, 1H), 7.16 (d, $J = 7.8$ Hz, 1H), 7.02 (t, $J = 7.8$ Hz, 1H), 4.02 (d, $J = 6.8$ Hz, CH_2), 3.37 (s, CH_2), 3.15-3.05 (m, CH_2), 1.95 (m, 1H), 0.97 (d, $J = 6.2$ Hz, CH_3).

GENERAL PROCEDURE 5 (GP5)

[0154] A 4 or 7 mL vial was charged with 4H-benzo[1,4]oxazin-3-one (1.0 equiv), Cs_2CO_3 (1.5 equiv) and 3-chloro-1-iodopropane (1.1 equiv) in 3 mL dry MeCN and shaken at rt for 66 – 72 h. The reaction mixture was diluted with 10 mL H_2O and extracted into CH_2Cl_2 or EtOAc (3 x 30 mL). The combined organic layers were dried over MgSO_4 or filtered through a PTFE Whatman filter and concentrated. The residue was purified by CC (Heptane/EtOAc) or used without further purification in the next step.

6-Bromo-4-(3-chloropropyl)-8-fluoro-4H-benzo[1,4]oxazin-3-one (95MF50(2084))

[0155] 6-Bromo-8-fluoro-4H-benzo[1,4]oxazin-3-one (95MF44) (0.091 g, 0.37 mmol), Cs_2CO_3 (0.180 g, 0.55 mmol) and 3-chloro-1-iodopropane (0.083 g, 0.41 mmol) were mixed according to GP5. CC (SiO_2 ; Heptane/EtOAc 9:1-4) gave the title compound (95MF50(2084)) (0.086 g, 72%). ^1H NMR (CDCl_3) δ 7.02 – 6.96 (m, 1H), 6.85 (d, $J = 5.2$ Hz, 1H), 4.65 (s, 2H), 4.04 – 4.11 (m, 2H), 3.62 (t, $J = 6.2$ Hz, 2H), 2.10 – 2.18 (m, 2H); ^{13}C NMR (CDCl_3) δ 163.8, 151.7 (d, $J = 250.9$ Hz), 133.1 (d, $J = 14.6$ Hz), 131.5 (d, $J = 3.8$ Hz), 115.1 (d, $J = 21.5$ Hz), 114.2 (d, $J = 10.0$ Hz), 113.4 (d, $J = 3.4$ Hz), 67.6, 42.2, 39.5, 30.0.

4-(3-Chloropropyl)-8-fluoro-4H-benzo[1,4]oxazin-3-one (95MF51(2085))

[0156] 8-Fluoro-4H-benzo[1,4]oxazin-3-one (95MF45) (0.290g, 1.74 mmol), Cs₂CO₃ (0.848 g, 2.6 mmol) and 3-chloro-1-iodopropane (0.390 g, 1.91 mmol) were mixed according to GP5. CC (SiO₂; Heptane/EtOAc 9:1-4) gave the title compound (95MF51(2082)) (0.254 g, 60%). ¹H NMR (CDCl₃) δ 7.01 – 6.95 (m, 1H), 6.88 – 6.82 (m, 2H), 4.66 (s, 2H), 4.13 – 4.08 (m, 2H), 3.63 (t, *J* = 6.0 Hz, 2H), 2.19 – 2.12 (m, 2H); ¹³C NMR (CDCl₃) δ 164.2, 152.1 (d, *J* = 246.8 Hz), 133.9 (d, *J* = 15.0 Hz), 130.6 (d, *J* = 3.1 Hz), 122.6 (d, *J* = 8.1 Hz), 111.8 (d, *J* = 18.4 Hz), 110.1 (d, *J* = 3.4 Hz), 67.8, 42.4, 39.5, 30.1.

6,8-Dichloro-4-(3-chloropropyl)-7-ethyl-4H-benzo[1,4]oxazin-3-one ((95MF52(2226))

[0157] 6,8-Dichloro-7-ethyl-4H-benzo[1,4]oxazin-3-one (95MF46) (0.342g, 1.39 mmol), Cs₂CO₃ (0.678 g, 2.08 mmol) and 3-chloro-1-iodopropane (0.313 g, 1.52 mmol) were mixed according to GP5. CC (SiO₂;Heptane/EtOAc 9:1-4) gave the title compound (95MF52(2226)) (0.301 g, 67%). ¹H NMR (CDCl₃) δ 7.01 (s, 1H), 4.68 (s, 2H), 4.06 (t, *J* = 7.2 Hz, 2H), 3.62 (t, *J* = 6.0 Hz, 2H), 2.91 (q, *J* = 7.6 Hz, 2H), 2.10-2.18 (m, 2H), 1.16 (t, *J* = 7.6 Hz, 3H); ¹³C NMR (CDCl₃) δ 163.8, 140.6, 135.8, 127.9, 127.7, 123.6, 113.8, 67.9, 42.2, 39.3, 30.0, 24.7, 12.7.

4-(3-Chloropropyl)-8-isopropyl-4H-benzo[1,4]oxazin-3-one (95MF98)

[0158] 8-Isopropyl-4H-benzo[1,4]oxazin-3-one (95MF83) (0.115g, 0.60 mmol), Cs₂CO₃ (0.293 g, 0.90 mmol) and 3-chloro-1-iodopropane (0.135 g, 0.66 mmol) were mixed according to GP5. CC (SiO₂;Heptane/EtOAc 9:1-4) gave the title compound (95MF98) (0.112 g, 70%). ¹H NMR (CDCl₃) δ 7.03 – 6.95 (m, 2H), 6.93 – 6.90 (m, 1H), 4.57 (s, 2H), 4.09 (m, 2H), 3.62 (t, *J* = 6.2 Hz, 2H), 3.33 – 3.25 (m, 1H), 2.20 – 2.13 (m, 2H), 1.22 (d, *J* = 7.2 Hz, 6H); ¹³CNMR(CDCl₃) δ 164.9, 142.8, 137.8, 128.5, 122.8, 121.4, 112.5, 67.7, 42.5, 39.3, 30.3, 27.2, 22.7.

4-(3-Chloropropyl)-6-fluoro-4H-benzo[1,4]oxazin-3-one (8173MF55b)

[0159] 6-Fluoro-4H-benzo[1,4]oxazin-3-one (8173MF55b) (0.090 g, 0.54 mmol), Cs₂CO₃ (0.263 g, 0.81 mmol) and 3-chloro-1-iodopropane (0.121 g, 0.59 mmol) were mixed according to GP5. CC (SiO₂;Heptane/EtOAc 10:1-5) gave the title compound (8173MF55b) (0.102 g, 78%). ¹HNMR(CDCl₃) δ 6.95 – 6.91 (m, 1H), 6.82 – 6.78 (m, 1H), 6.72 – 6.67 (m, 1H), 4.57 (s, 1H), 4.05 (t, *J* = 7.2 Hz, 2H), 3.62 (t, *J* = 6.2 Hz, 2H), 2.19 – 2.11 (m, 2H); ¹³CNMR(CDCl₃) δ 164.6, 158.6 (d, *J* = 240.7 Hz), 141.5 (d, *J* = 2.3 Hz), 129.6 (d, *J* = 10.5 Hz), 118.0 (d, *J* = 9.3 Hz), 110.0 (d, *J* = 23.1 Hz), 102.7 (d, *J* = 28.8 Hz), 67.8, 42.3, 39.3, 30.0.

4-(3-Chloropropyl)-7,8-difluoro-4H-benzo[1,4]oxazin-3-one (81MF2082b)

[0160] 7,8-Difluoro-4H-benzo[1,4]oxazin-3-one (81MF2082a) (0.119 g, 0.64 mmol), Cs₂CO₃ (0.314 g, 0.96 mmol) and 3-chloro-1-iodopropane (0.144 g, 0.70 mmol) were mixed according to GP5 giving the crude title compound (0.156 g); ¹H NMR (CDCl₃) δ 6.89 - 6.82 (m, 1H), 6.78 - 6.74 (m, 1H), 4.68 (s, 2H), 4.08 (t, *J* = 7.2 Hz, 2H), 3.62 (t, *J* = 6.4 Hz, 2H), 2.18 - 2.10 (m, 2H); ¹³C NMR (CDCl₃) δ 163.5, 147.7 (q, *J* = 245.6 Hz, *J* = 10.4 Hz), 141.0 (q, *J* = 249.4 Hz, *J* = 15.7 Hz), 135.5, 126.2, 109.9 (d, *J* = 18.4 Hz), 108.6 (q, *J* = 7.6 Hz, *J* = 4.2 Hz), 67.8, 42.3, 39.4, 30.0.

4-(3-Chloropropyl)-6-methoxy-4H-benzo[1,4]oxazin-3-one (81MF2249b)

[0161] 6-Methoxy-4H-benzo[1,4]oxazin-3-one (81MF2249a) (0.212 g, 1.18 mmol), Cs₂CO₃ (0.578 g, 1.77 mmol) and 3-chloro-1-iodopropane (0.265 g, 1.3 mmol) were mixed according to GP5. CC (SiO₂; Heptane/EtOAc 10:1-2) gave the title compound (81MF2249b) (0.127 g, 42%). ¹H NMR (CDCl₃) δ 6.88 (d, *J* = 8.8 Hz, 1H), 6.62 (d, *J* = 2.8 Hz, 1H), 6.50 (dd, *J* = 2.8 Hz, *J* = 8.8 Hz, 1H), 4.50 (s, 2H), 4.05 - 4.01 (m, 2H), 3.76 (s, 3H), 3.59 (t, *J* = 6.2 Hz, 2H), 2.16 - 2.09 (m, 2H); ¹³C NMR (CDCl₃) δ 164.8, 155.5, 139.3, 129.2, 117.4, 107.8, 101.9, 67.8, 55.8, 42.4, 38.9, 30.0.

4-(3-Chloropropyl)-7-fluoro-4H-benzo[1,4]oxazin-3-one (81MF763b)

[0162] 7-Fluoro-4H-benzo[1,4]oxazin-3-one (81MF763) (0.263 g, 1.57 mmol), Cs₂CO₃ (0.769 g, 2.36 mmol) and 3-chloro-1-iodopropane (0.354 g, 1.73 mmol) were mixed according to GP5 giving the crude title compound (0.40 g); ¹H NMR (CDCl₃) δ 7.01 - 6.91 (m, 1H), 6.79 - 6.73 (m, 2H), 4.60 (s, 2H), 4.08 (t, *J* = 7.2 Hz, 2H), 3.62 (t, *J* = 6.4 Hz, 2H), 2.18 - 2.11 (m, 2H).

4-(3-Chloropropyl)-4H-pyrido[4,3-b][1,4]thiazin-3-one (81MF939b)

[0163] 4H-pyrido[4,3-b][1,4]thiazin-3-one (81MF939a) (0.087 g, 0.52 mmol), Cs₂CO₃ (0.256 g, 0.78 mmol) and 3-chloro-1-iodopropane (0.116 g, 0.57 mmol) were mixed according to GP5 giving the crude title compound (0.139 g). ¹H NMR (CDCl₃) δ 8.43 (s, 1H), 8.17 (d, *J* = 5.2 Hz, 1H), 7.25 (d, *J* = 5.2 Hz, 1H), 4.20 - 4.15 (m, 2H), 3.55 (t, *J* = 6.2 Hz, 2H), 3.41 (s, 2H), 2.17 - 2.10 (m, 2H).

GENERAL PROCEDURE 6 (GP6)

[0164] A 100 mL flask was charged with 4H-benzo[1,4]oxazin-3-one (1.0 equiv), Cs₂CO₃ (1.5 equiv) and 3-chloro-1-iodopropane (1.1 equiv) in 50 mL dry MeCN and stirred at rt for 72 h. The reaction mixture was evaporated to dryness and diluted with 100 mL H₂O and

extracted into EtOAc (3 x 100 mL). The combined organic layers were dried over MgSO₄, filtrated, evaporated to dryness and purified by CC (Heptane/EtOAc).

6,8-Dichloro-4-(3-chloropropyl)-7-methyl-4H-benzo[1,4]oxazin-3-one (81MF2225b)

[0165] 6,8-Dichloro-7-methyl-4H-benzo[1,4]oxazin-3-one (81MF2225a) (2.33 g, 10.0 mmol), Cs₂CO₃ (4.88 g, 15.0 mmol) and 3-chloro-1-iodopropane (2.25 g, 11.0 mmol) were mixed according to GP6. CC (SiO₂; Heptane/EtOAc 10:1-5) gave the title compound (81MF2225b) (2.44 g, 79%). ¹H NMR (CDCl₃) δ 7.02 (s, 1H), 4.67 (s, 2H), 4.06 (t, *J* = 7.2 Hz, 2H), 3.62 (t, *J* = 6.2, 2H), 2.43 (s, 3H), 2.18 - 2.10 (m, 2H); ¹³C NMR (CDCl₃) δ 163.7, 140.5, 130.3, 128.3, 127.6, 124.1, 113.5, 67.9, 42.2, 39.3, 30.0, 17.2.

4-(3-Chloropropyl)-6,8-dimethyl-4H-benzo[1,4]oxazin-3-one (81MF2237b)

[0166] 6,8-Dimethyl-4H-benzo[1,4]oxazin-3-one (81MF2237a) (1.70 g, 9.60 mmol), Cs₂CO₃ (4.69 g, 14.4 mmol) and 3-chloro-1-iodopropane (2.15 g, 10.6 mmol) were mixed according to GP6. CC (SiO₂; Heptane/EtOAc 10:1-5) gave the title compound (81MF2237b) (0.96 g, 39%). ¹H NMR (CDCl₃) δ 6.72 - 6.69 (m, 2H), 4.56 (s, 2H), 4.07 (t, 2H), 3.62 (t, *J* = 6.4 Hz, 2H), 2.30 (s, 3H), 2.20 (s, 3H), 2.19 - 2.12 (m, 2H); ¹³C NMR (CDCl₃) δ 164.9, 141.5, 131.9, 128.0, 126.7, 126.4, 113.1, 67.8, 42.5, 39.0, 30.3, 21.2, 15.5.

6-tert-Butyl-4-(3-chloropropyl)-4H-benzo[1,4]oxazin-3-one (81MF2248b)

[0167] 6-tert-Butyl-4H-benzo[1,4]oxazin-3-one (81MF2248a) (2.07g, 10.0 mmol), Cs₂CO₃ (4.88 g, 15.0 mmol) and 3-chloro-1-iodopropane (2.25 g, 11.0 mmol) were mixed according to GP6. CC (SiO₂; Heptane/EtOAc 10:1-5) to give the title compound (81MF2248b) (1.39 g, 49%). ¹H NMR (CDCl₃) δ 7.12 (d, *J* = 2.0 Hz, 1H), 7.03 (dd, *J* = 8.4 Hz, *J* = 2.0 Hz, 1H), 6.92 (d, *J* = 8.4 Hz, 1H), 4.54 (s, 2H), 4.14 (t, *J* = 7.2 Hz, 2H), 3.65 (t, *J* = 6.0 Hz, 2H), 2.21 - 2.14 (m, 2H), 1.32 (s, 9H); ¹³C NMR (CDCl₃) δ 164.8, 146.4, 143.1, 127.9, 120.9, 116.7, 112.2, 67.8, 42.6, 38.9, 34.8, 31.6, 30.2.

6-Chloro-4-(3-chloropropyl)-7-nitro-4H-benzo[1,4]oxazin-3-one (81MF2253b)

[0168] Crude 6-Chloro-7-nitro-4H-benzo[1,4]oxazin-3-one (81MF2253a) (2.60 g, 10.0 mmol), Cs₂CO₃ (4.88 g, 15.0 mmol) and 3-chloro-1-iodopropane (2.25 g, 11.0 mmol) were mixed according to GP6. CC (SiO₂; Heptane/EtOAc 10:1-5) gave the title compound (81MF2253b) (1.23 g, 36%). ¹H NMR (CDCl₃) δ 7.66 (s, 1H), 7.20 (s, 1H), 4.70 (s, 2H), 4.12 (t, *J* = 7.6 Hz, 2H), 3.67 - 3.59 (m, 2H), 2.21 - 2.13 (m, 2H); ¹³C NMR (CDCl₃) δ 163.6, 143.5, 133.3, 133.2, 122.4, 117.2, 115.2, 67.4, 42.1, 39.6, 29.8.

7-Chloro-4-(3-chloropropyl)-4H-benzo[1,4]oxazin-3-one (81MF2271b)

[0169] 7-Chloro-4H-benzo[1,4]oxazin-3-one (81MF2271a) (1.74 g, 9.47 mmol), Cs_2CO_3 (4.63 g, 14.2 mmol) and 3-chloro-1-iodopropane (2.13 g, 10.4 mmol) were mixed according to GP6. CC (SiO_2 ; Heptane/EtOAc 10:1-5) gave the title compound (81MF2271b) (1.95 g, 79%). ^1H NMR (CDCl_3) δ 7.03 – 6.96 (m, 3H), 4.59 (s, 2H), 4.07 (t, $J = 7.2$ Hz, 2H), 3.61 (t, $J = 6.4$ Hz, 2H), 2.17 – 2.10 (m, 2H); ^{13}C NMR (CDCl_3) δ 164.0, 146.0, 129.1, 127.3, 123.0, 117.8, 115.5, 67.7, 42.4, 39.2, 30.0.

4-(3-Chloropropyl)-5-methyl-4H-benzo[1,4]oxazin-3-one (81MF941b)

[0170] 5-Methyl-4H-benzo[1,4]oxazin-3-one (81MF941a) (1.514 g, 9.28 mmol), Cs_2CO_3 (4.53 g, 13.9 mmol) and 3-chloro-1-iodopropane (2.09 g, 10.21 mmol) were mixed according to GP6. CC (SiO_2 ; Heptane/EtOAc 10:1-5) gave the title compound (81MF941b) (1.07 g, 48%). ^1H NMR (CDCl_3) δ 6.99 – 6.87 (m, 3H), 4.42 (s, 2H), 4.17 (t, $J = 7.2$ Hz, 2H), 3.45 (t, $J = 6.4$ Hz, 2H), 2.41 (s, 3H), 2.04 – 1.97 (m, 2H); ^{13}C NMR (CDCl_3) δ 168.3, 149.9, 129.1, 128.7, 126.9, 125.1, 115.0, 69.4, 42.2, 42.1, 30.6, 20.9.

4-(3-Chloropropyl)-7-methyl-4H-benzo[1,4]oxazin-3-one (81MF2246b)

[0171] 7-Methyl-4H-benzo[1,4]oxazin-3-one (81MF2246a) (1.42 g, 8.7 mmol), Cs_2CO_3 (4.24 g, 13.0 mmol) and 3-chloro-1-iodopropane (1.95 g, 9.5 mmol) were mixed according to GP6. CC (SiO_2 ; Heptane/EtOAc 10:1-5) gave the title compound (81MF2246b) (1.64 g, 79%). ^1H NMR (CDCl_3) δ 6.98 – 6.81 (m, 3H), 4.59 (s, 2H), 4.06 – 4.03 (m, 2H), 3.63 – 3.60 (m, 2H), 2.26 (s, 2H), 2.20 – 2.15 (m, 2H); ^{13}C NMR (CDCl_3) δ 164.8, 145.8, 134.3, 123.9, 118.1, 114.9, 68.0, 42.8, 39.4, 30.5, 21.0.

(R,S)-6-Methyl-4-oxiranylmethyl-4H-benzo[1,4]oxazin-3-one (101IS84F1)

[0172] A dry 7 mL vial was charged with 6-methyl-4H-benzo[1,4]oxazin-3-one (160 mg, 1.0 mmol), epichlorohydrin (0.147 g, 1.6 mmol), Cs_2CO_3 (0.820 g, 2.5 mmol) and dry DMF (1 mL), the mixture was then shaken at 60 °C for 36 h. The mixture was diluted with ether (20 mL) washed with water and brine (10 mL), dried, filtered and concentrated under reduced pressure to give an oil. Purification with flash CC (SiO_2 , CH_2Cl_2 : acetone/MeOH 95:3:2) gave the title compound (0.127 g, 39%). ^1H NMR (CDCl_3) δ 7.01 (d, $J = 1.2$ Hz, 1H), 6.84 (d, $J = 8.4$ Hz), 6.80 (dm, $J = 8.4$ Hz), 4.58 (ABq $J = 15.2, 21.2$ Hz, 2H), 4.50 (dd, $J = 3.2, 15.2$ Hz, 1H), 3.66 (dd, $J = 6, 15.2$ Hz), 3.23 (m, 1H), 2.86 (dd, $J = 4, 4.4$ Hz, 1H), 2.69 (dd, $J = 2.8, 4.8$ Hz, 1H), 2.33 (s, 3H); ^{13}C NMR (CDCl_3) δ 156.2, 143.3, 132.9, 129.0, 124.9, 116.9, 116.6, 68.0, 50.2, 25.8, 44.0, 21.3.

GENERAL PROCEDURE 7 (GP7)

[0173] To a dry 100 mL flask was charged 4*H*-benzo[1,4]oxazin-3-one (1.0 equiv), (3-bromo-2-methyl-propoxy)-*tert*-butyldimethylsilane (1.0 equiv), Cs₂CO₃ (2.5 equiv) dissolved in dry DMF (40 mL) and stirred under an inert atmosphere at 50 °C for 20 - 28 hours. To the reaction was added water (100 mL) and extraction using diethyl ether (3 x 150 mL). The combined organic layers were washed with brine (100 mL), dried over Na₂SO₄, and concentrated followed by purification by CC (Heptane/EtOAc)

(S)-4-[3-(*tert*-Butyldimethylsilyloxy)-2-methylpropyl]-6-fluoro-4*H*-benzo[1,4]oxazin-3-one
(111MF01)

[0174] 6-Fluoro-4*H*-benzo[1,4]oxazin-3-one (95MF88) (2.54 g, 15.2 mmol), (*R*)-3-bromo-2-methylpropoxy-*tert*-butyldimethylsilane (4.07g, 15.2 mmol) and Cs₂CO₃ (12.38 g, 38 mmol) were mixed according to GP7. CC (SiO₂; Heptane/EtOAc 9:1) gave the title compound (111MF01) (4.09 g, 76%). ¹H NMR (CDCl₃) δ 6.93 - 6.87 (m, 1H), 6.92 - 6.88 (m, 1H), 6.68 - 6.63 (m, 1H), 4.56 (m, 2H), 4.01 (m, 1H), 3.78 (m, 1H), 3.58 (m, 1H), 3.45 (m, 1H), 2.11 (m, 1H), 0.92 (s, 12H), 0.06 (d, *J* = 0.8 Hz, 6H); ¹³C NMR (CDCl₃) δ 164.8, 158.5 (d, *J* = 239.9 Hz), 141.6 (d, *J* = 2.7 Hz), 130.1 (d, *J* = 10.7 Hz), 117.6 (d, *J* = 9.3 Hz), 109.6 (d, *J* = 23.1 Hz), 103.6 (d, *J* = 28.8 Hz), 67.8, 65.9, 44.2, 34.5, 26.0, 18.4, 14.9, -5.4, -5.4.

(S)-4-[3-(*tert*-Butyldimethylsilyloxy)-2-methylpropyl]-7-fluoro-4*H*-benzo[1,4]oxazin-3-one
(111MF14)

[0175] 7-Fluoro-4*H*-benzo[1,4]oxazin-3-one (111MF12) (2.52 g, 15.1 mmol), (*S*)-3-bromo-2-methylpropoxy-*tert*-butyldimethylsilane (4.03 g, 15.1 mmol) and Cs₂CO₃ (12.3 g, 38 mmol) were mixed according to GP7. CC (SiO₂; Heptane/EtOAc 9:1) gave the title compound (111MF14) (3.79 g, 71%). ¹H NMR (CDCl₃) δ 7.12 (dd, *J* = 5.2 Hz, *J* = 8.8 Hz, 1H), 6.67 - 6.34 (m, 2H), 4.60 (q, *J* = 14.8 Hz, *J* = 25.4 Hz, 2H), 4.03 (dd, *J* = 8.4 Hz, *J* = 14.0 Hz, 1H), 3.82 (dd, *J* = 5.6 Hz, *J* = 14.0 Hz, 1H), 3.57 (dd, *J* = 4.8 Hz, *J* = 10.0 Hz, 1H), 3.45 (dd, *J* = 7.0 Hz, *J* = 9.8 Hz, 1H), 2.15 - 2.05 (m, 1H), 0.93 - 0.89 (m, 12H), 0.06 (s, 6H); ¹³C NMR (CDCl₃) δ 164.1, 158.9 (d, *J* = 243.7 Hz), 146.4 (d, *J* = 11.6 Hz), 125.3 (d, *J* = 3.0 Hz), 116.4 (d, *J* = 9.6 Hz), 109.1 (d, *J* = 22.7 Hz), 105.1 (d, *J* = 25.8 Hz), 67.8, 66.0, 44.1, 34.5, 26.0, 18.4, 14.9, -5.3, -5.4.

(S)-4-[3-(*tert*-Butyldimethylsilyloxy)-2-methylpropyl]-6-methoxy-4*H*-benzo[1,4]oxazin-3-one
(111MF32)

[0176] 6-Methoxy-4*H*-benzo[1,4]oxazin-3-one (111MF24) (2.7 g, 15.1 mmol), (*S*)-3-bromo-2-methylpropoxy-*tert*-butyldimethylsilane (4.03g, 15.1 mmol) and Cs₂CO₃ (12.3 g, 38 mmol) were mixed according to GP7. CC (SiO₂; Heptane/EtOAc 9:1) to give the title compound

(111MF32) (4.03 g, 80%). ^1H NMR (CDCl_3) δ 6.89 (d, $J = 8.8$ Hz, 1H), 6.71 (d, $J = 2.8$ Hz, 1H), 6.50 (dd, $J = 2.8$ Hz, $J = 8.6$ Hz, 1H), 4.53 (q, $J = 14.8$ Hz, $J = 29.2$ Hz, 2H), 3.98 (dd, $J = 8.8$ Hz, $J = 14.0$ Hz, 1H), 3.85 (dd, $J = 5.8$ Hz, $J = 14.2$ Hz, 1H), 3.77 (s, 3H), 3.57 (dd, $J = 9.2$ Hz, $J = 10.0$ Hz, 1H), 3.47 (dd, $J = 7.2$ Hz, $J = 10.0$ Hz, 1H), 2.20 - 2.12 (m, 1H), 0.91 (s, 12H), 0.05 (d, $J = 1.2$ Hz, 6H); ^{13}C NMR (CDCl_3) δ 165.3, 155.6, 139.7, 129.8, 117.2, 107.4, 103.3, 68.0, 66.2, 55.9, 43.9, 34.3, 26.1, 18.5, 14.7, -5.3, -5.4.

GENERAL PROCEDURE 8 (GP8)

[0177] To a 100 mL flask was charged 4-[3-(*tert*-Butyldimethylsilanyloxy)-2-methylpropyl]-4*H*-benzo[1,4]oxazin-3-one (1.0 equiv) and Tetrabutylammonium flouride monohydrate (1.3 equiv) and dissolved in 40 mL dry THF. The reaction was stirred in rt under an inert atmosphere for 20-24 hours. The reaction mixture was concentrated and purified by CC (Heptane/EtOAc).

(S)-6-Fluoro-4-(3-hydroxy-2-methylpropyl)-4*H*-benzo[1,4]oxazin-3-one (111MF03)

[0178] The compound (S)-4-[3-(*tert*-Butyldimethylsilanyloxy)-2-methylpropyl]-6-fluoro-4*H*-benzo[1,4]oxazin-3-one (111MF01) (4.09 g, 11.6 mmol) and tetrabutylammonium flouride monohydrate (4.30 g, 15.4 mmol) were mixed according to GP8. CC (SiO_2 ; Heptane/EtOAc 4:1-4) gave the title compound (111MF03) (2.63 g, 95%). ^1H NMR (CDCl_3) δ 6.92 (dd, $J = 5.2$ Hz, $J = 8.8$ Hz, 1H), 6.80 (dd, $J = 2.8$ Hz, $J = 10.0$ Hz, 1H), 6.71 - 6.66 (m, 1H), 4.59 (d, $J = 0.8$ Hz, 2H), 4.17 - 4.11 (m, 1H), 3.58 - 3.40 (m, 3H), 2.79 (s, 1H), 2.08 - 1.96 (m, 1H), 1.04 (d, $J = 7.2$ Hz, 3H); ^{13}C NMR (CDCl_3) δ 165.3, 158.4 (d, $J = 238.44$ Hz), 141.5 (d, $J = 2.7$ Hz), 129.5 (d, $J = 10.4$ Hz), 117.9 (d, $J = 9.3$ Hz), 110.2 (d, $J = 23.1$ Hz), 103.1 (d, $J = 28.4$ Hz), 67.5, 63.85, 43.8, 34.0, 14.9.

(S)-7-Fluoro-4-(3-hydroxy-2-methylpropyl)-4*H*-benzo[1,4]oxazin-3-one (111MF18)

[0179] The compound (S)-4-[3-(*tert*-Butyldimethylsilanyloxy)-2-methylpropyl]-7-fluoro-4*H*-benzo[1,4]oxazin-3-one (111MF14) (3.79 g, 10.7 mmol) and tetrabutylammonium flouride monohydrate (3.99 g, 14.3 mmol) were mixed according to GP8. CC (SiO_2 ; Heptane/EtOAc 4:1-4) gave the title compound (111MF18) (2.57 g, 100%). ^1H NMR (CDCl_3) δ 6.99 - 6.95 (m, 1H), 7.77 - 7.72 (m, 2H), 4.63 (m, 2H), 4.23 - 4.16 (m, 1H), 3.58 - 3.40 (m, 3H), 2.86 (s, 1H), 2.05 - 1.97 (m, 1H), 1.04 (d, $J = 6.8$ Hz, 3H); ^{13}C NMR (CDCl_3) δ 164.6, 159.2 (d, $J = 244.5$ Hz), 146.4 (d, $J = 11.6$ Hz), 124.9 (d, $J = 3.1$ Hz), 115.9 (d, $J = 9.6$ Hz), 109.4 (d, $J = 22.7$ Hz), 105.3 (d, $J = 26.1$ Hz), 67.5, 63.8, 43.8, 34.0, 15.0.

(S)-4-(3-Hydroxy-2-methylpropyl)-6-methoxy-4H-benzo[1,4]oxazin-3-one (111MF34)

[0180] The compound (S)-4-[3-(*tert*-Butyldimethylsilanyloxy)-2-methylpropyl]-6-methoxy-4H-benzo[1,4]oxazin-3-one (111MF32) (4.03 g, 12.0 mmol) and tetrabutylammonium fluoride monohydrate (4.46 g, 16.0 mmol) were mixed according to GP8. CC (SiO₂; Heptane/EtOAc 4:1-4) gave the title compound (111MF34) (2.70 g, 100%). ¹H NMR (CDCl₃) δ 6.91 (d, *J* = 8.8 Hz, 1H), 6.63 (d, *J* = 2.8 Hz, 1H), 6.54 (dd, *J* = 2.8 Hz, *J* = 8.8 Hz, 1H), 4.57 (s, 2H), 4.19 (dd, *J* = 9.4 Hz, *J* = 14.6 Hz, 1H), 3.78 (s, 3H), 3.56 - 3.39 (m, 3H), 2.84 (s, 1H), 2.09 - 1.99 (m, 1H), 1.05 (d, *J* = 7.2 Hz, 3H); ¹³C NMR (CDCl₃) 165.8, 155.5, 139.5, 129.4, 117.4, 107.7, 103.0, 67.7, 63.8, 56.0, 43.6, 34.1, 15.0.

[0169] GENERAL PROCEDURE 9 (GP9)

[0181] A 250 mL flask was charged with 4-(3-hydroxy-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (1.0 equiv) dissolved in CHCl₃ (100 mL). Then triphenylphosphine (2.2 equiv) and imidazole (2.4 equiv) was added. To the solution was added I₂ (2.8 equiv) and the reaction was stirred in rt for 15 - 18 hours. The reaction mixture was quenched with Na₂S₂O₃ (aqueous, sat) (100 mL). The phases were separated and the water phase washed with CH₂Cl₂ (150 mL). The combined organic layers were dried over Na₂SO₄, concentrated and purified by CC (Heptane/EtOAc).

(S)-6-Fluoro-4-(3-iodo-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (111MF04)

The compound (S)-6-Fluoro-4-(3-hydroxy-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (111MF03) (2.63 g, 11.0 mmol), triphenylphosphine (6.35 g, 24.2 mmol), imidazole (1.8 g, 26.4 mmol) and I₂ (7.81 g, 30.8 mmol) were mixed according to GP9. CC (SiO₂; Heptane/EtOAc 9:1-4) gave the title compound (111MF04) (3.86 g, 100 %). ¹H NMR (CDCl₃) δ 6.97 - 6.93 (m, 1H), 6.82 - 6.78 (m, 1H), 6.73 - 6.68 (m, 1H), 4.63 - 4.53 (m, 2H), 3.90 (d, *J* = 6.8 Hz, 2H), 3.20 - 3.16 (m, 2H), 2.15 - 2.04 (m, 1H), 1.06 (d, *J* = 6.4 Hz, 3H); ¹³C NMR (CDCl₃) δ 165.0, 158.5 (d, *J* = 240.2 Hz), 141.7 (d, *J* = 2.3 Hz), 129.6 (d, *J* = 10.4 Hz), 118.1 (d, *J* = 9.2 Hz), 110.1 (d, *J* = 23.4 Hz), 103.1 (d, *J* = 28.7 Hz), 67.8, 46.3, 33.5, 18.9, 11.6.

(S)-7-Fluoro-4-(3-iodo-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (111MF20)

[0182] The compound (S)-7-Fluoro-4-(3-hydroxy-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (111MF18) (2.57 g, 11.0 mmol), triphenylphosphine (6.61 g, 23.7 mmol), imidazole (1.76 g, 25.8 mmol) and I₂ (7.64 g, 30.1 mmol) were mixed according to GP9. CC (SiO₂; Heptane/EtOAc 9:1-4) gave the title compound (111MF20) (3.31 g, 89%). ¹H NMR (CDCl₃) δ 7.00 - 6.96 (m, 1H), 6.78 - 6.74 (m, 2H), 4.65 - 4.56 (m, 2H), 3.92 (d, *J* = 7.6 Hz, 2H), 3.21 - 3.13 (m, 2H), 2.13 - 2.03 (m, 1H), 1.04 (d, *J* = 6.4 Hz, 3H); ¹³C NMR (CDCl₃) δ 164.3, 159.0 (d, *J* = 244.4

(Hz), 146.6 (d, $J = 12.0$ Hz), 125.0 (d, $J = 3.0$ Hz), 115.9 (d, $J = 9.7$ Hz), 109.4 (d, $J = 22.5$ Hz), 105.5 (d, $J = 26.0$ Hz), 67.8, 46.3, 33.6, 18.9, 11.8.

(S)-4-(3-Iodo-2-methylpropyl)-6-methoxy-4H-benzo[1,4]oxazin-3-one (111MF36)

[0183] The compound (S)-4-(3-Hydroxy-2-methylpropyl)-6-methoxy-4H-benzo[1,4]oxazin-3-one (111MF34) (2.70 g, 12.0 mmol), triphenylphosphine (6.92 g, 26.4 mmol), Imidazole (1.96 g, 28.8 mmol) and I_2 (8.53 g, 33.6 mmol) were mixed according to GP9. CC (SiO_2 ; Heptane/EtOAc 9:1-4) gave the title compound (111MF36) (3.54 g, 82%). 1H NMR ($CDCl_3$) δ 6.92 (d, $J = 8.4$ Hz, 1H), 6.63 (d, $J = 2.8$ Hz, 1H), 6.53 (dd, $J = 2.8$ Hz, $J = 8.8$ Hz, 1H), 4.54 (q, $J = 14.8$ Hz, $J = 23.6$ Hz, 2H), 3.92 (d, $J = 7.4$ Hz, 2H), 3.80 (s, 3H), 3.18 (dd, $J = 1.0$ Hz, $J = 6$ Hz, 2H), 2.17 – 2.08 (m, 1H), 1.05 (d, $J = 6.8$ Hz, 3H); ^{13}C NMR ($CDCl_3$) δ 165.4, 155.6, 139.6, 129.4, 117.7, 108.0, 102.5, 68.0, 56.1, 46.1, 33.6, 18.9, 12.0.

(S)-4-[3-(tert-Butyldimethylsilyloxy)-2-methylpropyl]-6-methyl-4H-benzo[1,4]oxazin-3-one (101IS60-1)

[0184] A dry 50 mL r-flask was charged with 6-Methyl-4H-benzo[1,4]oxazin-3-one (0.59 g, 3.6 mmol), (R)-(3-bromo-2-methylpropoxy)-tert-butyldimethylsilane (1.0 g, 3.6 mmol), Cs_2CO_3 (2.9 g, 8.9 mmol) and 10 mL of dry DMF. The mixture was stirred at 50 °C overnight (15 h) and dissolved in ether (50 mL) washed with water (20 mL) and the water phase was extracted with ether (20 mL). The combined organic phases were then washed with brine, dried (Na_2SO_4), filtered, concentrated under reduced pressure and the resulting oil was purified by flash chromatography (SiO_2 ; Heptane/EtOAc 85:15) to yield the title compound as an oil (1.1 g, 88 %). 1H NMR ($CDCl_3$) δ 6.87 (d, $J = 1.6$ Hz, 1H), 6.81 (d, $J = 8.0$ Hz, 1H), 6.72 (dm, $J = 8.0$ Hz, 1H), 4.5 (bars, 2H), 3.93 (dd, $J = 8.8$, 14.0 Hz, 1H), 3.81 (dd, $J = 5.6$, 14.0 Hz, 1H), 3.53 (dd, $J = 4.8$, 10.2 Hz, 1H), 3.41 (dd, $J = 7.2$, 10.2 Hz, 1H), 2.25 (s, 3H), 2.18 (m, 1H), 0.87 (s, 9H), 0.83 (d, $J = 6.8$ Hz, 3H), 0.01 (s, 6H); ^{13}C NMR ($CDCl_3$) δ 170.5, 148.9, 137.8, 129.6, 122.2, 121.6, 73.3, 71.6, 49.0, 39.7, 31.5, 26.6, 23.8, 20.1, 0.0.

(S)-4-(3-Hydroxy-2-methylpropyl)-6-methyl-4H-benzo[1,4]oxazin-3-one (101IS60-2)

[0185] The compound (S)-4-[3-(tert-butyldimethylsilyloxy)-2-methylpropyl]-6-methyl-4H-benzo[1,4]oxazin-3-one (101IS60-1) (1.0 g, 2.9 mmol) was dissolved in dry THF (12 mL) and TBAF (1.2 g, 3.8 mmol) was added. The reaction was stirred at rt overnight and the solution was concentrated under reduced pressure, the remaining oil was diluted with EtOAc (60 mL) and washed with brine (3 x 30 mL), dried (Na_2SO_4) filtered and concentrated under reduced pressure. The remaining oil was purified by flash chromatography (SiO_2 ; Heptane/EtOAc 30:70) to

yield an oil which crystallized upon standing (0.69 g, 76 %). ¹H NMR (CDCl₃) δ 6.88 (d, *J* = 8.4 Hz, 1H), 6.83-6.78 (m, 2H), 4.59 (brs 2 H), 4.22 (dd *J* = 10.0, 14.4 Hz), 3.57-3.38 (m, 3H), 2.9 (vbrs, 1H), 2.33 (s, 3H), 2.04 (m, 1H), 1.08 (d, *J* = 7.2 Hz); ¹³C NMR (CDCl₃) δ 165.7, 143.4, 132.3, 124.9, 117.1, 115.9, 67.6, 63.7, 43.5, 34.2, 21.3, 15.1.

(S)-4-(3-Iodo-2-methylpropyl)-6-methyl-4H-benzof[1,4]oxazin-3-one (101IS70)

[0186] A dry 50 mL r-flask was charged with (S)-4-(3-hydroxy-2-methylpropyl)-6-methyl-4H-benzo[1,4]oxazin-3-one (1.0 g, 4.2 mmol), PPh₃ (2.2 g, 8.5 mmol), imidazole (0.58 g, 8.5 mmol) and dissolved with CH₂Cl₂ (25 mL). Iodine (2.2 g, 8.4 mmol) was then added in small portions over 4h period. After the last addition the reaction was poured onto SiO₂ and filtered. Concentration under reduced pressure yielded the crude title compound (1.5 g), which was used without further purification.

1-(3-Chloropropyl)-3,4-dihydro-1H-quinolin-2-one (85LM31)

[0187] A 50 mL flask was charged with 3,4-dihydro-1H-quinolin-2-one (2.00 g, 13.6 mmol) and sodium hydride (60% in oil, 0.712 g, 16.3 mmol) in DMF (50 mL, dry) and stirred at 0 °C for 1 h, followed by addition of 1-chloro-3-iodo-propane (2.77 g, 13.6 mmol) and stirring at rt for 20 h. The reaction mixture was quenched with water (10 mL), and the product was extracted into EtOEt (3 x 25 mL). The combined organic layers were dried (Na₂SO₄), evaporated and purified by flash CC (SiO₂; EtOAc/heptane 1:4) to give the crude title compound (85LM31) (2.25 g). ¹H NMR (CDCl₃) δ 7.29 – 7.22 (m, 1H), 7.17 (d, *J* = 7.4 Hz, 1H), 7.08 – 6.98 (m, 2H), 4.10 (t, *J* = 7.3 Hz, CH₂), 3.62 (t, *J* = 5.9 Hz, CH₂), 2.88 (t, *J* = 7.3 Hz, CH₂), 2.63 (t, *J* = 7.3 Hz, CH₂), 2.19 – 2.10 (m, 2H); ¹³C NMR (CDCl₃) δ 170.5, 140.0, 128.2, 127.8, 126.3, 123.2, 115.0, 43.3, 40.2, 32.2, 30.5, 26.0.

1-(3-Chloropropyl)-6-fluoro-3,4-dihydro-1H-quinolin-2-one (92LH79)

[0188] A reaction flask was charged with 6-fluoro-3,4-dihydro-1H-quinolin-2-one (0.180 g, 1.09 mmol) in dry DMF (2 mL) under Argon. NaH (60% in oil, 0.048 g, 1.20 mmol) was added and the mixture was stirred at rt for 0.5 h. Then 1-bromo-3-chloropropane (0.180 g, 1.14 mmol) was added followed by stirring at rt for 20 h. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The product was purified by flash CC (SiO₂; DCM) to give the title compound (92LH79) (0.193 g, 73%). ¹H NMR (CDCl₃) δ 7.02 – 6.88 (m, 3H), 4.09 – 4.05 (m, 2H), 3.61 (t, *J* = 6.3 Hz, CH₂), 2.87 (t, *J* = 6.7 Hz, CH₂), 2.65 – 2.61 (m, 2H), 2.16 – 2.09 (m, 2H);

^{13}C NMR (CDCl_3) δ 169.8, 158.4 ($J = 242.9$ Hz), 135.7 ($J = 2.7$ Hz), 128.5 ($J = 7.7$ Hz), 115.7 ($J = 8.1$ Hz), 115.1 ($J = 22.7$), 113.8 ($J = 22.3$ Hz), 42.6, 40.3, 31.5, 30.1, 25.5.

(*R,S*)-1-(3-Chloro-2-methylpropyl)-6-fluoro-3,4-dihydro-1*H*-quinolin-2-one (107LH68)

[0189] A reaction flask was charged with 6-fluoro-3,4-dihydro-1*H*-quinolin-2-one (0.496 g, 3.0 mmol) in dry DMF (3 mL) under Argon. NaH (60% in oil, 0.132 g, 3.3 mmol) was added and the mixture was stirred at rt for 45 min. Then (*R,S*)-1-bromo-3-chloro-2-methylpropane (0.513 g, 3.0 mmol) was added followed by stirring at rt for 20 h. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated. The crude product was purified by flash CC (SiO_2 ; EtOAc/n-heptane 1:1) to give the crude title compound (107LH68) (0.308 g).

1-(3-Chloropropyl)-6-methyl-3,4-dihydro-1*H*-quinolin-2-one (107LH14)

[0190] A reaction flask was charged with 6-methyl-3,4-dihydro-1*H*-quinolin-2-one (107LH05) (0.300 g, 1.26 mmol) in dry DMF (5 mL) under Argon. NaH (60% in oil, 0.055 g, 1.38 mmol) was added and the mixture was stirred at rt for 1 h. Then 1-bromo-3-chloropropane (0.198 g, 1.24 mmol) was added followed by stirring at rt for 20 h. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated. The crude product was purified by flash CC (SiO_2 ; DCM) to give the crude title compound (107LH14) (0.257 g).

1-(3-Chloropropyl)-7-fluoro-6-methyl-3,4-dihydro-1*H*-quinolin-2-one (112KK01)

[0191] A reaction flask was charged with 7-fluoro-6-methyl-3,4-dihydro-1*H*-quinolin-2-one (97KK40) (0.102 g, 0.57 mmol) in dry DMF (5 mL) under an argon atmosphere. Washed NaH (0.015 g, 0.63 mmol) was added and the mixture was stirred at rt for 1 h. Then 1-chloro-3-iodopropane (0.104 g, 0.51 mmol) dissolved in DMF (1 mL) was added followed by stirring at rt for 20 h. The reaction mixture was quenched with water, and the product extracted into Et_2O . The combined organic layers were washed with aqueous 4% MgSO_4 , dried over Na_2SO_4 , filtered, and concentrated. The product was purified by flash CC (SiO_2 ; DCM/n-heptane 2:1, DCM, MeOH/DCM 1:10) to give the title compound (112KK01) (0.050 g, 38%). ^1H NMR (CDCl_3) δ 6.95 – 6.93 (m, 1H), 6.73 (d, $J = 11.5$ Hz, 1H), 4.03 – 4.00 (m, 2H), 3.59 (t, $J = 6.5$ Hz, CH_2), 2.83 – 2.79 (m, 2H), 2.62 – 2.58 (m, 2H), 2.20 (d, $J = 1.8$ Hz, CH_3), 2.13 – 2.07 (m, 2H).

1-(3-Chloropropyl)-6,7-difluoro-3,4-dihydro-1*H*-quinolin-2-one (112KK03)

[0192] A reaction flask was charged with 6,7-difluoro-3,4-dihydro-1*H*-quinolin-2-one (97KK47) (0.181 g, 0.99 mmol) in dry DMF (5 mL) under an argon atmosphere. Washed NaH

(0.026 g, 1.08 mmol) was added and the mixture was stirred at rt for 0.5 h. Then 3-chloro-1-iodopropane (0.205 g, 1.00 mmol) dissolved in DMF (1 mL) was added followed by stirring at rt for 20 h. The reaction mixture was quenched with water, and the product extracted into Et₂O. The combined organic layers were washed with aqueous 4% MgSO₄, dried over Na₂SO₄, filtered, and concentrated. The product was purified by flash CC (SiO₂; DCM) to give the title compound (112KK03) (0.122 g, 47%). ¹H NMR (CD₃OD) δ 6.99 – 6.86 (m, 2H), 4.03 – 3.99 (m, 2H), 3.60 (t, *J* = 6.1, CH₂), 2.84 – 2.81 (m, 2H), 2.63 – 2.59 (m, 2H), 2.13 – 2.06 (m, 2H).

1-(3-Chloropropyl)-5-methyl-3,4-dihydro-1H-quinolin-2-one and 1-(3-chloropropyl)-7-methyl-3,4-dihydro-1H-quinolin-2-one

[0193] Neat 2-chloro-*N*-m-tolylacetamide (92LH85) (1.7 g, 8.5 mmol) was heated to 135 °C and AlCl₃ (3.4 mg, 26 mmol) was added under an Argon atmosphere, in small portions, during 30 min. The reaction was allowed cool to 60 °C and then HCl (10 mL, 4 M) was added. The mixture was extracted with EtOAc (2 x 30 mL) and the combined organic phase was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (SiO₂; CH₂Cl₂/MeOH 9:1) to yield The compound 7-Methyl-3,4-dihydro-1H-quinolin-2-one and 5-Methyl-3,4-dihydro-1H-quinolin-2-one (1.1 g). This mixture was dissolved in dry DMF(8 mL) and NaH (60% in oil, 310 mg, 7.7 mmol) was added and the solution was stirred under a N₂ atmosphere at rt for 45 min. Thereafter, 1-bromo-3-chloropropan was added and the reaction was stirred overnight at rt. The reaction mixture was diluted with EtOAc (50 mL) and washed with water (10 mL). The organic phase was dried over Na₂SO₄ filtered, concentrated under reduced pressure and the residue was purified by prep RP-HPLC to yield 1-(3-chloropropyl)-5-methyl-3,4-dihydro-1H-quinolin-2-one (0.057 g, 3%) and 1-(3-chloropropyl)-7-methyl-3,4-dihydro-1H-quinolin-2-one (0.12 g, 6%). 1-(3-Chloropropyl)-5-methyl-3,4-dihydro-1H-quinolin-2-one, (107LH27-11.7). Retention time = 11.7 min. ¹H NMR (CD₃OD) δ 7.12 (vbrt, 7.7 Hz, 1H), 6.98 (d, *J* = 8.0 Hz, 1H), 6.90 (d, *J* = 7.2 Hz, 1H), 4.09-4.02 (m, 2H), 3.59 (t, *J* = 6.4 Hz, 2H), 2.85-2.78 (m, 2H), 2.58-2.50 (m, 2H), 2.27 (s, 3H), 2.10-2.01 (m, 2H); ¹³C NMR (CD₃OD) δ 171.5, 139.2, 135.9, 126.9, 125.4, 125.3, 113.1, 42.2, 40.1, 31.1, 30.3, 21.2, 18.5. 1-(3-Chloropropyl)-7-methyl-3,4-dihydro-1H-quinolin-2-one, (107LH27-13.1). Retention time = 13.1 min. ¹H NMR (CD₃OD) δ 7.02 (brd, *J* = 7.6 Hz, 1H), 6.94 (brs, 1H), 6.81 (brd, *J* = 7.6 Hz, 1H), 4.03 (brt, *J* = 7.2 Hz, 2H), 3.58 (t, *J* = 6.2 Hz, 2H), 2.78 (t, *J* = 7.4 Hz, 2H), 2.51 (t, *J* = 7.4 Hz), 2.30 (s, 3H), 2.09-2.00 (m, 2H); ¹³C NMR (CD₃OD) δ 171.6, 139.0, 137.4, 127.8, 123.9, 115.7, 42.3, 39.8, 31.7, 30.3, 24.6, 20.4.

(S)-1-[3-(*t*-Butyldimethylsilyl)-2-methylpropyl]-3,4-dihydro-1*H*-quinolin-2-one (122LH13)

[0194] A reaction flask was charged with 3,4-dihydro-1*H*-quinolin-2-one (1.60 g, 10.9 mmol) in dry DMF (30 mL) under Argon. NaH (60% in oil, 0.480 g, 12.0 mmol) was added and the mixture was stirred at rt for 1 h. Then (*R*)-(3-bromo-2-methylpropoxy)-*t*-butyldimethylsilane (3.0 g, 10.9 mmol) was added followed by stirring at rt for 4 days. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The product was purified by flash CC (SiO₂; DCM) to give the title compounds (122LH13) (2.685 g, 74%).

(S)-1-(3-Hydroxy-2-methylpropyl)-3,4-dihydro-1*H*-quinolin-2-one (122LH16)

[0195] A reaction flask was charged with (*S*)-1-[3-(*t*-Butyldimethylsilyl)-2-methylpropyl]-3,4-dihydro-1*H*-quinolin-2-one (122LH13) (2.685 g, 8.05 mmol) and tetrabutylammonium fluoride (2.70 g, 10.3 mmol) in dry THF (20 mL) and stirred at rt for 20 h under an Argon atmosphere. The reaction mixture was concentrated, and the product purified by flash CC (SiO₂; n-heptane/EtOAc 1:1) to give the title compound (122) (1.54 g, 87%).

(S)-1-(3-Iodo-2-methylpropyl)-3,4-dihydro-1*H*-quinolin-2-one (122LH18)

[0196] A reaction flask was charged with (*S*)-1-(3-Hydroxy-2-methylpropyl)-3,4-dihydro-1*H*-quinolin-2-one (122LH16) (1.54 g, 7.0 mmol) dissolved in 50 mL DCM. PPh₃ (4.04 g, 15.4 mmol) and imidazole (1.14 g, 16.7 mmol) were added followed by stirring at rt for 15 min. The mixture was cooled with an ice-bath followed by addition of I₂ (5.00 g, 19.7 mmol). The reaction mixture was slowly warmed to rt and stirred over night. The reaction mixture was washed with a Na₂S₂O₃ solution, dried over Na₂SO₄, and concentrated. The product was purified by flash CC (SiO₂; n-heptane/EtOAc 1:1) to give the title compound (122LH18) (2.140 g, 93%).

1-(3-Chloropropyl)-1*H*-quinolin-2-one (107LH80)

[0197] A 7 mL vial was charged with 1*H*-quinolin-2-one (0.62 g, 4.2 mmol), 4 mL dry DMF and NaH (60% in oil, 0.200 g, 5.1 mmol). The mixture was stirred under a N₂ atmosphere at rt for 45 min, and thereafter 1-bromo-3-chloropropane (0.42 mL, 4.2 mmol) was added and the reaction was stirred at rt overnight. The reaction was diluted with EtOAc (50 mL) and washed with water (15 mL). The water phase was extracted with EtOAc (25 mL) and the combined organic phase was dried (Na₂SO₄), filtered, concentrated under reduced pressure and the residue was purified by flash chromatography (SiO₂; CH₂Cl₂) to yield the title compound (0.38 g, 41%), containing 15% of 1-(3-bromopropyl)-1*H*-quinolin-2-one. ¹H NMR (CD₃OD) δ 7.90 (d, *J* = 9.4 Hz, 1H), 7.73-7.57 (m, 3H), 7.34-7.28 (m, 1H), 6.66 (d, *J* = 9.4 Hz), 4.46 (t, *J* = 7.4 Hz, 2H), 3.71 (t, *J*

= 6.4 Hz, 2H), 2.21-2.02 (m, 2H); ^{13}C NMR (CD_3OD) δ 163.2, 140.7, 138.8, 131.3, 129.3, 122.8, 121.4, 120.2, 114.4, 42.18, 40.2, 30.5.

1-(3-Chloropropyl)-5-methyl-1H-quinolin-2-one, (107LH39)

[0198] A microwave vial was charged with 1-(3-chloropropyl)-5-methyl-3,4-dihydro-1H-quinolin-2-one (0.081 g, 0.34 mmol), DDQ (0.116 g, 0.51 mmol), dioxane (2 mL) and sealed. After microwave irradiation, 175 °C, 10 min, the reaction was diluted with EtOAc (50 mL), washed with sat aqueous NaHCO_3 (2 x 15 mL) and the organic phase was dried (Na_2SO_4), filtered, concentrated under reduced pressure and the residue was purified with prep RP-HPLC to yield the crude title compound (0.053 g), which was used without further purification. HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 236.2$.

1-(3-Chloropropyl)-7-methyl-1H-quinolin-2-one (107LH40)

[0199] A microwave vial was charged with 1-(3-chloropropyl)-7-methyl-3,4-dihydro-1H-quinolin-2-one (0.21 g, 0.88 mmol), DDQ (0.30 g, 1.3 mmol), dioxane (4 mL) and sealed. After microwave irradiation, 175 °C, 10 min, the reaction was diluted with EtOAc (50 mL), washed with sat aqueous NaHCO_3 (2 x 15 mL) and the organic phase was dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified with prep RP-HPLC to yield the crude title compound (0.130 g), which was used without further purification. HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 236.2$.

(S)-1-[3-(tert-Butyldimethylsilyloxy)-2-methylpropyl]-1H-quinolin-2-one (107LH43)

[0200] 1H-Quinolin-2-one (1.9 g, 13 mmol) and NaH (60% in oil, 0.58 g, 15 mmol) were added to dry DMF (30 mL) and the reaction was stirred under a N_2 atmosphere at rt for 45 min. Thereafter, (R)-(3-bromo-2-methylpropyl)-tert-butyldimethylsilane (3.7 g, 13 mmol) was added and the reaction was stirred for 72 h at 50 °C. The reaction was poured onto water and extracted with EtOAc (2 x 50 mL) and the combined organic phase was dried, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (SiO_2 ; CH_2Cl_2) to yield the title compound (2.10 g, 6.4 mmol, 48%). ^1H NMR (CDCl_3) δ 7.60-7.53 (m, 2H), 7.49-7.40 (m, 2H), 7.12 (dt, $J = 0.9, 7.6$ Hz, 1H), 6.62 (d, $J = 9.6$ Hz, 1H), 4.39 (dd, $J = 8.4, 14.0$ Hz, 1H), 4.15 (dd, $J = 5.4, 14.0$ Hz), 3.54 (dd, $J = 4.4, 10.2$ Hz, 1H), 3.45 (dd, $J = 7.6, 10.2$ Hz), 2.27-2.12 (m, 1H), 0.88 (s, 12 H), 0.01 (s, 6 H); ^{13}C NMR (CDCl_3) δ 168.2, 145.2, 144.5, 135.8, 134.3, 127.3, 127.2, 126.4, 120.5, 71.7, 50.4, 40.9, 31.4, 23.8, 20.4, 0.0.

(S)-1-(3-Hydroxy-2-methylpropyl)-1H-quinolin-2-one (107LH62)

[0201] TBAF (1.2 g, 4.6 mmol) and (S)-1-[3-(*tert*-butyldimethylsilyloxy)-2-methylpropyl]-1H-quinolin-2-one (0.31 g, 0.93 mmol) were dissolved in THF (5 mL) and stirred under an Argon atmosphere at rt overnight. The mixture was concentrated under reduced pressure and dissolved in EtOAc (30 mL). The solution was washed with water (15 mL), dried over Na₂SO₄, and concentrated under reduced pressure. The residue thereof was filtered through silica to give the crude title compound (0.19 g), which was used without further purification.

(S)-1-(3-Iodo-2-methylpropyl)-1H-quinolin-2-one (107LH64)

[0202] Imidazole (0.14 g, 2.1 mmol), crude (S)-1-(3-hydroxy-2-methyl-propyl)-1H-quinolin-2-one (0.19 g, 0.87 mmol) and PPh₃ (0.50 g, 1.9 mmol) were dissolved in CH₂Cl₂ (5 mL) and the solution was cooled to 0 °C, thereafter I₂ (0.61 g, 2.4 mmol) was added and the reaction reached rt overnight. The reaction diluted with CH₂Cl₂ (25 mL) and washed with sat aqueous Na₂SO₄ (2 x 25 mL) and the organic phase was dried over Na₂SO₄, filtered, concentrated under reduced pressure to yield the crude product that was used without further purification. HPLC-MS (ammonium acetate) [M+H]⁺ = 328.1.

GENERAL PROCEDURE 10 (GP10)

[0203] A 4 mL vial was charged with the appropriate heterocycle (1 equiv) and the appropriate piperidine (1.2 or 2 equiv) in dry MeCN (½ mL) and shaken. The reaction mixture was quenched with water (1 mL), and the product extracted into EtOAc (2 x 1 mL). The combined organic layers were purified by cation exchange CC and by flash CC.

(R)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-4H-benzo[1,4]thiazin-3-one (108LM43-40)

[0204] The compound (S)-4-(3-Iodo-2-methyl-propyl)-4H-benzo[1,4]thiazin-3-one (108LM37-34) (0.105 g, 0.304 mmol) and 4-butyl-piperidine (0.052 g, 0.369 mmol) in MeCN (½ mL) were reacted according to GP10 shaking at 60 °C for 3 days. Purified by cation exchange CC and flash CC (SiO₂; MeOH/DCM 1:20) to give the title compound (108LM43-40) (0.082 g, 75%). ¹H NMR (CDCl₃) δ 7.34 (d, *J* = 9.1 Hz, 1H), 7.25-7.17 (m, 2H), 7.02-6.95 (m, 1H), 4.15-3.99 (m, 2H), 3.35 (s, CH₂), 2.83 (bd, *J* = 10.4 Hz, 1H), 2.68 (bd, *J* = 10.4 Hz, 1H), 2.20-2.05 (m, 2H), 2.00-1.85 (m, 2H), 1.82-1.73 (m, 1H), 1.67-1.55 (m, 2H), 1.30-1.14 (m, 9H), 0.88 (t, *J* = 7.2, CH₃), 0.82 (d, *J* = 6.5 Hz, CH₃); ¹³C NMR (CDCl₃) δ 166.0, 139.2, 128.8, 127.1, 124.8, 123.5, 118.9, 63.8, 55.5, 54.4, 47.7, 36.6, 36.1, 32.9, 32.8, 32.1, 29.4, 29.3, 23.2, 16.7, 14.4; HPLC-MS (ammonium acetate) [M+H]⁺=361.3.

(R)-4-[2-Methyl-3-(4-propoxypiperidin-1-yl)propyl]-4H-benzo[1,4]thiazin-3-one (108LM49-46)

[0205] The compound (S)-4-(3-Iodo-2-methyl-propyl)-4H-benzo[1,4]thiazin-3-one (108LM37-34) (0.433 g, 1.25 mmol) and 4-propoxypiperidine (79KS66) (0.225 g, 1.55 mmol) in MeCN (½ mL) were reacted according to GP10 shaking at 60 °C for 4 days. Purified by cation exchange CC and flash CC (SiO₂; MeOH/DCM 1:20) to give the title compound (108LM49-46) (0.220 g, 49%). ¹H NMR (CDCl₃) δ 7.37 (d, *J* = 8.1 Hz, 1H), 7.25 - 7.20 (m, 2H), 7.05 - 6.97 (m, 1H), 4.18 - 4.00 (m, 2H), 3.42 - 3.35 (m, 4H), 3.30 - 3.20 (m, 1H), 2.80 - 2.70 (m, 1H), 2.65 - 2.55 (m, 1H), 2.20 - 2.05 (m, 3H), 2.00 - 1.82 (m, 4H), 1.62 - 1.50 (m, 4H), 0.92 (t, *J* = 7.4, CH₃), 0.82 (d, *J* = 6.8 Hz, CH₃), ¹³C NMR (CDCl₃) δ 166.1, 139.2, 128.8, 127.1, 124.9, 123.5, 118.8, 75.5, 69.8, 63.3, 52.7, 51.9, 47.6, 32.1, 32.0, 29.6, 23.5, 16.6, 10.9; HPLC-MS (ammonium acetate) [M+H]⁺=363.3.

(R)-4-[3-(4-Butylidene-piperidin-1-yl)-2-methyl-propyl]-4H-benzo[1,4]thiazin-3-one (108LM50-47)

[0206] The compound (S)-4-(3-Iodo-2-methyl-propyl)-4H-benzo[1,4]thiazin-3-one (108LM37-34) (0.432 g, 1.25 mmol) and 4-butylidenepiperidine (111MF05) (0.208 g, 1.49 mmol) in MeCN (½ mL) were reacted according to GP10 shaking at 60 °C for 4 days. Purified by cation exchange CC and flash CC (SiO₂; MeOH/DCM 1:20) to give the title compound (108LM50-47) (0.267 g, 60%). ¹H NMR (CDCl₃) δ 7.35 (d, *J* = 7.5 Hz, 1H), 7.26 - 7.18 (m, 2H), 6.98 (t, *J* = 7.5 Hz, 1H), 5.10 (t, *J* = 7.4 Hz, CH), 4.17 - 4.03 (m, 2H), 3.36 (s, CH₂), 2.43 - 2.33 (m, 2H), 2.30 - 2.08 (m, 8H), 2.00 - 1.90 (m, 3H), 1.28 - 1.38 (m, 2H), 0.90 - 0.80 (m, 6H); ¹³C NMR (CDCl₃) δ 166.0, 139.2, 136.4, 128.8, 127.1, 124.8, 123.5, 122.7, 118.8, 63.4, 56.4, 55.6, 47.7, 36.4, 32.1, 29.5, 29.4, 28.6, 23.4, 16.7, 14.0; HPLC-MS (ammonium acetate) [M+H]⁺=359.3.

(R)-4-[3-(3-Butyl-8-aza-bicyclo[3.2.1]oct-8-yl)-2-methyl-propyl]-4H-benzo[1,4]thiazin-3-one (108LM51-48)

[0207] The compound (S)-4-(3-Iodo-2-methyl-propyl)-4H-benzo[1,4]thiazin-3-one (108LM37-34) (0.093 g, 0.269 mmol) and 3-butyl-8-aza-bicyclo[3.2.1]octane (104KS29) (0.054 g, 0.323 mmol) in MeCN (½ mL) were reacted according to GP10 shaking at 40 °C for 5 days. Purified by cation exchange CC and flash CC (SiO₂; MeOH/DCM 1:10) to give the title compound (108LM51-48) (0.042 g, 40%). ¹H NMR (CDCl₃) δ 7.38 (d, *J* = 7.8 Hz, 1H), 7.33 (d, *J* = 8.1 Hz, 1H), 7.22 (t, *J* = 7.9 Hz, 1H), 7.00 (t, *J* = 8.0 Hz, 1H), 4.18 - 4.10 (m, 2H), 3.38 (s, CH₂), 3.15 - 3.00 (m, 2H), 2.30 - 2.22 (m, 1H), 2.20 - 2.10 (m, 1H), 1.90 - 1.75 (m, 3H), 1.60 - 1.40 (m, 5H), 1.40 - 1.15 (m, 8H), 0.90 - 0.82 (m, 6H); ¹³C NMR (CDCl₃) δ 166.1, 139.2, 128.7, 127.2, 124.7,

123.5, 119.1, 61.4, 60.1, 57.3, 47.6, 38.3, 36.9, 32.1, 31.2, 29.9, 29.4, 28.2, 27.2, 26.5, 23.1, 16.7, 14.3; HPLC-MS (ammonium acetate) $[M+H]^+ = 387.3$.

(R)-4-[2-Methyl-3-(3-pentyl-8-aza-bicyclo[3.2.1]oct-8-yl)propyl]-4H-benzo[1,4]thiazin-3-one
(108LM52-49)

[0208] The compound (S)-4-(3-Iodo-2-methylpropyl)-4H-benzo[1,4]thiazin-3-one (108LM37-34) (0.080 g, 0.231 mmol) and 3-pentyl-8-azabicyclo[3.2.1]octane (104KS32-2) (0.050 g, 0.276 mmol) in MeCN ($\frac{1}{2}$ mL) were reacted according to GP10 shaking at 40 °C for 5 days. Purified by cation exchange CC and flash CC (SiO_2 ; MeOH/DCM 1:50 + 1% Et_3N) to give the title compound (108LM52-49) (0.045 g, 49%). 1H NMR ($CDCl_3$) δ 7.36 (d, $J = 7.6$ Hz, 1H), 7.32 (d, $J = 7.7$ Hz, 1H), 7.22 (t, $J = 7.6$ Hz, 1H), 7.00 (t, $J = 7.6$ Hz, 1H), 4.16 (d, $J = 7.3$ Hz, CH_2), 3.34 (s, CH_2), 3.10 - 2.95 (m, 2H), 2.25 - 2.17 (m, 1H), 2.15 - 2.03 (m, 3H), 1.94 - 1.75 (m, 3H), 1.70 - 1.60 (m, 1H), 1.60 - 1.50 (m, 2H), 1.40 - 1.15 (m, 10H), 0.90 - 0.80 (m, 6H); ^{13}C NMR ($CDCl_3$) δ 166.1, 139.2, 128.7, 127.1, 124.7, 123.4, 119.1, 60.5, 59.0, 57.4, 47.5, 38.4, 36.4, 32.2, 32.1, 31.4, 29.9, 28.5, 28.4, 27.9, 27.2, 22.9, 16.7, 14.3; HPLC-MS (ammonium acetate) $[M+H]^+ = 401.3$.

GENERAL PROCEDURE 11 (GP11)

[0209] A 100 mL flask was charged with 4-(3-chloropropyl)-4H-benzo[1,4]oxazin-3-one (1.0 equiv), K_2CO_3 (2.0 equiv), NaI (2.0 equiv) and 4-Butylpiperidine (1.05 equiv) in 25 mL dry MeCN and stirred at rt for 168 h under N_2 atmosphere. The reaction mixture was evaporated to dryness and diluted with 100 mL H_2O and extracted into EtOAc (3 x 120 mL). The combined organic layers were dried over $MgSO_4$, evaporated to dryness, and purified by CC (Heptane:EtOAc or CH_2Cl_2 :MeOH).

4-[3-(4-Butylpiperidin-1-yl)propyl]-6,8-dichloro-7-methyl-4H-benzo[1,4]oxazin-3-one
(81MF2225F)

[0210] 6,8-Dichloro-4-(3-chloropropyl)-7-methyl-4H-benzo[1,4]oxazin-3-one (81MF2225b), (2.44 g, 7.92 mmol), K_2CO_3 (2.19 g, 15.84 mmol), NaI (2.37 g, 15.84 mmol) and 4-butylpiperidine (1.172 g, 8.3 mmol) were mixed according to GP11. CC (SiO_2 ; Heptane/EtOAc 10:1-4) gave the title compound (81MF2225F) (1.55 g, 47%). 1H NMR ($CDCl_3$) δ 7.11 (s, 1H), 4.65 (s, 2H), 3.93 (t, 2H), 2.86 (d, 2H), 2.41 (s, 3H), 2.41 (s, 3H), 2.33 (t, 2H), 1.92 - 1.77 (m, 4H), 1.65 (d, 2H), 1.31 - 1.19 (m, 9H), 0.88 (t, 3H); ^{13}C NMR ($CDCl_3$) δ 163.5, 140.5, 129.9, 128.1, 123.7, 114.0, 67.9, 55.8, 54.4, 40.1, 36.4, 36.0, 32.6, 29.2, 24.8, 23.1, 17.2, 14.2.

[0211] To the pure compound (0.235 g, 0.50 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.047 g, 0.52 mmol) in diethyl ether (2 mL). The formed crystals filtered

and washed with diethyl ether to give the title compound as oxalic salt (0.24 g, 94%); HPLC-MS (ammonium acetate) $[M+H]^+ = 413.2$

4-[3-(4-Butyl-piperidin-1-yl)propyl]-6,8-dimethyl-4H-benzo[1,4]oxazin-3-one (81MF2237F)

[0212] 4-(3-Chloropropyl)-6,8-dimethyl-4H-benzo[1,4]oxazin-3-one (81MF2237b) (0.96 g, 3.78 mmol), K_2CO_3 (1.05 g, 7.57 mmol), NaI (1.14 g, 7.57 mmol) and 4-butylpiperidine (0.56 g, 3.97 mmol) were mixed according to GP11. CC (SiO_2 ; Heptane/EtOAc 10:1-4) gave the title compound (81MF2237F) (0.98 g, 72%). 1H NMR ($CDCl_3$) δ 6.71 (s, 1H), 6.65 (s, 1H), 4.52 (s, 2H), 3.93 (t, $J = 7.2$, 2H), 2.87 (d, $J = 11.2$, 2H), 2.36 (t, $J = 7.2$ Hz, 2H), 2.27 (s, 3H), 2.18 (s, 3H), 1.81-1.89 (m, 4H), 1.65 (d, $J = 9.6$ Hz, 2H), 1.28-1.17 (m, 9H), 0.87 (t, $J = 6-8$ Hz, 3H); ^{13}C NMR ($CDCl_3$) δ 164.6, 141.4, 131.6, 128.3, 126.3, 126.1, 113.4, 67.8, 56.1, 54.3, 39.8, 36.4, 35.9, 32.7, 29.1, 25.0, 23.0, 21.1, 15.5, 14.2.

[0213] To the pure compound (0.193 g, 0.54 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.051 g, 0.57 mmol) in diethyl ether (2 mL). The formed crystals filtered and washed with diethyl ether to give the title compound as oxalic salt (0.22 g, 91%); HPLC-MS (ammonium acetate) $[M+H]^+ = 359.3$

6-tert-Butyl-4-[3-(4-butyl-piperidin-1-yl)propyl]-4H-benzo[1,4]oxazin-3-one (81MF2248F)

[0214] 6-tert-Butyl-4-(3-chloropropyl)-4H-benzo[1,4]oxazin-3-one (81MF2248b) (1.39 g, 4.93 mmol), K_2CO_3 (1.36 g, 9.85 mmol), NaI (1.48 g, 9.85 mmol) and 4-butylpiperidine (0.73 g, 5.17 mmol) were mixed according to GP11. CC (SiO_2 ; Heptane/EtOAc 10:1-4) gave the title compound (81MF2248F) (1.66 g, 87%). 1H NMR ($CDCl_3$) δ 7.01-6.98 (m, 2H), 6.91-6.88 (m, 1H), 4.55 (s, 2H), 3.99 (t, $J = 7.2$ Hz, 2H), 2.89 (d, $J = 6.4$ Hz, 2H), 2.42 (t, $J = 6.8$ Hz, 2H), 1.92-1.82 (m, 4H), 1.65 (d, $J = 9.6$ Hz, 2H), 1.31 (s, 9H), 1.29-1.17 (m, 9H), 0.88 (t, $J = 6.8$ Hz, 3H); ^{13}C NMR ($CDCl_3$) δ 164.6, 146.1, 143.3, 128.1, 120.6, 116.6, 112.2, 67.9, 56.5, 54.4, 39.8, 36.4, 35.9, 34.7, 32.6, 31.6, 29.2, 24.8, 23.1, 14.2.

[0215] To the pure compound (0.178 g, 0.46 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.044 g, 0.49 mmol) in diethyl ether (2 mL). The formed crystals filtered and washed with diethyl ether to give the title compound as oxalic salt (0.19 g, 87%); HPLC-MS (ammonium acetate) $[M+H]^+ = 387.4$

4-[3-(4-Butylpiperidin-1-yl)propyl]-5-methyl-4H-benzo[1,4]oxazin-3-one (81MF941x)

[0216] 4-(3-Chloropropyl)-5-methyl-4H-benzo[1,4]oxazin-3-one (81MF941b) (1.08 g, 4.48 mmol), K_2CO_3 (1.24 g, 8.95 mmol), NaI (1.34 g, 8.95 mmol) and 4-butylpiperidine (0.66 g, 4.70 mmol) were mixed according to GP11. CC (SiO_2 ; Heptane/EtOAc 10:1-4) gave the title compound (81MF941x) (0.814 g, 53%). 1H NMR ($CDCl_3$) δ 6.97-6.83 (m, 3H), 4.41 (s, 2H), 4.07

(t, $J = 7.2$ Hz, 2 H), 2.67 (d, $J = 10.8$ Hz, 2H), 2.39 (s, 3H), 2.18 (t, $J = 7.2$ Hz, 2 H), 1.76 (t, $J = 10.8$ Hz, 2H), 1.69 - 1.62 (m, 2H), 1.58 (d, $J = 10.0$ Hz, 2 H), 1.30 - 1.06 (m, 9H), 0.87 (t, $J = 6.8$ Hz, 3H); ^{13}C NMR (CDCl_3) δ 168.3, 150.0, 129.2, 128.9, 126.8, 124.8, 114.8, 69.5, 55.7, 54.2, 42.6, 36.4, 35.9, 32.6, 29.2, 25.3, 23.0, 20.9, 14.2.

[0217] To the pure compound (0.177 g, 0.52 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.047 g, 0.49 mmol) in diethyl ether (2 mL). The formed crystals were filtered and washed with diethyl ether to give the title compound as oxalic salt (0.21 g, 92%); HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 345.1$

4-[3-(4-Butylpiperidin-1-yl)propyl]-7-methyl-4H-benzo[1,4]oxazin-3-one (81MF2246F)

[0218] 4-(3-Chloropropyl)-7-methyl-4H-benzo[1,4]oxazin-3-one (81MF2246b) (1.64 g, 6.84 mmol), K_2CO_3 (1.89 g, 13.68 mmol), NaI (2.05 g, 13.68 mmol) and 4-butylpiperidine (1.02 g, 7.18 mmol) were mixed according to GP11. CC (SiO_2 ; Heptane/EtOAc 10:1-4) gave the title compound (81MF2246F) (1.85 g, 79%). ^1H NMR (CDCl_3) δ 6.97 (d, $J = 8.0$ Hz, 1H), 6.82 - 6.78 (m, 2H), 4.54 (s, 2H), 3.94 (t, $J = 7.2$ Hz, 2H), 2.86 (d, $J = 10.8$ Hz, 2H), 2.37 (t, $J = 7.0$ Hz, 2H), 2.28 (s, 3H), 1.92 - 1.79 (m, 4H), 1.66 (d, $J = 9.2$ Hz, 2H), 1.31 - 1.18 (m, 9H), 0.88 (t, $J = 7.2$ Hz, 3H) ^{13}C NMR (CDCl_3) δ 164.2, 145.3, 133.9, 126.3, 123.3, 117.7, 115.0, 67.8, 56.0, 54.3, 39.7, 36.5, 36.0, 32.7, 29.2, 24.9, 23.1, 20.8, 14.2.

[0219] To the pure compound (0.156 g, 0.45 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.042 g, 0.47 mmol) in diethyl ether (2 mL). The formed crystals were filtered and washed with diethyl ether to give the title compound as oxalic salt (0.192 g, 97%); HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 345.1$

4-[3-(4-Butylpiperidin-1-yl)propyl]-6-chloro-7-nitro-4H-benzo[1,4]oxazin-3-one (81MF2253x)

[0220] 6-Chloro-4-(3-chloropropyl)-7-nitro-4H-benzo[1,4]oxazin-3-one (81MF2253b) (1.23 g, 4.05 mmol), K_2CO_3 (1.12 g, 8.09 mmol), NaI (1.21 g, 8.09 mmol) and 4-butylpiperidine (0.60 g, 4.24 mmol) were mixed according to GP11. CC (SiO_2 ; Heptane/EtOAc 10:1-4) gave the title compound (81MF2253x) (0.698 g, 42%). ^1H NMR (CDCl_3) δ 7.61 (s, 1H), 7.36 (s, 1H), 4.66, (s, 2H), 3.99 (t, $J = 6.8$ Hz, 2H), 2.85 (d, $J = 11.2$ Hz, 2H), 2.34 (t, $J = 6.4$ Hz, 2H), 1.94 - 1.80 (m, 4H), 1.67 (d, $J = 10.0$ Hz, 2H), 1.31 - 1.20 (m, 9H), 0.88 (t, $J = 6.4$ Hz, 3H); ^{13}C NMR (CDCl_3) δ 163.4, 143.4, 141.9, 133.9, 122.1, 117.7, 114.8, 67.5, 55.5, 54.4, 40.5, 36.4, 36.0, 32.6, 29.2, 24.6, 23.0, 14.2.

[0221] To the pure compound (0.128 g, 0.31 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.029 g, 0.33 mmol) in diethyl ether (2 mL). The formed crystals were filtered and washed with diethyl ether to give the title compound as oxalic salt (0.125 g, 80%); HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 410.1$

4-[3-(4-Butylpiperidin-1-yl)propyl]-7-chloro-4H-benzo[1,4]oxazin-3-one (81MF2271x)

[0222] 7-Chloro-4-(3-chloropropyl)-4H-benzo[1,4]oxazin-3-one (81MF2271b) (1.953 g, 7.49 mmol), K₂CO₃ (2.07 g, 14.9 mmol), NaI (2.24 g, 14.9 mmol) and 4-butylpiperidine (1.11 g, 7.86 mmol) were mixed according to GP11. CC (SiO₂; Heptane/EtOAc 10:1-4) gave the title compound (81MF2271x) (2.46 g, 90%). ¹H NMR (CDCl₃) δ 7.08 – 6.96 (m, 3H), 4.57 (s, 2H), 3.95 (t, *J* = 7.2 Hz, 2H), 2.85 (d, *J* = 10.8 Hz, 2H), 2.35 (t, *J* = 7.2 Hz, 2H), 1.93 – 1.78 (m, 4H), 1.66 (d, *J* = 9.2 Hz, 2H), 1.31 – 1.18 (m, 9H), 0.88 (t, *J* = 6.4 Hz, 3H); ¹³C NMR (CDCl₃) δ 163.7, 146.0, 128.7, 127.7, 122.7, 117.6, 116.1, 67.7, 55.9, 54.3, 39.9, 36.5, 36.0, 32.7, 29.2, 24.8, 23.1, 14.2.

[0223] To the pure compound (0.171 g, 0.47 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.043 g, 0.49 mmol) in diethyl ether (2 mL). The formed crystals were filtered and washed with diethyl ether to give the title compound as oxalic salt (0.206 g, 97%); HPLC-MS (ammonium acetate) [M+H]⁺ = 365.1

GENERAL PROCEDURE 12 (GP12)

[0224] A 4 mL vial was charged with 4-(3-chloropropyl)-4H-benzo[1,4]oxazin-3-one (1.0 equiv), K₂CO₃ (2.0 equiv), NaI (2.0 equiv) and amine (1.05 equiv) in 3 mL dry MeCN and shaken at 60 °C for 100 h. The reaction mixture was evaporated to dryness, diluted with 4 mL H₂O, extracted into CH₂Cl₂ (3 x 10 mL), and filtered through a PTFE Whatman filter. The combined organic layers were evaporated to dryness and purified by CC (Heptane/EtOAc or CH₂Cl₂/MeOH) or Prep TLC (Heptane/EtOAc or CH₂Cl₂/MeOH).

4-[3-(4-Butylpiperidin-1-yl)propyl]-6-fluoro-4H-benzo[1,4]oxazin-3-one (8173MF55F)

[0225] 4-(3-Chloropropyl)-6-fluoro-4H-benzo[1,4]oxazin-3-one (8173MF55b) (0.102 g, 0.42 mmol), K₂CO₃ (0.12 g, 0.84 mmol), NaI (0.13 g, 0.84 mmol) and 4-butylpiperidine (0.06 g, 0.44 mmol) were mixed according to GP12. CC (SiO₂; Heptane/EtOAc 10:1-4) gave the title compound (8183MF55F) (0.12 g, 80%). ¹H NMR (CDCl₃) δ 6.96 (dd, *J* = 10.4 Hz, *J* = 2.8 Hz, 1H), 6.87 (dd, *J* = 9.6 Hz, *J* = 5.2 Hz, 1H), 6.66 – 6.12 (m, 1H), 4.51 (s, 2H), 3.91 (t, *J* = 7.2 Hz, 2H), 2.84 (d, *J* = 11.2 Hz, 2H), 2.32 (t, *J* = 7.2 Hz, 2H), 1.91 – 1.77 (m, 4H), 1.64 (d, *J* = 9.6 Hz, 2H), 1.29 – 1.16 (m, 9H), 0.86 (t, *J* = 6.8 Hz, 3H); ¹³C NMR (CDCl₃) δ 164.2, 158.5 (d, *J* = 239.5 Hz), 141.4 (d, *J* = 2.7 Hz), 130.0 (d, *J* = 10.4 Hz), 117.5 (*J* = 9.3 Hz), 109.5 (d, *J* = 23.5 Hz), 103.2 (d, *J* = 28.8 Hz), 67.7, 55.7, 54.3, 40.0, 36.4, 35.9, 32.6, 29.1, 24.7, 23.0, 14.2.

[0226] To the pure compound (0.12 g, 0.34 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.032 g, 0.37 mmol) in diethyl ether (2 mL). The formed crystals were filtered and washed with diethyl ether to give the title compound as oxalic salt (0.128 g, 87%). HPLC-MS (ammonium acetate) [M+H]⁺ = 349.2.

4-[3-(4-Butylpiperidin-1-yl)propyl]-7,8-difluoro-4H-benzo[1,4]oxazin-3-one (81MF2082x)

[0227] 4-(3-Chloropropyl)-7,8-difluoro-4H-benzo[1,4]oxazin-3-one (81MF2082b) (0.16 g, 0.60 mmol), K₂CO₃ (0.17 g, 11.9 mmol), NaI (0.18 g, 11.9 mmol) and 4-butylpiperidine (0.09 g, 0.63 mmol) were mixed according to GP12. CC (SiO₂; Heptane/EtOAc 10:1-4) gave the title compound (81MF2082x) (0.14 g, 65%). ¹H NMR (CDCl₃) δ 6.88 – 6.76 (m, 2H) 4.66 (s, 2H), 3.96 (t, *J* = 7.2 Hz, 2H), 2.84 (d, *J* = 11.2, 2H), 2.34 (t, *J* = 6.8 Hz, 2H), 1.91 – 1.78 (m, 4H), 1.67 (d, *J* = 9.6 Hz, 2H), 1.30 – 1.15 (m, 9H); ¹³C NMR (CDCl₃) δ 163.1, 147.4 (q, *J* = 245.0 Hz, *J* = 10.6 Hz), 140.1 (q, *J* = 248.7 Hz, *J* = 15.7 Hz), 135.4 (d, *J* = 12.0 Hz), 126.5, 109.5 (d, *J* = 18.4 Hz), 109.0 (q, *J* = 7.6 Hz, *J* = 3.8 Hz), 67.8, 55.8, 52.3, 40.1, 36.4, 35.9, 32.7, 29.1, 24.8, 23.0, 14.2.

[0228] To the pure compound (0.14 g, 0.39 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.042 g, 0.46 mmol) in diethyl ether (2 mL). The formed crystals were filtered and washed with diethyl ether to give the title compound as oxalic salt (0.16 g, 89%). HPLC-MS (ammonium acetate) [M+H]⁺ = 367.3.

4-[3-(4-Butylpiperidin-1-yl)propyl]-4H-pyrido[4,3-b][1,4]thiazin-3-one (81MF939)

[0229] 4-(3-Chloropropyl)-4H-pyrido[4,3-b][1,4]thiazin-3-one (81MF939b) (0.14 g, 0.57 mmol), K₂CO₃ (0.16 g, 11.4 mmol), NaI (0.18 g, 11.4 mmol) and 4-butylpiperidine (0.09 g, 0.60 mmol) were mixed according to GP12. CC (SiO₂; Heptane/EtOAc 10:1-4) gave the title compound (81MF939) (0.064 g, 32%). ¹H NMR (CDCl₃) δ 8.48 (s, 1H), 8.17 (d, *J* = 5.2 Hz, 1H), 7.25 (d, *J* = 4.8 Hz, 1H), 4.06-4.12 (m, 2H), 3.41 (s, 2H), 2.82 (d, *J* = 11.2, 2H), 2.33 (t, *J* = 6.8 Hz, 2H), 1.83-1.89 (m, 4H), 1.64 (d, *J* = 9.2 Hz, 2H), 1.16-1.29 (m, 9H), 0.87 (t, *J* = 6.8 Hz, 3H); ¹³C NMR (CDCl₃) δ 163.91, 143.84, 138.92, 136.20, 134.04, 122.31, 55.80, 54.32, 43.29, 36.43, 35.99, 32.68, 30.78, 29.19, 25.20, 23.05, 14.24.

[0230] To the pure compound (0.064 g, 0.18 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.020 g, 0.22 mmol) in diethyl ether (2 mL). The formed crystals were filtered and washed with diethyl ether to give the title compound as oxalic salt (0.16 g, 89%); HPLC-MS (ammonium acetate) [M+H]⁺ = 348.2

4-[3-(4-Propoxypiperidin-1-yl)propyl]-4H-benzo[1,4]thiazin-3-one (81MF07KS)

[0231] 4-(3-Chloropropyl)-4H-benzo[1,4]thiazin-3-one (81MF07) (0.18 g, 0.74 mmol), K₂CO₃ (0.20 g, 14.8 mmol), NaI (0.22 g, 14.8 mmol) and 4-propoxypiperidine (0.12 g, 0.81 mmol) were mixed according to GP12. CC (SiO₂; Heptane/EtOAc 4:1-4) gave the title compound (81MF07KS) (0.205 g, 79%). ¹H NMR (CDCl₃) δ 7.33 (d, *J* = 7.6 Hz, 2H), 7.21 (d, *J* = 3.2 Hz, 2H), 7.00 – 6.96 (m, 1H), 4.03 (t, *J* = 7.2 Hz, 2H), 3.38 – 3.34 (m, 4H), 3.26 – 3.21 (m, 1H), 2.69 (t, *J* = 5.6 Hz, 2H), 2.33 (t, *J* = 7.2 Hz, 2H), 2.04 (t, *J* = 9.8 Hz, 2H), 1.86 – 1.76 (m, 4H), 1.58 – 1.51

(m, 4H), 0.90 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (CDCl_3) δ 165.2, 139.7, 128.5, 127.2, 124.1, 123.4, 118.1, 75.2, 69.7, 55.4, 51.5, 43.2, 31.8, 31.7, 25.3, 23.4, 10.8.

[0232] To the pure compound (0.205 g, 0.58 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.058 g, 0.64 mmol) in diethyl ether (2 mL). The formed crystals were filtered and washed with diethyl ether to give the title compound as oxalic salt (0.192 g, 74%). HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 349.2$.

4-[3-(4-Propoxypiperidin-1-yl)propyl]-4H-benzo[1,4]oxazin-3-one (81(81MF08KS))

[0233] 4-(3-Chloropropyl)-4H-benzo[1,4]oxazin-3-one (81MF08) (0.13 g, 0.58 mmol), K_2CO_3 (0.16 g, 1.15 mmol), NaI (0.17 g, 1.15 mmol) and 4-propoxypiperidine (0.089 g, 0.60 mmol) were mixed according to GP12. CC (SiO_2 ; Heptane/EtOAc 4:1-4) gave the title compound (81(81MF08KS)) (0.147 g, 76%). ^1H NMR (CDCl_3) δ 7.11 – 7.08 (m, 1H), 7.01 – 6.94 (m, 3H), 4.55 (s, 2H), 3.96 (t, $J = 7.2$ Hz, 2H), 3.37 (t, $J = 6.8$ Hz, 2H), 3.28 – 3.21 (m, 1H), 2.74 – 2.69 (m, 2H), 2.36 (t, $J = 7.2$ Hz, 2H), 2.10 – 2.03 (m, 2H), 1.90 – 1.77 (m, 4H), 1.61 – 1.51 (m, 4H), 0.90 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (CDCl_3) δ 164.3, 145.4, 128.7, 123.8, 122.8, 117.1, 115.1, 75.1, 69.6, 67.7, 55.5, 51.5, 39.6, 31.6, 24.9, 23.4, 10.7.

[0234] To the pure compound (0.147 g, 0.44 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.048 g, 0.53 mmol) in diethyl ether (2 mL). The formed crystals were filtered and washed with diethyl ether to give the title compound as oxalic salt (0.160 g, 86%). HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 333.3$.

4-[3-(4-Butylpiperidin-1-yl)propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (81MF763)

[0235] 4-(3-Chloropropyl)-7-fluoro-4H-benzo[1,4]oxazin-3-one (81MF763b) (0.40 g, 1.6 mmol), K_2CO_3 (0.44 g, 3.2 mmol), NaI (0.48 g, 3.2 mmol) and 4-butylpiperidine (0.24 g, 1.70 mmol) were mixed according to GP12. CC (SiO_2 ; Heptane/EtOAc 4:1-4) gave the title compound (81MF763) (0.26 g, 46%). ^1H NMR (CDCl_3) δ 7.09 – 7.04 (m, 1H), 6.74 – 6.69 (m, 2H), 4.58 (s, 2H), 3.95 (t, $J = 7.2$ Hz, 2H), 2.84 (d, $J = 11.2$ Hz, 2H), 3.45 (t, $J = 6.8$ Hz, 2H), 1.91 – 1.78 (m, 4H), 1.66 (d, $J = 9.2$ Hz, 2H), 1.29 – 1.16 (m, 9H), 0.88 (t, 7.2 Hz, 3H); ^{13}C NMR (CDCl_3) δ 163.6, 158.9 (d, $J = 243.7$ Hz), 146.3 (d, $J = 11.5$ Hz), 125.2 (d, $J = 3.0$ Hz), 115.9 (d, $J = 9.7$ Hz), 109.1 (d, $J = 22.8$ Hz), 105.1 (d, $J = 26.1$ Hz), 67.8, 55.9, 54.3, 39.9, 36.5, 36.0, 32.7, 29.2, 24.8, 23.1, 14.2.

[0236] To the pure compound (0.26 g, 0.74 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.073 g, 0.818 mmol) in diethyl ether (2 mL). The formed crystals were filtered and washed with diethyl ether to give the title compound as oxalic salt (0.26 g, 78%) HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 349.3$.

4-[3-(4-Butyldenepiperidin-1-yl)propyl]-4H-benzo[1,4]thiazin-3-one (81MF26)

[0237] 4-(3-Chloropropyl)-4H-benzo[1,4]thiazin-3-one (81MF07) (0.073 g, 0.30 mmol), K₂CO₃ (0.12 g, 0.90 mmol), NaI (0.090 g, 0.6 mmol) and 4-butyldenepiperidine (0.050 g, 0.28 mmol) were mixed according to GP12. Prep TLC (SiO₂; CH₂Cl₂/MeOH 10:1) gave the title compound (81MF26) (0.034 g, 33%). ¹H NMR (CDCl₃) δ 7.34 – 7.31 (m, 1H), 7.23 – 7.20 (m, 1H), 7.00 – 6.95 (m, 1H), 5.10 (t, *J* = 7.2 Hz, 1H), 4.04 (t, *J* = 7.2 Hz, 2H), 3.34 (s, 2H), 2.37 – 2.32 (m, 6H), 2.23 – 2.14 (m, 2H), 1.96 – 1.90 (m, 2H), 1.86 – 1.78 (m, 2H), 1.37 – 1.27 (m, 2H), 0.86 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (CDCl₃) δ 165.1, 139.6, 136.0, 128.5, 127.2, 124.1, 123.4, 122.7, 118.1, 55.6, 55.4, 54.8, 43.2, 36.1, 31.7, 29.2, 28.3, 25.2, 23.2, 13.8.

[0238] To the pure compound (0.034 g, 0.10 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.010 g, 0.10 mmol) in diethyl ether (2 mL). The formed crystals were filtered and washed with diethyl ether to give the title compound as oxalic salt (0.030 g, 69%); HPLC-MS (ammonium acetate) [M+H]⁺ = 345.2

4-[3-(4-Butyldenepiperidin-1-yl)propyl]-4H-benzo[1,4]oxazin-3-one (81MF25)

[0239] 4-(3-Chloropropyl)-4H-benzo[1,4]oxazin-3-one (81MF08) (0.068 g, 0.30 mmol), K₂CO₃ (0.12 g, 0.90 mmol), NaI (0.090 g, 0.60 mmol) and 4-butyldenepiperidine (0.050 g, 0.28 mmol) were mixed according to GP12. Prep TLC (SiO₂; CH₂Cl₂/MeOH 10:1) gave the title compound (81MF25) (0.070 g, 71%). ¹H NMR (CDCl₃) δ 7.12 (d, *J* = 6.8 Hz, 1H), 7.03 – 6.95 (m, 3H), 5.12 (*J* = 7.4 Hz, 1H), 4.56 (s, 1H), 3.99 (t, *J* = 7.6 Hz, 2H), 2.41 – 2.36 (m, 6H), 2.26 – 2.17 (m, 2H), 1.98 – 1.81 (m, 4H), 1.38 – 1.28 (m, 2H), 0.87 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (CDCl₃) δ 164.3, 145.5, 136.0, 128.7, 123.8, 122.8, 122.8, 117.1, 115.2, 67.7, 55.7, 55.6, 54.9, 39.7, 36.1, 29.2, 28.4, 24.8, 23.2, 13.8.

[0240] To the pure compound (0.070 g, 0.21 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.020 g, 0.22 mmol) in diethyl ether (2 mL). The formed crystals were filtered and washed with diethyl ether to give the title compound as oxalic salt (0.087 g, 97%) HPLC-MS (ammonium acetate) [M+H]⁺ = 329.3.

4-[3-(3-Butyldene-8-aza-bicyclo[3.2.1]oct-8-yl)-propyl]-4H-benzo[1,4]oxazin-3-one (81MF24)

[0241] 4-(3-Chloropropyl)-4H-benzo[1,4]oxazin-3-one (81MF08) (0.030 g, 0.13 mmol), K₂CO₃ (0.037 g, 0.26 mmol), NaI (0.040 g, 0.27 mmol) and 3-butyldene-8-azabicyclo[3.2.1]octane (0.029 g, 0.17 mmol) were mixed according to GP12. Prep TLC (SiO₂; CH₂Cl₂/MeOH 10:1) gave the title compound (81MF24) (0.019 g, 41%). ¹H NMR (CDCl₃) δ 7.22 – 7.19 (m, 1H), 7.05 – 6.96 (m, 3H), 5.24 (t, *J* = 7.2 Hz, 1H), 5.08 (s, 2H), 4.06 (t, *J* = 6.4 Hz, 2H), 2.61 (t, *J* = 6.8 Hz, 2H), 2.30 (s, 2H), 2.03 – 1.83 (m, 7H), 1.58 – 1.43 (m, 2H), 1.39 – 1.22 (m, 3

H), 0.89 (m, 3 H); ^{13}C NMR (CDCl_3) δ 164.5, 145.5, 131.4, 128.7, 127.9, 124.0, 123.0, 117.1, 115.5, 67.8, 60.4, 60.2, 48.8, 41.0, 39.6, 33.7, 29.5, 26.8, 26.4, 25.8, 23.2, 13.9.

[0242] To the pure compound (0.019 g, 0.05 mmol) dissolved in diethyl ether (2 mL) was added oxalic acid (0.005 g, 0.006 mmol) in diethyl ether (1 mL). The formed crystals were filtered and washed with diethyl ether to give the title compound as oxalic salt (0.012 g, 50%); HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 355.3$

4-[3-(4-Butylpiperidin-1-yl)propyl]-6-methoxy-4H-benzo[1,4]oxazin-3-one (81MF2249)

[0243] 4-(3-Chloropropyl)-6-methoxy-4H-benzo[1,4]oxazin-3-one (81MF2249b) (0.127 g, 0.50 mmol), K_2CO_3 (0.137 g, 1.0 mmol), NaI (0.149 g, 1.0 mmol) and 4-butylpiperidine (0.075 g, 0.52 mmol) were mixed according to GP12. CC (SiO_2 ; Heptane/EtOAc 4:1-4) gave the title compound (81MF2249) (0.14 g, 85%). ^1H NMR (CDCl_3) δ 6.88 (d, $J = 8.8$ Hz, 1H), 6.67 (d, $J = 2.4$ Hz, 1H), 6.49 (dd, $J = 8.8$ Hz, $J = 2.4$ Hz, 1H), 4.51 (s, 2H), 3.93 (t, 7.2 Hz, 2H), 3.77 (s, 3H), 2.86 (d, $J = 10.8$ Hz, 2H), 2.36 (t, $J = 7.2$ Hz, 2H), 1.90 – 1.80 (m, 4H), 1.64 (d $J = 8.8$ Hz, 2H), 1.29 – 1.17 (m, 9H), 0.88 (t, $J = 6.2$ Hz, 3H); ^{13}C NMR (CDCl_3) δ 168.8, 155.6, 139.6, 129.7, 117.2, 107.2, 102.9, 68.0, 56.1, 56.0, 54.4, 39.9, 36.5, 35.9, 32.6, 29.2, 24.9, 23.0, 14.2.

[0244] To the pure compound (0.14 g, 0.37 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.037 g, 0.41 mmol) in diethyl ether (2 mL). The formed crystals were filtered and washed with diethyl ether to give the title compound as oxalic salt (0.15 g, 90%). HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 361.3$.

GENERAL PROCEDURE 13 (GP13)

[0245] A 7 mL vial was charged with 4-(3-chloropropyl)-4H-benzo[1,4]oxazin-3-one (1.0 equiv), K_2CO_3 (2.0 equiv), NaI (2.0 equiv) and 4-Butylpiperidine (1.05 equiv) in 5 mL dry MeCN and shaken at 60 °C for 48 h. The reaction mixture was evaporated to dryness, diluted with 10 mL H_2O , extracted into CH_2Cl_2 (3 x 13 mL), and filtered through a PTFE Whatman filter. The combined organic layers were evaporated to dryness and purified by CC (Heptane/EtOAc or $\text{CH}_2\text{Cl}_2/\text{MeOH}$) or prep TLC (Heptane/EtOAc or $\text{CH}_2\text{Cl}_2/\text{MeOH}$).

4-[3-(4-Butylpiperidin-1-yl)propyl]-6,8-dichloro-7-ethyl-4H-benzo[1,4]oxazin-3-one (95MF60)

[0246] 6,8-Dichloro-4-(3-chloro-propyl)-7-ethyl-4H-benzo[1,4]oxazin-3-one ((95MF52(2226)) (0.30 g, 0.93 mmol), K_2CO_3 (0.26 g, 1.86 mmol), NaI (0.28 g, 1.86 mmol) and 4-butylpiperidine (0.14 g, 0.98 mmol) were mixed according to GP13. CC (SiO_2 ; $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 10:0.2-4) gave the title compound (95MF60) (0.24 g, 59%). ^1H NMR (CDCl_3) δ 7.10 (s, 1H), 4.65 (s, 2H), 3.93 (t, $J = 6.8$ Hz, 2H), 2.95 – 2.81 (m, 4H), 2.33 (t, $J = 6.8$ Hz, 2H), 1.90 – 1.78 (m, 4H), 1.66 (d, $J = 10.0$ Hz, 2H) 1.30 – 1.13 (m, 12H), 0.88 (s, 3H); ^{13}C NMR (CDCl_3) δ 163.5, 140.6,

135.3, 128.2, 127.7, 123.2, 114.3, 67.9, 55.8, 54.4, 40.1, 36.4, 36.0, 32.7, 29.2, 24.8, 24.6, 23.1, 14.2, 12.7; HPLC-MS (ammonium acetate) $[M+H]^+ = 427.2$.

4-[3-(4-Butylpiperidin-1-yl)propyl]-8-fluoro-4H-benzo[1,4]oxazin-3-one (95MF59)

[0247] 4-(3-Chloropropyl)-8-fluoro-4H-benzo[1,4]oxazin-3-one (95MF51(2085)) (0.25 g, 1.04 mmol), K_2CO_3 (0.29 g, 2.1 mmol), NaI (0.31 g, 2.1 mmol) and 4-butylpiperidine (0.15 g, 1.1 mmol) were mixed according to GP13. CC (SiO_2 ; CH_2Cl_2 /MeOH 10:0.2-4) gave the title compound (95MF59) (0.29 g, 80%). 1H NMR ($CDCl_3$) δ 6.92 – 6.84 (m, 2H), 6.79 – 6.74 (m, 1H), 4.59 (s, 2H), 3.93 (t, $J = 7.4$ Hz, 2H), 2.81 (d, $J = 10.8$ Hz, 2H), 2.31 (t, $J = 7.0$ Hz, 2H), 1.87 – 1.75 (m, 4H), 1.62 (d, $J = 9.2$ Hz, 2H), 1.27 – 1.12 (m, 9H), 0.84 (t, $J = 6.8$ Hz, 3H); ^{13}C NMR ($CDCl_3$) δ 163.7, 151.8 (d, $J = 246.0$ Hz), 133.8 (d, $J = 14.6$ Hz), 130.7 (d, $J = 3.5$ Hz), 122.1 (d, $J = 8.0$ Hz), 111.2 (d, $J = 18.4$ Hz), 110.4 (d, $J = 3.4$ Hz), 67.6, 55.8, 54.2, 40.0, 36.4, 35.8, 32.6, 29.0, 24.8, 22.9, 14.1.

[0248] To the pure compound (0.29 g, 0.83 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.078 g, 0.86 mmol) in diethyl ether (2 mL). The formed crystals were filtered and washed with diethyl ether to give the title compound as oxalic salt (0.31 g, 85%). HPLC-MS (ammonium acetate) $[M+H]^+ = 349.3$.

6-Bromo-4-[3-(4-butylpiperidin-1-yl)propyl]-8-fluoro-4H-benzo[1,4]oxazin-3-one (95MF58)

[0249] 6-Bromo-4-(3-chloropropyl)-8-fluoro-4H-benzo[1,4]oxazin-3-one (95MF50(2084)) (0.086 g, 0.27 mmol), K_2CO_3 (0.074 g, 0.53 mmol), NaI (0.080 g, 0.53 mmol) and 4-butylpiperidine (0.039 g, 0.28 mmol) were mixed according to GP13. CC (SiO_2 ; CH_2Cl_2 /MeOH 10:0.2-4) gave the title compound (95MF58) (0.040 g, 35%). 1H NMR ($CDCl_3$) δ 6.92 – 6.84 (m, 2H), 6.79 – 6.74 (m, 1H), 4.59 (s, 2H), 3.93 (t, $J = 7.4$ Hz, 2H), 2.81 (d, $J = 10.8$ Hz, 2H), 2.31 (t, $J = 7.0$ Hz, 2H), 1.87 – 1.75 (m, 4H), 1.62 (d, $J = 9.2$ Hz, 2H), 1.27 – 1.12 (m, 9H), 0.84 (t, $J = 6.8$ Hz, 3H); ^{13}C NMR ($CDCl_3$) δ 163.7, 151.8 (d, $J = 246.0$ Hz), 133.8 (d, $J = 14.6$ Hz), 130.7 (d, $J = 3.5$ Hz), 122.1 (d, $J = 8.0$ Hz), 111.2 (d, $J = 18.4$ Hz), 110.4 (d, $J = 3.4$ Hz), 67.6, 55.8, 54.2, 40.0, 36.4, 35.8, 32.6, 29.0, 24.8, 22.9, 14.1.

[0250] To the pure compound (0.040 g, 0.09 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.009 g, 0.098 mmol) in diethyl ether (2 mL). The formed crystals were filtered and washed with diethyl ether to give the title compound as oxalic salt (0.040 g, 82%). HPLC-MS (ammonium acetate) $[M+H]^+ = 427.2$.

[0212] 4-[3-(4-Butylpiperidin-1-yl)propyl]-8-isopropyl-4H-benzo[1,4]oxazin-3-one (111MF02)

[0251] 4-(3-Chloropropyl)-8-isopropyl-4H-benzo[1,4]oxazin-3-one (95MF98) (0.112 g, 0.42 mmol), K_2CO_3 (0.115 g, 0.84 mmol), NaI (0.125 g, 0.84 mmol) and 4-butylpiperidine

(0.062 g, 0.44 mmol) were mixed according to GP13. Prep TLC (SiO₂; CH₂Cl₂/MeOH 10:1) gave the title compound (111MF02) (0.06 g, 39%). ¹H NMR (CDCl₃) δ 6.99 – 6.91 (m, 3H), 4.55 (s, 2H), 3.96 (t, *J* = 7.4 Hz, 2H), 3.27 (m, 1H), 2.89 (d, *J* = 11.2 Hz, 2H), 2.40 (t, *J* = 7.2 Hz, 2H), 1.93 – 1.83 (m, 4H), 1.66 (d, *J* = 9.6 Hz, 2H); 1.27 – 1.20 (m, 15H), 0.88 (t, *J* = 6.8 Hz, 3H); ¹³C NMR (CDCl₃) δ 164.7, 142.9, 137.5, 128.7, 122.6, 121.1, 112.9, 67.7, 56.0, 54.2, 39.9, 36.4, 35.9, 32.5, 29.1, 27.2, 24.9, 23.0, 22.7, 14.2.

[0252] To the pure compound (0.06 g, 0.16 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.016 g, 0.18 mmol) in diethyl ether (2 mL). The formed crystals were filtered and washed with diethyl ether to give the title compound as oxalic salt (0.07 g, 88%). HPLC-MS (ammonium acetate) [M+H]⁺ = 373.3.

(*R,S*)-4-[3-(4-Butylpiperidin-1-yl)-2-hydroxy-propyl]-6-methyl-4*H*-benzo[1,4]oxazin-3-one (101IS86)

[0253] A dry 4 mL vial was charged with (*R,S*)-6-methyl-4-oxiranylmethyl-4*H*-benzo[1,4]oxazin-3-one (0.090 g, 0.41 mmol), 4-butylpiperidine (0.090 g, 0.60 mmol), K₂CO₃ (0.097 g, 0.70 mmol) and dry THF (2 mL). The mixture was shaken at 40 °C for 74 h and was thereafter concentrated under reduced pressure and the residue was diluted with EtOAc (20 mL) and washed with water (10 mL), brine, dried over Na₂SO₄. Filtration, concentration under reduced pressure and purification of the residue with flash chromatography (SiO₂; CH₂Cl₂/acetone/MeOH 85:10:5) gave the title product as an oil (0.080 g, 54%). ¹H NMR (CD₃OD) δ 7.12 (s, 1H), 6.85 (d, *J* = 8.2 Hz, 1H), 6.81 (brd, *J* = 8.2 Hz, 1H), 4.53 (ABq, 14.8, 18.0 Hz, 2H), 4.12 – 4.02 (m, 2H), 3.95 – 3.85 (m, 1H), 3.05 – 2.98 (m, 1H), 2.92 – 2.84 (m, 1H), 2.48 – 2.40 (m, 2H), 2.31 (s, 3H), 2.10 – 1.98 (m, 2H), 1.71 – 1.62 (m, 2H), 1.35 – 1.15 (m, 9H), 0.90 (t, *J* = 6.8 Hz). ¹³C NMR (CD₃OD) δ 166.0, 143.7, 132.4, 128.8, 124.4, 116.5, 116.4, 67.5, 65.9, 62.8, 54.6, 54.5, 46.1, 36.3, 35.6, 32.2 (br), 29.0, 22.8, 20.0, 13.3.

[0254] The product was dissolved in diethyl ether and oxalic acid (1.1 equiv) dissolved in diethyl ether was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.033 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 361.3.

(*R,S*)-4-[3-(4-Butylpiperidin-1-yl)-2-hydroxypropyl]-4*H*-benzo[1,4]oxazin-3-one (101IS85)

[0255] Epichlorohydrin (0.48 g, 5.2 mmol), Cs₂CO₃ (2.3 g, 7.0 mmol), 4*H*-benzo[1,4]oxazin-3-one (0.52 g, 3.5 mmol) were stirred with dry DMF (7 mL) for 22 h. Thereafter the mixture was diluted with ether (50 mL) and washed with water (10 mL) and brine (10 mL). The organic phase was dried over Na₂SO₄, filtered, concentrated under reduced pressure and the residue was purified by flash chromatography (SiO₂; CH₂Cl₂/acetone/MeOH 95:3:2). The resulting oil (0.50 g, 2.5 mmol) was dissolved in THF, 4-butylpiperidine (0.43 g, 3.0 mmol) and K₂CO₃ (0.83 g,

6.0 mmol) were added and the reaction was shaken at 40 °C for 72 h. The reaction was thereafter concentrated under reduced pressure, and the residue was purified by flash CC (SiO₂; CH₂Cl₂/acetone/MeOH 85:10:5) to give the title compound (0.43 g, 1.2 mmol, 35%). ¹H NMR (CD₃OD) δ 7.32 (brd, *J* = 7.2 Hz, 1H), 7.06-6.94 (m, 3H), 4.58 (ABq, *J* = 14.8, 17.6 Hz, 2H), 4.13-4.03 (m, 2H), 3.91 (dd, *J* = 8.8, 15.2 Hz), 3.97 (brd, *J* = 10.7 Hz, 1H), 2.87 (brd, *J* = 10.1 Hz), 2.43 (d, *J* = 6 Hz, 2H), 2.09-1.96 (m, 2H), 1.69-1.60 (m, 2H), 1.34-1.16 (m, 9H), 0.90 (t, *J* = 6.8 Hz); ¹³C NMR (CD₃OD) δ 165.8, 145.8, 129.2, 124.0, 122.6, 116.7, 116.2, 67.4, 65.9, 54.7, 54.5, 46.2, 36.3, 35.6, 32.2 (br), 29.0, 22.8, 13.3.

[0256] The product was dissolved in diethyl ether and oxalic acid (1.1 equiv) dissolved in diethyl ether was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.037 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 347.3.

(-)-4-[3-(4-Butylpiperidin-1-yl)-2-hydroxypropyl]-4H-benzo[1,4]oxazin-3-one (101IS95)

[0257] Following the method outlined above for (*R,S*)-4-[3-(4-butylpiperidin-1-yl)-2-hydroxypropyl]-4H-benzo[1,4]oxazin-3-one using (R)-(-)-epichlorohydrine (97% ee), (instead of racemic epichlorohydrin, gave the title compound. The optical purity was determined by HPLC analysis (Chiralpak AD, 250 x 4.6, 5 μm; hexane/*i*-PrOH/diethylamine 95:4.7:0.3, 0.5 mL/min) to be 96.3% ee. ([α]_D²⁰ = -6, c = 0.5, EtOH).

¹H NMR, ¹³C NMR and HPLC-MS spectral data were identical to those of the racemic compound.

(*R,S*)-4-[3-(4-Butylpiperidin)-2-methoxypropyl]-4H-benzo[1,4]oxazin-3-one (101IS91)

[0258] A dry 4 mL vial was charged with NaH (6.5 mg, 0.15 mmol) and then a solution of (*R,S*)-4-[3-(4-Butylpiperidin-1-yl)-2-hydroxypropyl]-4H-benzo[1,4]oxazin-3-one (101IS85) (0.043 g, 0.12 mmol) in dry THF (1 mL) was added and the mixture was allowed to stir at rt for 2 h. Thereafter, neat MeI (7.5 μl, 0.12 mmol) was added and after another 2h at rt the reaction mixture was quenched with water (2 mL) and extracted with EtOAc (3 x 10 mL). The organic phase was dried over Na₂SO₄, filtered, concentrated under reduced pressure and the residue was purified by flash chromatography (SiO₂; CH₂Cl₂/acetone/MeOH 90:6:4) to yield the title compound as an oil (5.1 mg, 12%). ¹H NMR (CD₃OD) δ 7.25 (dm, *J* = 7.2 Hz, 1H), 7.00-6.88 (m, 3H), 4.49 (ABq, *J* = 15.2, 18.8 Hz, 2H), 4.06-3.94 (m, 2H), 3.69-3.61 (m, 1H), 3.25 (s, 3H), 2.94-2.82 (m, 2H), 2.54-2.36 (m, 2H), 2.10-1.94 (m, 2H), 1.64-1.55 (m, 2H), 1.25-1.05 (m, 9H), 0.81 (t, *J* = 6.8 Hz); ¹³C NMR (CD₃OD) δ 165.9, 146.0, 129.1, 124.2, 122.7, 116.8, 116.1, 76.0, 67.5, 60.2, 57.2, 54.6, 54.5, 43.7, 36.2, 35.3, 31.8, 28.9, 22.8, 13.2; HPLC-MS (ammonium acetate) [M+H]⁺ = 361.3.

(R,S)-4-[2-Hydroxy-3-(3-pentylbicyclo[3.2.1]oct-8-yl)-propyl]-4H-benzo[1,4]oxazin-3-one
(123IS03)

[0259] Epichlorohydrin (0.48 g, 5.2 mmol), Cs₂CO₃ (2.3 g, 7.0 mmol), 4H-benzo[1,4]oxazin-3-one (0.52 g, 3.5 mmol) were stirred with dry DMF (7 mL) for 22 h. Thereafter the mixture was diluted with ether (50 mL) washed with water (10 mL) and then brine (10 mL). The organic phase was dried over Na₂SO₄, filtered, concentrated under reduced pressure and the residue was purified by flash CC (SiO₂; CH₂Cl₂/acetone/MeOH 95:3:2). Of the resulting oil (0.060 g, 0.29 mmol) was dissolved in DMF (1.5 mL), 3-pentyl-8-azabicyclo[3.2.1]octane (0.060 g, 0.33 mmol) and Cs₂CO₃ (0.30 g, 0.81 mmol) were added and the mixture was shaken at 65 °C for 72 h. The mixture was then poured into ether (25 mL) washed with water (10 mL) and the water phase was extracted with ether (20 mL). The combined organic phase was washed with brine (10 mL), dried over Na₂SO₄, filtered, concentrated under reduced pressure and the residue was purified by cation exchange CC, followed by flash CC (SiO₂; CH₂Cl₂:acetone:MeOH 85/10/5) to yield the title compound (0.060 g, 33% (from 4H-benzo[1,4]oxazin-3-one)). ¹H NMR (CDCl₃) δ 7.42 (dm, *J* = 7.2 Hz, 1H), 7.05-6.94 (m, 3H), 4.60 (ABq, *J* = 14.8, 16.8 Hz, 2H), 4.15 (dd, *J* = 3.2, 14.0 Hz, 1H), 3.86-3.78 (m, 3H), 3.14 (m, 2H), 2.54 (dd, *J* = 4.8, 12.5 Hz, 1H), 2.22 (dd, *J* = 9.2, 12.4 Hz), 2.16-1.98 (m, 2H), 1.98-1.83 (m, 2H), 1.72-1.55 (m, 3H), 1.43-1.34 (m, 2H), 1.42-1.15 (m, 8H), 0.87 (t, *J* = 7.2 Hz). ¹³C NMR (CDCl₃) δ 165.3, 145.5, 129.7, 124.2, 122.9, 117.0, 116.6, 67.9, 67.4, 60.9, 58.6, 56.7, 46.7, 38.3, 36.7, 36.5, 28.5, 28.3, 28.2, 27.1, 22.9, 14.3. HPLC-MS (ammonium acetate) [M+H]⁺ = 387.3.

4-[2-(4-Butylpiperidin-1-ylmethyl)allyl]-4H-benzo[1,4]oxazin-3-one (123IS02)

[0260] 3-Chloro-2-chloromethyl-1-propene (0.20 g, 1.5 mmol), 4H-benzo[1,4]oxazin-3-one (0.15 g, 1.0 mmol) and Cs₂CO₃ (0.65 g, 2.0 mmol) were mixed with 1 mL DMF and were shaken at 65 °C for 5 h. The mixture was diluted with ether (20 mL) and washed with water (20 mL) and the water phase was extracted with ether (20 mL). The combined organic phase was washed with brine (10 mL), dried over Na₂SO₄, filtered concentrated under reduced pressure and the residue was purified by flash CC (SiO₂; heptane/EtOAc 70:30). This product (0.080 g, 0.34 mmol) was dissolved in DMF (1 mL), thereafter 4-butylpiperidine (0.053 g, 0.37 mmol) and Cs₂CO₃ (0.23 g, 0.71 mmol) were added and the mixture was shaken at 65 °C for 24 h. The mixture was then poured into ether (25 mL) washed with water (10 mL) and the water phase was extracted with ether (20 mL). The combined organic phase was washed with brine (10 mL), dried over Na₂SO₄, filtered, concentrated under reduced pressure and the residue was purified by cation exchange CC, followed by flash CC (SiO₂; EtOAc/MeOH/NH₄OH (25% NH₃ in water) 97.5:2:0.5), to yield the title compound (0.075 g, 21%). ¹H NMR (CDCl₃) δ 7.05-2.92 (m, 4H), 5.01 (brs, 1H),

4.82 (brs, 1H), 4.64 (brs 2H), 4.57 (brs, 2H), 2.94 (brs, 2H), 2.86 (brd, $J = 10.4$ Hz, 2H), 1.93-1.82 (m, 2H), 1.71-1.62 (m, 2H), 1.34-1.15 (m, 9H), 0.89 (t, $J = 6.2$ Hz, 3H); ^{13}C NMR (CDCl_3) δ 1.64.5, 145.4, 129.2, 123.9, 122.8, 116.9, 113.2, 67.9, 63.2, 54.4, 44.8, 36.6, 36.0, 32.8, 29.3, 23.1, 14.3; HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 343.3$.

(R,S)-4-[3-(4-Butylpiperidin-1-yl)-2-fluoropropyl]-4H-benzo[1,4]oxazin-3-one (101IS96)

[0261] A 4mL vial was charged with (R,S)-4-butyl-1-(3-chloro-2-fluoropropyl)piperidine (0.020 g, 85 μmol) and 4H-benzo[1,4]oxazin-3-one (0.023 g 0.16 mmol) and CH_3CN (1 mL). The mixture was stirred at 60 °C for 70 h and the mixture was diluted with MeOH and filtered through a small silica pad onto a cationic-exchange CC. Concentration under reduced pressure yielded an oil that was purified by flash chromatography (SiO_2 ; heptane:EtOAc 50/50;) to yield the title compound as an oil (0.011 g, 38%). ^1H NMR (CD_3OD) δ 7.28-7.24 (m, 1H), 7.07-6.96 (m, 3H), 5.05 (dm, $J = 50.4$ Hz), (ABq, $J = 15.2$, 20.0 Hz), 4.29-4.12 (m, 2H), 3.00-2.92 (m, 2H), 2.78-2.60 (m, 2H), 2.14-2.05 (m, 2H), 1.73-1.63 (m, 2H), 1.35-1.16 (m, 10H), 0.90 (t, $J = 6.8$ Hz, 3H). ^{13}C NMR (CD_3OD) δ 165.8, 145.8, 129.0, 124.2, 122.7, 116.8, 117.0, 116.8, 89.5 (d, $J = 174$ Hz), 67.4, 60.1 (d, $J = 21$ Hz), 54.5, 43.8 (d, $J = 23$ Hz), 36.2, 35.4, 32.0, 31.9, 28.9, 22.8, 13.2.

[0262] The product was dissolved in diethyl ether and oxalic acid (1.1 equiv) dissolved in diethyl ether was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.037 g). HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 349.3$.

(S)-4-[3-(4-Butyl-piperidin-1-yl)-2-methyl-propyl]-4H-benzo[1,4]oxazin-3-one (108LM53-50)

[0263] A 4 ml vial was charged with crude (R)-4-(3-iodo-2-methyl-propyl)-4H-benzo[1,4]oxazin-3-one (108LM46-43) (0.312 g) and 4-butyl-piperidine (0.210 g, 1.49 mmol) in dry MeCN ($\frac{1}{2}$ ml) and shaken at 60°C for 3 days. The reaction mixture was quenched with water (1 ml), and the product extracted into EtOAc (2 x 1 ml). The combined organic layers were added a cation exchange column. The column was washed with MeOH (2 column volumes) then the product was eluted of the column using 8% ammonium hydroxide in MeOH (2 column volumes). The product was purified by flash CC (SiO_2 ; MeOH/DCM 1:20) to give the title compound (108LM53-50) (0.193 g, 17% - 3 steps). ^1H NMR (CDCl_3) δ 7.18 (d, $J = 7.8$ Hz, 1H), 7.03 - 6.96 (m, 3H), 4.58 (ABq, $J = 14.3$ Hz, $J = 33.9$ Hz, CH_2), 4.05 - 3.90 (m, 2H), 2.88 (bd, $J = 10.4$ Hz, 1H), 2.71 (bd, $J = 10.4$ Hz, 1H), 2.25 - 2.01 (m, 3H), 2.00 - 1.92 (m, 1H), 1.83 - 1.75 (m, 1H), 1.68 - 1.56 (m, 2H), 1.33 - 1.12 (m, 9H), 0.95 - 0.85 (m, 6H); ^{13}C NMR (CDCl_3) δ 164.9, 145.7, 128.9, 123.8, 122.7, 117.2, 115.8, 67.8, 64.2, 55.8, 54.4, 45.4, 36.6, 36.1, 33.0, 32.8, 29.3, 23.2, 17.1, 14.4; HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 345.3$.

(R)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-4H-benzo[1,4]oxazin-3-one (108LM22-20)

[0264] The compound (S)-4-(3-Iodo-2-methyl-propyl)-4H-benzo[1,4]oxazin-3-one (108LM27-24) (0.063 g, 0.19 mmol) and 4-butyl-piperidine (0.053 g, 0.38 mmol) in MeCN (½ mL) were reacted according to GP10 shaking at 50 °C for 1 day and at 70 °C for 2 days. Purified by cation exchange CC and flash CC (SiO₂; MeOH/DCM 1:50) to give the title compound (108LM22-20) (0.051 g, 79%). ¹H NMR (CDCl₃) δ 7.18 - 7.15 (m, 1H), 7.02 - 6.96 (m, 3H), 4.60 (ABq, *J* = 15.0 Hz, *J* = 31.3 Hz, CH₂), 3.99 (dd, *J* = 8.1 Hz, 13.8 Hz, 1H), 3.92 (dd, *J* = 5.0 Hz, 13.8 Hz, 1H), 2.88 (bd, *J* = 10.0 Hz, 1H), 2.72 (bd, *J* = 10.0 Hz, 1H), 2.26-2.02 (m, 3H), 2.00 - 1.92 (m, 1H), 1.85 - 1.75 (m, 1H), 1.70 - 1.59 (m, 2H), 1.32 - 1.14 (m, 9H), 0.92 - 0.85 (m, 6H); HPLC-MS (ammonium acetate) [M+H]⁺=345.3.

GENERAL PROCEDURE 14 (GP14)

[0265] A 4 mL vial was charged with the appropriate heterocycle (1 equiv) and the appropriate piperidine (1.1 equiv) and shaken at 60 °C for 2 days. Et₃N (½ mL) was added and shaking was continued for 1 day. The reaction mixture was quenched with water (1 mL), and Et₂O (1 mL) and sodium hydroxide (until pH 10) were added. The product was extracted into Et₂O (2 x 1 mL). The combined organic layers were dried over Na₂SO₄, and concentrated. The product was purified by cation exchange CC followed by flash CC (Si₂O; MeOH/DCM 1:50).

(R)-4-[2-Methyl-3-(4-propoxypiperidin-1-yl)-propyl]-4H-benzo[1,4]oxazin-3-one (108LM32-29)

[0266] The compound (S)-4-(3-Iodo-2-methyl-propyl)-4H-benzo[1,4]oxazin-3-one (108LM27-24) (0.202 g, 0.61 mmol) and 4-propoxy-piperidine (79KS66) (0.097 g, 0.67 mmol) in MeCN (½ mL) were reacted according to GP14 to give the title compound (108LM32-29) (0.136 g, 65%). ¹H NMR (CDCl₃) δ 7.15 (bd, *J* = 7.3 Hz, 1H), 7.03 - 6.95 (m, 3H), 4.60 (ABq, *J* = 13.9 Hz, *J* = 31.6 Hz, CH₂), 4.05 - 3.90 (m, 2H), 3.48 (t, *J* = 7.0 Hz, CH₂), 3.28 - 3.20 (m, 1H), 2.79 (bs, 1H), 2.63 (bs, 1H), 2.27 - 2.11 (m, 3H), 2.10 - 1.93 (m, 2H), 1.92 - 1.83 (m, 2H), 1.63 - 1.52 (m, 4H), 0.94 - 0.86 (m, 6H); ¹³C NMR (CDCl₃) δ 164.5, 145.4, 128.5, 123.4, 122.3, 116.9, 115.2, 75.0, 69.4, 67.4, 63.2, 52.5, 51.5, 45.0, 31.6, 31.5, 29.1, 23.1, 16.6, 10.5; HPLC-MS (ammonium acetate) [M+H]⁺=347.3.

(R)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-4H-benzo[1,4]oxazin-3-one (108LM33-30)

The compound (S)-4-(3-Iodo-2-methyl-propyl)-4H-benzo[1,4]oxazin-3-one (108LM27-24) (0.441 g, 1.33 mmol) and 4-butylidenepiperidine (111MF05) (0.204 g, 1.47 mmol) in MeCN (½ mL) were reacted according to GP14 to give the title compound (108LM33-30) (0.293 g, 64%). ¹H NMR (CDCl₃) δ 7.19 (bd, *J* = 7.0 Hz, 1H), 7.04-6.97 (m, 3H), 5.13 (t, *J* = 7.9 Hz, CH), 4.60 (ABq,

$J = 14.1$ Hz, $J = 16.2$ Hz, CH₂), 4.00 (d, $J = 7.0$ Hz, CH₂), 2.50-2.38 (m, 2H), 2.35-2.05 (m, 9H), 1.95 (dt, $J = 7.0$ Hz, CH₂), 1.50 - 1.40 (m, 2H), 0.94-0.86 (m, 6H); ¹³C NMR (CDCl₃) δ 165.0, 145.8, 136.3, 128.9, 123.8, 122.8, 122.7, 117.3, 115.7, 67.9, 63.7, 56.5, 55.7, 45.5, 36.4, 29.4, 28.6, 23.4, 17.1, 13.9; HPLC-MS (ammonium acetate) [M+H]⁺=343.3.

GENERAL PROCEDURE 15 (GP15)

[0267] A 7 mL vial was charged with the appropriate heterocycle (1 equiv) and the appropriate piperidine (1.1 equiv) in Et₃N (½ mL) and shaken at 60°C for 4 days. The reaction mixture was quenched with water (1 mL), and Et₂O (1 mL) and sodium hydroxide (until pH 10) were added. The product was extracted into Et₂O (10 x 1 mL) and EtOAc (10 x 1 mL). The combined organic layers were dried (Na₂SO₄), and concentrated. The product was purified by cation exchange CC followed by flash CC (SiO₂; MeOH/DCM 1:20).

(R)-4-[3-(3-Butyl-8-aza-bicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4H-benzo[1,4]oxazin-3-one (108LM38-35)

[0268] The compound (S)-4-(3-Iodo-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (108LM27-24) (0.092 g, 0.28 mmol) and 3-butyl-8-aza-bicyclo[3.2.1]octane (104KS29) (0.051 g, 0.31 mmol) in Et₃N (½ mL) were reacted according to GP15 to give the title compound (108LM38-35) (0.068 g, 64%). ¹H NMR (CDCl₃) δ 7.32 (d, $J = 6.7$ Hz, 1H), 7.03 - 6.95 (m, 3H), 4.60 (ABq, $J = 7.2$ Hz, $J = 10.8$ Hz, CH₂), 4.12-4.00 (m, 2H), 3.16 (bs, 1H), 3.07 (bs, 1H), 2.33 (dd, $J = 6.1$ Hz, $J = 2.1$ Hz, 1H), 2.12 (t, $J = 4.7$ Hz, 1H), 2.01 - 1.78 (m, 2H), 1.58 - 1.40 (m, 5H), 1.38 - 1.13 (m, 9H), 0.92 - 0.84 (m, 6H); ¹³C NMR (CDCl₃) δ 164.9, 145.7, 128.9, 123.7, 122.7, 117.1, 116.2, 67.9, 61.8, 60.0, 58.1, 45.4, 38.7, 38.6, 37.1, 31.6, 29.4, 28.2, 27.4, 26.5, 23.1, 17.1, 14.3; HPLC-MS (ammonium acetate) [M+H]⁺=371.3.

(R)-4-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-4H-benzo[1,4]oxazin-3-one (108LM39-36)

The compound (S)-4-(3-Iodo-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (108LM27-24) (0.083 g, 0.25 mmol) and 3-pentyl-8-aza-bicyclo[3.2.1]octane (104KS32-2) (0.051 g, 0.28 mmol) in Et₃N (½ mL) were reacted according to GP15 to give the title compound (108LM39-36) (0.061 g, 63%). ¹H NMR (CDCl₃) δ 7.33 - 7.29 (m, 1H), 7.03 - 6.96 (m, 3H), 4.60 (ABq, $J = 14.8$ Hz, $J = 37.1$ Hz, CH₂), 4.14 - 4.00 (m, 2H), 3.13 (bs, 1H), 3.05 (bs, 1H), 2.63 - 2.50 (m, 1H), 2.17 - 2.03 (m, 3H), 2.00 - 1.80 (m, 3H), 1.72 - 1.53 (m, 3H), 1.42 - 1.15 (m, 10H), 0.93 - 0.85 (m, 6H); ¹³C NMR (CDCl₃) δ 165.0, 145.7, 128.9, 123.7, 122.6, 117.1, 116.1, 67.9, 60.9, 58.9, 58.2, 45.3, 38.4,

37.0, 36.8, 32.2, 31.7, 28.5, 28.3, 27.2, 22.9, 17.1, 14.3; HPLC-MS (ammonium acetate) $[M+H]^+=385.3$.

GENERAL PROCEDURE 16 (GP16)

[0269] A 7 mL vial charged with 4-(3-iodo-2-methylpropyl)-4*H*-benzo[1,4]oxazin-3-one (1.0 equiv) and amine (1.0 equiv) was shaken at 60 °C for 20 hours. The reaction mixture was added Et₃N (2.5 equiv) and shaken at 60 °C for 60 - 80 hours. The reaction mixture was concentrated, dissolved in 1 M NaOH (10 mL), extracted into CH₂Cl₂ (3x 15mL), and dried through a PTFE Whatman filter. The combined organic layers were concentrated and purified by cation exchange CC and CC (Heptane/EtOAc) or Prep HPLC.

(R)-6-Fluoro-4-[2-methyl-3-(4-propoxy-piperidin-1-yl)-propyl]-4*H*-benzo[1,4]oxazin-3-one (108LM30-27)

[0270] The compound (*S*)-6-Fluoro-4-(3-iodo-2-methyl-propyl)-4*H*-benzo[1,4]oxazin-3-one (111MF04) (0.400 g, 1.15 mmol) and 4-propoxy-piperidine (79KS66) (0.332 g, 2.29 mmol) in MeCN (½ mL) were reacted according to GP10 shaking at 60 °C for 3 days and at 70 °C for 1 day. Purified by cation exchange CC and flash CC (SiO₂; MeOH/DCM 1:50 → 1:20) to give the title compound (108LM30-27) (0.263 g, 63%). ¹H NMR (CDCl₃) δ 6.96 (dd, *J* = 9.7 Hz, *J* = 2.9 Hz, 1H), 6.91 (dd, *J* = 8.9 Hz, *J* = 4.9 Hz, 1H), 6.66 (dt, *J* = 8.9 Hz, *J* = 2.9 Hz, 1H), 4.56 (ABq, *J* = 15.5 Hz, *J* = 31.7 Hz, CH₂), 3.95 (dd, *J* = 13.5 Hz, *J* = 8.1 Hz, 1H), 3.88 (dd, *J* = 13.5 Hz, *J* = 4.7 Hz, 1H), 3.38 (t, *J* = 6.7 Hz, CH₂), 3.32-3.23 (m, 1H), 2.79 (bs, 1H), 2.62 (bs, 1H), 2.26-2.12 (m, 3H), 2.19-1.95 (m, 2H), 1.94-1.84 (m, 2H), 1.66-1.53 (m, 4H), 0.95-0.85 (m, 6H); ¹³C NMR (CDCl₃) δ 164.9, 158.5 (d, *J* = 952.8 Hz, 1H), 141.7 (d, *J* = 9.2 Hz, 1H), 130.0 (d, *J* = 42.4 Hz, 1H), 117.7 (d, *J* = 38.4 Hz, 1H), 109.6 (d, *J* = 93.2 Hz, 1H), 103.4 (d, *J* = 114.4 Hz, 1H), 75.2, 69.8, 67.9, 63.7, 52.8, 52.0, 45.7, 31.8, 31.6, 29.5, 23.5, 17.1, 10.9; HPLC-MS (ammonium acetate) $[M+H]^+=365.3$.

(R)-4-[3-(4-Butyridenepiperidin-1-yl)-2-methyl-propyl]-6-fluoro-4*H*-benzo[1,4]oxazin-3-one (111MF06)

[0271] The compound (*S*)-6-Fluoro-4-(3-iodo-2-methyl-propyl)-4*H*-benzo[1,4]oxazin-3-one (111MF04) (0.718 g, 2.06 mmol) and 4-Butyridenepiperidine (0.301 g, 2.16 mmol) were mixed according to GP16. CC (SiO₂; Heptane/EtOAc 4:1-4) gave the title compound (111MF06) (0.40 g, 54%). ¹H NMR (CDCl₃) δ 7.01 (dd, *J* = 3.0 Hz, *J* = 10.2 Hz, 1H), 6.90 (dd, *J* = 5.4 Hz, *J* = 8.6 Hz, 1H), 6.89 - 6.63 (m, 1H), 5.12 (t, *J* = 7.4 Hz, 1H), 4.63 - 4.51 (m, 2H), 4.02 - 3.89 (m, 1H), 2.51 - 2.44 (m, 2H), 2.32 - 2.23 (m, 5H), 2.21 - 2.15 (m, 5H), 2.11 - 2.03 (m, 1H), 1.98 - 1.93 (m, 2H), 1.39 - 1.29 (m, 2H), 0.91 - 0.86 (m, 6H); ¹³C NMR (CDCl₃) δ 164.8, 158.5 (d, *J* =

239.4 Hz), 141.6 (d, $J = 2.7$ Hz), 136.2, 130.0 (d, $J = 10.8$ Hz), 122.7, 117.6 (d, $J = 9.3$ Hz), 109.5 (d, $J = 23.1$ Hz), 103.4 (d, $J = 29.1$ Hz), 67.8, 63.7, 56.6, 55.8, 45.7, 36.2, 29.4, 29.3, 28.4, 23.3, 17.0, 13.9.

[0272] To the pure compound (0.38 g, 1.0 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.104 g, 1.15 mmol) in diethyl ether (2 mL). The formed crystals filtered and washed with diethyl ether to give the title compound as oxalic salt (0.44 g, 92%); HPLC-MS (ammonium acetate) $[M+H]^+ = 361.4$

(R)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6-fluoro-4H-benzo[1,4]oxazin-3-one (111MF08)

[0273] The compound (S)-6-Fluoro-4-(3-iodo-2-methyl-propyl)-4H-benzo[1,4]oxazin-3-one (111MF04) (0.873 g, 2.50 mmol) and 4-Butylpiperidine (0.371 g, 2.63 mmol) were mixed according to GP16. CC (SiO₂; Heptane/EtOAc 4:1-4) gave the title compound (111MF08) (0.53 g, 58%). ¹H NMR (CDCl₃) δ 7.01 (d, $J = 10.0$ Hz, 1H), 6.92 – 6.88 (m, 1H), 6.68 – 6.64 (m, 1H), 5.57 (q, $J = 32.4$ Hz, $J = 15.2$ Hz, 2H), 4.02 – 3.83 (m, 2H), 2.92 – 2.70 (m, 2H), 2.23 – 2.10 (m, 2H), 2.04 – 1.97 (m, 2H), 1.81 (t, $J = 10.8$ Hz, 1H), 1.72 – 1.61 (m, 2H), 1.36 – 1.19 (m, 9H), 0.90 – 0.88 (m, 6H); ¹³C NMR (CDCl₃) δ 164.8, 158.5 (d, $J = 239.4$ Hz), 141.6 (d, $J = 2.3$ Hz), 130.0 (d, $J = 10.4$ Hz), 117.6 (d, $J = 9.6$ Hz), 109.4 (d, $J = 23.1$ Hz), 103.5 (d, $J = 29.3$ Hz), 67.8, 64.1, 56.0, 54.3, 45.7, 36.5, 36.0, 33.0, 32.5, 29.5, 29.2, 23.1, 17.1, 14.3.

[0274] To the pure compound (0.53 g, 1.5 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.104 g, 1.15 mmol) in diethyl ether (2 mL). The formed crystals filtered and washed with diethyl ether to give the title compound as oxalic salt (0.614 g, 93%); HPLC-MS (ammonium acetate) $[M+H]^+ = 363.3$.

(R)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-fluoro-4H-benzo[1,4]oxazin-3-one (111MF26)

[0275] The compound (S)-6-Fluoro-4-(3-iodo-2-methyl-propyl)-4H-benzo[1,4]oxazin-3-one (111MF04) (0.219 g, 0.6 mmol) and 3-butyl-8-azabicyclo[3.2.1]octane (0.10 g, 0.6 mmol) were mixed according to GP16. CC (SiO₂; Heptane/EtOAc (4:1-4) gave the title compound (111MF26) (0.16 g, 58%). ¹H NMR (CDCl₃) δ 7.16 (dd, $J = 2.8$ Hz, $J = 10.0$ Hz, 1H), 6.90 (dd, $J = 5.0$ Hz, $J = 9.0$ Hz, 1H), 6.69 – 6.63 (m, 1H), 4.58 (q, $J = 14.8$ Hz, $J = 38.0$ Hz, 2H), 4.10 – 3.93 (m, 2H), 3.16 – 3.06 (m, 2H), 2.33 (dd, $J = 4.0$ Hz, $J = 12.8$ Hz, 1H), 2.05 (t, $J = 11.6$ Hz, 1H), 1.94 – 1.82 (m, 2H), 1.58 – 1.43 (m, 6H), 1.39 – 1.32 (m, 2H), 1.31 – 1.15 (m, 6H), 0.90 – 0.87 (m, 6H); ¹³C NMR (CDCl₃) δ 164.9, 158.5 (d, $J = 239.4$ Hz), 141.6 (d, $J = 2.7$ Hz), 130.0 (d, $J = 10.4$ Hz), 117.5 (d, $J = 9.3$ Hz), 109.4 (d, $J = 23.5$ Hz), 103.9 (d, $J = 28.9$ Hz), 67.8, 61.9, 60.1, 58.2, 45.6, 38.6, 38.5, 36.9, 31.8, 29.4, 28.2, 27.4, 26.5, 23.1, 17.1, 14.3.

[0276] To the pure compound (0.16 g, 0.41 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.039 g, 0.43 mmol) in diethyl ether (2 mL). The formed crystals filtered and washed with diethyl ether to give the title compound as oxalic salt (0.173 g, 88%); HPLC-MS (ammonium acetate) $[M+H]^+ = 389.3$

(R)-6-Fluoro-4-[2-methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)-propyl]-4H-benzo[1,4]oxazin-3-one (111MF27)

[0277] The compound (S)-6-Fluoro-4-(3-iodo-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (111MF04) (0.208 g, 0.6 mmol) and 3-Pentyl-8-azabicyclo[3.2.1]octane (0.10 g, 0.56 mmol) were mixed according to GP16. CC (SiO₂; Heptane/EtOAc 4:1-4) gave the title compound (111MF27) (0.16 g, 58%). ¹H NMR (CDCl₃) δ 7.13 (dd, *J* = 2.8 Hz, *J* = 10.0 Hz, 1H), 6.90 (dd, *J* = 5.2 Hz, *J* = 8.8 Hz, 1H), 6.68 - 6.63 (m, 1H), 4.57 (q, *J* = 14.8 Hz, *J* = 40.0 Hz, 1H), 4.11 - 3.94 (m, 2H), 3.14 - 3.04 (m, 2H), 2.30 (dd, *J* = 4.0 Hz, *J* = 12.8 Hz, 1H), 2.20 - 2.09 (m, 2H), 2.06 - 2.00 (m, 1H), 1.95 - 1.82 (m, 3H), 1.71 - 1.52 (m, 3H), 1.40 - 1.34 (m, 2H), 1.32 - 1.19 (m, 8H), 0.89 - 0.85 (m, 6H); ¹³C NMR (CDCl₃) δ 164.9, 158.5 (d, *J* = 239.4 Hz), 141.6 (d, *J* = 2.6 Hz), 130.0 (d, *J* = 10.8 Hz), 117.5 (d, *J* = 9.3 Hz), 109.4 (d, *J* = 23.4 Hz), 103.8 (d, *J* = 28.9 Hz), 67.8, 61.0, 59.0, 58.2, 45.5, 38.4, 36.6, 36.5, 32.8, 31.8, 28.4, 28.4, 28.2, 27.2, 22.8, 7.0, 14.2.

[0278] To the pure compound (0.16 g, 0.41 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.039 g, 0.43 mmol) in diethyl ether (2 mL). The formed crystals filtered and washed with diethyl ether to give the title compound as oxalic salt (0.198 g, 97%); HPLC-MS (ammonium acetate) $[M+H]^+ = 403.3$

(R)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-7-Fluoro-4H-benzo[1,4]oxazin-3-one (112KK04)

[0279] A microwave vial was charged with (S)-7-fluoro-4-(3-iodo-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (111MF20) (0.274 g, 0.78 mmol) and 4-butylpiperidine (0.226 g, 1.60 mmol) in MeCN (4 mL) and sealed. After microwave irradiation, 100 °C, 60 min, the reaction mixture was purified by cation exchange CC followed by flash CC (SiO₂; CH₂Cl₂/MeOH 50:1) to give the title compound (112KK04) (0.180 g, 63%). ¹H NMR (CD₃OD) δ 7.24 - 7.21 (m, 1H), 6.81 - 6.76 (m, 2H), 4.60 (ABq, *J* = 17.4 Hz, *J* = 15.1 Hz, CH₂), 3.98 (dd, *J* = 14.3 Hz, *J* = 5.9 Hz, 1H), 3.87 (dd, *J* = 14.3 Hz, *J* = 7.6 Hz, 1H), 2.86 (d, *J* = 11.0 Hz, 1H), 2.73 (d, *J* = 9.8 Hz, 1H), 2.28 - 2.23 (m, 1H), 2.16 - 2.08 (m, 2H), 1.93 - 1.81 (m, 2H), 1.79 - 1.62 (m, 2H), 1.32 - 1.13 (m, 9H), 0.93 - 0.88 (m, 2 CH₃); ¹³C NMR (CD₃OD) δ 166.1, 160.3 (d, *J* = 242.3 Hz), 148.1 (d, *J* = 11.9 Hz), 126.4 (d, *J* = 2.9 Hz), 117.8 (d, *J* = 9.4 Hz), 109.9 (d, *J* = 22.9 Hz), 105.7 (d, *J* = 26.1 Hz), 68.6, 65.1, 56.3, 55.4, 46.6, 37.5, 37.0, 33.6, 33.4, 30.1, 29.9, 24.0, 17.2, 14.4.

[0280] The product was dissolved in MeOH/Et₂O and oxalic acid dissolved in Et₂O was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.176 g). HPLC-MS (ammonium acetate) $[M+H]^+ = 363.29$.

(R)-7-Fluoro-4-[2-methyl-3-(4-propoxypiperidin-1-yl)propyl]-4H-benzo[1,4]oxazin-3-one
(111MF28)

[0281] The compound (S)-7-Fluoro-4-(3-iodo-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (111MF20) (0.501 g, 1.43 mmol) and 4-propyloxypiperidine (0.205 g, 1.43 mmol) were mixed according to GP16. CC (SiO₂; Heptane/EtOAc 4:1-4) gave the title compound (111MF28) (0.375 g, 71%). ¹H NMR (CDCl₃) δ 7.12 – 7.08 (m, 1H), 6.74 – 6.69 (m, 2H), 4.59 (q, *J* = 15.0 Hz, *J* = 31.0 Hz, 2H), 4.01 – 3.88 (m, 2H), 3.39 (t, *J* = 6.8 Hz, 2H), 3.29 – 3.22 (m, 1H), 2.77 (t, *J* = 6.3 Hz, 1H), 2.63 (t, *J* = 5.6 Hz, 1H), 2.26 – 2.12 (m, 3H), 2.04 – 1.96 (m, 2H), 1.88 – 1.84 (m, 2H), 1.62 – 1.50 (m, 4H), 0.93 – 0.87 (m, 6H); ¹³C NMR (CDCl₃) δ 164.2, 158.9 (d, *J* = 241.9 Hz), 146.5 (d, *J* = 12.1 Hz), 125.2 (d, *J* = 3.0 Hz), 116.1 (d, *J* = 9.6 Hz), 109.0 (d, *J* = 22.3 Hz), 105.2 (d, *J* = 25.8 Hz), 75.2, 69.8, 67.8, 63.5, 52.8, 51.8, 45.5, 31.9, 31.8, 29.4, 23.5, 17.0, 10.8.

[0282] To the pure compound (0.375 g, 1.03 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.097 g, 1.08 mmol) in diethyl ether (2 mL). The formed crystals filtered and washed with diethyl ether to give the title compound as oxalic salt (0.41 g, 88%); HPLC-MS (ammonium acetate) $[M+H]^+ = 365.3$.

(R)-4-[3-(4-Butyldenepiperidin-1-yl)-2-methylpropyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one
(111MF29)

[0283] The compound (S)-7-Fluoro-4-(3-iodo-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (111MF20) (0.515 g, 1.47 mmol) and 4-butyldenepiperidine (0.205 g, 1.47 mmol) were mixed according to GP16. CC (SiO₂; Heptane/EtOAc 4:1-4) gave the title compound (111MF29) (0.393 g, 73%). ¹H NMR (CDCl₃) δ 7.17 – 7.12 (m, 1H), 6.74 – 6.69 (m, 2H), 5.15 – 5.11 (t, *J* = 7.2 Hz, 1H), 4.61 (q, *J* = 15.2 Hz, 2H), 4.04 – 3.92 (m, 2H), 2.48 – 2.40 (m, 2H), 2.32 – 2.13 (m, 9H), 1.96 (q, *J* = 7.2 Hz, 2H), 1.38 – 1.30 (m, 2H), 0.91 – 0.86 (m, 6H); ¹³C NMR (CDCl₃) δ 164.1, 158.9 (d, *J* = 243.4 Hz), 146.5 (d, *J* = 11.9 Hz), 136.1, 125.2 (d, *J* = 3.0 Hz), 128.9, 116.2 (d, *J* = 22.7 Hz), 109.0 (d, *J* = 22.7 Hz), 105.2 (d, *J* = 26.2 Hz), 67.8, 63.7, 56.5, 55.7, 54.6, 36.3, 29.3, 28.5, 23.3, 17.1, 13.9.

[0284] To the pure compound (0.393 g, 1.09 mmol) dissolved in diethyl ether (4 mL) was added oxalic acid (0.103 g, 1.14 mmol) in diethyl ether (2 mL). The formed crystals filtered and washed with diethyl ether to give the title compound as oxalic salt (0.46 g, 94%); HPLC-MS (ammonium acetate) $[M+H]^+ = 361.3$.

(R)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (112KK05)

[0285] A microwave vial was charged with (S)-7-fluoro-4-(3-Iodo-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (111MF20) (0.047 g, 0.13 mmol) and 3-butyl-8-azabicyclo[3,2,1]octane (0.039 g, 0.23 mmol) in MeCN (2 mL) and sealed. After microwave irradiation, 100 °C, 60 min, the reaction mixture was purified by cation exchange CC followed by flash CC (SiO₂; CH₂Cl₂/MeOH 50:1) to give the title compound (112KK05) (0.017 g, 33%). ¹H NMR (CD₃OD) δ 7.34 – 7.30 (m, 1H), 6.80 – 6.75 (m, 2H), 4.61 (ABq, *J* = 18.8 Hz, *J* = 15.1 Hz, CH₂), 4.04 (dd, *J* = 14.3 Hz, *J* = 5.9 Hz, 1H), 3.93 (dd, *J* = 14.3 Hz, *J* = 8.2 Hz, 1H), 3.18 – 3.10 (m, 2H), 2.36 – 2.23 (m, 2H), 2.03 – 1.85 (m, 3H), 1.62 – 1.45 (m, 5H), 1.36 – 1.14 (m, 8H), 0.92 – 0.87 (m, 2 CH₃); ¹³C NMR (CD₃OD) δ 166.2, 160.4 (d, *J* = 242.3 Hz), 148.1 (d, *J* = 11.9 Hz), 126.3 (d, *J* = 2.9 Hz), 118.1 (d, *J* = 9.7 Hz), 109.8 (d, *J* = 22.9 Hz), 105.7 (d, *J* = 26.5 Hz), 68.6, 62.5, 61.2, 58.3, 46.4, 39.0, 37.9, 32.1, 30.2, 29.0, 27.8, 27.2, 23.9, 17.2, 14.4.

[0286] The product was dissolved in MeOH/Et₂O and oxalic acid dissolved in Et₂O was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.016 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 389.34.

(R)-7-Fluoro-4-[2-methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)-propyl]-4H-benzo[1,4]oxazin-3-one (111MF30)

[0287] The compound (S)-7-Fluoro-4-(3-iodo-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (111MF20) (0.208 g, 0.59 mmol) and 3-Pentyl-8-azabicyclo[3.2.1]octane (0.106 g, 0.58 mmol) were mixed according to GP16. CC (SiO₂; Heptane/EtOAc 4:1-4) and prep HPLC gave the title compound (111MF30) (0.070 g, 29%). ¹H NMR (CDCl₃) δ 7.23 – 7.19 (m, 1H), 6.66 – 6.60 (m, 2H), 4.60 – 4.46 (m, 2H), 4.05 – 3.99 (m, 1H), 3.95 – 3.90 (m, 1H), 3.06 – 3.03 (m, 1H), 2.99 – 2.96 (m, 1H), 2.24 – 2.19 (m, 1H), 2.07 – 1.94 (m, 3H), 1.90 – 1.73 (m, 3H), 1.60 – 1.45 (m, 3H), 1.33 – 1.25 (m, 2H), 1.24 – 1.12 (m, 8H), 0.83 – 0.78 (m, 6H); ¹³C NMR (CDCl₃) δ 164.1, 158.8 (d, *J* = 243.3 Hz), 146.4 (d, *J* = 11.5 Hz), 125.1 (d, *J* = 3.1 Hz), 116.6 (d, *J* = 9.3 Hz), 108.9 (d, *J* = 22.8 Hz), 105.0 (d, *J* = 25.7 Hz), 67.7, 60.9, 58.8, 58.1, 45.4, 38.3, 36.8, 36.6, 32.1, 31.6, 28.5, 28.4, 28.1, 27.0, 22.8, 17.0, 14.2.

[0288] To the pure compound (0.070 g, 0.17 mmol) dissolved in diethyl ether (1 mL) was added oxalic acid (0.016 g, 0.18 mmol) in diethyl ether (1 mL). The formed crystals filtered and washed with diethyl ether to give the title compound as oxalic salt (0.082 g, 96 %); HPLC-MS (ammonium acetate) [M+H]⁺ = 402.56

(R)-4-[3-(4-Butylpiperidin-1-yl)-2-methyl-propyl]-6-methoxy-4H-benzo[1,4]oxazin-3-one
(111MF38)

[0289] The compound (S)-4-(3-Iodo-2-methylpropyl)-6-methoxy-4H-benzo[1,4]oxazin-3-one (111MF36) (0.636 g, 1.77 mmol) and 4-butylpiperidine (0.226 g, 1.6 mmol) were mixed according to GP16. CC (SiO₂; Heptane/EtOAc 4:1-4) and prep HPLC gave the title compound (111MF38) (0.245 g, 27%). ¹H NMR (CDCl₃) δ 6.89 (d, *J* = 8.8 Hz, 1H), 6.72 (d, *J* = 2.4 Hz, 1H), 6.50 (dd, *J* = 2.8, *J* = 8.8 Hz, 1H), 4.54 (q, *J* = 32.4, *J* = 14.8, 2H), 3.94 - 3.90 (m, 2H), 3.77 (s, 3H), 2.90 (d, *J* = 11.2 Hz, 1H), 2.72 (d, *J* = 10.8 Hz, 1H), 2.25 - 2.10 (m, 3H), 1.93 (t, *J* = 11.2 Hz, 1H), 1.80 (t, *J* = 11.2 Hz, 1H), 1.61 (d, *J* = 10.8 Hz, 2H), 1.31 - 1.19 (m, 9H), 0.90 - 0.86 (m, 6H); ¹³C NMR (CDCl₃) δ 165.3, 155.5, 139.7, 129.8, 117.2, 107.1, 103.3, 68.0, 64.2, 55.9, 55.7, 54.5, 45.5, 36.5, 36.0, 32.9, 32.5, 29.2, 29.2, 23.1, 16.9, 14.3.

[0290] To the pure compound (0.245 g, 0.65 mmol) dissolved in diethyl ether (2 mL) was added oxalic acid (0.062 g, 0.68 mmol) in diethyl ether (2 mL). The formed crystals filtered and washed with diethyl ether to give the title compound as oxalic salt (0.229 g, 75 %) HPLC-MS (ammonium acetate) [M+H]⁺ = 375.3.

(R)-4-[3-(4-Butylenepiperidin-1-yl)-2-methylpropyl]-6-methoxy-4H-benzo[1,4]oxazin-3-one(111MF39)

[0291] The compound (S)-4-(3-Iodo-2-methylpropyl)-6-methoxy-4H-benzo[1,4]oxazin-3-one (111MF36) (0.612 g, 1.69 mmol) and 4-butylenepiperidine (0.212 g, 1.5 mmol) were mixed according to GP16. CC (SiO₂; Heptane/EtOAc 4:1-4) gave the title compound (111MF39) (0.489 g, 77%). ¹H NMR (CDCl₃) δ 6.90 (d, *J* = 8.4 Hz, 1H), 6.73 (d, *J* = 2.8 Hz, 1H), 6.50 (dd, *J* = 8.4 Hz, *J* = 2.8 Hz, 1H), 5.11 (t, *J* = 7.6 Hz, 1H), 4.54 (q, *J* = 14.4 Hz, 2H), 3.97 - 3.94 (d, *J* = 6.8 Hz, 2H), 3.78 (s, 3H), 2.48 - 2.41 (m, 2H), 2.33 - 2.23 (m, 5H), 2.20 - 2.13 (m, 4H), 1.96 (q, *J* = 7.4 Hz, 2H), 1.40 - 1.29 (m, 2H), 0.91 - 0.86 (m, 6H); ¹³C NMR (CDCl₃) δ 165.3, 155.5, 139.8, 136.5, 129.8, 122.5, 117.2, 107.0, 103.4, 68.1, 63.8, 56.5, 56.0, 55.7, 45.5, 36.2, 29.3, 29.2, 28.4, 23.3, 16.9, 13.9; HPLC-MS; (ammonium acetate) [M+H]⁺ = 373.3.

(R)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-methoxy-4H-benzo[1,4]oxazin-3-one (111MF40)

[0292] The compound (S)-4-(3-Iodo-2-methylpropyl)-6-methoxy-4H-benzo[1,4]oxazin-3-one (111MF36) (0.239 g, 0.66 mmol) and 3-Butyl-8-aza-bicyclo[3.2.1]octane (0.100 g, 0.60 mmol) were mixed according to GP16. CC (SiO₂; Heptane/EtOAc 4:1-4) gave the title compound (111MF40) (0.163 g, 61%). ¹H NMR (CDCl₃) δ 6.88 (d, *J* = 8.8 Hz, 1H), 6.85 (d, *J* = 2.8 Hz, 1H), 6.49 (dd, *J* = 8.8 Hz, *J* = 2.8 Hz, 1H), 4.61 - 4.47 (m, 2H), 4.01 - 3.99 (m, 2H), 3.77 (s, 3H), 3.17 - 3.04 (m, 2H), 2.35 - 2.29 (m, 1H), 2.14 - 1.79 (m, 3H), 1.57 - 1.13 (m, 6H), 0.88

(m, 3H); ^{13}C NMR (CDCl_3) δ 165.4, 155.6, 139.8, 129.8, 117.1, 107.0, 103.8, 68.0, 61.6, 60.2, 58.1, 56.0, 45.4, 38.5, 38.4, 36.9, 31.6, 29.4, 28.2, 27.3, 26.5, 23.9, 14.3; HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 401.3$.

(R)-6-Methoxy-4-[2-methyl-3-(3-pentyl-8-aza-bicyclo[3.2.1]oct-8-yl)propyl]-4H-benzo[1,4]oxazin-3-one (111MF41)

[0293] The compound (S)-4-(3-Iodo-2-methylpropyl)-6-methoxy-4H-benzo[1,4]oxazin-3-one (111MF36) (0.226 g, 0.63 mmol) and 3-pentyl-8-azabicyclo[3.2.1]octane (0.101 g, 0.56 mmol) were mixed according to GP16. CC (SiO_2 ; heptane/EtOAc 4:1-4) and prep HPLC gave the title compound (111MF41) (0.101 g, 39%). ^1H NMR (CDCl_3) δ 6.89 (d, $J = 8.8$ Hz, 1H), 6.81 (d, $J = 2.8$ Hz, 1H), 6.49 (dd, $J = 8.8$ Hz, $J = 2.8$ Hz, 1H), 4.60 – 4.46 (m, 2H), 4.01 (d, $J = 6.8$ Hz, 2H), 3.77 (s, 3H), 3.15 – 3.02 (m, 2H), 2.32 – 2.26 (m, 1H), 2.20 – 1.79 (m; 7H), 1.68 – 1.51 (m, 3H), 1.42 – 1.16 (m, 10H), 0.89 – 0.85 (m, 6H); ^{13}C NMR (CDCl_3) δ 168.4, 155.6, 139.8, 129.8, 117.0, 106.9, 103.8, 68.0, 60.6, 59.1, 58.1, 56.0, 45.3, 39.4, 36.6, 36.4, 32.2, 31.5, 28.4, 28.4, 28.0, 27.3, 22.8, 16.8, 14.2; HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 415.3$.

(R)-6-Methoxy-4-[2-methyl-3-(4-propoxypiperidin-1-yl)propyl]-4H-benzo[1,4]oxazin-3-one (111MF42)

[0294] The compound (S)-4-(3-Iodo-2-methylpropyl)-6-methoxy-4H-benzo[1,4]oxazin-3-one (111MF36) (0.556 g, 1.5 mmol) and 4-propyloxypiperidine (0.20 g, 1.4 mmol) were mixed according to GP16. CC (SiO_2 ; Heptane/EtOAc 4:1-4) gave the title compound (111MF42) (0.30 g, 53%). ^1H NMR (CDCl_3) δ 6.89 (d, $J = 8.8$ Hz, 1H), 6.85 (d, 2.8 Hz, 1H), 6.49 (dd, $J = 8.8$ Hz, $J = 2.8$ Hz, 1H), 4.53 (q, $J = 14.6$ Hz, 2H), 3.93 (d, $J = 6.6$ Hz, 2H), 3.77 (s, 3H), 3.38 (t, $J = 6.8$ Hz, 2H), 3.29 – 3.22 (m, 1H), 2.80 – 2.77 (t, 6.4 Hz, 1H), 2.65 – 2.61 (t, $J = 6.0$ Hz, 1H), 2.29 – 2.00 (m, 5H), 1.88 – 1.84 (m, 2H), 1.65 – 1.53 (m, 4H), 0.94 – 0.87 (m, 6H); ^{13}C NMR (CDCl_3) δ 165.4, 155.5, 139.8, 129.8, 117.2, 107.1, 103.3, 75.1, 69.7, 68.0, 63.7, 56.0, 52.5, 51.9, 45.4, 31.6, 31.5, 29.2, 23.5, 16.9, 10.8; HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 377.3$.

GENERAL PROCEDURE 17 (GP17)

[0295] A 7 mL vial was charged with the crude 4-(3-iodo-2-methylpropyl)-6-methyl-4H-benzo[1,4]oxazin-3-one (1 equiv), Et_3N (0.5 mL) and the secondary amine (1.2-1.5 equiv). This mixture was shaken at 60 °C for 72 h and thereafter diluted with MeOH (10 mL) and concentrated with basic Al_2O_3 (2 g) and purified by flash chromatography.

(R)-6-Methyl-4-[2-methyl-3-(4-propoxypiperidin-1-yl)-propyl]-4H-benzo[1,4]oxazin-3-one
(101IS69)

[0296] Crude (S)-4-(3-iodo-2-methylpropyl)-6-methyl-4H-benzo[1,4]oxazin-3-one (0.23 g), 4-propyloxypiperidine (0.12 g, .81 mmol) and Et₃N (0.5 mL) were reacted according to GP17. Flash CC (SiO₂; CH₂Cl₂/acetone/MeOH 90:5:5) gave the title compound (0.20 g, 83%). ¹H NMR (CD₃OD) δ 6.97 (brs, 1H), 6.79 (d, *J* = 8.0 Hz, 1H), 6.75 (dm, *J* = 8.0 Hz, 1H), 4.47 (brs, 2H), 3.97 (dd, *J* = 6.4, 14.4 Hz, 1H), 8.82 (dd, *J* = 7.2, 14.4 Hz, 1H), 3.44 (brs, 1H), 3.33 (t, *J* = 6.8 Hz, 2H), 3.10 - 2.90 (m, 2H), 2.90 - 2.6 (m, 3H), 2.29 (m, 1H), 2.24 (s, 3H), 1.98 - 1.86 (m, 2H), 1.78 - 1.64 (m, 2H), 1.47 (tq, *J* = 14.4, 7.2 Hz, 2H), 0.92 (d, *J* = 6.4 Hz), 0.83 (t, *J* = 7.2 Hz); ¹³C NMR (CD₃OD) δ 166.4, 143.8, 132.8, 128.3, 124.7, 116.7, 116.1, 69.9, 67.4, 61.5, 50.7, 50.5, 44.1, 28.9, 28.6, 23.0, 20.0 15.6, 9.8.

[0297] The product was dissolved in diethyl ether and oxalic acid (1.1 equiv) dissolved in diethyl ether was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.204 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 361.3.

(R)-4-[3-(4-Butyldenepiperidin-1-yl)-2-methylpropyl]-6-methyl-4H-benzo[1,4]oxazin-3-one
(101IS71-A)

[0298] Crude (S)-4-(3-iodo-2-methylpropyl)-6-methyl-4H-benzo[1,4]oxazin-3-one (0.34 g), Et₃N (0.5 mL) and 4-butyldenepiperidine (0.17 g, 1.2 mmol) were reacted according to GP17. Flash CC (SiO₂; CH₂Cl₂/acetone/MeOH 90:7:3) gave the title compound (0.22 g, 58%). ¹H NMR (CD₃OD) δ 7.01 (s, 1H), 6.86 (d, *J* = 8.0 Hz, 1H), 6.82 (dm, *J* = 8.0 Hz, 1H), 5.12 (t, *J* = 7.2 Hz, 1H), 4.52 (ABq, *J* = 14.8, 20.8 Hz, 2H), 4.03 (dd, *J* = 5.6, 14.4 Hz, 1H), 3.91 (dd, *J* = 8.0, 14.4 Hz, 1H), 2.48 - 2.34 (m, 2H), 2.33 - 2.11 (m, 8H), 2.31 (s, 3H), 1.96 (q, *J* = 7.2 Hz, 2H), 1.34 (m, 2H), 0.91 - 0.86 (m, 6H); ¹³C NMR (CD₃OD) δ 165.9, 143.9, 136.0, 132.4, 128.3, 124.3, 122.4, 116.6, 116.2, 67.4, 63.6, 56.3, 55.4, 45.0, 28.92, 28.85, 28.0, 23.0, 20.0, 15.9, 12.8.

[0299] The product was dissolved in diethyl ether and oxalic acid (1.1 equiv) dissolved in diethyl ether was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.236 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 367.3.

(R)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6-methyl-4H-benzo[1,4]oxazin-3-one (101IS71-D)

[0300] Crude (S)-4-(3-iodo-2-methylpropyl)-6-methyl-4H-benzo[1,4]oxazin-3-one (0.30 g), Et₃N (0.5 mL) and 4-butylpiperidine (0.15 g, 1.0 mmol) were reacted according to GP17. Flash CC (SiO₂; CH₂Cl₂/acetone/MeOH 90:7:3) gave the title compound (0.26 g, 84%). ¹H NMR (CD₃OD) δ 7.00 (s, 1H), 6.86 (d, *J* = 8.0 Hz, 1H), 6.81 (dm, *J* = 8.0 Hz, 1H), 4.52 (ABq, *J* = 14.4, 20.8 Hz, 2H), 3.99 (dd, *J* = 6.0, 14.4 Hz, 1H), 3.90 (dd, *J* = 8.4, 14.4 Hz, 1H), 2.97 (brd, *J* = 11.2

Hz, 1H), 2.82 (brd, $J = 8.4$ Hz, 1H), 2.39 - 2.10 (m, 2H), 2.31 (s, 3H), 2.07 - 1.88 (m, 2H), 1.73 - 1.62 (m, 2H), 1.35 - 1.18 (m, 9H), 0.94 - 0.08 (m, 6H); ^{13}C NMR (CD_3OD) δ 166.0, 143.8, 132.4, 128.3, 124.3, 116.6, 116.2, 67.4, 63.6, 55.0, 54.2, 44.8, 36.2, 35.6, 32.1 (br), 28.9, 28.8, 22.8, 20.0, 15.9, 13.2.

[0301] The product was dissolved in diethyl ether and oxalic acid (1.1 equiv) dissolved in diethyl ether was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.253 g). HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 359.3$.

(R)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-methyl-4H-benzo[1,4]oxazin-3-one (101IS71-B3)

[0302] Crude (S)-4-(3-iodo-2-methylpropyl)-6-methyl-4H-benzo[1,4]oxazin-3-one (0.19 g, 0.54 mmol), Et_3N (0.5 mL) and 3-butyl-8-azabicyclo[3.2.1]octane (0.10 g, 0.61 mmol) were reacted according to GP17. Flash CC (SiO_2 ; $\text{CH}_2\text{Cl}_2/i\text{-PrOH}$ 92:8) gave the title compound (0.13 g, 62%). ^1H NMR (CD_3OD) δ 7.05 (s, 1H), 6.86 (d, $J = 8.4$ Hz, 1H), 6.81 (dm, $J = 8.4$ Hz, 1H), 4.52 (ABq $J = 14.8, 24.8$ Hz, 2H), 4.05 (dd, $J = 5.6, 14.0$ Hz, 1H), 3.94 (dd, $J = 8.8, 14.0$ Hz, 1H), 3.05-3.16 (m, 2H), 2.35-2.14 (m, 2H), 2.31 (s, 3H), 2.05-1.78 (m, 3H), 1.63-1.40 (m, 5H), 1.36-1.12 (m, 5H), 0.99 (d, $J = 6.4$ Hz, 3H), 0.90 (t, $J = 6.8$ Hz, 3H); ^{13}C NMR (CD_3OD) δ 167.4, 144.9, 133.7, 129.2, 125.6, 117.7, 117.3, 68.5, 63.2 (br), 62.5 (br), 56.0 (Br), 43.3, 37.8 (br), 31.3, 30.5, 30.0, 28.3, 26.7, 26.4, 23.7, 21.0, 16.8, 14.2.

[0303] The product was dissolved in diethyl ether and oxalic acid (1.1 equiv) dissolved in diethyl ether was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.104 g). HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 349.3$.

(R)-4-[3-(3-Pentyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-methyl-4H-benzo[1,4]oxazin-3-one (101IS71-C3)

[0304] Crude (S)-4-(3-Iodo-2-methylpropyl)-6-methyl-4H-benzo[1,4]oxazin-3-one (0.15 g), Et_3N (0.5 mL) and 3-pentyl-8-azabicyclo[3.2.1]octane (95 mg, 5.2 mmol) were reacted according to GP17. Flash CC (SiO_2 ; $\text{CH}_2\text{Cl}_2/i\text{-PrOH}$ 92:8) gave the title compound (0.12 g, 68%). ^1H NMR (CD_3OD) δ 7.06 (s, 1H), 6.86 (d, $J = 8.0$ Hz, 1H), 6.81 (brd, $J = 8.0$ Hz, 1H), 4.52 (ABq, $J = 14.8, 27.2$ Hz, 2H), 4.06 (dd, $J = 5.6, 14.2$ Hz, 1H), 4.96 (dd, $J = 8.8, 14.2$ Hz, 1H), 3.16-3.02 (m, 2H), 2.34-2.07 (m, 7H), 2.31 (s, 3H), 2.04-1.81 (m, 3H), 1.70-1.55 (m, 3H), 1.46-1.21 (m, 10H), 0.92-0.85 (m, 6H); ^{13}C NMR (CD_3OD) δ 167.2, 145.1, 133.6, 129.4, 125.5, 117.7, 117.5, 68.7, 61.6, 60.2, 58.6, 46.1, 39.6, 37.2, 36.9, 33.1, 32.4, 29.6, 29.5, 28.5, 27.8, 23.7, 21.18, 17.0, 14.4.

[0305] The product was dissolved in diethyl ether and oxalic acid (1.1 equiv) dissolved in diethyl ether was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.128 g). HPLC-MS (ammonium acetate) $[M+H]^+ = 399.3$.

1-[3-(4-Propoxypiperidin-1-yl)propyl]-3,4-dihydro-1H-quinolin-2-one (85LM32)

[0306] A 4 mL vial was charged with crude 1-(3-chloro-propyl)-3,4-dihydro-1H-quinolin-2-one (85LM31) (0.200 g), 4-propoxy-piperidine (79KS-66) (0.130 g, 0.897 mmol), potassium carbonate (0.247 g, 1.79 mmol) and sodium iodide (0.269 g, 1.79 mmol) in MeCN (2 mL) and shaken at 50°C for 20 h. The reaction mixture was quenched with water (1 mL), and the product was extracted into EtOAc (3 x 1 mL). The combined organic layers were dried over Na_2SO_4 , evaporated and purified by flash CC (SiO_2 ; MeOH/DCM 0:1 \rightarrow 3:7) to give the title compound (85LM32) (0.012 g, total yield 3%). 1H NMR ($CDCl_3$) δ 7.25 (t, $J = 7.4$ Hz, 1H), 7.18 - 7.08 (m, 2H), 6.98 (t, $J = 7.4$ Hz, 1H), 3.98 (t, $J = 7.6$ Hz, CH_2), 3.38 (t, $J = 6.8$ Hz, CH_2), 3.35 - 3.25 (m, 1H), 2.87 (t, $J = 7.6$ Hz, CH_2), 2.80 - 2.70 (m, 2H), 2.65 - 2.60 (m, 2H), 2.45 - 2.35 (m, 2H), 2.20 - 2.10 (m, 2H), 1.95 - 1.80 (m, 4H), 1.65 - 1.50 (m, 4H), 0.95 (t, $J = 7.6$ Hz, CH_3); ^{13}C NMR ($CDCl_3$) δ 170.2, 140.0, 128.2, 127.5, 126.6, 122.8, 115.3, 70.0, 56.0, 51.8, 40.5, 32.0, 31.5, 25.8, 25.2, 22.8, 10.7; HPLC-MS (ammonium acetate) $[M+H]^+ = 331.3$.

1-[3-(4-Butylpiperidin-1-yl)propyl]-6-fluoro-3,4-dihydro-1H-quinolin-2-one (92LH81)

[0307] A 4 mL vial was charged with 1-(3-chloropropyl)-6-fluoro-3,4-dihydro-1H-quinolin-2-one (92LH79) (0.090 g, 0.37 mmol), 4-butylpiperidine (0.078 g, 0.55 mmol), KI (0.091 g, 0.55 mmol), and K_2CO_3 (0.076 g, 0.55 mmol) in MeCN and shaken at 50 ° for 20 h. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated. The product was purified by flash CC (SiO_2 ; EtOAc) to give the title compound (92LH81) (0.090 g, 70%). 1H NMR (CD_3OD) δ 7.19 - 7.15 (m, 1H), 6.99 - 6.97 (m, 2H), 3.97 (t, $J = 6.4$ Hz, CH_2), 2.90 - 2.87 (m, 4H), 2.59 (t, $J = 7.6$ Hz, CH_2), 2.38 (t, $J = 7.6$ Hz, CH_2); 1.96 - 1.78 (m, 4H), 1.67 (d, $J = 9.6$ Hz, 2H), 1.29 - 1.22 (m, 9H), 0.90 - 0.88 (m, 3H); ^{13}C NMR (CD_3OD) δ 172.1, 160.0 (d, $J = 241.8$ Hz), 136.7 (d, $J = 2.3$ Hz), 130.6 (d, $J = 7.7$ Hz), 117.8 (d, $J = 8.1$ Hz), 115.9 (d, $J = 23.1$ Hz), 114.6 (d, $J = 22.7$ Hz), 57.0, 55.0, 41.6, 37.4, 36.9, 33.1, 32.4, 30.1, 26.2, 25.5, 23.9, 14.4; HPLC-MS (ammonium acetate) $[M+H]^+ = 347.33$.

6-Fluoro-1-[3-(4-propoxypiperidin-1-yl)propyl]-3,4-dihydro-1H-quinolin-2-one (107LH70)

[0308] A 4 mL vial was charged with 1-(3-chloropropyl)-6-fluoro-3,4-dihydro-1H-quinolin-2-one (92LH79) (0.242 g, 1.00 mmol), 4-propoxypiperidine (0.143 g, 1.00 mmol), KI (0.250 g, 1.50 mmol), and K_2CO_3 (0.207 g, 1.50 mmol) in MeCN (2 mL) and shaken at 40 ° for 20

h. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated. The product was purified by flash CC (SiO_2 ; EtOAc, MeOH/EtOAc 1:4) to give the title compound (107LH70) (0.165 g, 47%). ^1H NMR (CD_3OD) δ 7.19 – 7.15 (m, 1H), 7.01 – 6.97 (m, 2H), 3.96 (t, $J = 7.4$ Hz, CH_2), 3.40 (t, $J = 6.6$ Hz, CH_2), 3.35 – 3.30 (m, 3H), 2.88 (t, $J = 6.8$ Hz, 2H), 2.76 (m, 2H), 2.60 – 2.57 (m, 2H), 2.43 – 2.39 (m, 2H), 2.22 – 2.17 (m, 2H), 1.90 – 1.78 (m, 4H), 1.61 – 1.50 (m, 4H), 0.91 (t, $J = 7.4$ Hz, CH_3); ^{13}C NMR (CD_3OD) δ 172.2, 160.0 (d, $J = 242.2$ Hz), 136.7 (d, $J = 2.3$ Hz), 130.6 (d, $J = 7.7$ Hz), 117.8 (d, $J = 8.5$ Hz), 115.9 (d, $J = 23.1$ Hz), 114.64 (d, $J = 22.3$ Hz), 75.6, 70.7, 56.5, 52.0, 41.6, 32.4, 31.8, 26.1, 25.5, 24.2, 11.0; HPLC-MS (ammonium acetate) $[\text{M}+\text{H}^+] = 349.30$.

(R,S)-1-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6-fluoro-3,4-dihydro-1H-quinolin-2-one
(107LH71-1)

[0309] A 4 mL vial was charged with crude (R,S)-1-(3-chloro-2-methylpropyl)-6-fluoro-3,4-dihydro-1H-quinolin-2-one (107LH68) (0.154 g), 4-butylpiperidine (0.141 g, 1.0 mmol), KI (0.250 g, 1.5 mmol), and K_2CO_3 (0.207 g, 1.5 mmol) in DMF (2 mL) and shaken at 100° for 20 h. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated. The crude product was purified by cation exchange CC and flash CC (SiO_2 ; EtOAc) to give the title compound (107LH77-1) (0.069 g, total yield 13%). ^1H NMR (CD_3OD) δ 7.22 – 7.18 (m, 1H), 7.00 – 6.93 (m, 1H), 3.94 (d, $J = 6.8$ Hz, 2H), 2.91 – 2.86 (m, 3H), 2.74 (d, $J = 10.2$ Hz, 1H), 2.62 – 2.58 (m, 2H), 2.24 – 2.02 (m, 3), 1.90 – 1.81 (m, 2H), 1.66 – 1.61 (m, 2H), 1.30 – 1.19 (m, 9H), 0.89 (t, $J = 6.6$ Hz, CH_3), 0.86 (d, $J = 6.7$ Hz, CH_3); ^{13}C NMR (CD_3OD) δ 172.7, 160.0 (d, $J = 241.8$ Hz), 136.7 (d, $J = 2.7$ Hz), 130.9 (d, $J = 8.1$ Hz), 118.4 (d, $J = 8.1$ Hz), 115.9 (d, $J = 23.5$ Hz), 114.4 (d, $J = 22.7$ Hz), 65.0, 56.1, 55.6, 46.9, 37.5, 37.0, 33.5, 33.4, 32.6, 30.1, 30.1, 26.2, 24.0, 17.2, 14.4.

[0310] The product was dissolved in acetone and oxalic acid dissolved in acetone was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.076 g). HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 361.32$.

(R,S)-6-Fluoro-1-[3-(4-propoxypiperidin-1-yl)-2-methylpropyl]-3,4-dihydro-1H-quinolin-2-one
(107LH71-2)

[0311] A 4 mL vial was charged with crude (R,S)-1-(3-chloro-2-methylpropyl)-6-fluoro-3,4-dihydro-1H-quinolin-2-one (107LH68) (0.154 g), 4-propoxypiperidine (0.143 g, 1.0 mmol), KI (0.250 g, 1.5 mmol), and K_2CO_3 (0.207 g, 1.5 mmol) in DMF (2 mL) and shaken at 100° for 20 h. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated. The crude

product was purified by cation exchange CC and flash CC (SiO₂; EtOAc) to give the title compound (107LH77-2) (0.053 g, total yield 10%). ¹H NMR (CD₃OD) δ 7.23 – 7.19 (m, 1H), 7.00 – 6.95 (m, 1H), 3.95 (d, *J* = 7.0 Hz, 2H), 3.41 (t, *J* = 6.6 Hz, CH₂), 3.31 – 3.27 (m, 1H), 2.90 (t, *J* = 6.6 Hz, 2H), 2.74 – 2.71 (m, 1H), 2.64 – 2.58 (m, 3H), 2.26 – 2.00 (m, 5H), 1.89 – 1.85 (m, 2H), 1.60 – 1.49 (m, 4H), 0.91 (t, *J* = 7.4 Hz, CH₃), 0.86 (d, *J* = 6.7 Hz, CH₃); ¹³C NMR (CD₃OD) δ 172.7, 160.0 (d, *J* = 242.2 Hz), 136.7 (d, *J* = 2.7 Hz), 130.9 (d, *J* = 7.7 Hz), 118.3 (d, *J* = 8.1 Hz), 115.9 (d, *J* = 23.1 Hz), 114.5 (d, *J* = 22.7 Hz), 76.4, 70.7, 64.4, 53.2, 52.8, 46.9, 32.5, 32.4, 32.3, 30.3, 26.17, 26.15, 24.2, 17.1, 11.0.

[0312] The product was dissolved in acetone and oxalic acid dissolved in acetone was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.048 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 363.30.

1-[3-(4-Butylpiperidin-1-yl)propyl]-6-chloro-3,4-dihydro-1H-quinolin-2-one (107LH36)

[0313] A reaction flask was charged with 6-chloro-3,4-dihydro-1H-quinolin-2-one (107LH30) (0.100 g, 0.55 mmol) in dry DMF (2 mL) under Argon. NaH (60% in oil, 0.024 g, 0.60 mmol) was added and the mixture was stirred at rt for 0.5 h. Then 1-bromo-3-chloropropane (0.087 g, 0.55 mmol) was added followed by stirring at 30 ° for 20 h. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The crude material was dissolved in MeCN (3 mL) followed by addition of 4-butylpiperidine (0.078 g, 0.055 mmol), KI (0.166 g, 1.00 mmol), and K₂CO₃ (0.138 g, 1.00 mmol) and shaken at 50 ° for 2 days. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The product was purified by prep RP-HPLC to give the title compound (107LH36) (0.047 g, 24%). ¹H NMR (CD₃OD) δ 7.25 – 7.13 (m, 3H), 3.96 (t, *J* = 7.2 Hz, CH₂), 2.95 – 2.86 (m, 4H), 2.61 – 2.57 (m, 2H), 2.45 – 2.41 (m, 2H), 2.04 – 1.98 (m, 2H), 1.87 – 1.79 (m, 2H), 1.28 – 1.18 (m, 9H), 0.90 (t, *J* = 7.0 Hz, CH₃); ¹³C NMR (CD₃OD) δ 172.3, 139.2, 130.2, 129.3, 128.9, 128.4, 117.8, 56.8, 54.9, 41.4, 37.2, 36.6, 32.9, 32.4, 30.0, 26.0, 25.3, 23.9, 14.4; HPLC-MS (ammonium acetate) [M+H]⁺ = 363.28.

1-[3-(4-Butylpiperidin-1-yl)propyl]-6-methyl-3,4-dihydro-1H-quinolin-2-one (107LH18-1)

[0314] A 4 mL vial was charged with crude 1-(3-chloropropyl)-6-methyl-3,4-dihydro-1H-quinolin-2-one (107LH14) (0.128 g), 4-butylpiperidine (0.076 g, 0.54 mmol), KI (0.166 g, 1.00 mmol), and K₂CO₃ (0.138 g, 1.00 mmol) in MeCN (2 mL) and shaken at 50 ° for 20 h. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The product was purified by flash CC (SiO₂; EtOAc, MeOH/EtOAc 1:4) to give the title compound (107LH18-1) (0.088 g, total yield

41%). ¹H NMR (CD₃OD) δ 7.07 – 7.01 (m, 3H), 3.94 (t, *J* = 7.4 Hz, CH₂), 2.90 – 2.80 (m, 4H), 2.57 – 2.53 (m, 2H), 2.39 – 2.33 (m, 2H), 2.27 (s, 3H, CH₃), 1.95 – 1.90 (m, 2H), 1.85 – 1.79 (m, 2H), 1.66 (d, *J* = 9.8 Hz, 2H), 1.30 – 1.17 (m, 9H), 0.89 (t, *J* = 6.8 Hz, CH₃); ¹³C NMR (CD₃OD) δ 172.4, 137.9, 134.1, 129.8, 129.0, 128.0, 116.3, 57.1, 55.0, 41.3, 37.4, 36.8, 33.1, 32.8, 30.1, 26.2, 25.5, 23.9, 20.7, 14.4; HPLC-MS (ammonium acetate) [M+H⁺] = 343.33.

6-Methyl-1-[3-(4-propoxypiperidin-1-yl)propyl]-3,4-dihydro-1H-quinolin-2-one (107LH18-2)

[0315] A 4 mL vial was charged with 1-(3-Chloropropyl)-6-methyl-3,4-dihydro-1H-quinolin-2-one (107LH14) (0.128 g), 4-propoxypiperidine (0.079 g, 0.54 mmol), KI (0.166 g, 1.0 mmol), and K₂CO₃ (0.138 g, 1.0 mmol) in MeCN (2 mL) and shaken at 50 ° for 20 h. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The product was purified by flash CC (SiO₂; EtOAc, MeOH/EtOAc 1:4) to give the title compound (107LH18-2) (0.108 g, total yield 50%). ¹H NMR (CD₃OD) δ 7.05 – 7.00 (m, 3H), 3.95 (t, *J* = 7.2, CH₂), 3.41 – 3.30 (m, 3H), 2.84 – 2.76 (m, 4H), 2.57 – 2.53 (m, 2H), 2.47 – 2.43 (m, 2H), 2.27 (s, 3H, CH₃), 2.27 – 2.22 (m, 2H), 1.90 – 1.81 (m, 4H), 1.63 – 1.52 (m, 4H), 0.91 (t, *J* = 7.4 Hz, CH₃); ¹³C NMR (CD₃OD) δ 172.4, 137.8, 134.0, 129.8, 129.0, 128.0, 116.2, 75.3, 70.7, 56.5, 51.9, 41.2, 32.8, 31.7, 26.2, 25.5, 24.3, 20.7, 11.0; HPLC-MS (ammonium acetate) [M+H⁺] = 345.30.

1-[3-(4-Butylpiperidin-1-yl)propyl]-7-fluoro-3,4-dihydro-1H-quinolin-2-one (107LH21)

[0316] A reaction flask was charged with 7-fluoro-3,4-dihydro-1H-quinolin-2-one (97LH36) (0.080 g, 0.48 mmol) in dry DMF (2 mL) under Argon. NaH (60% in oil, 0.021 g, 0.53 mmol) was added and the mixture was stirred at rt for 0.5 h. Then 1-bromo-3-chloropropane (0.075 g, 0.48 mmol) was added followed by stirring at rt for 20 h. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The crude material was dissolved in MeCN (3 mL) followed by addition of 4-butylpiperidine (0.071 g, 0.50 mmol), KI (0.166 g, 1.00 mmol), and K₂CO₃ (0.138 g, 1.00 mmol) and shaken at 50 ° for 4 days. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The product was purified by flash CC (SiO₂; EtOAc) to give the title compound (107LH21) (0.062 g, 37%). ¹H NMR (CD₃OD) δ 7.20 – 7.17 (m, 1H), 7.01 – 6.98 (m, 1H), 6.76 – 6.72 (m, 1H), 3.95 (t, *J* = 7.4 Hz, CH₂), 2.93 – 2.84 (m, 4H), 2.61 – 2.57 (m, 2H), 2.42 – 2.38 (m, 2H), 2.00 – 1.94 (m, 2H), 1.84 – 1.80 (m, 2H), 1.68 (d, *J* = 10.0 Hz, 2H), 1.30 – 1.22 (m, 9H), 0.89 (t, *J* = 6.8 Hz, CH₃); HPLC-MS (ammonium acetate) [M+H⁺] = 347.31.

1-[3-(4-Butylpiperidin-1-yl)propyl]-5-methyl-3,4-dihydro-1H-quinolin-2-one (107LH28)

[0317] A 4 mL vial was charged with 1-(3-chloropropyl)-5-methyl-3,4-dihydro-1H-quinolin-2-one (107LH27-11,3) (0.057 g, 0.24 mmol), 4-butylpiperidine (0.042 g, 0.30 mmol), KI (0.083 g, 0.50 mmol), and K₂CO₃ (0.069 g, 0.50 mmol) in MeCN and shaken at 50 °. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The product was purified by flash CC (SiO₂; EtOAc, MeOH/EtOAc 1:4) to give the title compound (107LH28) (0.060 g, 74%). ¹H NMR (CD₃OD) δ 7.15 (t, *J* = 8.0 Hz, 1H), 7.03 (d, *J* = 8.2 Hz, 1H), 6.92 (d, *J* = 7.4 Hz), 4.00 (t, *J* = 7.2 Hz, CH₂), 3.10 (d, *J* = 12.1 Hz, 2H), 2.87 – 2.83 (m, 2H), 2.66 – 2.62 (m, 2H), 2.59 – 2.55 (m, 2H), 2.31 – 2.25 (m, 2H), 2.29 (s, CH₃), 1.93 – 1.87 (m, 2H), 1.76 (d, *J* = 11.7 Hz, 2H), 1.31 – 1.24 (m, 9H), 0.90 (t, *J* = 6.8 Hz, CH₃); ¹³C NMR (CD₃OD) δ 172.7, 140.2, 137.0, 128.1, 126.6, 126.5, 114.5, 56.5, 54.6, 41.2, 37.0, 36.0, 32.2, 32.2, 30.0, 25.0, 23.9, 22.4, 19.7, 14.4; HPLC-MS (ammonium acetate) [M+H]⁺ = 343.36.

1-[3-(4-Butylpiperidin-1-yl)propyl]-7-methyl-3,4-dihydro-1H-quinolin-2-one (107LH29)

[0318] A 4 mL vial was charged with 1-(3-chloropropyl)-7-methyl-3,4-dihydro-1H-quinolin-2-one (107LH27-13,1) (0.117 g, 0.49 mmol), 4-butylpiperidine (0.071 g, 0.50 mmol), KI (0.166 g, 1.00 mmol), and K₂CO₃ (0.138 g, 1.00 mmol) in MeCN and shaken at 50 °. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The product was purified by flash CC (SiO₂; EtOAc, MeOH/EtOAc 1:4) to give the title compound (107LH28) (0.060 g, 74%). ¹H NMR δ 7.06 (d, *J* = 7.4 Hz, 1H), 6.97 (s, 1H), 6.84 (d, *J* = 7.6 Hz, 1H), 3.97 (t, *J* = 7.4 Hz, CH₂), 2.91 (d, *J* = 11.2 Hz, 2H), 2.82 (t, *J* = 6.8 Hz, CH₂), 2.57 – 2.54 (m, 2H), 2.41 – 2.37 (m, 2H), 2.33 (s, CH₃), 1.98 – 1.92 (m, 2H), 1.87 – 1.79 (m, 2H), 1.68 (d, *J* = 9.6 Hz, 2H), 1.30 – 1.17 (m, 9H), 0.89 (t, *J* = 6.8 Hz, CH₃); ¹³C NMR (CD₃OD) δ 172.7, 140.1, 138.5, 128.9, 125.1, 124.9, 117.0, 57.0, 55.0, 41.3, 37.3, 36.8, 33.1, 30.1, 25.8, 25.6, 23.9, 21.6, 14.4; HPLC-MS (ammonium acetate) [M+H]⁺ = 343.37.

1-[3-(4-Butylpiperidin-1-yl)propyl]-7-fluoro-6-methyl-3,4-dihydro-1H-quinolin-2-one (112KK06)

[0319] A 4 mL vial was charged with 1-(3-chloropropyl)-7-fluoro-6-methyl-3,4-dihydro-1H-quinolin-2-one (112KK01) (0.047 g, 0.18 mmol), 4-butylpiperidine (0.039 g, 0.28 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in MeCN (2 mL) and shaken at 50 ° for 20 h. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were purified by cation exchange CC followed by purification by flash CC (SiO₂; MeOH/DCM 1:10) to give the title compound (112KK06) (0.022 g, 34%). ¹H NMR (CD₃OD) δ 7.05 (d, *J* = 8.4 Hz, 1H), 6.93 (d, *J* = 11.7 Hz, 1H), 3.93 (t, *J* = 7.2 Hz,

CH₂), 2.93 (d, $J = 11.1$ Hz, 2H), 2.83 (t, $J = 6.9$ Hz, CH₂), 2.60 – 2.56 (m, 2H), 2.44 – 2.40 (m, 2H), 2.19 (d, $J = 1.8$ Hz, CH₃), 2.03 – 1.98 (m, 2H), 1.86 – 1.79 (m, 2H), 1.69 (d, $J = 11.0$ Hz, 2H), 1.31 – 1.19 (m, 9H), 0.89 (t, $J = 6.6$ Hz, CH₃); ¹³C NMR (CD₃OD) δ 172.4, 161.7 (d, $J = 241.0$ Hz), 139.5 (d, $J = 10.0$ Hz), 131.7 (d, $J = 6.1$ Hz), 123.5 (d, $J = 3.6$ Hz), 119.9 (d, $J = 17.4$ Hz), 104.0 (d, $J = 28.1$ Hz), 56.8, 55.0, 41.5, 37.3, 36.7, 33.0, 32.8, 30.1, 25.5, 25.3, 23.9, 14.4, 13.7.

[0320] The product was dissolved in MeOH/Et₂O and oxalic acid dissolved in Et₂O was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.018 g). HPLC-MS (ammonium acetate) $[M+H]^+ = 361.35$.

1-[3-(4-Butylpiperidin-1-yl)propyl]-6,7-difluoro-3,4-dihydro-1H-quinolin-2-one (112KK07)

[0321] A 4 mL vial was charged with 1-(3-chloropropyl)-6,7-difluoro-3,4-dihydro-1H-quinolin-2-one (112KK03) (0.123 g, 0.47 mmol), 4-butylpiperidine (0.074 g, 0.52 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in MeCN (2 mL) and shaken at 50 ° for 20 h. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were purified by cation exchange CC followed by purification by flash CC (SiO₂; MeOH/DCM 1:10) to give the title compound (112KK07) (0.097 g, 57%). ¹H NMR (CD₃OD) δ 7.20 – 7.09 (m, 2H), 3.91 (t, $J = 7.2$ Hz, CH₂), 2.90 – 2.82 (m, 4H), 2.59 – 2.55 (m, 2H), 2.38 – 2.34 (m, 2H), 1.97 – 1.91 (m, 2H), 1.82 – 1.75 (m, 2H), 1.66 (d, $J = 9.8$ Hz, 2H), 1.28 – 1.16 (m, 9H), 0.87 (t, $J = 6.7$ Hz, CH₃); ¹³C NMR (CD₃OD) δ 172.1, 150.4 (q, $J = 243.2$ Hz, $J = 13.2$ Hz), 146.9 (q, $J = 243.2$ Hz, $J = 12.6$ Hz), 137.3 (q, $J = 8.1$ Hz, $J = 2.9$ Hz), 124.9 (q, $J = 5.8$ Hz, $J = 3.9$ Hz), 117.6 (d, $J = 18.7$ Hz), 106.4 (d, $J = 22.6$ Hz), 56.8, 55.0, 41.8, 37.4, 36.8, 33.1, 32.4, 30.1, 25.5, 25.3, 23.9, 14.4.

[0322] The product was dissolved in MeOH/Et₂O and oxalic acid dissolved in Et₂O was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.046 g). HPLC-MS (ammonium acetate) $[M+H]^+ = 365.32$.

6,7-Difluoro-1-[3-(4-propoxypiperidin-1-yl)propyl]-3,4-dihydro-1H-quinolin-2-one (122LH7)

[0323] A 4 mL vial was charged with 1-(3-chloropropyl)-6,7-difluoro-3,4-dihydro-1H-quinolin-2-one (112KK03) (0.286 g, 1.1 mmol), 4-propoxypiperidine (0.160 g, 1.1 mmol), KI (0.250 g, 1.5 mmol), and K₂CO₃ (0.207 g, 1.54 mmol) in MeCN (2.5 mL) and shaken at 40 ° for 2 days. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The crude product was purified by cation exchange CC followed by flash CC (SiO₂; EtOAc) and then prep RP-HPLC to give the title compound (122LH07) (0.165 g, 41%). ¹H NMR (CD₃OD) δ 7.22 – 7.11 (m, 2H), 3.94 (t, $J = 7.2$ Hz, CH₂), 3.42 – 3.35 (m, 3H), 2.89 – 2.83 (m, 4H), 2.62 – 2.51 (m, 4H), 2.40 – 2.36 (m, 2H), 1.95 – 1.82 (m, 4H), 1.69 – 1.51 (m, 4H), 0.91 (t, $J = 7.2$ Hz, CH₃); ¹³C NMR

(CD₃OD) δ 172.0, 150.3 (q, $J = 243.3$ Hz, $J = 13.5$ Hz), 146.9 (q, $J = 243.3$ Hz, $J = 12.7$ Hz), 137.3 (q, $J = 8.1$ Hz, $J = 2.7$ Hz), 124.9 (q, $J = 5.8$ Hz, $J = 3.8$ Hz), 117.6 (d, $J = 18.8$ Hz), 106.3 (d, $J = 22.7$ Hz), 74.8, 70.7, 56.1, 51.7, 41.5, 32.3, 31.4, 25.5, 25.1, 24.3, 11.0.

[0324] The product was dissolved in acetone and oxalic acid dissolved in acetone was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.154 g). HPLC-MS (ammonium acetate) $[M+H]^+ = 367.25$.

(*R,S*)-1-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6,7-difluoro-3,4-dihydro-1*H*-quinolin-2-one
(122LH11-1)

[0325] A reaction flask was charged with 6,7-difluoro-3,4-dihydro-1*H*-quinolin-2-one (97KK47) (0.183 g, 1.0 mmol) in dry DMF (1 mL) under Argon. NaH (60% in oil, 0.050 g, 1.3 mmol) was added and the mixture was stirred at rt for 0.5 h. Then (*R,S*)-1-bromo-3-chloro-2-methylpropane (0.172 g, 1.0 mmol) was added followed by stirring at rt for 20 h. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. After purification by flash CC (SiO₂; EtOAc/n-heptane 1:1), the crude product was solvated in DMF (0.5 mL) and added 4-butylpiperidine 0.085 g, 0.6 mmol), NaI (0.113 g, 0.075 mmol), and K₂CO₃ (0.104 g, 0.075 mmol) followed by stirring at 50 ° for 3 days. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The crude product was purified by cation exchange CC and prep RP-HPLC to give the title compound (122LH11-1). ¹H NMR (CD₃OD) δ 7.25 – 7.20 (m, 1H), 7.16 – 7.12 (m, 1H), 3.97 (dd, $J = 14.3$ Hz, $J = 8.4$ Hz, 1H), 3.85 (dd, $J = 14.5$ Hz, $J = 5.1$ Hz, 1H), 2.94 – 2.85 (m, 3H), 2.78 (d, $J = 9.4$ Hz, 1H), 2.66 – 2.57 (m, 2H), 2.27 – 2.13 (m, 2H), 2.03 – 1.85 (m, 3H), 1.67 – 1.65 (m, 2H), 1.31 – 1.22 (m, 9H), 0.90 (t, $J = 6.6$ Hz, CH₃), 0.87 (d, $J = 6.7$ Hz, CH₃).

[0326] The crude product was dissolved in acetone and oxalic acid dissolved in acetone was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.025 g, 7%). HPLC-MS (ammonium acetate) $[M+H]^+ = 379.27$.

(*R,S*)-6,7-Difluoro-1-[3-(4-propoxypiperidin-1-yl)-2-methylpropyl]-3,4-dihydro-1*H*-quinolin-2-one
(122LH11-2)

[0327] A reaction flask was charged with 6,7-difluoro-3,4-dihydro-1*H*-quinolin-2-one (97KK47) (0.183 g, 1.0 mmol) in dry DMF (1 mL) under Argon. NaH (60% in oil, 0.050 g, 1.3 mmol) was added and the mixture was stirred at rt for 0.5 h. Then (*R,S*)-1-bromo-3-chloro-2-methylpropane (0.172 g, 1.0 mmol) was added followed by stirring at rt for 20 h. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. After purification by flash CC (SiO₂;

EtOAc/n-heptane 1:1), the crude product was solvated in DMF (0.5 mL) and added 4-butylpiperidine 0.085 g, 0.6 mmol), NaI (0.113 g, 0.075 mmol), and K₂CO₃ (0.104 g, 0.075 mmol) followed by stirring at 50 ° for 3 days. The reaction mixture was quenched with water, and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The crude product was purified by cation exchange CC and prep RP-HPLC to give the crude title compound (122LH11-2). ¹H NMR (CD₃OD) δ 7.24 – 7.12 (m, 2H), 3.97 (dd, *J* = 14.5 Hz, *J* = 8.6 Hz, 1H), 3.87 (dd, *J* = 14.3 Hz, *J* = 5.1 Hz, 1H), 3.41 (t, *J* = 6.7 Hz, CH₂), 3.35 – 3.28 (m, 1H), 2.89 – 2.85 (m, 2H), 2.78 – 2.75 (m, 1H), 2.66 – 2.59 (m, 3H), 2.26 – 2.21 (m, 1H), 2.17 – 2.11 (m, 2H), 2.07 – 1.97 (m, 2H), 1.90 – 1.86 (m, 2H), 1.61 – 1.51 (m, 4H), 0.92 (t, *J* = 7.4 Hz, CH₃), 0.86 (d, *J* = 6.6 Hz, CH₃); ¹³C NMR (CD₃OD) δ 172.5, 150.3 (q, *J* = 242.9 Hz, *J* = 13.1 Hz), 146.8 (q, *J* = 243.3 Hz, *J* = 13.1 Hz), 137.3 (q, *J* = 8.1 Hz, *J* = 2.7 Hz), 125.1 (q, *J* = 5.8 Hz, *J* = 3.8 Hz), 117.6 (d, *J* = 18.8 Hz), 106.7 (d, *J* = 22.7 Hz), 76.3, 70.9, 64.5, 53.4, 52.8, 47.1, 32.5, 32.4, 30.5, 25.5, 24.3, 17.2, 11.0.

[0328] The crude product was dissolved in acetone and oxalic acid dissolved in acetone was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.030 g, 8%). HPLC-MS (ammonium acetate) [M+H]⁺ = 381.27.

1-[3-(4-Butylpiperidin-1-yl)propyl]-6-fluoro-7-methyl-3,4-dihydro-1*H*-quinolin-2-one (107LH93-1)

[0329] A reaction flask was charged with 6-fluoro-7-methyl-3,4-dihydro-1*H*-quinolin-2-one (0.150 g, 0.84 mmol) in dry DMF (1 mL) under N₂. NaH (60% in oil, 0.038 g, 0.92 mmol) was added and stirred at rt for 30 min. Then 3-chloro-1-iodopropane (0.131 g, 0.84 mmol) was added followed by stirring at r.t for 20 h. The reaction mixture was quenched with water and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The crude material was dissolved in MeCN (2 mL) followed by addition of 4-butylpiperidine (0.085 g, 0.6 mmol), NaI (0.150 g, 1.0 mmol), and K₂CO₃ (0.138 g, 1.0 mmol) and shaken at 50 °C for 20 h. The reaction mixture was quenched with water and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The residue was purified by cation exchange CC followed by flash CC (SiO₂; EtOAc) to give the title compound (107LH93-1) (0.166 g, total yield 55%). ¹H NMR (CH₃OD) δ 7.00 (d, *J* = 6.4 Hz, 1H), 6.88 (d, *J* = 9.2 Hz, 1H), 3.98 – 3.91 (m, 2H), 2.93 – 2.86 (m, 2H), 2.85 – 2.78 (m, 2H), 2.58 – 2.52 (m, 2H), 2.40 – 2.43 (m, 2H), 2.25 (d, *J* = 2.0 Hz, 3H), 1.98 – 1.76 (m, 4H), 1.70 – 1.62 (m, 2H), 1.35 – 1.22 (m, 9 H), 0.88 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (CH₃OD) δ 171.1, 157.2 (d, *J* = 241 Hz), 135.1 (d, *J* = 3 Hz), 126.5 (d, *J* = 8 Hz), 123.2 (d, *J* = 18 Hz), 118.1 (d, *J* = 5 Hz), 114.3 (d, *J* = 24 Hz), 55.8, 43.9, 40.4, 36.2, 35.7, 32.0, 31.5, 29.0, 24.6, 24.3, 22.8, 13.4 (br).

[0330] The product was dissolved in acetone and oxalic acid (1.1 equiv) dissolved in acetone was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.172 g). HPLC-MS (ammonium acetate) $[M+H]^+ = 363.4$.

6-Fluoro-7-methyl-1-[3-(4-propoxypiperidin-1-yl)propyl]-3,4-dihydro-1H-quinolin-2-one
(107LH93-2)

[0331] A reaction flask was charged with 6-fluoro-7-methyl-3,4-dihydro-1H-quinolin-2-one (0.150 g, 0.84 mmol) in dry DMF (1 mL) under N_2 . NaH (60% in oil, 0.038 g, 0.92 mmol) was added and stirred at rt for 30 min. Then 3-chloro-1-iodopropane (0.131 g, 0.84 mmol) was added followed by stirring at r.t for 20 h. The reaction mixture was quenched with water and the product extracted into EtOAc. The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated. The crude material was dissolved in MeCN (2 mL) followed by addition of 4-propoxypiperidine (0.086 g, 0.6 mmol), NaI (0.150 g, 1.0 mmol), and K_2CO_3 (0.138 g, 1.0 mmol) and shaken at 50 °C for 20 h. The reaction mixture was quenched with water and the product extracted into EtOAc. The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated. The residue was purified by cation exchange CC followed by flash CC (SiO_2 ; EtOAc) to give the title compound (107LH93-2) (0.171 g, total yield 56%). 1H NMR (CH_3OD) δ 7.00 (d, $J = 6.4$ Hz, 1H), 6.87 (d, $J = 9.2$ Hz, 1H), 3.94 (brt, $J = 7.2$ Hz, 2H), 3.39 (t, $J = 6.6$ Hz, 2H), 3.35 - 3.26 (m, 1H), 2.85 - 2.70 (m, 4 H), 2.58 - 2.51 (m, 2H), 2.39 (brt, 7.4 Hz, 2H), 2.24 (d, $J = 1.6$ Hz, 3H), 2.21 - 2.12 (m, 2 H), 1.92 - 1.75 (m, 4 H), 1.62 - 1.48 (m, 4H), 0.91 (t, $J = 7.4$ Hz); ^{13}C NMR (CH_3OD) δ 171.0, 157.1 (d, $J = 241$), 135.2 (d, $J = 3$ Hz), 126.5 (d, $J = 8$ Hz), 123.2 (d, $J = 18$ Hz), 118.1 (d, $J = 5$ Hz), 114.3 (d, $J = 24$ Hz), 74.6, 69.5, 55.4, 51.0, 40.4, 31.5, 30.9, 24.7, 24.5, 23.2, 13.5 (br), 10.0.

[0332] The product was dissolved in acetone and oxalic acid (1.1 equiv) dissolved in acetone was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.172 g). HPLC-MS (ammonium acetate) $[M+H]^+ = 364.3$.

(R,S)-1-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6-fluoro-7-methyl-3,4-dihydro-1H-quinolin-2-one (107LH94-1)

[0333] A reaction flask was charged with 6-fluoro-7-methyl-3,4-dihydro-1H-quinolin-2-one (0.150 g, 0.84 mmol) in dry DMF (1 mL) under N_2 . NaH (60% in oil, 0.038 g, 0.92 mmol) was added and stirred at rt for 30 min. Then (R,S)-1-bromo-3-chloro-2-methylpropane (0.144 g, 0.84 mmol) was added followed by stirring at r.t for 20 h. The reaction mixture was quenched with water and the product extracted into EtOAc. The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated. The crude material was dissolved in dry DMF (2 mL) followed by addition of 4-butylpiperidine (0.085 g, 0.6 mmol), NaI (0.150 g, 1.0 mmol), and K_2CO_3 (0.138 g,

1.0 mmol) and shaken at 100 °C for 20 h. The reaction mixture was quenched with water and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The residue was purified by cation-exchange CC followed by flash CC (SiO₂; EtOAc) to give the title compound (107LH94-1) (0.045 g, total yield 14%). ¹H NMR (CH₃OD) δ 7.01 (d, *J* = 6.4 Hz, 1H), 6.90 (d, *J* = 9.2 Hz), 4.03 - 3.88 (m, 2H), 2.90 (brd, *J* = 10.8 Hz, 2H), 2.83 (brt, *J* = 7.0 Hz, 2 H), 2.75 (brd, *J* = 10.2 Hz), 2.64 - 2.50 (m, 2 H), 2.26 - 1.98 (m, 6H), 1.93 - 1.78 (m, 2H), 1.68 - 1.58 (m, 2H), 1.35 - 1.14 8 (m, 9H), 0.89 (t, *J* = 6.8 Hz, 3H), 0.84 (d, *J* = 6.8 Hz, 3H); ¹³C NMR (CH₃OD) δ 171.6, 156.1 (d, *J* = 241 Hz), 135.1 (d, *J* = 3 Hz), 126.9 (d, *J* = 8 Hz), 123.0, (d, *J* = 19 Hz), 118.6 (d, *J* = 5 Hz), 114.3 (d, *J* = 24 Hz), 63.9, 55.1, 54.4, 45.5, 36.3, 35.9, 32.4 (br), 31.6, 29.0, 28.8, 24.6, 22.8, 16.0, 13.5 (br).

[0334] The product was dissolved in acetone and oxalic acid (1.1 equiv) dissolved in acetone was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.037 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 375.3.

(*R,S*)-6-Fluoro-7-methyl-1-[2-methyl-3-(4-propoxypiperidin-1-yl)-propyl]-3,4-dihydro-1*H*-quinolin-2-one (107LH94-2)

[0335] A reaction flask was charged with 6-fluoro-7-methyl-3,4-dihydro-1*H*-quinolin-2-one (0.150 g, 0.84 mmol) in dry DMF (1 mL) under N₂. NaH (60% in oil, 0.038 g, 0.92 mmol) was added and stirred at rt for 30 min. Then (*R,S*)-1-bromo-3-chloro-2-methylpropane (0.144 g, 0.84 mmol) was added followed by stirring at r.t for 20 h. The reaction mixture was quenched with water and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The crude material was dissolved in dry DMF (2 mL) followed by addition of 4-propoxypiperidine (0.086 g, 0.6 mmol), NaI (0.150 g, 1.0 mmol), and K₂CO₃ (0.138 g, 1.0 mmol) and shaken at 100 °C for 20 h. The reaction mixture was quenched with water and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The residue was purified by cation-exchange CC followed by flash CC (SiO₂; EtOAc) to give the title compound (107LH94-2) (0.033 g, total yield 10%). ¹H NMR (CH₃OD) δ 7.02 (d, *J* = 6.8 Hz, 1H), 6.91 (d, *J* = 9.6 Hz, 1H), 3.95 (d, *J* = 7.2 Hz, 2H), 3.41 (t, *J* = 6.6 Hz, 2H), 3.33 - 3.25 (m, 1H), 2.84 (brt, *J* = 7.4 Hz), 2.79 - 2.71 (m, 1H), 2.67 - 2.51 (m, 3H), 2.28 - 1.98 (m, 8H), 1.92 - 1.83 (m, 2H), 1.60 - 1.48 (m, 4H), 0.91 (t, *J* = 7.6 Hz, 3H), 0.85 (d, *J* = 6.4 Hz, 3H); ¹³C NMR (CH₃OD) δ 171.7, 157.2 (d, *J* = 241 Hz), 135.1 (d, *J* = 3 Hz), 126.9 (d, *J* = 8 Hz), 123.1 (d, *J* = 18 Hz), 114.3 (d, *J* = 24 Hz), 75.2, 69.5, 52.1, 51.7, 45.5, 31.6, 31.3, 29.0, 24.6, 23.1, 15.9, 13.5, 13.3, 9.8.

[0336] The product was dissolved in acetone and oxalic acid (1.1 equiv) dissolved in acetone was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.036 g). HPLC-MS (ammonium acetate) $[M+H]^+ = 377.3$.

1-[3-(4-Butyl-piperidin-1-yl)propyl]-6-fluoro-5-methyl-3,4-dihydro-1H-quinolin-2-one (107LH95-1)

[0337] A reaction flask was charged with 6-fluoro-5-methyl-3,4-dihydro-1H-quinolin-2-one (0.090 g, 0.50 mmol) in dry DMF (0.5 mL) under N₂. NaH (60% in oil, 0.023 g, 0.55 mmol) was added and stirred at rt for 30 min. Then 3-chloro-1-iodopropane (0.079 g, 0.50 mmol) was added followed by stirring at r.t for 20 h. The reaction mixture was quenched with water and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The crude material was dissolved in MeCN (2 mL) followed by addition of 4-butylpiperidine (0.085 g, 0.6 mmol), NaI (0.150 g, 1.0 mmol), and K₂CO₃ (0.138 g, 1.0 mmol) and shaken at 50 °C for 20 h. The reaction mixture was quenched with water and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The residue was purified by cation-exchange CC followed by flash CC (SiO₂; EtOAc) to give the title compound (107LH95-1) (0.059 g, total yield 33%). ¹H NMR (CH₃OD) δ 7.02 (dd, *J* = 4.8, 9.2 Hz, 1H), 6.98 - 6.92 (m, 1H), 3.95 (brt, *J* = 7.4 Hz, 2H), 2.92 - 2.82 (m, 4H), 2.59 - 2.52 (m, 2H), 2.39 - 2.32 (m, 2H), 2.00 (d, *J* = 1.6 Hz, 3H), 1.97 - 1.75 (m, 4H), 1.66 (brd, 10.8 Hz, 2H), 1.35 - 1.12 (m, 9H), 0.89 (t, *J* = 6.4 Hz); ¹³C NMR (CH₃OD) δ 170.9, 157.6 (d, *J* = 240 Hz), 135.4 (d, *J* = 3 Hz), 128.1 (d, *J* = 4 Hz), 122.7 (d, *J* = 18 Hz), 114.2 (d, *J* = 8 Hz), 112.9, (d, *J* = 25 Hz), 55.9, 53.9, 40.6, 36.2, 35.7, 31.9, 30.9, 28.9, 24.4, 22.8, 21.4 (br), 13.2, 9.7 (br).

[0338] The product was dissolved in acetone and oxalic acid (1.1 equiv) dissolved in acetone was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.058 g). HPLC-MS (ammonium acetate) $[M+H]^+ = 361.3$.

6-Fluoro-5-methyl-1-[3-(4-propoxypiperidin-1-yl)propyl]-3,4-dihydro-1H-quinolin-2-one (107LH95-2)

[0339] A reaction flask was charged with 6-fluoro-5-methyl-3,4-dihydro-1H-quinolin-2-one (0.090 g, 0.50 mmol) in dry DMF (0.5 mL) under N₂. NaH (60% in oil, 0.023 g, 0.55 mmol) was added and stirred at rt for 30 min. Then 3-chloro-1-iodopropane (0.079 g, 0.50 mmol) was added followed by stirring at r.t for 20 h. The reaction mixture was quenched with water and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The crude material was dissolved in MeCN (2 mL) followed by addition of 4-propoxypiperidine (0.086 g, 0.6 mmol), NaI (0.150 g, 1.0 mmol), and K₂CO₃ (0.138 g, 1.0 mmol) and shaken at 50 °C for 20 h. The reaction mixture was quenched with water and the product

extracted into EtOAc. The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated. The residue was purified by cation-exchange CC followed by flash CC (SiO_2 ; EtOAc) to give the title compound (107LH95-2) (0.074 g, total yield 41%). ^1H NMR (CH_3OD) δ 7.03 (dd, $J = 4.8, 9.2$ Hz, 1H), 6.99 - 6.92 (m, 1H), 3.98 (brt, $J = 7.4$ Hz, 2H), 3.46 - 3.38 (m, 3H), 2.95 - 2.84 (m, 4H), 2.64 - 2.42 (m, 6H), 2.20 (d, $J = 2.0$ Hz, 3H), 1.98 - 1.83 (m, 4H), 1.72 - 1.30 (m, 4H), 0.92 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (CH_3OD) δ 171.1, 157.7 (d, $J = 240$ Hz), 135.4 (d, $J = 3$ Hz), 128.1 (d, $J = 4$ Hz), 122.8 (d, $J = 18$ Hz), 114.1, (d, $J = 9$ Hz), 113.0 (d, $J = 25$ Hz), 73.1, 69.7, 55.0, 50.3, 40.3, 30.8, 29.9, 23.9, 23.1, 22.7, 21.4, 9.8 (br).

[0340] The product was dissolved in acetone and oxalic acid (1.1 equiv) dissolved in acetone was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.067 g). HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 363.3$.

(R)-1-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-3,4-dihydro-1H-quinolin-2-one (107LH47-A)

[0341] A 4 mL vial was charged with (S)-1-(3-iodo-2-methylpropyl)-3,4-dihydro-1H-quinolin-2-one (122LH18) (0.329 g, 1.0 mmol) and 4-butylpiperidine (0.283 g, 2.0 mmol) in MeCN (2 mL) and shaken at 60° for 20 h. The reaction mixture was concentrated, and the product purified by flash CC (SiO_2 ; EtOAc, EtOAc/MeOH 4:1) to give the title compound (107LH47-A) (0.186 g, 54%). ^1H NMR (CD_3OD) δ 7.26 - 7.19 (m, 3H), 7.04 - 7.00 (m, 1H), 2.93 - 2.88 (m, 3H), 2.77 (d, $J = 10.4$ Hz, 2H), 2.62 - 2.58 (m, 2H), 2.29 - 2.06 (m, 3H), 1.93 - 1.86 (m, 2H), 1.68 - 1.62 (m, 2H), 1.31 - 1.22 (m, 9H), 0.91 - 0.86 (m, 2 CH_3); ^{13}C NMR (CD_3OD) δ 173.2, 140.3, 129.1, 128.5, 128.4, 124.4, 166.9, 64.9, 56.0, 55.6, 37.5, 36.9, 33.4, 33.3, 32.9, 30.1, 30.1, 26.2, 24.0, 17.2, 14.4.

[0342] The product was dissolved in acetone and oxalic acid dissolved in acetone was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.222 g). HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 343.33$.

(R)-1-[2-Methyl-3-(4-propoxypiperidin-1-yl)propyl]-3,4-dihydro-1H-quinolin-2-one (107LH48)

[0343] A 4 mL vial was charged with (S)-1-(3-iodo-2-methylpropyl)-3,4-dihydro-1H-quinolin-2-one (122LH18) (0.493 g, 1.5 mmol) and 4-propoxypiperidine (0.430 g, 3.0 mmol) in MeCN (2 mL) and shaken at 60° for 20 h. The reaction mixture was quenched with water, basified with ammonium hydroxide, and the product extracted into EtOAc. The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated. The product was purified by flash CC (SiO_2 ; EtOAc, EtOAc/MeOH 4:1) to give the title compound (107LH48) (0.197 g, 38%). ^1H NMR (CD_3OD) δ 7.26 - 7.19 (m, 3H), 7.03 - 6.98 (m, 1H), 3.96 (d, $J = 7.0$ Hz, 2H), 3.40 (t, $J = 6.7$ Hz, 2H), 2.90 - 2.86 (m, 2H), 2.74 - 2.71 (m, 1H), 2.65 - 2.54 (m, 3H), 2.26 - 1.99 (m, 6H), 1.87 - 1.84 (m, 2H), 1.59 - 1.49 (m, 4H), 0.91 (t, $J = 7.4$ Hz, CH_3), 0.85 (d, $J = 6.6$ Hz, CH_3); ^{13}C NMR

(CD₃OD) δ 173.0, 140.3, 129.1, 128.4, 128.4, 124.3, 116.8, 76.3, 70.7, 64.5, 53.2, 52.8, 32.9, 32.4, 32.4, 30.3, 26.2, 24.3, 17.1, 11.0.

[0344] The product was dissolved in acetone and oxalic acid dissolved in acetone was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.189 g). HPLC-MS (ammonium acetate) $[M+H]^+ = 345.31$.

(R)-1-[3-(4-Butyldenepiperidin-1-yl)-2-methylpropyl]-3,4-dihydro-1H-quinolin-2-one (107LH53)

[0345] A 4 mL vial was charged with (S)-1-(3-iodo-2-methylpropyl)-3,4-dihydro-1H-quinolin-2-one (122LH18) (0.169 g, 0.51 mmol) and 4-butyldenepiperidine (0.200 g, 1.4 mmol) in MeCN (2 mL) and shaken at 40 ° for 20 h. The reaction mixture was quenched with water, basified with ammonium hydroxide, and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The product was purified by flash CC (SiO₂; n-heptane/EtOAc 4:1) to give the title compound (107LH53) (0.116 g, 67%). ¹H NMR (CD₃OD) δ 7.23 – 7.18 (m, 3H), 7.02 – 6.98 (m, 1H), 5.11 (t, $J = 7.4$ Hz, 1H), 3.98 (d, $J = 6.8$ Hz, 2H), 2.89 – 2.85 (m, 2H), 2.61 – 2.56 (m, 2H), 2.40 – 2.35 (m, 2H), 3.32 – 2.04 (m, 11H), 1.98 – 1.92 (m, 2H), 1.36 – 1.29 (m, 2H), 0.90 – 0.85 (m, 2 CH₃); ¹³C NMR (CD₃OD) δ 173.0, 140.3, 137.1, 129.1, 128.4, 128.4, 124.3, 123.7, 116.9, 64.6, 57.4, 56.6, 46.5, 37.0, 32.9, 30.2, 30.1, 29.1, 26.3, 24.2, 17.2, 14.1.

[0346] The product was dissolved in acetone and oxalic acid dissolved in acetone was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.130 g). HPLC-MS (ammonium acetate) $[M+H]^+ = 341.33$.

(R)-1-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-3,4-dihydro-1H-quinolin-2-one (107LH54)

[0347] A 4 mL vial was charged with (S)-1-(3-iodo-2-methylpropyl)-3,4-dihydro-1H-quinolin-2-one (122LH18) (0.185 g, 0.56 mmol) and 3-butyl-8-azabicyclo[3.2.1]octane (0.100 g, 0.60 mmol) in MeCN (0.5 mL) and shaken at 40 ° for 20 h. The reaction mixture was quenched with water, basified with ammonium hydroxide, and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The product was purified by flash CC (SiO₂; n-heptane/EtOAc 4:1) to give the title compound (107LH54) (0.063 g, 30%). ¹H NMR (CD₃OD) δ 7.29 – 7.19 (m, 3H), 7.03 – 6.99 (m, 1H), 4.03 – 4.00 (m, 2H), 3.14 – 3.13 (m, 1H), 3.07 – 3.05 (m, 1H), 2.90 – 2.86 (m, 2H), 2.62 – 2.57 (m, 2H), 2.28 – 2.19 (m, 2H), 1.97 – 1.82 (m, 3), 1.58 – 1.42 (m, 5H), 1.34 – 1.15 (m, 8H), 0.90 – 0.87 (m, 6H); ¹³C NMR (CD₃OD) δ 173.1, 140.3, 129.1, 128.4, 128.3, 124.3, 117.2, 62.2, 61.2, 58.2, 46.5, 39.0, 38.0, 32.9, 32.1, 30.3, 29.1, 27.8, 27.3, 26.3, 24.0, 17.1, 14.5.

[0348] The product was dissolved in acetone and oxalic acid dissolved in acetone was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.064 g). HPLC-MS (ammonium acetate) $[M+H]^+ = 369.34$.

(R)-1-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-3,4-dihydro-1H-quinolin-2-one (107LH55)

[0349] A 4 mL vial was charged with (S)-1-(3-iodo-2-methylpropyl)-3,4-dihydro-1H-quinolin-2-one (122LH18) (0.185 g, 0.56 mmol) and 3-pentyl-8-azabicyclo[3.2.1]octane (0.112 g, 0.62 mmol) in MeCN (0.5 mL) and shaken at 40 ° for 20 h. The reaction mixture was quenched with water, basified with ammonium hydroxide, and the product extracted into EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The product was purified by flash CC (SiO₂; n-heptane/EtOAc 4:1) to give the title compound (107LH55) (0.075 g, 35%). ¹H NMR (CD₃OD) δ 7.28 – 7.18 (m, 3H), 7.01 (t, *J* = 7.2 Hz, 1H), 4.03 (d, *J* = 7.0 Hz, 2H), 3.11 – 3.04 (m, 2H), 2.90 – 2.85 (m, 2), 2.64 – 2.56 (m 2H), 2.28 – 2.11 (m, 4H), 1.97 – 1.84 (m, 3H), 1.66 – 1.54 (m, 3H), 1.42 – 1.21 (m, 10H), 0.90 – 0.85 (m, 2 CH₃); ¹³C NMR (CD₃OD) δ 173.1, 140.3, 129.1, 128.4, 128.3, 124.3, 117.1, 61.4, 60.2, 58.3, 46.4, 39.5, 37.1, 37.0, 33.1, 32.9, 32.2, 29.5, 29.4, 28.5, 27.9, 26.3, 23.7, 17.1, 14.4.

[0350] The product was dissolved in acetone and oxalic acid dissolved in acetone was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.054 g). HPLC-MS (ammonium acetate) $[M+H]^+ = 383.35$.

1-[3-(4-Butylpiperidin-1-yl)propyl]-1H-quinolin-2-one (092LH70-A)

[0351] A 7mL vial was charged with 1-(3-chloropropyl)-1H-quinolin-2-one (0.450 g, 2.0 mmol), K₂CO₃ (0.34 g, 2.5 mmol), KI (0.42 g, 2.5 mmol), 4-butylpiperidine (0.30 g, 2.1 mmol) and dry CH₃CN (3 mL). The mixture was shaken at 50 °C for 60 h and thereafter diluted with EtOAc (50 mL) and washed with water (50 mL). The water phase was extracted with EtOAc (2 x 50 mL). The combined organic phase was dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by flash CC (SiO₂; EtOAc/MeOH 4:1) followed by prep RP-HPLC to give the title compound (0.32g, 49%). ¹H NMR (CD₃OD) δ 7.88 (d, *J* = 9.6 Hz), 7.68 (brd, *J* = 8.0 Hz), 7.65-7.61 (m, 2H), 7.33-7.25 (m, 1H), 6.64 (d, 9.6 Hz), 4.39-4.32 (m, 2H), 2.95-2.86 (m, 2H), 2.50-2.43 (m, 2H), 2.01-1.86 (m, 4H), 1.71-1.62 (m, 2H), 1.35-1.12 (m, 9H), 0.89 (t, *J* = 6.6 Hz); ¹³C NMR (CD₃OD) δ 163.1, 140.4, 139.0, 131.1, 129.2, 122.6, 121.4, 120.3, 114.7, 55.8, 53.9, 40.6, 36.2, 35.7, 32.0, 28.9, 24.7, 22.8, 13.2.

[0352] The product was dissolved in acetone and oxalic acid (1.1 equiv) dissolved in acetone was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.356 g). HPLC-MS (ammonium acetate) $[M+H]^+ = 327.3$.

1-[3-(4-Propoxypiperidin-1-yl)propyl]-1H-quinolin-2-one, (092LH69)

[0353] A 4 mL vial was charged with 1-(3-chloropropyl)-1H-quinolin-2-one (0.069 g, 0.31 mmol), K₂CO₃ (0.069 g, 0.50 mmol), KI (0.083 g, 0.50 mmol), 4-propoxypiperidine (0.050 g, 0.35 mmol) and dry CH₃CN (2 mL). The mixture was shaken at 50 °C for 24 h and thereafter diluted with water (25 mL) and EtOAc (25 mL). The phases were separated and the water phase was extracted with EtOAc (2 x 50 mL). The combined organic phase was then dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by flash CC (SiO₂; EtOAc/MeOH 4:1) followed by prep RP-HPLC to give the title compound (0.060 g, 59%). ¹H NMR (CD₃OD) δ 7.85 (d, *J* = 9.4 Hz, 1H), 7.65 (brd, *J* = 7.2 Hz, 1H), 7.63 (m, 2 H), 7.29-7.22 (m, 1H), 6.62, (d, *J* = 9.4 Hz), 4.36-4.29 (m, 1H), 3.38 (t, *J* = 6.6 Hz, 2H), 3.34-3.24 (m, 1H), 2.78-2.69 (m, 2H), 2.48-2.41 (m, 2H), 2.18-2.09 (m, 2H), 1.94-1.82 (m, 4 H), 1.59-1.47 (m, 4H), 0.90 (t, *J* = 7.4 Hz); ¹³C NMR (CD₃OD) δ 162.0, 140.3, 139.0, 131.1, 129.2, 122.6, 121.4, 120.3, 114.7, 74.7, 69.5, 55.4, 51.0, 40.6, 31.0, 24.9, 32.1, 9.9; HPLC-MS (ammonium acetate) [M+H]⁺ = 329.3.

1-[3-(4-Butylpiperidin-1-yl)propyl]-6-fluoro-1H-quinolin-2-one (107LH22)

[0354] A 4 mL vial was charged with 6-fluoro-1H-quinolin-2-one (0.056 g, 0.34 mmol), dry DMF (2 mL) and NaH (60% in oil, 0.015 g, 0.34 mmol). The mixture was stirred at rt for 1 h under a N₂ atmosphere, and thereafter 1-bromo-3-chloropropane (34 µl, 0.34 mmol) was added and the mixture was then shaken at rt for 20 h. The reaction was diluted with diethyl ether (25 mL) and washed with water (15 mL). The organic phase was washed with water (15 mL) and brine (15 mL), dried over Na₂SO₄, and concentrated under reduced pressure. The oily residue was diluted with CH₃CN (2 mL) and KI (0.083 g, 0.50 mmol), K₂CO₃ (0.069 g, 0.50 mmol) and 4-butylpiperidine (0.048 g, 0.34 mmol) was added. The mixture was shaken at 50 °C for 72 h and then diluted with EtOAc (25 mL) and washed with water (15 mL). The water phase was extracted (2 x 25 mL) and the combined organic phase was dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by cation-exchange CC followed by flash CC (SiO₂; EtOAc/MeOH 4:1) to yield the title compound (0.034 g, 29%). ¹H NMR (CD₃OD) δ 7.90 (d, *J* = 9.2 Hz, 1H), 7.69 (dd, *J* = 4.0, 8.8 Hz, 1H), 7.50-7.41 (m, 2H), 6.72 (d, *J* = 8.8 Hz, 1H), 4.41 (t, *J* = 6.8 Hz, 2H), 3.02-2.95 (m, 2H), 2.65-2.60 (m, 2 H), 2.19-2.08 (m, 2H), 1.91-1.82 (m, 4 H), 1.53-1.21 (m, 9H), 0.90 (t, *J* = 7.0 Hz); ¹³C NMR (CD₃OD) δ 169.9, 158.4 (d, *J* = 242 Hz), 139.8 (d, *J* = 3 Hz), 134.4 (d, *J* = 2 Hz), 122.5 (d, *J* = 9 Hz), 121.6, 119.9 (d, *J* = 24 Hz), 116.8 (d, *J* = 8 Hz), 113.9 (d = 23 Hz), 54.4, 53.0, 40.1, 34.5, 34.1, 30.1, 28.7, 23.3, 22.6, 13.2; HPLC-MS (ammonium acetate) [M+H]⁺ = 345.3.

1-[3-(4-Butylpiperidin-1-yl)propyl]-6-methyl-1*H*-quinolin-2-one (107LH32-A)

[0355] A 4 mL vial was charged with 6-methyl-1*H*-quinolin-2-one (0.110 g, 0.71 mmol), dry DMF (2 mL) and NaH (60% in oil, 0.031 g, 0.78 mmol). The mixture was shaken under a N₂ atmosphere for 1h, and thereafter 1-bromo-3-chloropropane (70 µl, 0.71 mmol) was added. The reaction was shaken at rt for 20 h and then poured into diethyl ether (25 mL) and washed with water (15 mL). The ether phase was washed with water (15 mL) and brine (15 mL). The organic phase was dried over Na₂SO₄, and concentrated under reduced pressure. The residue was diluted with CH₃CN (2 mL) and KI (0.160 g, 1.0 mmol), K₂CO₃ (0.140 g, 1.0 mmol) and 4-butylpiperidine (0.100 g, 0.71 mmol) was added. The mixture was shaken at 50 °C for 72 h and then poured onto The compound EtOAc (25 mL) and water (15 mL). The water phase was extracted (2 x 25 mL) and the combined organic phase was dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by flash CC (SiO₂; EtOAc/MeOH 4:1) followed by prep RP-HPLC to give the title compound (0.058 g, 23%). ¹H NMR (CD₃OD) δ 7.78 (d, *J* = 9.2 Hz, 1H), 7.52-7.40 (m, 3H), 6.60 (d, *J* = 9.2 Hz, 1H), 4.3 (t, *J* = 7.6 Hz, 2H), 2.92-2.2.85 (m, 2H), 2.50-2.39 (m, 2H), 2.39 (s, 3H), 1.99-1.84 (m, 4H), 1.69-1.61 (m, 2H), 1.35-1.11 (m, 9H), 0.88 (t, *J* = 6.8 Hz); ¹³C NMR (CD₃OD) δ 162.9, 140.1, 137.0, 132.5, 132.3, 128.8, 121.4, 120.2, 114.6, 55.8, 53.9, 40.6, 36.2, 35.7, 32.0, 28.9, 24.8, 22.8, 19.4, 13.3; HPLC-MS (ammonium acetate) [M+H]⁺ = 341.3.

1-[3-(4-Butylpiperidin-1-yl)propyl]-7-fluoro-1*H*-quinolin-2-one (107LH33-A)

[0356] A 4 mL vial was charged with 7-fluoro-1*H*-quinolin-2-one (0.032 g, 0.19 mmol), NaH (60% in oil, 8.7 mg, .21 mmol) and dry DMF (2.5 mL). The mixture was shaken at rt for 1 h and then 1-bromo-3-chloropropane (20 µl, 0.19 mmol) was added and the reaction was shaken overnight shaken at rt overnight. The mixture was then diluted with ether (25 mL) and washed water (15 mL), the ether phase was washed with water (15 mL) and brine (15 mL). The organic phase was dried over Na₂SO₄, and concentrated under reduced pressure. The oily residue was diluted with CH₃CN (2 mL) and to the resulting solution was added: KI (0.050 g, 0.30 mmol), K₂CO₃ (0.041 g, 0.30 mmol) and 4-butylpiperidine (0.028 g, 0.20 mmol). The mixture was shaken at 50 °C for 72 h and then poured onto The compound EtOAc (25 mL) and water (15 mL). The water phase was extracted (2 x 25 mL) and the combined organic phase was dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by flash CC (SiO₂; EtOAc/MeOH 4:1) followed by prep RP-HPLC to give the title compound (7.0 mg, 11%). ¹H NMR (CD₃OD) δ 7.89 (d, *J* = 9.6 Hz, 1H), 7.73 (dd, *J* = 6.2, 8.6 Hz, 1H), 7.47 (dd, *J* = 2.4, 11.6 Hz, 1H), 7.08 (dt, *J* = 2.4, 8.6 Hz, 1H), 6.60 (d *J* = 9.6 Hz, 1H), 4.33 (t, *J* = 7.6 Hz, 2H), 2.98 - 2.00 (m, 2H), 2.50 - 2.42 (m, 2H), 2.05 - 1.86 (m, 4H), 1.55 - 1.64 (m, 2H), 1.36 - 1.15 (m, 9H), 0.90 (t, *J* = 6.8 Hz); ¹³C NMR (CD₃OD) δ 164.7 (d, *J* = 248), 163.2, 140.9 (br), 139.9, 131.4 (d, *J* = 10 Hz), 119.3

(d, $J = 3$ Hz), 118.1 (br), 110.6 (d, $J = 23$ Hz), 101.6 (d, $J = 28$ Hz), 55.5, 53.9, 41.0, 36.8, 35.6, 31.9, 28.9, 24.5, 22.7, 13.2; HPLC-MS (ammonium acetate) $[M+H]^+ = 345.3$

1-[3-(4-Butylpiperidin-1-yl)propyl]-6-methoxy-1H-quinolin-2-one (107LH37-A)

[0357] A 4 mL vial was charged with 6-methoxy-1H-quinolin-2-one (0.032 g, 0.18 mmol) dry DMF (2 mL) and NaH (60% in oil, 8 mg, 0.20 mmol), thereafter the mixture was stirred at 45 °C for 45 min under a N₂ atmosphere, followed by the addition of 1-bromo-3-chloropropane (18 µl, 0.18 mmol) and the mixture was shaken at 30 °C overnight. The reaction was then diluted with ether (25 mL) and washed with water (15 mL) and brine (15 mL), dried over Na₂SO₄, and concentrated under reduced pressure. The oily residue was diluted with CH₃CN (3 mL) and KI (0.080 g, 0.50 mmol), K₂CO₃ (0.070 g, 0.50 mmol) and 4-butylpiperidine (0.028 g, 0.20 mmol) were added. The mixture was shaken at 50 °C for 48 h and then diluted with EtOAc (25 mL) and washed with water (15 mL). The water phase was extracted (2 x 25 mL) and the combined organic phase was dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by prep RP-HPLC to give the title compound (0.028 g, 44%). ¹H NMR (CD₃OD) δ 7.85 (d, $J = 9.6$ Hz, 1H), 7.56 (d, $J = 9.2$ Hz, 1H), 7.26 (dd, $J = 2.8, 9.6$ Hz, 1H), 7.19 (d, $J = 2.8$ Hz, 1H), 6.65 (d, $J = 9.6$ Hz, 1H), 4.34 (t, $J = 7.2$ Hz, 2H), 3.85 (s, 3H), 3.07-2.98 (m, 2H), 2.64 - 2.58 (m, 2H), 2.19 - 2.10 (m, 2H), 2.04 - 1.94 (m, 2H), 1.76 - 1.66 (m, 2H), 1.35 - 0.96 (m, 9H), 0.89 (t, $J = 6.8$ Hz); ¹³C NMR (CD₃OD) δ 162.7, 155.5, 140.1, 133.3, 122.3, 120.6, 120.1, 116.1, 110.5, 55.3, 55.0, 53.6, 40.5, 36.0, 35.2, 31.4, 28.8 24.4, 22.7, 13.2; HPLC-MS (ammonium acetate) $[M+H]^+ = 357.3$.

1-[3-(4-Butylpiperidin-1-yl)propyl]-6-chloro-1H-quinolin-2-one (107LH38-A)

[0358] A 4 mL vial was charged with 6-chloro-1H-quinolin-2-one (107LH35) (0.085 g, 0.47 mmol), dry DMF (3 mL) and NaH (60% in oil, 0.023 g, 0.56 mmol) and the mixture was stirred at rt for 45 min under a N₂ atmosphere. Thereafter, 1-bromo-3-chloropropane (18 µl, 0.18 mmol) was added and the mixture was shaken at rt overnight, the reaction diluted with ether (25 mL) and washed with water (15 mL). The ether phase was washed with brine (15 mL), dried over Na₂SO₄, concentrated under reduced pressure. The oily residue was diluted with dry CH₃CN (2 mL) and KI (0.170 g, 1.0 mmol), K₂CO₃ (0.140 g, 1.0 mmol) and 4-butylpiperidine (0.071 g, 0.50 mmol) were added. The mixture was shaken at 50 °C for 24 h and then diluted with EtOAc (25 mL) and washed with water (15 mL). The water phase was extracted (2 x 25 mL) and the combined organic phases were dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by prep RP-HPLC to give the title compound (32 mg, 89 µmol, 19 %). ¹H NMR (CD₃OD) δ 7.80 (d, $J = 9.2$ Hz, 1H), 7.66 (brs, 1H), 7.60 - 7.51 (m, 2H), 6.65 (d, $J = 9.6$ Hz, 1H), 5.30 (t, $J = 7.6$ Hz, 2H), 3.09 - 2.95 (m, 2H), 2.68 - 2.57 (m, 2H), 2.24 - 2.06 (m, 2H), 2.00 - 1.90 (m, 2H), 1.75 -

1.64 (m, 2H), 1.32 - 1.12 (m, 9H), 0.84 (t, 6.4 Hz, 3H); ^{13}C NMR (CD_3OD) δ 162.6, 139.2, 137.4, 130.8, 128.0, 127.8, 122.4, 121.5, 116.3, 55.0, 53.3, 40.3, 35.7, 34.8, 31.0, 28.6, 23.9, 22.5, 13.0; HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 361.3$.

1-[3-(4-Butylpiperidin-1-yl)propyl]-5-methyl-1H-quinolin-2-one (107LH45)

[0359] A 4mL vial was charged with 1-(3-chloropropyl)-5-methyl-1H-quinolin-2-one (0.053 g, 0.23 mmol), KI (0.083 g, 0.5 mmol), K_2CO_3 (0.069 g, 0.50 mmol) and 4-butylpiperidine (50 μL , 0.30 mmol) in CH_3CN (2 mL). The mixture was shaken at 50 $^\circ\text{C}$ for 72 h and then diluted with EtOAc (25 mL) and washed with water (15 mL). The water phase was extracted (2 x 25 mL) and the combined organic phases were dried over Na_2SO_4 , and concentrated under reduced pressure. The residue was purified by flash CC (SiO_2 ; EtOAc/MeOH 1:4) to give the title compound (0.058 g, 74%). ^1H NMR (CD_3OD) δ 8.13 (d, $J = 9.8$ Hz, 1H), 7.56 - 7.46 (m, 2H), 7.15 (brd, 6.8 Hz, 2H), 6.67 (d, $J = 9.8$ Hz, 1H), 4.38 (t, $J = 7.2$ Hz, 2H), 3.10 - 3.03 (m, 2H), 2.68 - 2.61 (m, 2H), 2.57 (s, 3H), 2.25 - 2.15 (m, 2H), 2.04 - 1.95 (m, 2H), 1.78 - 1.69 (m, 2H), 1.36 - 1.16 (m, 9H), 0.89 (t, $J = 7.0$ Hz, 3H); ^{13}C NMR (CD_3OD) δ 162.3, 138.7, 136.6, 136.2, 130.4, 123.6, 119.4, 118.9, 112.4, 54.7, 52.9, 39.9, 35.3, 34.5, 30.7, 28.2, 23.7, 22.1, 17.3, 12.6; HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 341.3$.

1-[3-(4-Butyl-piperidin-1-yl)propyl]-7-methyl-1H-quinolin-2-one (107LH46-A)

[0360] A 4mL vial was charged with 1-(3-chloro-propyl)-7-methyl-1H-quinolin-2-one 107LH40 (0.130 g, 0.56 mmol), KI (0.170 g, 1.0 mmol), K_2CO_3 (0.140 g, 1.0 mmol) and 4-butylpiperidine (100 μL , 0.60 mmol) in CH_3CN (2 mL). The mixture was shaken at 50 $^\circ\text{C}$ for 72 h and then poured onto The compound EtOAc (25 mL) and water (15 mL). The water phase was extracted (2 x 25 mL) and the combined organic phases were dried over Na_2SO_4 , and concentrated under reduced pressure. The residue was purified by flash CC (SiO_2 ; EtOAc/MeOH 1:4) to give the title compound (0.017 g, 6%). ^1H NMR (CD_3OD) δ 7.84 (d, $J = 9.4$ Hz), 7.56 (d, $J = 8.0$ Hz, 1H), 7.43 (brs, 1H), 7.14 (brd, $J = 8$ Hz, 1H), 6.58 (d, $J = 9.4$ Hz), 4.36 (d, $J = 7.2$ Hz, 2 H), 3.02 - 2.95 (m, 2H), 2.57 - 2.48 (m, 2H), 2.51 (s, 3H), 2.09 - 1.91 (m, 4H), 1.75 - 1.65 (m, 2H), 1.36 - 1.16 (m, 9H), 0.89 (t, $J = 6.8$ Hz, 3H); ^{13}C NMR (CD_3OD) δ 163.3, 142.2, 140.3, 139.1, 129.1, 124.1, 119.3, 119.0, 114.7, 55.6, 53.8, 40.4, 36.1, 35.5, 31.8, 28.9, 24.6, 22.7, 21.1, 13.2; HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 341.3$.

(R)-1-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-1H-quinolin-2-one (107LH52)

[0361] A 4mL vial was charged with crude (S)-1-(3-iodo-2-methyl-propyl)-1H-quinolin-2-one (0.66 g), 4-butylpiperidine (0.43 g, 3.0 mmol) and dry CH_3CN (1 mL). The mixture

was shaken at 50 °C for 72 h and then poured onto The compound EtOAc (50 mL) and water (25 mL). The water phase was extracted (2 x 25 mL) and the combined organic phases were dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by flash CC (SiO₂; EtOAc/MeOH 1:4) and then cation-exchange CC producing the title compound (0.300 g, 44%). ¹H NMR (CD₃OD) δ 7.88 (d, *J* = 9.2 Hz, 1H), 7.73 - 7.66 (m, 2H), 7.61 (t, *J* = 8.0 Hz, 1H), 7.29 (t, *J* = 7.4 Hz, 1H), 6.65 (d, *J* = 9.2 Hz, 1H), 4.42 - 4.26 (m, 2H), 2.90 (brd, *J* = 11.4 Hz, 1H), 2.74 (brd, *J* = 11.4 Hz, 1H), 2.40 - 2.16 (m, 3 H), 1.94 - 1.78 (m, 2H), 1.64 - 1.54 (m, 2H), 1.35 - 1.00 (m, 9H), 0.96 - 0.85 (m, 6H); ¹³C NMR (CD₃OD) δ 163.7, 140.2, 139.5, 130.8, 129.1, 122.5, 121.4, 120.4, 115.3, 64.0, 55.1, 54.2, 46.8, 36.3, 35.8, 32.4, 32.3, 29.8, 28.9, 22.8, 16.1, 13.2.

[0362] The product was dissolved in acetone and tartaric acid (1.1 equiv) dissolved in acetone was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.277 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 341.3.

(R)-1-[2-Methyl-3-(4-propoxypiperidin-1-yl)-propyl]-1H-quinolin-2-one(107LH65)

[0363] A 4mL vial was charged with crude (S)-1-(3-iodo-2-methylpropyl)-1H-quinolin-2-one (0.190 g), 4-propyloxypiperidine (0.137 g, 0.96 mmol) and dry CH₃CN (2.5 mL). The mixture was shaken at 50 °C for 24 h and then purified by cation-exchange CC followed by flash CC (SiO₂; EtOAc/MeOH 1:4) to give the title compound (0.051 g, 17%). ¹H NMR (CD₃OD) δ 7.85 (d, *J* = 9.6 Hz), 7.70 - 7.63 (m, 2H), 7.60 (brt, *J* = 7.8 Hz, 1H), 7.26 (brt, 7.6 Hz), 6.63 (d, *J* = 9.6 Hz, 1H), 4.39 - 4.23 (m, 2H), 3.37 (t, *J* = 6.6 Hz), 3.28 - 3.18 (m, 1H), 2.77-2.69 (m, 1H), 2.64 - 2.58 (m, 1H), 2.35 (dd, *J* = 8.4, 12.0 Hz), 2.51 - 2.21 (m, 1H), 2.18 (dd, *J* = 4.8, 12.0 Hz), 2.13 - 2.04 (m, 1H), 2.00 - 1.92 (m, 1H), 1.84 - 1.75 (m, 2H), 1.58 - 1.32 (m, 4 H), 0.95 - 0.85 (m, 6H); ¹³C NMR (CD₃OD) δ 163.7, 140.2, 139.5, 130.8, 129.2, 12.5, 121.4, 120.4, 115.2, 75.3, 69.5, 63.6, 52.3, 51.5, 46.8, 31.4, 31.3, 30.0, 23.1, 16.1, 9.8.

[0364] The product was dissolved in acetone and oxalic acid (1.1 equiv) dissolved in acetone was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.032 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 343.3.

1-[3-(4-Allyloxypiperidin-1-yl)propyl]-1H-quinolin-2-one (107LH85)

[0365] A 4 mL vial was charged with 1-(3-chloropropyl)-1H-quinolin-2-one (0.130 g, 0.6 mmol), NaI (0.225 g, 1.5 mmol), K₂CO₃ (0.210 g, 1.5 mmol), 4-allyloxypiperidine (0.085 g, 0.60 mmol) and dry CH₃CN (1 mL). The mixture was shaken at 40 °C for 72 h and then poured onto The compound EtOAc (25 mL) and water (15 mL). The water phase was extracted (2 x 25 mL) and the combined organic phases were dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by flash CC (SiO₂; EtOAc/MeOH 4:1) followed by cation-

exchange CC to yield the title compound (0.140 g, 70%). ^1H NMR (CD_3OD) δ 7.81 (d, $J = 9.6$ Hz, 1H), 7.64-7.55 (m, 3H), 7.27-7.21 (m, 1H), 6.61 (d, $J = 9.6$ Hz, 1H), 5.93-5.82 (m, 1H), 5.27-5.20 (m, 1H), 5.13-5.07 (m, 1H), 4.33-4.26 (m, 2H), 3.40-3.28 (m, 2H), 2.76-2.67 (m, 2H), 2.47-2.39 (m, 2H), 2.18-2.08 (m, 1H), 1.93-1.80 (m, 4H), 1.61-1.50 (m, 2H); ^{13}C NMR (CD_3OD) δ 162.9, 140.3, 139.0, 135.5, 131.1, 129.2, 122.6, 121.3, 120.4, 115.5, 114.7, 74.2, 68.7, 55.3, 51.0, 40.6, 30.9, 24.9.

[0366] The product was dissolved in acetone and oxalic acid (1.1 equiv) dissolved in acetone was added. The formed crystals were filtered and washed with acetone to give the title compound as oxalic salt (0.140 g). HPLC-MS (ammonium acetate) $[\text{M}+\text{H}]^+ = 327.3$.

GENERAL PROCEDURE 18 (GP18)

[0367] A 7 mL vial was charged with heterocycle (1 equiv), (*R,S*)-1-bromo-3-chloro-2-methylpropane (1.2 equiv), and Cs_2CO_3 (2 equiv) in MeCN (4 mL) and stirred at 50 ° for 20 h. The reaction mixture was added water, and the product extracted into EtOAc. The combined organic layers were filtered through a PTFE filter and concentrated. The product was used for the next reaction step without further purification.

(*R,S*)-4-(3-Chloro-2-methylpropyl)-6-methyl-4*H*-benzo[1,4]oxazin-3-one (112KK19-a)

[0368] 6-Methyl-4*H*-benzo[1,4]oxazin-3-one (0.512 g, 3.14 mmol), (*R,S*)-1-bromo-3-chloro-2-methylpropane (0.646 g, 3.77 mmol), and Cs_2CO_3 (2.036 g, 6.25 mmol) in MeCN (4 mL) were reacted and worked up according to GP18 to give the crude title compound (112KK19-a) (0.692 g).

(*R,S*)-4-(3-Chloro-2-methylpropyl)-6-fluoro-4*H*-benzo[1,4]oxazin-3-one (112KK19-b)

[0369] 6-Fluoro-4*H*-benzo[1,4]oxazin-3-one (0.502 g, 3.00 mmol), (*R,S*)-1-bromo-3-chloro-2-methylpropane (0.617 g, 3.60 mmol), and Cs_2CO_3 (1.983 g, 6.09 mmol) in MeCN (4 mL) were reacted and worked up according to GP18 to give the crude title compound (112KK19-b) (0.768 g).

(*R,S*)-4-(3-Chloro-2-methylpropyl)-7-fluoro-4*H*-benzo[1,4]oxazin-3-one (112KK19-c)

[0370] 7-Fluoro-4*H*-benzo[1,4]oxazin-3-one (0.498 g, 2.98 mmol), (*R,S*)-1-bromo-3-chloro-2-methylpropane (0.613 g, 3.58 mmol), and Cs_2CO_3 (1.985 g, 6.09 mmol) in MeCN (4 mL) were reacted and worked up according to GP18 to give the crude title compound (112KK19-c) (0.694 g).

(R,S)-3-(3-Chloro-2-methylpropyl)-3H-benzothiazol-2-one (112KK19-d)

[0371] Benzothiazol-2-ol (0.476 g, 3.15 mmol), (R,S)-1-bromo-3-chloro-2-methylpropane (0.648 g, 3.78 mmol), and Cs_2CO_3 (2.024 g, 6.21 mmol) in MeCN (4 mL) were reacted and worked up according to GP18 to give the crude title compound (112KK19-d) (0.804 g).

GENERAL PROCEDURE 19 (GP19)

[0372] A 7 mL vial was charged with heterocycle (1 equiv), (R,S)-1-bromo-3-chloro-2-methylpropane (1 equiv), and Cs_2CO_3 (1.5 equiv) in MeCN (3 mL) and stirred at 50 ° for 20 h. The reaction mixture was added water and the product extracted into EtOAc. The combined org. layers were dried over Na_2SO_4 , filtered, and concentrated. The product was purified by flash CC (SiO_2 ; EtOAc/n-heptane 1:1).

(R,S)-4-(3-Chloro-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (107LH61-1)

[0373] 4H-benzo[1,4]oxazin-2-one (0.447 g, 3.0 mmol), (R,S)-1-bromo-3-chloro-2-methylpropane (0.514 g, 3.0 mmol), and Cs_2CO_3 (1.466 g, 4.5 mmol) in MeCN (3 mL) were reacted and purified according to GP19 to give the crude title compound (107LH61-1) (0.595 g).

(R,S)-4-(3-Chloro-2-methylpropyl)-4H-benzo[1,4]thiazin-3-one (107LH61-2)

[0374] 4H-Benzo[1,4]thiazin-3-one (0.496 g, 3.0 mmol), (R,S)-1-bromo-3-chloro-2-methylpropane (0.514 g, 3.0 mmol), and Cs_2CO_3 (1.466 g, 4.5 mmol) in MeCN (3 mL) were reacted and purified according to GP19 to give the crude title compound (107LH61-2) (0.593 g).

(R,S)-4-(3-Chloro-2-methylpropyl)-6-methoxy-4H-benzo[1,4]oxazin-3-one (107LH69)

[0375] 6-Methoxy-4H-benzo[1,4]oxazin-3-one (111MF24) (0.538 g, 3.0 mmol), (R,S)-1-bromo-3-chloro-2-methylpropane (0.514 g, 3.0 mmol), and Cs_2CO_3 (1.466 g, 4.5 mmol) in MeCN (3 mL) were reacted and purified according to GP19 to give the crude title compound (107LH69) (0.658 g).

(R,S)-1-(3-Chloro-2-methylpropyl)-3,4-dihydro-1H-quinolin-2-one (107LH63)

[0376] A reaction flask was charged with 3,4-dihydro-1H-quinolin-2-one (1.00 g, 6.8 mmol) in dry DMF (10 mL). NaH 60% (0.300 g, 7.5 mmol) was added and the mixture was stirred at rt for 1 h under an Argon atmosphere. Then (R,S)-1-bromo-3-chloro-2-methylpropane (1.165 g, 6.8 mmol) was added followed by stirring at rt for 20 h. The crude product was concentrated and purified by flash CC (SiO_2 ; EtOAc/n-heptane 1:1) to give the crude title compound (107LH63) (0.753 g)

GENERAL PROCEDURE 20 (GP20)

[0377] A 4 mL vial was charged with crude heterocycle, amine, NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF and stirred at 100 ° for 5 days. The reaction mixture was added water and the product extracted into EtOAc. The crude product was purified by cation exchange CC and then prep. RP-HPLC to give the title compound.

(R,S)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6-methyl-4H-benzo[1,4]oxazin-3-one
(112KK20-a1)

[0378] Crude (R,S)-4-(3-chloro-2-methylpropyl)-6-methyl-4H-benzo[1,4]oxazin-3-one (112KK19-a) (0.046 g), 4-butylpiperidine (0.050 g, 0.35 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1.4 mL) were reacted and purified according to GP20 to give the title compound (112KK20-a1) (0.007 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 359.32.

(R,S)-4-[2-Methyl-3-(4-propoxypiperidin-1-yl)propyl]-6-methyl-4H-benzo[1,4]oxazin-3-one
(112KK20-a2)

[0379] Crude (R,S)-4-(3-chloro-2-methylpropyl)-6-methyl-4H-benzo[1,4]oxazin-3-one (112KK19-a) (0.046 g), 4-propoxypiperidine (0.050 g, 0.35 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1.4 mL) were reacted and purified according to GP20 to give the title compound (112KK20-a2) (0.010 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 361.29.

(R,S)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-6-methyl-4H-benzo[1,4]oxazin-3-one
(112KK20-a3)

[0380] Crude (R,S)-4-(3-chloro-2-methylpropyl)-6-methyl-4H-benzo[1,4]oxazin-3-one (112KK19-a) (0.046 g), 4-butylidenepiperidine (0.053 g, 0.38 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1.4 mL) were reacted and purified according to GP20 to give the title compound (112KK20-a3) (0.008 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 357.30.

(R,S)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-methyl-4H-benzo[1,4]oxazin-3-one
(112KK20-a4)

[0381] Crude (R,S)-4-(3-chloro-2-methylpropyl)-6-methyl-4H-benzo[1,4]oxazin-3-one (112KK19-a) (0.023 g), 3-butyl-8-azabicyclo[3.2.1]octane (0.025 g, 0.15 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1.2 mL) were reacted and purified according to GP20 to give the title compound (112KK20-a4) (0.007 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 385.32.

(R,S)-4-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-6-methyl-4H-benzo[1,4]oxazin-3-one (112KK20-a5)

[0382] Crude (R,S)-4-(3-chloro-2-methylpropyl)-6-methyl-4H-benzo[1,4]oxazin-3-one (112KK19-a) (0.023 g), 3-pentyl-8-azabicyclo[3.2.1]octane (0.024 g, 0.13 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1.2 mL) were reacted and purified according to GP20 to give the title compound (112KK20-a5) (0.002 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 399.35.

(R,S)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6-fluoro-4H-benzo[1,4]oxazin-3-one (112KK20-b1)

[0383] Crude (R,S)-4-(3-chloro-2-methylpropyl)-6-fluoro-4H-benzo[1,4]oxazin-3-one (112KK19-b) (0.051 g), 4-butylpiperidine (0.050 g, 0.35 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1.4 mL) were reacted and purified according to GP20 to give the title compound (112KK20-b1) (0.011 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 363.28.

(R,S)-6-Fluoro-4-[2-methyl-3-(4-propoxypiperidin-1-yl)propyl]-4H-benzo[1,4]oxazin-3-one (112KK20-b2)

[0384] Crude (R,S)-4-(3-chloro-2-methylpropyl)-6-fluoro-4H-benzo[1,4]oxazin-3-one (112KK19-b) (0.051 g), 4-propoxypiperidine (0.050 g, 0.35 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1.4 mL) were reacted and purified according to GP20 to give the title compound (112KK20-b2) (0.010 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 365.26.

(R,S)-4-[3-(4-Butyldenepiperidin-1-yl)-2-methylpropyl]-6-fluoro-4H-benzo[1,4]oxazin-3-one (112KK20-b3)

[0385] Crude (R,S)-4-(3-chloro-2-methylpropyl)-6-fluoro-4H-benzo[1,4]oxazin-3-one (112KK19-b) (0.051 g), 4-butyldenepiperidine (0.053 g, 0.38 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1.4 mL) were reacted and purified according to GP20 to give the title compound (112KK20-b3) (0.011 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 361.27.

(R,S)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-fluoro-4H-benzo[1,4]oxazin-3-one (112KK20-b4)

[0386] Crude (R,S)-4-(3-chloro-2-methylpropyl)-6-fluoro-4H-benzo[1,4]oxazin-3-one (112KK19-b) (0.026 g), 3-butyl-8-azabicyclo[3.2.1]octane (0.025 g, 0.15 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1.2 mL) were reacted and purified according to

GP20 to give the title compound (112KK20-b4) (0.009 g). HPLC-MS (ammonium acetate) $[M+H]^+$ = 389.30.

(R,S)-6-Fluoro-4-[2-methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-4H-benzo[1,4]oxazin-3-one (112KK20-b5)

[0387] Crude (R,S)-4-(3-chloro-2-methylpropyl)-6-fluoro-4H-benzo[1,4]oxazin-3-one (112KK19-b) (0.026 g), 3-pentyl-8-azabicyclo[3.2.1]octane (0.024 g, 0.13 mmol), NaI (0.100 g, 0.67 mmol), and K_2CO_3 (0.075 g, 0.54 mmol) in DMF (1.2 mL) were reacted and purified according to GP20 to give the title compound (112KK20-b5) (0.009 g). HPLC-MS (ammonium acetate) $[M+H]^+$ = 403.31.

(R,S)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (112KK20-c1)

[0388] Crude (R,S)-4-(3-chloro-2-methylpropyl)-7-fluoro-4H-benzo[1,4]oxazin-3-one (112KK19-c) (0.046 g), 4-butylpiperidine (0.050 g, 0.35 mmol), NaI (0.100 g, 0.67 mmol), and K_2CO_3 (0.075 g, 0.54 mmol) in DMF (1.4 mL) were reacted and purified according to GP20 to give the title compound (112KK20-c1) (0.002 g). HPLC-MS (ammonium acetate) $[M+H]^+$ = 363.29.

(R,S)-7-Fluoro-4-[2-methyl-3-(4-propoxypiperidin-1-yl)propyl]-4H-benzo[1,4]oxazin-3-one (112KK20-c2)

[0389] Crude (R,S)-4-(3-chloro-2-methylpropyl)-7-fluoro-4H-benzo[1,4]oxazin-3-one (112KK19-c) (0.046 g), 4-propoxypiperidine (0.050 g, 0.35 mmol), NaI (0.100 g, 0.67 mmol), and K_2CO_3 (0.075 g, 0.54 mmol) in DMF (1.4 mL) were reacted and purified according to GP20 to give the title compound (112KK20-c2) (0.002 g). HPLC-MS (ammonium acetate) $[M+H]^+$ = 365.28.

(R,S)-4-[3-(4-Butyridenepiperidin-1-yl)-2-methylpropyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (112KK20-c3)

[0390] Crude (R,S)-4-(3-chloro-2-methylpropyl)-7-fluoro-4H-benzo[1,4]oxazin-3-one (112KK19-c) (0.046 g), 4-butyridenepiperidine (0.053 g, 0.38 mmol), NaI (0.100 g, 0.67 mmol), and K_2CO_3 (0.075 g, 0.54 mmol) in DMF (1.4 mL) were reacted and purified according to GP20 to give the title compound (112KK20-c3) (0.008 g). HPLC-MS (ammonium acetate) $[M+H]^+$ = 361.29.

(R,S)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (112KK20-c4)

[0391] Crude (R,S)-4-(3-chloro-2-methylpropyl)-7-fluoro-4H-benzo[1,4]oxazin-3-one (112KK19-c) (0.023 g), 3-butyl-8-azabicyclo[3.2.1]octane (0.025 g, 0.15 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1.2 mL) were reacted and purified according to GP20 to give the title compound (112KK20-c4) (0.004 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 389.31.

(R,S)-7-Fluoro-4-[2-methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-4H-benzo[1,4]oxazin-3-one (112KK20-c5)

[0392] Crude (R,S)-4-(3-chloro-2-methylpropyl)-7-fluoro-4H-benzo[1,4]oxazin-3-one (112KK19-c) (0.023 g), 3-pentyl-8-azabicyclo[3.2.1]octane (0.024 g, 0.13 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1.2 mL) were reacted and purified according to GP20 to give the title compound (112KK20-c5) (0.002 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 403.32.

(R,S)-3-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-3H-benzothiazol-2-one (112KK20-d1)

[0393] Crude (R,S)-3-(3-chloro-2-methylpropyl)-3H-benzothiazol-2-one (112KK19-d) (0.054 g), 4-butylpiperidine (0.050 g, 0.35 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1.4 mL) were reacted and purified according to GP20 to give the title compound (112KK20-d1) (0.012 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 347.28.

(R,S)-4-[2-Methyl-3-(4-propoxypiperidin-1-yl)propyl]-3H-benzothiazol-2-one (112KK20-d2)

[0394] Crude (R,S)-3-(3-chloro-2-methylpropyl)-3H-benzothiazol-2-one (112KK19-d) (0.054 g), 4-propoxypiperidine (0.050 g, 0.35 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1.4 mL) were reacted and purified according to GP20 to give the title compound (112KK20-d2) (0.011 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 349.25.

(R,S)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-3H-benzothiazol-2-one (112KK20-d3)

[0395] Crude (R,S)-3-(3-chloro-2-methylpropyl)-3H-benzothiazol-2-one (112KK19-d) (0.054 g), 4-butylidenepiperidine (0.053 g, 0.38 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1.4 mL) were reacted and purified according to GP20 to give the title compound (112KK20-d3) (0.011 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 345.27.

(R,S)-3-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-3H-benzothiazol-2-one
(112KK20-d4)

[0396] Crude (R,S)-3-(3-chloro-2-methylpropyl)-3H-benzothiazol-2-one (112KK19-d) (0.027 g), 3-butyl-8-azabicyclo[3.2.1]octane (0.025 g, 0.15 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1.2 mL) were reacted and purified according to GP20 to give the title compound (112KK20-d4) (0.011 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 373.30.

(R,S)-3-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-3H-benzothiazol-2-one
(112KK20-d5)

[0397] Crude (R,S)-3-(3-chloro-2-methylpropyl)-3H-benzothiazol-2-one (112KK19-d) (0.027 g), 3-pentyl-8-azabicyclo[3.2.1]octane (0.024 g, 0.13 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1.2 mL) were reacted and purified according to GP20 to give the title compound (112KK20-d5) (0.011 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 387.30.

(R,S)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-4H-benzo[1,4]oxazin-3-one (107LH74-a1)

[0398] Crude (R,S)-4-(3-chloro-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (107LH61-1) (0.149 g), 4-butylpiperidine (0.042 g, 0.30 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1 mL) were reacted and purified according to GP20 to give the title compound (107LH74-a1) (0.092 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 345.30.

(R,S)-4-[2-Methyl-3-(4-propoxypiperidin-1-yl)propyl]-4H-benzo[1,4]oxazin-3-one (107LH74-a2)

[0399] Crude (R,S)-4-(3-chloro-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (107LH61-1) (0.149 g), 4-propoxypiperidine (0.043 g, 0.30 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1 mL) were reacted and purified according to GP20 to give the title compound (107LH74-a2) (0.077 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 347.30.

(R,S)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-4H-benzo[1,4]oxazin-3-one (107LH74-a3)

[0400] Crude (R,S)-4-(3-chloro-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (107LH61-1) (0.149 g), 4-butylidenepiperidine (0.042 g, 0.30 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1 mL) were reacted and purified according to GP20 to give the title compound (107LH74-a3) (0.083 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 343.30.

(R,S)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4H-benzo[1,4]oxazin-3-one
(107LH74-a4)

[0401] Crude (R,S)-4-(3-chloro-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (107LH61-1) (0.074 g), 3-butyl-8-azabicyclo[3.2.1]octane (0.025 g, 0.15 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1 mL) were reacted and purified according to GP20 to give the title compound (107LH74-a4) (0.046 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 371.33.

(R,S)-4-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-4H-benzo[1,4]oxazin-3-one
(107LH74-a5)

[0402] Crude (R,S)-4-(3-chloro-2-methylpropyl)-4H-benzo[1,4]oxazin-3-one (107LH61-1) (0.074 g), 3-pentyl-8-azabicyclo[3.2.1]octane (0.027 g, 0.15 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1 mL) were reacted and purified according to GP20 to give the title compound (107LH74-a5) (0.053 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 385.34.

(R,S)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-4H-benzo[1,4]thiazin-3-one (107LH74-b1)

[0403] Crude (R,S)-4-(3-chloro-2-methylpropyl)-4H-benzo[1,4]thiazin-3-one (107LH61-2) (0.148 g), 4-butylpiperidine (0.042 g, 0.30 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1 mL) were reacted and purified according to GP20 to give the title compound (107LH74-b1) (0.083 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 361.29.

(R,S)-1-[2-Methyl-3-(4-propoxypiperidin-1-yl)propyl]-4H-benzo[1,4]thiazin-3-one (107LH74-b2)

[0404] Crude (R,S)-1-(3-chloro-2-methylpropyl)-4H-benzo[1,4]thiazin-3-one (107LH61-2) (0.148 g), 4-propoxypiperidine (0.043 g, 0.30 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1 mL) were reacted and purified according to GP20 to give the title compound (107LH74-b2) (0.071 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 363.27.

(R,S)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-4H-benzo[1,4]thiazin-3-one (107LH74-b3)

[0405] Crude (R,S)-4-(3-chloro-2-methylpropyl)-4H-benzo[1,4]thiazin-3-one (107LH61-2) (0.148 g), 4-butylidenepiperidine (0.042 g, 0.30 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1 mL) were reacted and purified according to GP20 to give the title compound (107LH74-b3) (0.064 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 359.27.

(R,S)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4H-benzo[1,4]thiazin-3-one
(107LH74-b4)

[0406] Crude (R,S)-4-(3-chloro-2-methylpropyl)-4H-benzo[1,4]thiazin-3-one (107LH61-2) (0.074 g), 3-butyl-8-azabicyclo[3.2.1]octane (0.025 g, 0.15 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1 mL) were reacted and purified according to GP20 to give the title compound (107LH74-b4) (0.040 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 387.30.

(R,S)-4-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-4H-benzo[1,4]thiazin-3-one
(107LH74-b5)

[0407] Crude (R,S)-4-(3-chloro-2-methylpropyl)-4H-benzo[1,4]thiazin-3-one (107LH61-2) (0.074 g), 3-pentyl-8-azabicyclo[3.2.1]octane (0.027 g, 0.15 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1 mL) were reacted and purified according to GP20 to give the title compound (107LH74-b5) (0.040 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 401.30.

(R,S)-1-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-3,4-dihydro-1H-quinolin-2-one (107LH74-c1)

[0408] Crude (R,S)-1-(3-chloro-2-methylpropyl)-3,4-dihydro-1H-quinolin-2-one (107LH63) (0.188 g), 4-butylpiperidine (0.042 g, 0.30 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1 mL) were reacted and purified according to GP20 to give the title compound (107LH74-c1) (0.047 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 343.32.

(R,S)-1-[2-Methyl-3-(4-propoxypiperidin-1-yl)propyl]-3,4-dihydro-1H-quinolin-2-one (107LH74-c2)

[0409] Crude (R,S)-1-(3-chloro-2-methylpropyl)-3,4-dihydro-1H-quinolin-2-one (107LH63) (0.188 g), 4-propoxypiperidine (0.043 g, 0.30 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1 mL) were reacted and purified according to GP20 to give the title compound (107LH74-c2) (0.040 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 345.32.

(R,S)-1-[3-(4-Butyldenepiperidin-1-yl)-2-methylpropyl]-3,4-dihydro-1H-quinolin-2-one
(107LH74-c3)

[0410] Crude (R,S)-1-(3-chloro-2-methylpropyl)-3,4-dihydro-1H-quinolin-2-one (107LH63) (0.188 g), 4-butyldenepiperidine (0.042 g, 0.30 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1 mL) were reacted and purified according to GP20 to give the title compound (107LH74-c3) (0.038 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 341.31.

(R,S)-1-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-3,4-dihydro-1H-quinolin-2-one
(107LH74-c4)

[0411] Crude (R,S)-1-(3-chloro-2-methylpropyl)-3,4-dihydro-1H-quinolin-2-one (107LH63) (0.094 g), 3-butyl-8-azabicyclo[3.2.1]octane (0.025 g, 0.15 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1 mL) were reacted and purified according to GP20 to give the title compound (107LH74-c4) (0.025 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 369.33.

(R,S)-1-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-3,4-dihydro-1H-quinolin-2-one
(107LH74-c5)

[0412] Crude (R,S)-1-(3-chloro-2-methylpropyl)-3,4-dihydro-1H-quinolin-2-one (107LH63) (0.094 g), 3-pentyl-8-azabicyclo[3.2.1]octane (0.027 g, 0.15 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1 mL) were reacted and purified according to GP20 to give the title compound (107LH74-c5) (0.023 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 383.34.

(R,S)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6-methoxy-4H-benzo[1,4]oxazin-3-one
(107LH74-d1)

[0413] Crude (R,S)-4-(3-chloro-2-methylpropyl)-6-methoxy-4H-benzo[1,4]oxazin-3-one (107LH69) (0.165 g), 4-butylpiperidine (0.042 g, 0.30 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1 mL) were reacted and purified according to GP20 to give the title compound (107LH74-d1) (0.094 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 375.31.

(R,S)-4-[2-Methyl-3-(4-propoxypiperidin-1-yl)-6-methoxy]-4H-benzo[1,4]oxazin-3-one
(107LH74-d2)

[0414] Crude (R,S)-4-(3-chloro-2-methylpropyl)-6-methoxy-4H-benzo[1,4]oxazin-3-one (107LH69) (0.165 g), 4-propoxypiperidine (0.043 g, 0.30 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1 mL) were reacted and purified according to GP20 to give the title compound (107LH74-d2) (0.086 g). HPLC-MS (ammonium acetate) [M+H]⁺ = 377.29.

(R,S)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-6-methoxy-4H-benzo[1,4]oxazin-3-one
(107LH74-d3)

[0415] Crude (R,S)-4-(3-chloro-2-methylpropyl)-6-methoxy-4H-benzo[1,4]oxazin-3-one (107LH69) (0.165 g), 4-butylidenepiperidine (0.042 g, 0.30 mmol), NaI (0.100 g, 0.67 mmol), and K₂CO₃ (0.075 g, 0.54 mmol) in DMF (1 mL) were reacted and purified according to GP20 to

give the title compound (107LH74-d3) (0.086 g). HPLC-MS (ammonium acetate) $[M+H]^+ = 373.29$.

(R,S)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-methoxy-4H-benzo[1,4]oxazin-3-one (107LH74-d4)

[0416] Crude (R,S)-4-(3-chloro-2-methylpropyl)-6-methoxy-4H-benzo[1,4]oxazin-3-one (107LH69) (0.082 g), 3-butyl-8-azabicyclo[3.2.1]octane (0.025 g, 0.15 mmol), NaI (0.100 g, 0.67 mmol), and K_2CO_3 (0.075 g, 0.54 mmol) in DMF (1 mL) were reacted and purified according to GP20 to give the title compound (107LH74-d4) (0.044 g). HPLC-MS (ammonium acetate) $[M+H]^+ = 401.32$.

(R,S)-1-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-6-methoxy-4H-benzo[1,4]oxazin-3-one (107LH74-d5)

[0417] Crude (R,S)-4-(3-chloro-2-methylpropyl)-6-methoxy-4H-benzo[1,4]oxazin-3-one (107LH69) (0.082 g), 3-pentyl-8-azabicyclo[3.2.1]octane (0.027 g, 0.15 mmol), NaI (0.100 g, 0.67 mmol), and K_2CO_3 (0.075 g, 0.54 mmol) in DMF (1 mL) were reacted and purified according to GP20 to give the title compound (107LH74-d5) (0.051 g). HPLC-MS (ammonium acetate) $[M+H]^+ = 415.34$.

1-[3-(4-Butyl-piperidin-1-yl)-propyl]-1,2,3,4-tetrahydro-quinoline (55-LH-12-2)

[0418] A solution of *n*-butyllithium in hexane (1.5M, 7.3 mL, 11 mmol) was added drop wise to a solution of 1,2,3,4-tetrahydro-quinoline (1.256 mL, 10 mmol) in tetrahydrofuran (10 mL) at $-78^\circ C$ under an atmosphere of argon. The reaction mixture was stirred for $\frac{1}{2}$ h then 1-chloro-3-iodopropane (1.0 mL, 9.5 mmol) was added. The reaction mixture was stirred at $-78^\circ C$ for $\frac{1}{2}$ h then stirred for additional 16 h at room temperature. Tetrahydrofuran was evaporated off and the solid was dissolved in acetonitrile (10 mL). KI (1.83 g, 11 mmol), K_2CO_3 (2.76 g, 20 mmol) and 4-butylpiperidine (1.66 mL, 10 mmol) were added. The slurry was stirred at $50^\circ C$ for 48 h then water (10 mL) was added and the product was extracted with ethyl acetate (2 x 20 mL). The organic layer was dried (Na_2SO_4) and concentrated *in vacuo*. The product was purified by column chromatography (eluent: ethyl acetate) to give the title compound (1.11 g, 35%). Oxalate-salt was prepared from oxalic acid (1.1 eq.) in acetone. HPLC-MS: $M+1^+ = 315.1$ (MS(%) = 95). 1H NMR (400 MHz, $CDCl_3$): δ = 0.89 (3H, t), 1.18-1.34 (9H, m), 1.64-1.70 (2H, m), 1.79 (2H, quin.), 1.85-1.98 (4H, m), 2.36 (2H, t), 2.74 (2H, t), 2.92 (2H, broad d), 3.24-3.31 (4H, m), 6.54 (1H, ddd), 6.60 (1H, dd), 6.93 (1H, dd), 7.03 (1H, ddd). ^{13}C NMR ($CDCl_3$): δ 14.3, 22.5, 23.1, 24.2, 28.4, 29.3, 32.7, 36.0, 36.5, 49.6, 49.8, 54.4, 56.7, 110.9, 115.5, 122.5, 127.3, 129.3, 145.6.

1-[3-(4-Butyl-piperidin-1-yl)-propyl]-2-methyl-1,2,3,4-tetrahydro-quinoline (55-LH-28-8)

[0419] 2-Methyl-1,2,3,4-tetrahydroquinoline (346 mg, 2.35 mmol) was converted to the title product according to the procedure for the synthesis of 1-[3-(4-butyl-piperidin-1-yl)-propyl]-1,2,3,4-tetrahydro-quinoline. Yield: 88.6 mg, 11%. HPLC-MS: $M+1^+ = 329.5$ (UV/MS(%) = 100/99). ^1H NMR (400 MHz, CDCl_3): δ = 0.89 (3H, t), 1.11 (3H, d), 1.16-1.34 (9H, m), 1.67 (2H, broad d), 1.65-2.03 (8H, m), 2.39 (2H, t), 2.57-2.66 (1H, m), 2.74-2.85 (1H, m), 2.93 (2H, broad d), 3.12-3.21 (1H, m), 3.33-3.42 (1H, m), 3.44-3.52 (1H, m), 6.45 (1H, t), 6.54 (1H, d), 6.87 (1H, d), 6.97 (1H, t). ^{13}C NMR (CD_3OD): δ 13.2, 17.8, 22.8, 23.7, 24.4, 28.0, 28.9, 31.9, 35.7, 36.2, 52.7, 53.9, 54.0, 56.4, 110.8, 115.1, 121.9, 126.7, 128.7, 144.2.

1-[3-(4-Butyl-piperidin-1-yl)-propyl]-6-methyl-1,2,3,4-tetrahydro-quinoline (55-LH-44A)

[0420] 6-Methyl-1,2,3,4-tetrahydroquinoline (346 mg, 2.35 mmol) was converted to the title product according to the procedure for the synthesis of 1-[3-(4-butyl-piperidin-1-yl)-propyl]-1,2,3,4-tetrahydro-quinoline. Yield: 137 mg, 18%. HPLC-MS: $M+1^+ = 329.5$ (UV/MS(%) = 98/99). ^1H NMR (400 MHz, CDCl_3): δ = 0.89 (3H, t), 1.14-1.34 (9H, m), 1.68 (2H, broad d), 1.76 (2H, quin.), 1.85-1.99 (4H, m), 2.14 (3H, s), 2.34-2.39 (2H, m), 2.66 (2H, t), 2.92 (2H, broad d), 3.18-3.26 (4H, m), 6.49 (1H, d), 6.58 (1H, broad s), 6.76 (1H, broad d). ^{13}C NMR (CD_3OD): δ 13.2, 19.2, 22.5, 22.8, 23.2, 28.0, 28.9, 31.9, 35.7, 36.2, 49.4, 49.6, 53.9, 56.5, 111.3, 122.7, 124.7, 127.2, 129.6, 143.2.

1-[3-(4-Butyl-piperidin-1-yl)-propyl]-8-methyl-1,2,3,4-tetrahydro-quinoline (77-LH-1)

[0421] 8-Methyl-1,2,3,4-tetrahydroquinoline (125 mg, 0.85 mmol), 1-chloro-3-iodopropane (82 μl , 0.77 mmol) and Cs_2CO_3 (415 mg, 1.27 mmol) in acetonitrile (2 mL) were shaken at 60°C for 7 days. KI (140 mg, 0.85 mmol), K_2CO_3 (117 mg, 0.85 mmol) and 4-butylpiperidine (113 μl , 0.68 mmol) were added and the reaction mixture was shaken at 60°C for 2 days. Water (5 mL) was added and the product was extracted with ethyl acetate (2 x 10 mL). The organic layer was dried (Na_2SO_4) and concentrated *in vacuo*. The product was purified by column chromatography (eluent: 20% methanol in ethyl acetate) to yield the title compound. Yield: 45.6 mg (20.4 %). HPLC-MS: $M+1^+ = 329.5$ (UV/MS(%) = 99/97). ^1H NMR (400 MHz, CDCl_3): δ = 0.89 (3H, t), 1.18-1.34 (9H, m), 1.70 (2H, broad d), 1.75-1.92 (4H, m), 1.99 (2H, broad t), 2.22 (3H, s), 2.38 (2H, dd), 2.70-2.81 (4H, m), 2.96 (2H, broad d), 3.04-3.10 (2H, m), 6.76 (1H, t), 6.80 (1H, broad d), 6.91 (1H, broad d). ^{13}C NMR (CD_3OD): δ 13.2, 17.2, 18.0, 18.1, 22.8, 25.7, 27.7, 28.9, 31.9, 35.7, 36.2, 52.7, 53.9, 56.3, 121.5, 127.1, 128.7, 128.9, 131.0, 148.0.

1-[3-(4-Butyl-piperidin-1-yl)-propyl]-7-fluoro-2-methyl-1,2,3,4-tetrahydro-quinoline (77-LH-2)

[0422] 7-Fluoro-2-methyl-1,2,3,4-tetrahydro-quinoline (165 mg, 1.0 mmol) was converted to the title product according to the procedure for the synthesis of 1-[3-(4-butyl-piperidin-1-yl)-propyl]-8-methyl-1,2,3,4-tetrahydro-quinoline. Yield: 43.2 mg, 16%. HPLC-MS: $M+1^+ = 347.5$ (UV/MS(%) = 95/92). ^1H NMR (400 MHz, CDCl_3): $\delta = 0.89$ (3H, t), 1.10 (3H, d), 1.18-1.36 (9H, m), 1.66-1.91 (6H, m), 2.00-2.10 (2H, m), 2.44 (2H, t), 2.62 (1H, dt), 2.74-2.85 (1H, m), 2.99 (2H, broad d), 3.16 (1H, q), 3.30-3.40 (1H, m), 3.41-3.49 (1H, m), 6.63-6.74 (1H, m), 6.63-6.74 (2H, m). ^{13}C NMR (CD_3OD): δ 13.2, 17.6, 22.7, 23.7, 23.8, 24.3, 29.9, 28.9, 31.7, 35.5, 36.1, 52.6, 53.8, 56.2, 112.7 (d), 114.8 (d), 123.7, 140.8, 153.5, 155.8.

1-[3-(4-Butyl-piperidin-1-yl)-propyl]-7-trifluoromethyl-1,2,3,4-tetrahydro-quinoline (55-LH-54)

[0423] 7-Trifluoromethyl-1,2,3,4-tetrahydro-quinoline (0.50 g, 2.5 mmol) was converted to the title product according to the procedure for the synthesis of 1-[3-(4-butyl-piperidin-1-yl)-propyl]-1,2,3,4-tetrahydro-quinoline. Yield: 1.71 mg, 18%. HPLC-MS: $M+1^+ = 347.5$ (UV/MS(%) = 99/91). ^1H NMR (400 MHz, CDCl_3): $\delta = 0.89$ (3H, t), 1.14-1.36 (9H, m), 1.68 (2H, broad d), 1.79 (2H, quin.), 1.86-2.03 (4H, m), 2.38 (2H, dd), 2.75 (2H, dd), 2.94 (2H, broad d), 3.32 (4H, m), 6.71 (1H, d), 6.75 (1H, s), 6.99 (1H, d).

1-[3-(4-Butyl-piperidin-1-yl)-propyl]-3,4-dihydro-1H-quinolin-2-one (77-LH-28-1)

[0424] A suspension of NaH in mineral oil (55-60%) (712 mg) was added to a solution of 3,4-dihydro-1H-quinolin-2-one (2.0 g, 13.6 mmol) in *N,N*-dimethylformamide (50 mL) at 0°C. The reaction mixture was stirred at 0°C for 1 h. then 1-bromo-3-chloropropane (1.34 mL, 13.6 mmol) was added. The slurry was stirred for additional 16 h. at ambient temperature then water (50 mL) was added and the product was extracted with diethyl ether (2 x 50 mL). The organic layer was dried (Na_2SO_4) and concentrated *in vacuo*. The product was purified by flash-chromatography (eluent: dichloromethane) to give 1-[3-chloropropyl]-3,4-dihydro-1H-quinolin-2-one (2.41 g, 10.8 mmol). KI (2.5 g, 15 mmol), K_2CO_3 (2.1 g, 15 mmol) and 4-butylpiperidine (1.8 mL, 15 mmol) were added to a solution of 1-[3-chloropropyl]-3,4-dihydro-1H-quinolin-2-one (2.41 g, 10.8 mmol) in acetonitrile (50 mL). The reaction mixture was stirred at 60°C for 16 h. The acetonitrile was evaporated *in vacuo*, water (50 mL) was added and the product was extracted with ethyl acetate (2 x 50 mL). The organic layer was dried (Na_2SO_4), filtered and concentrated *in vacuo*. Purification by flash-chromatography (eluent: ethyl acetate) gave the title product. Yield: 2.06 g, 58%. Oxalate-salt was prepared from oxalic acid (1.1 eq.) in acetone. HPLC-MS: $M+1^+ = 329.5$ (UV/MS(%) = 100/100). ^1H NMR (400 MHz, CD_3OD): $\delta = 0.89$ (3H, t), 1.12-1.36 (9H, m), 1.67 (2H, broad d), 1.83 (2H, quin.), 1.97 (2H, broad t), 2.41 (2H, t), 2.59 (2H, t), 2.84-2.96 (4H, m), 3.99 (2H, t), 7.02 (1H, broad t), 7.16 (1H, broad d), 7.20 (1H, broad d), 7.25 (1H, broad

t). ^{13}C NMR (CD_3OD): δ 13.2, 22.8, 24.3, 25.0, 28.9, 31.6, 31.9 (2C), 35.6, 36.2, 40.1, 53.8 (2C), 55.9, 115.2, 123.2, 127.0, 127.4, 127.9, 139.1, 171.5.

1-[3-(4-Butyl-piperidin-1-yl)-propyl]-6-methoxy-3,4-dihydro-1H-quinolin-2-one (77-LH-22A)

[0425] 6-Methoxy-3,4-dihydro-1H-quinolin-2-one (108 mg, 0.61 mmol), 1-chloro-3-iodopropane (64 μL , 0.6 mmol) and Cs_2CO_3 (290 mg, 0.9 mmol) in acetonitrile (2 mL) were shaken at 60°C for 14 h then the reaction was cooled to room temperature. Water (5 mL) was added and the product was extracted with ethyl acetate (2 x 10 mL). The organic layer was dried (Na_2SO_4), filtered and concentrated *in vacuo*. The syrup was dissolved in acetonitrile (4 mL). KI (83 mg, 3.6 mmol), K_2CO_3 (100 mg, 0.6 mmol) and 4-butylpiperidine (83 μL , 0.5 mmol) were added and the reaction mixture was shaken at 60°C for 16 h. Water (5 mL) was added and the product was extracted with ethyl acetate (2 x 10 mL). The organic layer was dried (Na_2SO_4) and concentrated *in vacuo*. The product was purified by column chromatography (eluent: 20% methanol in ethyl acetate) to yield the title compound. Yield: 24.8 mg, 11.3%. HPLC-MS: $\text{M}+1^+ = 359.5$ (UV/MS(%) = 90/78). ^1H NMR (400 MHz, CDCl_3): δ = 0.89 (3H, t), 1.12-1.34 (9H, m), 1.67 (2H, broad d), 1.85 (2H, quin.), 1.93 (2H, broad t), 2.39 (2H, t), 2.59 (2H, dd), 2.83 (2H, t), 2.90 (2H, broad d), 3.76 (3H, s), 3.94 (2H, t), 6.70 (1H, d), 6.74 (1H, dd), 7.01 (1H, d). ^{13}C NMR (CDCl_3): δ 14.3, 23.0, 25.0, 26.1, 29.2, 32.1, 32.5 (2C), 35.9, 36.4, 40.8, 54.3 (2C), 55.8, 56.3, 112.2, 114.2, 116.2, 128.3, 133.4, 155.4, 169.9

4-[3-(4-Butyl-piperidin-1-yl)-propyl]-6-methyl-4H-benzo[1,4]oxazin-3-one 64-(LHY-89-6)

[0426] 6-Methyl-4H-benzo[1,4]oxazin-3-one (82 mg, 0.5 mmol), 1-chloro-3-iodopropane (50 μL , 0.5 mmol) and Cs_2CO_3 (163 mg, 0.5 mmol) in acetonitrile (2 mL) were shaken at 50°C for 24 h then the reaction mixture was concentrated *in vacuo*. The product (4-[3-chloropropyl]-6-methyl-4H-benzo[1,4]-oxazin-3-one) was purified on an Isco CombiFlash Sq 16x (4 g silica column, eluting 0-20% ethyl acetate in heptanes) then dissolved in acetonitrile (2 mL). K_2CO_3 (85 mg, 0.5 mmol) and 4-butylpiperidine (80 μL , 0.5 mmol) were added. The reaction mixture was shaken at 60°C for 16 h then cooled to room temperature. Dichloromethane (2 mL) and PS-isocyanate (loading 1.47 mmol/g, 100 mg) were added. The mixture was filtered after 5 h and the organic layer was loaded onto a Varian SCX ion exchange column. The column was washed with methanol (2 x 5 mL) then the product was eluted off the column using 10% ammonium hydroxide in methanol (6 mL). The solute was concentrated *in vacuo* to give the title product. Yield: 100 mg, 58%. HPLC-MS: $\text{M}+1^+ = 345.5$ (UV/MS(%) = 99/99). ^1H NMR (400 MHz, CDCl_3): δ = 0.89 (3H, t), 1.15-1.30 (9H, m), 1.65 (2H, broad d), 1.81-1.89 (4H, m), 2.30 (3H, s), 2.36 (2H, t), 2.86 (2H, broad d), 3.94 (2H, dd), 4.51 (2H, s), 6.76 (1H, dd), 6.84 (1H, d), 6.86

(1H, d). ¹³C NMR (CDCl₃): δ 14.3, 21.3, 23.1, 25.1, 29.2, 32.8 (2C), 36.0, 36.5, 39.8, 54.4 (2C), 56.1, 67.9, 115.8, 116.9, 124.3, 128.6, 132.5, 143.4, 164.6.

6-Acetyl-4-[3-(4-butyl-piperidin-1-yl)-propyl]-4H-benzo[1,4]oxazin-3-one (64-LHY-89-5)

[0427] 6-Acetyl-4H-benzo[1,4]oxazin-3-one (96 mg, 0.5 mmol) was converted to the title product according to the procedure for the synthesis of 4-[3-(4-butyl-piperidin-1-yl)-propyl]-6-methyl-4H-benzo[1,4]oxazin-3-one. Yield: 120 mg, 64%. HPLC-MS: M+1⁺ = 373.5 (UV/MS(%) = 99/100). ¹H NMR (400 MHz, CDCl₃): δ= 0.89 (3H, t), 1.13-1.27 (9H, m), 1.63 (2H, broad d), 1.81-1.88 (4H, m), 2.37 (2H, t), 2.55 (3H, s), 2.84 (2H, broad d), 4.02 (2H, dd), 4.65 (2H, s), 6.99 (1H, d), 7.58 (1H, dd), 7.66 (1H, d). ¹³C NMR (CDCl₃): δ 14.3, 23.1, 24.7, 26.5, 29.2, 32.7 (2C), 36.0, 36.5, 39.9, 54.4 (2C), 56.3, 67.6, 114.9, 117.0, 125.3, 128.8, 132.4, 149.5, 163.5, 196.3.

4-[3-(4-Butyl-piperidin-1-yl)-propyl]-6-methyl-3,4-dihydro-2H-benzo[1,4]oxazine (64-LHY-91-6)

[0428] A solution of borane in THF (1M, 0.5 mL, 0.5 mmol) was added to a solution of 4-[3-(4-butyl-piperidin-1-yl)-propyl]-6-methyl-4H-benzo[1,4]oxazin-3-one (50 mg, 0.15 mmol) in THF (6 mL). The reaction mixture was stirred at 40°C for 16 h then aqueous HCl (4M, 10 mL) was added drop wise at room temperature. The reaction mixture was stirred for 16 h then concentrated *in vacuo*. A solution of K₂CO₃ (0.5 g) in water (5 mL) was added and the product was extracted with dichloromethane (2 x 10 mL). The organic layer was dried (Na₂SO₄) and concentrated *in vacuo*. The product was purified on an Isco CombiFlash Sq 16x (4 g silica column, eluting 0-20% ethyl acetate in heptanes + 1% Et₃N). Yield: 29.2 mg, 56%. HPLC-MS: M+1⁺ = 373.5 (UV/MS(%) = 95/90). ¹H NMR (400 MHz, CDCl₃): δ= 0.90 (3H, t), 1.18-1.35 (9H, m), 1.68 (2H, broad d), 1.78 (2H, quin.), 1.89 (2H, broad t), 2.24 (3H, s), 2.35 (2H, t), 2.89 (2H, broad d), 3.27 (2H, t), 3.31 (2H, t), 4.19 (2H, t), 6.39 (1H, broad d), 6.52 (1H, broad s), 6.66 (1H, d). ¹³C NMR (CDCl₃): δ 14.3, 21.4, 23.1, 24.2, 29.3, 32.8 (2C), 36.1, 36.6, 47.4, 49.3, 54.5 (2C), 56.5, 64.7, 113.0, 116.2, 117.7, 131.1, 135.3, 142.0.

4-[3-(4-Butyl-piperidin-1-yl)-propyl]-6-ethyl-3,4-dihydro-2H-benzo[1,4]oxazine (64-LHY-91-5)

[0429] 6-Acetyl-4-[3-(4-butyl-piperidin-1-yl)-propyl]-4H-benzo[1,4]oxazin-3-one (60 mg, 0.161 mmol) was converted to the title product according to the procedure for the synthesis of 4-[3-(4-butyl-piperidin-1-yl)-propyl]-6-methyl-3,4-dihydro-2H-benzo[1,4]oxazine. Yield: 22 mg, 40%. HPLC-MS: M+1⁺ = 373.5 (UV/MS(%) = 98/97). ¹H NMR (400 MHz, CDCl₃): δ= 0.89 (3H, t), 1.18-1.35 (12H, m), 1.68 (2H, broad d), 1.75 (2H, quin.), 1.89 (2H, broad t), 2.35 (2H, t), 2.53 (2H, qv), 2.89 (2H, broad d), 3.26-3.33 (4H, m), 4.20 (2H, t), 6.43 (1H, dd), 6.53 (1H, d), 6.69 (1H, d). ¹³C NMR (CDCl₃): δ 14.3, 16.2, 23.1, 24.2, 28.9, 29.3, 32.8 (2C), 36.1, 36.6, 47.4, 49.4, 54.5 (2C), 56.5, 64.7, 112.0, 116.2, 116.5, 135.3, 137.7, 142.2.

4-(3-Chloropropyl)-4H-benzo[1,4]thiazin-3-one (81MF07)

[0430] 2H-1,4-benzothiazine-3(4H)-one (1.0 g, 6.05 mmol) and Cs_2CO_3 (2.96 g, 9.08 mmol) were dissolved in dry acetonitrile (20 mL) under nitrogen atmosphere and stirred at rt for 30 min. 3-chloro-1-iodopropane (1.37 g, 6.66 mmol) dissolved in acetonitrile (4 mL) was added via a syringe. The reaction mixture was stirred at rt for 18 hours and concentrated *in vacuo*. Water (150 mL) was added and the reaction mixture was extracted with ethyl acetate (3 x 150 mL). The combined organic phases were dried (MgSO_4) and concentrated *in vacuo* to give 1.45 g of crude. The crude product was subjected to CC[eluent:Heptane:EtOAc(4:1)] to give the pure title compound as a slightly yellow oil. Yield 1.37 g, 90.2 %. R_f = 0.24 [Heptane:EtOAc(4:1)], ^1H NMR (CDCl_3): δ 2.14 (m, 2H), 3.38 (s, 2H), 3.36 (t, 2H), 4.17 (t, 2H), 7.03 (t, 1H), 7.18 (d, 1H), 7.26 (t, 1H), 7.37 (d, 1H). ^{13}C NMR (CDCl_3): δ 30.61, 31.81, 42.48, 42.66, 117.87, 123.78, 124.29, 127.52, 127.52, 128.78, 139.40, 165.51

4-[3-(4-Butyl-piperidin-1-yl)-propyl]-4H-benzo[1,4]thiazin-3-one (81MF09)

[0431] NaI (1.24 g, 8.27 mmol), K_2CO_3 (1.14 g, 8.27 mmol), and 4-butylpiperidine (0.62 g, 4.34 mmol) in acetonitrile (10 mL) were stirred at rt. 4-(3-chloropropyl)-4H-benzo[1,4]thiazin-3-one (1.0 g, 4.14 mmol) in acetonitrile (15 mL) was added via a syringe. The reaction was stirred at 60 °C for 13 hours and then at 80 °C for another 25 hours under nitrogen atmosphere and concentrated *in vacuo*. Water (150 mL) was added and the reaction mixture was extracted with ethyl acetate (3 x 150 mL). The combined organic phases were dried (Na_2SO_4) and concentrated *in vacuo* to give 1.63 g of crude. The crude product was subjected to CC[eluent:EtOAc:MeOH(100:1-5%)] to give the pure title compound. Yield 1.06 g 74.2 % HPLC-MS [$M + \text{H}$] $^+$ 347 (UV/MS(%))=100/99. ^1H NMR (CDCl_3): δ 0.88 (t, 3H), 1.23 (m, 9H), 1.64 (d, 2H), 1.85 (m, 4H), 2.34 (t, 2H), 2.83 (d, 2H), 3.36 (s, 1H), 4.03 (t, 2H), 6.99 (m, 1H), 7.22 (d, 2H), 7.34 (d, 1H). ^{13}C NMR (CDCl_3): δ 14.21, 23.03, 25.23, 29.15, 31.80, 32.63, 35.90, 36.44, 43.28, 54.26, 55.91, 118.18, 123.45, 124.17, 127.27, 128.56, 139.63, 165.19.

[0432] To 4-[3-(4-butyl-piperidin-1-yl)-propyl]-4H-benzo[1,4]thiazin-3-one (1.06 g, mmol) in 30 ml diethyl ether was charged oxalic acid (0.28 g, 3.1 mmol) dissolved in diethyl ether (5 mL). The formed crystals were filtered off and washed with diethyl ether (5 x 10 mL) to give 1.21 g of the oxalic salt after drying. HPLC-MS [$M + \text{H}$] $^+$ 347 (UV/MS(%))=100/99.

4-(3-Chloropropyl)-4H-benzo[1,4]oxazin-3-one (81MF08)

[0433] 2H-1,4 benzoxazine-3(4H)one (1.0 g, 6.70 mmol) and Cs_2CO_3 (3.28 g, 10.1 mmol) were dissolved in dry acetonitrile (20 mL) under nitrogen atmosphere and stirred at rt for 30 min. 3-chloro-1-iodopropane (1.58 g, 7.38 mmol) dissolved in acetonitrile (4 mL) was added via a syringe. The reaction mixture was stirred at rt for 18 hours and concentrated *in vacuo*. Water (150

mL) was added and the reaction mixture was extracted with ethyl acetate (3 x 150 mL). The combined organic phases were dried (MgSO₄) and concentrated *in vacuo* to give 1.65 g of crude. The crude product was subjected to CC[eluent:Heptane:EtOAc(4:1)] to give the pure title compound as a colorless oil. Yield 1.36 g, 89.2 %. R_f = 0.24 [Heptane:EtOAc(4:1)], ¹H NMR (CDCl₃): δ 2.16 (m, 2H), 3.62 (t, 2H), 4.10 (t, 2H), 4.59 (s, 2H), 7.00 (m, 2H), 7.05 (m, 2H), ¹³C NMR (CDCl₃): δ 30.16, 39.04, 42.45, 67.72, 114.80, 117.38, 123.07, 124.14, 128.49, 145.47, 164.58.

4-[3-(4-Butyl-piperidin-1-yl)-propyl]-4H-benzo[1,4]oxazin-3-one (81MF10)

[0434] NaI (1.33 g, 8.87 mmol), K₂CO₃ (1.23 g, 8.90 mmol), and 4-butylpiperidine (0.66 g, 4.71 mmol) in acetonitrile (10 mL) were stirred at rt. 4-(3-chloropropyl)-4H-benzo[1,4]oxazin-3-one (1.0 g, 4.43 mmol) in acetonitrile (15 mL) was added via a syringe. The reaction was stirred at 60 °C for 13 hours and then at 80 °C for another 5 hours under nitrogen atmosphere and concentrated *in vacuo*. Water (150 mL) was added and the reaction mixture was extracted with ethyl acetate (3 x 150 mL). The combined organic phases were dried (Na₂SO₄) and concentrated *in vacuo* to give 1.58 g of crude. The crude product was subjected to CC[eluent:EtOAc:MeOH(100:1-5%)] to give the pure title compound. Yield 0.82 g 56.0 % HPLC-MS [$M + H$]⁺ 331 (UV/MS(%)=100/99). ¹H NMR (CDCl₃): δ 0.88 (t, 3H), 1.21 (m, 6H), 1.26 (m, 3H), 1.66 (d, 2H), 1.86 (m, 4H), 2.37 (t, 2H), 2.86 (d, 2H), 3.97 (t, 2H), 4.58 (s, 2H), 6.99 (m, 3H), 7.11 (d, 1H), ¹³C NMR (CDCl₃): δ 14.22, 23.04, 24.90, 29.17, 32.68, 35.95, 36.46, 39.74, 54.31, 56.02, 67.77, 115.26, 117.15, 122.83, 123.83, 128.78, 145.50, 164.34.

[0435] To 4-[3-(4-Butyl-piperidin-1-yl)-propyl]-4H-benzo[1,4]oxazin-3-one (0.82 g, mmol) in 30 ml diethyl ether was charged oxalic acid (0.25 g, 2.8 mmol) dissolved in diethyl ether (5 mL). The formed crystals were filtered off and washed with diethyl ether (5 x 10 mL) to give 0.75 g of the oxalic salt after drying. HPLC-MS [$M + H$]⁺ 331 (UV/MS(%)=100/99)

Example 2

Pharmacological Data


[0436] Receptor Selection and Amplification (R-SAT) assays were carried out using the cloned M1 - M5 receptors essentially as described in: Brauner-Osborne H, Brann MR. Pharmacology of muscarinic acetylcholine receptor subtypes (m1-m5): high throughput assays in mammalian cells. Eur J Pharmacol 1996 Jan 4;295(1):93-102, and Spalding TA, Trotter C, Skjaerbaek N, Messier TL, Currier EA, Burstein ES, Li D, Hacksell U, Brann MR. Discovery of an ectopic activation site on the M(1) muscarinic receptor. Mol Pharmacol. 2002 Jun;61(6):1297-302.

Compound Number	m1 %Efficacy pEC ₅₀		m2 %Efficacy pEC ₅₀		m3 %Efficacy pEC ₅₀		m4 %Efficacy pEC ₅₀		m5 %Efficacy pEC ₅₀	
55-LH-28-1 (1549)	87	7.5	41	5.8	No response		66	6.2	No response	
77-LH-1 (1606)	No response		No response		No response		No response		No response	
55-LH-28-8 (1598)	45	6.7	67	<5.5	No response		64	<5.5	Not tested	
55-LH-12-2	72	7.3	35	6.2	No response		68	6.0	No response	
55LH44-A	54	6.5	No response		No response		28	<5.5	Not tested	
55LH54	57	6.4	No response		No response		No response		No response	
73MF01	90	7.7	55	6.3	No response		65	6.8	49	6.2
73MF02	90	7.6	50	6.0	No response		75	6.6	30	6.3
77LH02-1917	55	6.7	No response		No response		37	<5.5	No response	
64LHY89-5	45	5.6	No response		No response		No response		Not tested	
64LHY89-6	80	7.4	35	6.2	No response		50	6.5	48	6.2
64LHY91-5	69	6.8	No response		No response		51	5.7	38	6.2
64LHY91-6	86	7.2	31	6.9	No response		52	6.6	No response	
77LH22-A	76	7.1	No response		No response		No response		37	<5.5
82LHY19	81	7.7	39	6.3	No response		46	6.8	Not tested	
77LH61-A	79	7.5	28	<5.5	No response		33	5.8	51	<5.5
81MF24	96	7.8	70	7.0	No response		Not tested		Not tested	
81MF763	92	7.5	47	6.6	No response		57	6.4	50	5.9
85LM47A	122	7.9	74	6.0	No response		91	6.1	35	<5.5
85LM96-86R	106	7.6	97	6.2	30	5.9	94	5.8	90	5.6
85LM96-87R	101	7.7	116	5.9	36	6.0	140	6.1	62	6.0
107LH55	103	8.9	28	7.5	No response		54	7.3	No response	
108LM39-36	106	8.8	37	8.1	No response		71	7.7	No response	
107LH74-3D	97	8.0	No response		Not tested		Not tested		Not tested	
112KK20-c5	117	8.3	No response		No response		Not tested		Not tested	
107LH95-1	103	7.6	No response		Not tested		Not tested		Not tested	

CLAIMS

What is claimed is:

1. A compound of formula I, as well as salts and isomers thereof



I

wherein

R¹ is a monoradical selected from the group consisting of optionally substituted C₁₋₆-alkyl, optionally substituted C₂₋₆-alkylidene, optionally substituted C₂₋₆-alkenyl, optionally substituted C₂₋₆-alkynyl, optionally substituted O-C₁₋₆-alkyl, optionally substituted O-C₂₋₆-alkenyl, optionally substituted O-C₂₋₆-alkynyl; optionally substituted S-C₁₋₆-alkyl, optionally substituted S-C₂₋₆-alkenyl, optionally substituted S-C₂₋₆-alkynyl;

m is 0, 1 or 2;

C_3-C_4 is CH_2-CH or $CH=Cor$ C_4 is CH and C_3 is absent;

R² and R³ are independently selected from the group consisting of hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted O-C₁₋₆ alkyl, halogen, hydroxy or selected such that R² and R³ together form a ring system;

each R⁴ and R⁵ is independently selected from the group consisting of hydrogen, halogen, hydroxy, optionally substituted C₁₋₆-alkyl, optionally substituted O-C₁₋₆-alkyl, optionally substituted aryl-C₁₋₆-alkyl, and optionally substituted arylheteroalkyl;

L¹ and L² are biradicals independently selected from the group consisting of -C(R⁶)=C(R⁷), -C(R⁶)=N-, -N=C(R⁶)-, -S-, -NH- and -O-; wherein only one of L¹ and L² may be selected from the group consisting of -S-, -NH- and -O-;

Y is selected from the group consisting of O, S, and H₂;


X is a biradical selected from the group consisting of $-C(R^6)(R^7)-C(R^6)(R^7)-$, $-C(R^6)=C(R^7)-$, $-O-C(R^6)(R^7)-$, $C(R^6)(R^7)-O-$, $-S-C(R^6)(R^7)-$, $-C(R^6)(R^7)-S-$, $-N(R^N)-C(R^6)(R^7)-$, $-C(R^6)(R^7)-N(R^N)-$, $-C(R^6)(R^7)-C(R^6)(R^7)-C(R^6)(R^7)-$, $-O-C(R^6)(R^7)-C(R^6)(R^7)-$, $-S-C(R^6)(R^7)-C(R^6)(R^7)-$, $N(R^N)-C(R^6)(R^7)-C(R^6)(R^7)-$, $-C(R^6)(R^7)-C(R^6)(R^7)-O-$, $-C(R^6)(R^7)-C(R^6)(R^7)-S-$, $-C(R^6)(R^7)-C(R^6)(R^7)-N(R^N)-$, $-C(R^6)(R^7)-C(R^6)=C(R^7)-$, and $-C(R^6)=C(R^7)-C(R^6)(R^7)-$, wherein R^6 and R^7 are independently selected from the group consisting of hydrogen, halogen, hydroxy, nitro, cyano, $NR^N R^N$, $N(R^N)-C(O)N(R^N)$, optionally substituted C_{1-6} -alkyl, C_{2-6} -alkenyl, C_{2-6} -alkynyl, optionally

substituted O-C₁₋₆-alkyl, optionally substituted O-aryl, optionally substituted O-C₂₋₆-alkenyl, optionally substituted O-C₂₋₆-alkynyl


wherein R^N is selected from the group consisting of hydrogen, and optionally substituted C₁₋₆-alkyl.

2. The compound according to claim 1, wherein R¹ is selected from the group consisting of optionally substituted C₁₋₆-alkyl, optionally substituted C₁₋₆-alkylidene, and optionally substituted O-C₁₋₆-alkyl

3. The compound according to claim 1, wherein R², R³, m, C₃-C₄ are selected such that




is selected from the group consisting of




wherein R⁸ is present 0, 1, or 2 times and is independently selected from the group consisting of optionally substituted C₁₋₆ alkyl, optionally substituted O-C₁₋₆ alkyl, halogen, hydroxy.

4. The compound according to claim 1, wherein C₃-C₄, m, R² and R³ are hydrogen or selected such that R² and R³ together form a ring system such that




is selected from the group consisting of




5. The compound according to claim 1, wherein R² and R³ are independently selected from the group consisting of hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted O-C₁₋₆ alkyl, halogen and hydroxy.

6. The compound according to claim 1, wherein m is 1.

7. The compound according to claim 1, wherein m is 0, C_3 is absent, and C_4 is CH such that



is




8. The compound according to claim 1 wherein X is selected from the group consisting of $-C(R^6)(R^7)-C(R^6)(R^7)-$, $-C(R^6)=C(R^7)-$, $-O-C(R^6)(R^7)-$, $-C(R^6)(R^7)-O-$, $-S-C(R^6)(R^7)-$, $-C(R^6)(R^7)-S-$, $-N(R^N)-C(R^6)(R^7)-$, $-C(R^6)(R^7)-N(R^N)-$.

9. The compound according to claim 1 wherein Y is selected from the group consisting of O and H_2 .

10. The compound according to claim 1 wherein L^1 and L^2 are independently selected from the group consisting of $-C(R^6)=C(R^7)-$, $-C(R^6)=N-$, and $-N=C(R^7)-$.

11. The compound according to claim 1, of formula Ia



Ia

wherein R^1 is selected from the group consisting of optionally substituted C_{1-6} -alkyl, optionally substituted C_{1-6} -alkylidene, optionally substituted C_{2-6} -alkenyl, optionally substituted C_{2-6} -alkynyl, optionally substituted $O-C_{1-6}$ -alkyl, and optionally substituted $O-C_{2-6}$ -alkenyl; and R^2 , R^3 , R^4 , X , Y , R^6 and R^7 are as defined in claim 1.

12. The compound claim 11, wherein the optionally substituted C_{1-6} -alkyl is selected from the group consisting of unsubstituted C_{1-6} -alkyl, and C_{1-6} -alkoxyalkyl, and wherein Y is selected from the group consisting of O and H_2 , and wherein X is selected from the group consisting of $-C(R^6)(R^7)-C(R^6)(R^7)-$, $-C(R^6)=C(R^7)-$, $-O-C(R^6)(R^7)-$, $-C(R^6)(R^7)-O-$, $-S-C(R^6)(R^7)-$, $-C(R^6)(R^7)-S-$, and wherein L^1 and L^2 are independently selected from the group consisting of $-C(R^6)=C(R^7)-$, $-C(R^6)=N-$, and $-N=C(R^7)-$, and wherein R^4 selected from the group consisting of hydrogen, halogen, hydroxy, optionally substituted C_{1-6} -alkyl, and optionally substituted $O-C_{1-6}$ -alkyl.

13. The compound according to claim 1 selected from the group consisting of 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-1,2,3,4-tetrahydro-quinoline; 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-2-methyl-1,2,3,4-tetrahydro-quinoline; 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-6-methyl-1,2,3,4-tetrahydro-quinoline; 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-8-methyl-1,2,3,4-tetrahydro-quinoline; 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-7-fluoro-2-methyl-1,2,3,4-tetrahydro-quinoline; 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-7-trifluoromethyl-1,2,3,4-tetrahydro-quinoline; 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-6-methoxy-3,4-dihydro-1*H*-quinolin-2-one; 4-[3-(4-Butyl-piperidin-1-yl)-propyl]-4*H*-benzo[1,4]thiazin-3-one; 4-[3-(4-Butyl-piperidin-1-yl)-propyl]-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butyl-piperidin-1-yl)-propyl]-6-methyl-4*H*-benzo[1,4]oxazin-3-one; 6-Acetyl-4-[3-(4-butyl-piperidin-1-yl)-propyl]-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butyl-piperidin-1-yl)-propyl]-6-methyl-3,4-dihydro-2*H*-benzo[1,4]oxazine; 4-[3-(4-Butyl-piperidin-1-yl)-propyl]-6-ethyl-3,4-dihydro-2*H*-benzo[1,4]oxazine; (*R*)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-4*H*-benzo[1,4]thiazin-3-one; (*R*)-4-[2-Methyl-3-(4-propoxypiperidin-1-yl)propyl]-4*H*-benzo[1,4]thiazin-3-one; (*R*)-4-[3-(4-Butylidene-piperidin-1-yl)-2-methyl-propyl]-4*H*-benzo[1,4]thiazin-3-one; (*R*)-4-[3-(3-Butyl-8-aza-bicyclo[3.2.1]oct-8-yl)-2-methyl-propyl]-4*H*-benzo[1,4]thiazin-3-one; (*R*)-4-[2-Methyl-3-(3-pentyl-8-aza-bicyclo[3.2.1]oct-8-yl)propyl]-4*H*-benzo[1,4]thiazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-6,8-dichloro-7-methyl-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butyl-piperidin-1-yl)propyl]-6,8-dimethyl-4*H*-benzo[1,4]oxazin-3-one (81MF2237F); 6-*tert*-Butyl-4-[3-(4-butyl-piperidin-1-yl)propyl]-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-5-methyl-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-7-methyl-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-6-chloro-7-nitro-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-7-chloro-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-6-fluoro-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-7,8-difluoro-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-4*H*-pyrido[4,3-*b*][1,4]thiazin-3-one; 4-[3-(4-Propoxypiperidin-1-yl)propyl]-4*H*-benzo[1,4]thiazin-3-one; 4-[3-(4-Propoxypiperidin-1-yl)propyl]-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-7-fluoro-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butylidenepiperidin-1-yl)propyl]-4*H*-benzo[1,4]thiazin-3-one; 4-[3-(4-Butylidenepiperidin-1-yl)propyl]-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(3-Butylidene-8-aza-bicyclo[3.2.1]oct-8-yl)-propyl]-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-6-methoxy-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-6,8-dichloro-7-ethyl-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-8-fluoro-4*H*-benzo[1,4]oxazin-3-one; 6-Bromo-4-[3-(4-butylpiperidin-1-yl)propyl]-8-fluoro-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-8-isopropyl-4*H*-benzo[1,4]oxazin-3-one; (*R,S*)-4-[3-(4-Butylpiperidin-1-yl)-2-hydroxy-propyl]-6-methyl-4*H*-benzo[1,4]oxazin-3-one; (*R,S*)-4-[3-(4-Butylpiperidin-1-yl)-2-

hydroxypropyl]-4*H*-benzo[1,4]oxazin-3-one; (-)-4-[3-(4-Butylpiperidin-1-yl)-2-hydroxypropyl]-4*H*-benzo[1,4]oxazin-3-one; (*R,S*)-4-[3-(4-Butylpiperidin-2-methoxypropyl)-4*H*-benzo[1,4]oxazin-3-one; (*R,S*)-4-[2-Hydroxy-3-(3-pentylbicyclo[3.2.1]oct-8-yl)-propyl]-4*H*-benzo[1,4]oxazin-3-one; 4-[2-(4-Butylpiperidin-1-ylmethyl)allyl]-4*H*-benzo[1,4]oxazin-3-one; (*R,S*)-4-[3-(4-Butylpiperidin-1-yl)-2-fluoropropyl]-4*H*-benzo[1,4]oxazin-3-one; (*S*)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[2-Methyl-3-(4-propoxypiperidin-1-yl)-propyl]-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(3-Butyl-8-aza-bicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-4*H*-benzo[1,4]oxazin-3-one; (*R*)-6-Fluoro-4-[2-methyl-3-(4-propoxy-piperidin-1-yl)-propyl]-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methyl-propyl]-6-fluoro-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6-fluoro-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-fluoro-4*H*-benzo[1,4]oxazin-3-one; (*R*)-6-Fluoro-4-[2-methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)-propyl]-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-7-Fluoro-4*H*-benzo[1,4]oxazin-3-one; (*R*)-7-Fluoro-4-[2-methyl-3-(4-propoxypiperidin-1-yl)propyl]-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-7-fluoro-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-7-fluoro-4*H*-benzo[1,4]oxazin-3-one; (*R*)-7-Fluoro-4-[2-methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)-propyl]-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(4-Butylpiperidin-1-yl)-2-methyl-propyl]-6-methoxy-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-6-methoxy-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-methoxy-4*H*-benzo[1,4]oxazin-3-one; (*R*)-6-Methoxy-4-[2-methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-4*H*-benzo[1,4]oxazin-3-one; (*R*)-6-Methoxy-4-[2-methyl-3-(4-propoxypiperidin-1-yl)propyl]-4*H*-benzo[1,4]oxazin-3-one; (*R*)-6-Methyl-4-[2-methyl-3-(4-propoxypiperidin-1-yl)-propyl]-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-6-methyl-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6-methyl-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-methyl-4*H*-benzo[1,4]oxazin-3-one; (*R*)-4-[3-(3-Pentyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-methyl-4*H*-benzo[1,4]oxazin-3-one; 1-[3-(4-Propoxypiperidin-1-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-6-fluoro-3,4-dihydro-1*H*-quinolin-2-one; 6-Fluoro-1-[3-(4-propoxypiperidin-1-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-one; (*R,S*)-1-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6-fluoro-3,4-dihydro-1*H*-quinolin-2-one; (*R,S*)-6-Fluoro-1-[3-(4-propoxypiperidin-1-yl)-2-methylpropyl]-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-6-chloro-3,4-dihydro-1*H*-quinolin-

2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-6-methyl-3,4-dihydro-1*H*-quinolin-2-one; 6-Methyl-1-[3-(4-propoxypiperidin-1-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-7-fluoro-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-5-methyl-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-7-methyl-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-7-fluoro-6-methyl-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-6,7-difluoro-3,4-dihydro-1*H*-quinolin-2-one; 6,7-Difluoro-1-[3-(4-propoxypiperidin-1-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-one; (*R,S*)-1-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6,7-difluoro-3,4-dihydro-1*H*-quinolin-2-one; (*R,S*)-6,7-Difluoro-1-[3-(4-propoxypiperidin-1-yl)-2-methylpropyl]-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-6-fluoro-7-methyl-3,4-dihydro-1*H*-quinolin-2-one; 6-Fluoro-7-methyl-1-[3-(4-propoxypiperidin-1-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-one; (*R,S*)-1-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6-fluoro-7-methyl-3,4-dihydro-1*H*-quinolin-2-one; (*R,S*)-6-Fluoro-7-methyl-1-[2-methyl-3-(4-propoxypiperidin-1-yl)-propyl]-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-6-fluoro-5-methyl-3,4-dihydro-1*H*-quinolin-2-one; 6-Fluoro-5-methyl-1-[3-(4-propoxypiperidin-1-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-one; (*R*)-1-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-3,4-dihydro-1*H*-quinolin-2-one; (*R*)-1-[2-Methyl-3-(4-propoxypiperidin-1-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-one; (*R*)-1-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-3,4-dihydro-1*H*-quinolin-2-one; (*R*)-1-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-3,4-dihydro-1*H*-quinolin-2-one; (*R*)-1-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-1*H*-quinolin-2-one; 1-[3-(4-Propoxypiperidin-1-yl)propyl]-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-6-fluoro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-6-methyl-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-7-fluoro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-6-methoxy-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-6-chloro-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-5-methyl-1*H*-quinolin-2-one; 1-[3-(4-Butylpiperidin-1-yl)propyl]-7-methyl-1*H*-quinolin-2-one; (*R*)-1-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-1*H*-quinolin-2-one; (*R*)-1-[2-Methyl-3-(4-propoxypiperidin-1-yl)-propyl]-1*H*-quinolin-2-one; 1-[3-(4-Allyloxypiperidin-1-yl)propyl]-1*H*-quinolin-2-one; (*R,S*)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6-methyl-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-4-[2-Methyl-3-(4-propoxypiperidin-1-yl)propyl]-6-methyl-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-6-methyl-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-methyl-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-4-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-6-methyl-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6-fluoro-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-6-Fluoro-4-[2-methyl-3-(4-propoxypiperidin-1-yl)propyl]-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-6-fluoro-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-4-[3-(3-

Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-fluoro-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-6-Fluoro-4-[2-methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-7-fluoro-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-7-Fluoro-4-[2-methyl-3-(4-propoxypiperidin-1-yl)propyl]-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-7-fluoro-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-7-fluoro-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-7-Fluoro-4-[2-methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-3-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-3*H*-benzothiazol-2-one; (*R,S*)-4-[2-Methyl-3-(4-propoxypiperidin-1-yl)propyl]-3*H*-benzothiazol-2-one; (*R,S*)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-3*H*-benzothiazol-2-one; (*R,S*)-3-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-3*H*-benzothiazol-2-one; (*R,S*)-3-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-3*H*-benzothiazol-2-one; (*R,S*)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-4-[2-Methyl-3-(4-propoxypiperidin-1-yl)propyl]-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-4-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-4*H*-benzo[1.4]thiazin-3-one; (*R,S*)-1-[2-Methyl-3-(4-propoxypiperidin-1-yl)propyl]-4*H*-benzo[1.4]thiazin-3-one; (*R,S*)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-4*H*-benzo[1.4]thiazin-3-one; (*R,S*)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4*H*-benzo[1.4]thiazin-3-one; (*R,S*)-4-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-4*H*-benzo[1.4]thiazin-3-one; (*R,S*)-1-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-3,4-dihydro-1*H*-quinolin-2-one; (*R,S*)-1-[2-Methyl-3-(4-propoxypiperidin-1-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-one; (*R,S*)-1-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-3,4-dihydro-1*H*-quinolin-2-one; (*R,S*)-1-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-3,4-dihydro-1*H*-quinolin-2-one; (*R,S*)-1-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-3,4-dihydro-1*H*-quinolin-2-one; (*R,S*)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6-methoxy-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-4-[2-Methyl-3-(4-propoxypiperidin-1-yl)-6-methoxy]-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-4-[3-(4-Butylidenepiperidin-1-yl)-2-methylpropyl]-6-methoxy-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-4-[3-(3-Butyl-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-methoxy-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-1-[2-Methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-6-methoxy-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-4-[3-(4-Butylpiperidin-1-yl)-2-methylpropyl]-6,7-difluoro-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-6,7-Difluoro-4-[2-methyl-3-(3-pentyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-4-[3-(3-Butoxy-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-6-fluoro-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-6-Fluoro-4-[3-[3-(2-methoxyethyl)-8-azabicyclo[3.2.1]oct-8-yl]-2-methylpropyl]-4*H*-benzo[1.4]oxazin-3-one; (*R,S*)-4-[3-(3-Butylazetidin-1-yl)-2-methylpropyl]-6-

fluoro-4*H*-benzo[1,4]oxazin-3-one; (*R,S*)-6-Fluoro-4-[2-methyl-3-(3-propoxyazetidin-1-yl)propyl]-4*H*-benzo[1,4]oxazin-3-one; (*R,S*)-4-[3-(3-Butylazetidin-1-yl)-2-methoxypropyl]-6-fluoro-4*H*-benzo[1,4]oxazin-3-one; 4-[3-(4-Butyl-3-fluoropiperidin-1-yl)-2-methylpropyl]-6-fluoro-4*H*-benzo[1,4]oxazin-3-one.

14. A composition comprising
 - i) one or more compounds of formula I, as defined in claim 1, and
 - ii) at least one pharmaceutically acceptable excipient or carrier.
15. A method of treating a disease in a mammal, wherein modulation of the activity of a cholinergic receptor is associated with a physiologically beneficial response in said disease of said mammal,

said method comprising administering an effective amount of a compound of formula I, as defined in claim 1.
16. The method according to claim 15, wherein the cholinergic receptor is a muscarinic receptor.
17. The method according to claim 15, wherein the cholinergic receptor is a muscarinic M₁-receptor subtype.
18. The method according to claim 15, wherein the cholinergic receptor is the muscarinic M₄-receptor subtype.
19. The method according to claim 15, wherein the physiologically beneficial response is associated with the selective modulation of the muscarinic M₁-receptor subtype in relation to the muscarinic M₂- or M₃-receptor subtypes.
20. The method according to claim 15 wherein the compound is a muscarinic agonist.
21. A method of increasing an activity of a cholinergic receptor comprising contacting the cholinergic receptor or a system containing the cholinergic receptor with an effective amount of at least one compound as defined in claim 1.
22. A method of treating or preventing or alleviating the symptoms associated with a disorder in a mammal, comprising the administration of an effective amount of at least one compound as defined in claim 1, said disorder associated with a muscarinic receptor, such as M₁ muscarinic receptor subtype.
23. The method of claim 22, wherein the disorder is selected from the group consisting of cognitive impairment, forgetfulness, confusion, memory loss, attentional deficits, deficits in visual perception, depression, pain, sleep disorders, psychosis, and increased intraocular pressure.
24. The method of claim 22, wherein the disorder is selected from the group consisting of neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, schizophrenia, Huntington's chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Downs Syndrome, Pick

disease, dementia, clinical depression, age-related cognitive decline, attention-deficit disorder, sudden infant death syndrome, and glaucoma.

25. The method according to claim 15, wherein the disease or disorder is a mental disorder and the physiologically beneficial response is due to modulation in terms of M_1 agonism; M_1 and M_4 agonism; both M_1 agonism and D_2 antagonism; or M_1 and M_4 agonism and D_2 antagonism.

27. Use of a compound of formula I, as defined in any one of claims 1 to 14, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, or a pharmaceutical composition comprising either entity, for the preparation of a medicament for the treatment of diseases or disorders associated with a cholinergic receptor or ligand thereof.

28. Use of a compound of formula I, as defined in any one of claims 1 to 14, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, or a pharmaceutical composition comprising either entity, for the preparation of a medicament for the treatment of diseases or disorders selected from the group consisting of Alzheimer's disease, Parkinson's disease, schizophrenia, Huntington's chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Down Syndrome, Pick disease, dementia, clinical depression, age-related cognitive decline, cognitive impairment, forgetfulness, confusion, memory loss, attentional deficits, deficits in visual perception, depression, pain, sleep disorders, psychosis, sudden infant death syndrome, increased intraocular pressure and glaucoma.

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
17 July 2003 (17.07.2003)

PCT

(10) International Publication Number
WO 03/057672 A3(51) International Patent Classification⁷: C07D 417/06,
A61K 31/435, A61P 43/00, C07D 451/02, 413/06, 513/04,
401/04 // (C07D 513/04, 279:00, 221:00)

(21) International Application Number: PCT/US02/41617

(22) International Filing Date:
23 December 2002 (23.12.2002)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
60/344,722 28 December 2001 (28.12.2001) US(71) Applicant: ACADIA PHARMACEUTICALS, INC.
[US/US]; 3911 Sorrento Valley Boulevard, San Diego, CA
92121-1402 (US).(72) Inventors: SKJAERBAEK, Niels; Fagerparken 33,
DK-2950 Vedbaek (DK). KOCH, Kristian, Norup; Bor-
thigsgade 11, DK-2100 Copenhagen (DK). FRIBERG,
Bo, Lennart, Mikael; Nikolaigatan 24, S-214 21 Malmoe
(SE). TOLF, Bo-Ragnar; Ringstedgade 2, DK-2100
Copenhagen (DK).(74) Agent: HUNT, Dale, C.; Knobbe, Martens, Olson & Bear,
LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US).(81) Designated States (*national*): AE, AG, AL, AM, AT (util-
ity model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (util-
ity model), DE, DK (utility model), DK, DM, DZ, EC, EE
(utility model), EE, ES, FI (utility model), FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR,
TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
13 November 2003For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS



(1)

(57) Abstract: The present invention
relates to tetrahydroquinoline compounds
as formulas I, as well as salts and isomers
thereof wherein m is 0, 1 or 2; C₃-C₄ is
CH₂-CH or CH=Cor C₄ is CH and
C₃ is absent; L¹ and L² are biradicals
independently selected from the group
consisting of -C(R⁶)=C(R⁷), -C(R⁶)=N,
-N=C(R⁶)-, -S-, -NH- and -O-; wherein only
one of L¹ and L² may be selected from the
group consisting of -S-, NH - and O; Y isselected from the group consisting of O, S, and H₂; X is a biradical as muscarinic receptor agonists; compositions comprising the
same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition
associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using
said compounds.

WO 03/057672 A3

INTERNATIONAL SEARCH REPORT

Int ☐ National Application No

PCT/US 02/41617

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D417/06 A61K31/435 A61P43/00 C07D451/02 C07D413/06
C07D513/04 C07D401/04 //(C07D513/04,279:00,221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01 83472 A (ACADIA PHARMACEUTICALS) 8 November 2001 (2001-11-08) claims	1,27
A	WO 01 27104 A (BANYU PHARMACEUTICAL CO., LTD.) 19 April 2001 (2001-04-19) abstract	1,27
A	US 5 770 734 A (ANNMARIE LOUISE SABB) 23 June 1998 (1998-06-23) column 2 -column 3	1,27
A	WO 99 50247 A (ACADIA PHARMACEUTICALS, INC.) 7 October 1999 (1999-10-07) page 3; example XIV	1,27

☐ Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

8 August 2003

Date of mailing of the international search report

25/08/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Van Bijlen, H

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 02/41617

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 15-20, 22-25 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/41617

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0183472	A	08-11-2001	AU 5919001 A	12-11-2001
			BR 0110420 A	01-07-2003
			CA 2407594 A1	08-11-2001
			EP 1278741 A1	29-01-2003
			NO 20025115 A	19-12-2002
			WO 0183472 A1	08-11-2001
			US 2002037886 A1	28-03-2002
WO 0127104	A	19-04-2001	AU 7686500 A	23-04-2001
			CA 2387535 A1	19-04-2001
			EP 1221443 A1	10-07-2002
			WO 0127104 A1	19-04-2001
US 5770734	A	23-06-1998	US 5149815 A	22-09-1992
			US 5093333 A	03-03-1992
WO 9950247	A	07-10-1999	AU 762726 B2	03-07-2003
			AU 3218799 A	18-10-1999
			BR 9909277 A	16-10-2001
			CA 2326804 A1	07-10-1999
			CN 1303376 T	11-07-2001
			EP 1068185 A1	17-01-2001
			JP 2002509918 T	02-04-2002
			NO 20004912 A	23-11-2000
			WO 9950247 A1	07-10-1999
			US 6528529 B1	04-03-2003